{
  "1,2-benzodiazepine": {
    "name": "1,2-Benzodiazepine",
    "smiles": "N1N=CC=CC2=CC=CC=C12",
    "molecular_weight": 144.18,
    "log_p": 2.11,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "1,2-distearoyllecithin": {
    "name": "1,2-Distearoyllecithin",
    "smiles": "CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC",
    "molecular_weight": 790.16,
    "log_p": 12.17,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 42,
    "approved": true,
    "source": "FDA"
  },
  "1,2-icosapentoyl-sn-glycero-3-phosphoserine": {
    "name": "1,2-icosapentoyl-sn-glycero-3-phosphoserine",
    "smiles": "[H]C(N)(COP(O)(=O)OCC([H])(COC(=O)CCC\\C=C/C\\C=C/C\\C=C/C\\C=C/C\\C=C/CC)OC(=O)CCCC\\C=C/C\\C=C/C\\C=C/C\\C=C/C\\C=C/CC)C(O)=O",
    "molecular_weight": 842.06,
    "log_p": 11.22,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 37,
    "approved": true,
    "source": "FDA"
  },
  "1-palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))": {
    "name": "1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))",
    "smiles": "CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\\C=C/CCCCCCCC",
    "molecular_weight": 749.02,
    "log_p": 10.45,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 39,
    "approved": true,
    "source": "FDA"
  },
  "2,2'-dibenzothiazyl disulfide": {
    "name": "2,2'-Dibenzothiazyl disulfide",
    "smiles": "S(SC1=NC2=CC=CC=C2S1)C1=NC2=CC=CC=C2S1",
    "molecular_weight": 332.5,
    "log_p": 5.71,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "2-mercaptobenzothiazole": {
    "name": "2-mercaptobenzothiazole",
    "smiles": "S=C1NC2=C(S1)C=CC=C2",
    "molecular_weight": 167.26,
    "log_p": 2.96,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "4-(isopropylamino)diphenylamine": {
    "name": "4-(Isopropylamino)diphenylamine",
    "smiles": "CC(C)NC1=CC=C(NC2=CC=CC=C2)C=C1",
    "molecular_weight": 226.32,
    "log_p": 4.25,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "5-o-phosphono-alpha-d-ribofuranosyl diphosphate": {
    "name": "5-O-phosphono-alpha-D-ribofuranosyl diphosphate",
    "smiles": "O[C@H]1[C@@H](O)[C@@H](OP(O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O",
    "molecular_weight": 390.07,
    "log_p": -2.23,
    "hbd": 7,
    "hba": 9,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "abacavir": {
    "name": "Abacavir",
    "smiles": "NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1",
    "molecular_weight": 286.34,
    "log_p": 1.09,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "nucleoside reverse transcriptase inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "abametapir": {
    "name": "Abametapir",
    "smiles": "CC1=CC=C(N=C1)C1=CC=C(C)C=N1",
    "molecular_weight": 184.24,
    "log_p": 2.76,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "metalloproteinase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "abarelix": {
    "name": "Abarelix",
    "smiles": "CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O",
    "molecular_weight": 1416.09,
    "log_p": 1.17,
    "hbd": 13,
    "hba": 16,
    "rotatable_bonds": 38,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "gonadotropin releasing factor hormone receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "abemaciclib": {
    "name": "Abemaciclib",
    "smiles": "CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1",
    "molecular_weight": 506.61,
    "log_p": 4.94,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "CDK inhibitor",
    "disease_area": "oncology",
    "indication": "breast cancer"
  },
  "abiraterone": {
    "name": "Abiraterone",
    "smiles": "[H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C",
    "molecular_weight": 349.52,
    "log_p": 5.4,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "androgen biosynthesis inhibitor",
    "disease_area": "oncology",
    "indication": "prostate cancer"
  },
  "abrocitinib": {
    "name": "Abrocitinib",
    "smiles": "CCCS(=O)(=O)N[C@H]1C[C@H](C1)N(C)C1=C2C=CNC2=NC=N1",
    "molecular_weight": 323.42,
    "log_p": 1.25,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "acalabrutinib": {
    "name": "Acalabrutinib",
    "smiles": "CC#CC(=O)N1CCC[C@H]1C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=CC=CC=N1",
    "molecular_weight": 465.52,
    "log_p": 3.31,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "Bruton's tyrosine kinase (BTK) inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "mantle cell lymphoma (MCL)"
  },
  "acamprosate": {
    "name": "Acamprosate",
    "smiles": "CC(=O)NCCCS(O)(=O)=O",
    "molecular_weight": 181.21,
    "log_p": -0.6,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glutamate receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "abstinence from alcohol"
  },
  "acarbose": {
    "name": "Acarbose",
    "smiles": "[H]C(=O)[C@H](O)[C@@H](O)[C@]([H])(O[C@@]1([H])O[C@H](CO)[C@@]([H])(O[C@H]2O[C@H](C)[C@@H](N[C@@]3([H])C=C(CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)CO",
    "molecular_weight": 645.61,
    "log_p": -8.72,
    "hbd": 14,
    "hba": 19,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucosidase inhibitor",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "acebutolol": {
    "name": "Acebutolol",
    "smiles": "CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(=C1)C(C)=O",
    "molecular_weight": 336.43,
    "log_p": 2.37,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology | cardiology",
    "indication": "hypertension | ventricular arrhythmias"
  },
  "aceclidine": {
    "name": "Aceclidine",
    "smiles": "CC(=O)OC1CN2CCC1CC2",
    "molecular_weight": 169.22,
    "log_p": 0.64,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor agonist",
    "disease_area": "ophthalmology",
    "indication": "glaucoma"
  },
  "aceclofenac": {
    "name": "Aceclofenac",
    "smiles": "OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl",
    "molecular_weight": 354.19,
    "log_p": 3.91,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "prostanoid receptor antagonist",
    "disease_area": "rheumatology | rheumatology | rheumatology | rheumatology | rheumatology | rheumatology",
    "indication": "ankylosing spondylitis | ischiadynia | lumbago | osteoarthritis | periarthritis | rheumatoid arthritis"
  },
  "acemetacin": {
    "name": "Acemetacin",
    "smiles": "COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCC(O)=O",
    "molecular_weight": 415.83,
    "log_p": 3.47,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "rheumatology",
    "indication": "osteoarthritis"
  },
  "acenocoumarol": {
    "name": "Acenocoumarol",
    "smiles": "CC(=O)CC(C1=CC=C(C=C1)[N+]([O-])=O)C1=C(O)C2=CC=CC=C2OC1=O",
    "molecular_weight": 353.33,
    "log_p": 3.52,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin K antagonist",
    "disease_area": "hematology",
    "indication": "deep vein thrombosis (DVT)"
  },
  "acetaminophen": {
    "name": "Acetaminophen",
    "smiles": "CC(=O)NC1=CC=C(O)C=C1",
    "molecular_weight": 151.16,
    "log_p": 1.35,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "acetarsol": {
    "name": "Acetarsol",
    "smiles": "CC(=O)NC1=CC(=CC=C1O)[As](O)(O)=O",
    "molecular_weight": 275.09,
    "log_p": -1.09,
    "hbd": 4,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "gastroenterology",
    "indication": "diarrhea"
  },
  "acetazolamide": {
    "name": "Acetazolamide",
    "smiles": "CC(=O)NC1=NN=C(S1)S(N)(=O)=O",
    "molecular_weight": 222.25,
    "log_p": -0.86,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "carbonic anhydrase inhibitor",
    "disease_area": "ophthalmology",
    "indication": "glaucoma"
  },
  "acetic acid": {
    "name": "Acetic acid",
    "smiles": "CC(O)=O",
    "molecular_weight": 60.05,
    "log_p": 0.09,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "acetohexamide": {
    "name": "Acetohexamide",
    "smiles": "CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1",
    "molecular_weight": 324.4,
    "log_p": 2.21,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATP channel blocker",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "acetohydroxamic acid": {
    "name": "Acetohydroxamic acid",
    "smiles": "CC(=O)NO",
    "molecular_weight": 75.07,
    "log_p": -0.49,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "acetophenazine": {
    "name": "Acetophenazine",
    "smiles": "CC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1",
    "molecular_weight": 411.57,
    "log_p": 3.49,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "psychosis"
  },
  "acetyl sulfisoxazole": {
    "name": "Acetyl sulfisoxazole",
    "smiles": "CC(=O)N(C1=C(C)C(C)=NO1)S(=O)(=O)C1=CC=C(N)C=C1",
    "molecular_weight": 309.35,
    "log_p": 1.62,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "acetylcarnitine": {
    "name": "Acetylcarnitine",
    "smiles": "CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C",
    "molecular_weight": 203.24,
    "log_p": -1.24,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "acetylcholine": {
    "name": "Acetylcholine",
    "smiles": "CC(=O)OCC[N+](C)(C)C",
    "molecular_weight": 146.21,
    "log_p": 0.26,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor agonist",
    "disease_area": "gastroenterology | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | pulmonary",
    "indication": "chest congestion | drowsiness | fatigue | headache | indigestion"
  },
  "acetylcysteine": {
    "name": "Acetylcysteine",
    "smiles": "CC(=O)N[C@@H](CS)C(O)=O",
    "molecular_weight": 163.2,
    "log_p": -0.49,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "mucolytic agent",
    "disease_area": "gastroenterology | gastroenterology",
    "indication": "acetaminophen overdose | hepatic injury"
  },
  "acetyldigitoxin": {
    "name": "Acetyldigitoxin",
    "smiles": "[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1",
    "molecular_weight": 806.99,
    "log_p": 3.82,
    "hbd": 4,
    "hba": 14,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "acetylene": {
    "name": "Acetylene",
    "smiles": "C#C",
    "molecular_weight": 26.04,
    "log_p": 0.25,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "acetylsalicylic acid": {
    "name": "Acetylsalicylic acid",
    "smiles": "CC(=O)OC1=CC=CC=C1C(O)=O",
    "molecular_weight": 180.16,
    "log_p": 1.31,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "acipimox": {
    "name": "Acipimox",
    "smiles": "CC1=[N+]([O-])C=C(N=C1)C(O)=O",
    "molecular_weight": 154.12,
    "log_p": -0.28,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cholesterol inhibitor",
    "disease_area": "endocrinology",
    "indication": "hyperlipidemia"
  },
  "acitretin": {
    "name": "Acitretin",
    "smiles": "COC1=C(C)C(C)=C(\\C=C\\C(\\C)=C\\C=C\\C(\\C)=C\\C(O)=O)C(C)=C1",
    "molecular_weight": 326.44,
    "log_p": 5.17,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "retinoid receptor agonist",
    "disease_area": "dermatology",
    "indication": "psoriasis"
  },
  "aclidinium": {
    "name": "Aclidinium",
    "smiles": "OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1",
    "molecular_weight": 484.66,
    "log_p": 4.67,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "pulmonary | pulmonary | pulmonary",
    "indication": "bronchitis | chronic obstructive pulmonary disease (COPD) | emphysema"
  },
  "acrivastine": {
    "name": "Acrivastine",
    "smiles": "[H]\\C(CN1CCCC1)=C(\\C1=CC=C(C)C=C1)C1=CC=CC(=N1)C(\\[H])=C(/[H])C(O)=O",
    "molecular_weight": 348.45,
    "log_p": 4.02,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy",
    "indication": "allergic rhinitis"
  },
  "activated charcoal": {
    "name": "Activated charcoal",
    "smiles": "[C]",
    "molecular_weight": 12.01,
    "log_p": 0.08,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "acyclovir": {
    "name": "Acyclovir",
    "smiles": "NC1=NC(=O)C2=C(N1)N(COCCO)C=N2",
    "molecular_weight": 225.21,
    "log_p": -1.33,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA polymerase inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "chicken pox | genitial herpes | shingles"
  },
  "adagrasib": {
    "name": "Adagrasib",
    "smiles": "[H][C@@]1(COC2=NC3=C(CCN(C3)C3=CC=CC4=C3C(Cl)=CC=C4)C(=N2)N2CCN(C(=O)C(F)=C)[C@@]([H])(CC#N)C2)CCCN1C",
    "molecular_weight": 604.13,
    "log_p": 4.73,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "adapalene": {
    "name": "Adapalene",
    "smiles": "COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2",
    "molecular_weight": 412.53,
    "log_p": 6.68,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "retinoid receptor agonist",
    "disease_area": "dermatology",
    "indication": "acne vulgaris (AV)"
  },
  "adefovir dipivoxil": {
    "name": "Adefovir dipivoxil",
    "smiles": "CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C",
    "molecular_weight": 501.48,
    "log_p": 2.7,
    "hbd": 1,
    "hba": 13,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA"
  },
  "ademetionine": {
    "name": "Ademetionine",
    "smiles": "C[S+](CC[C@H](N)C([O-])=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CN=C2N",
    "molecular_weight": 398.45,
    "log_p": -3.26,
    "hbd": 4,
    "hba": 11,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "methyltransferase stimulant | phosphodiesterase inhibitor",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "attention-deficit/hyperactivity disorder (ADHD) | depression"
  },
  "adenine": {
    "name": "Adenine",
    "smiles": "NC1=C2NC=NC2=NC=N1",
    "molecular_weight": 135.13,
    "log_p": -0.06,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Preclinical",
    "moa": "protein synthesis stimulant",
    "disease_area": "",
    "indication": ""
  },
  "adenosine": {
    "name": "Adenosine",
    "smiles": "NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1",
    "molecular_weight": 267.25,
    "log_p": -1.98,
    "hbd": 4,
    "hba": 9,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adenosine receptor agonist",
    "disease_area": "cardiology",
    "indication": "Wolff-Parkinson-White Syndrome (WPW)"
  },
  "adenosine phosphate": {
    "name": "Adenosine phosphate",
    "smiles": "NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1",
    "molecular_weight": 347.22,
    "log_p": -1.86,
    "hbd": 5,
    "hba": 10,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "adiphenine": {
    "name": "Adiphenine",
    "smiles": "CCN(CC)CCOC(=O)C(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 311.43,
    "log_p": 3.7,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "spasms"
  },
  "afamelanotide": {
    "name": "Afamelanotide",
    "smiles": "CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O",
    "molecular_weight": 1646.87,
    "log_p": -4.1,
    "hbd": 23,
    "hba": 21,
    "rotatable_bonds": 50,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "melanocyte-stimulating hormone mimetic | melatonin receptor agonist",
    "disease_area": "dermatology",
    "indication": "erythropoietic protoporphyria (epp)"
  },
  "afatinib": {
    "name": "Afatinib",
    "smiles": "CN(C)C\\C=C\\C(=O)NC1=C(O[C@H]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1",
    "molecular_weight": 485.95,
    "log_p": 4.39,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "EGFR inhibitor",
    "disease_area": "oncology",
    "indication": "non-small cell lung cancer (NSCLC)"
  },
  "agomelatine": {
    "name": "Agomelatine",
    "smiles": "COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1",
    "molecular_weight": 243.31,
    "log_p": 2.53,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "melatonin receptor agonist | serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "ajmaline": {
    "name": "Ajmaline",
    "smiles": "[H][C@]12C[C@]34[C@H](O)C1[C@@]1([H])C[C@]([H])(N2[C@H](O)[C@H]1CC)[C@]3([H])N(C)C1=CC=CC=C41",
    "molecular_weight": 326.44,
    "log_p": 1.55,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "cardiology | cardiology, Tachycardias | Tachycardias",
    "indication": "atrial fibrillation (af) | Wolff-Parkinson-White Syndrome (WPW) | wolff-parkinson-white syndrome (wpw), atrial fibrillation (af)"
  },
  "alatrofloxacin": {
    "name": "Alatrofloxacin",
    "smiles": "[H][C@@]12CN(C[C@]1([H])[C@H]2NC(=O)[C@H](C)NC(=O)[C@H](C)N)C1=NC2=C(C=C1F)C(=O)C(=CN2C1=CC=C(F)C=C1F)C(O)=O",
    "molecular_weight": 558.52,
    "log_p": 0.9,
    "hbd": 4,
    "hba": 8,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "albendazole": {
    "name": "Albendazole",
    "smiles": "CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2",
    "molecular_weight": 265.34,
    "log_p": 3.24,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "tubulin polymerization inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "cystic hydatid disease | parenchymal neurocysticercosis"
  },
  "alcaftadine": {
    "name": "Alcaftadine",
    "smiles": "CN1CCC(CC1)=C1C2=NC=C(C=O)N2CCC2=CC=CC=C12",
    "molecular_weight": 307.4,
    "log_p": 2.78,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy",
    "indication": "allergic conjunctivitis"
  },
  "alclofenac": {
    "name": "Alclofenac",
    "smiles": "OC(=O)CC1=CC(Cl)=C(OCC=C)C=C1",
    "molecular_weight": 226.66,
    "log_p": 2.53,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "rheumatology",
    "indication": "rheumatoid arthritis"
  },
  "alclometasone": {
    "name": "Alclometasone",
    "smiles": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])[C@H](Cl)CC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 408.92,
    "log_p": 2.02,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "alcloxa": {
    "name": "Alcloxa",
    "smiles": "[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-].NC(=O)NC1NC(=O)[N-]C1=O",
    "molecular_weight": 314.55,
    "log_p": -5.86,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "alectinib": {
    "name": "Alectinib",
    "smiles": "CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=O",
    "molecular_weight": 482.63,
    "log_p": 4.77,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ALK tyrosine kinase receptor inhibitor",
    "disease_area": "oncology",
    "indication": "non-small cell lung cancer (NSCLC)"
  },
  "alendronic acid": {
    "name": "Alendronic acid",
    "smiles": "NCCCC(O)(P(O)(O)=O)P(O)(O)=O",
    "molecular_weight": 249.1,
    "log_p": -1.27,
    "hbd": 6,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "alfacalcidol": {
    "name": "Alfacalcidol",
    "smiles": "CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)C[C@H](O)C1=C",
    "molecular_weight": 400.65,
    "log_p": 6.59,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin D receptor agonist",
    "disease_area": "endocrinology",
    "indication": "vitamin D deficiency"
  },
  "alfentanil": {
    "name": "Alfentanil",
    "smiles": "CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C2=CC=CC=C2)C1=O",
    "molecular_weight": 416.53,
    "log_p": 1.38,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "alfuzosin": {
    "name": "Alfuzosin",
    "smiles": "COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N(C)CCCNC(=O)C1CCCO1",
    "molecular_weight": 389.46,
    "log_p": 1.35,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "urology",
    "indication": "benign prostatic hyperplasia (BPH)"
  },
  "alimemazine": {
    "name": "Alimemazine",
    "smiles": "CC(CN(C)C)CN1C2=CC=CC=C2SC2=CC=CC=C12",
    "molecular_weight": 298.46,
    "log_p": 4.49,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor agonist | histamine receptor antagonist",
    "disease_area": "allergy | neurology/psychiatry | neurology/psychiatry | pulmonary",
    "indication": "cough suppressant | itching | sedative | urticaria"
  },
  "aliskiren": {
    "name": "Aliskiren",
    "smiles": "COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1",
    "molecular_weight": 551.77,
    "log_p": 3.29,
    "hbd": 4,
    "hba": 7,
    "rotatable_bonds": 19,
    "approved": true,
    "source": "FDA"
  },
  "alitretinoin": {
    "name": "Alitretinoin",
    "smiles": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C\\C=C\\C(\\C)=C\\C(O)=O",
    "molecular_weight": 300.44,
    "log_p": 5.6,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "allantoin": {
    "name": "Allantoin",
    "smiles": "NC(=O)NC1NC(=O)NC1=O",
    "molecular_weight": 158.12,
    "log_p": -2.18,
    "hbd": 4,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cosmetic",
    "disease_area": "dermatology",
    "indication": "skin protectant"
  },
  "alloin": {
    "name": "Alloin",
    "smiles": "OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(CO)C=C2O",
    "molecular_weight": 418.4,
    "log_p": -0.89,
    "hbd": 7,
    "hba": 9,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "allopurinol": {
    "name": "Allopurinol",
    "smiles": "OC1=NC=NC2=C1C=NN2",
    "molecular_weight": 136.11,
    "log_p": 0.06,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "xanthine oxidase inhibitor",
    "disease_area": "rheumatology | urology",
    "indication": "gout | kidney stones"
  },
  "almasilate": {
    "name": "Almasilate",
    "smiles": "O.[Mg++].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-]",
    "molecular_weight": 280.45,
    "log_p": -12.24,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "almitrine": {
    "name": "Almitrine",
    "smiles": "FC1=CC=C(C=C1)C(N1CCN(CC1)C1=NC(NCC=C)=NC(NCC=C)=N1)C1=CC=C(F)C=C1",
    "molecular_weight": 477.56,
    "log_p": 4.26,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "neurotransmitter agonist",
    "disease_area": "pulmonary",
    "indication": "chronic obstructive pulmonary disease (COPD)"
  },
  "almotriptan": {
    "name": "Almotriptan",
    "smiles": "CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2",
    "molecular_weight": 335.47,
    "log_p": 2.2,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "migraine headache"
  },
  "alogliptin": {
    "name": "Alogliptin",
    "smiles": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O",
    "molecular_weight": 339.4,
    "log_p": 0.39,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dipeptidyl peptidase inhibitor",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "alosetron": {
    "name": "Alosetron",
    "smiles": "CN1C2=C(C3=CC=CC=C13)C(=O)N(CC1=C(C)NC=N1)CC2",
    "molecular_weight": 294.36,
    "log_p": 2.41,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "serotonin receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "alpelisib": {
    "name": "Alpelisib",
    "smiles": "CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F",
    "molecular_weight": 441.48,
    "log_p": 3.84,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PI3K inhibitor",
    "disease_area": "oncology",
    "indication": "breast cancer"
  },
  "alpha-amyl cinnamaldehyde": {
    "name": "alpha-Amyl cinnamaldehyde",
    "smiles": "CCCCC\\C(C=O)=C\\C1=CC=CC=C1",
    "molecular_weight": 202.3,
    "log_p": 3.85,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "alpha-arbutin": {
    "name": "alpha-Arbutin",
    "smiles": "OC[C@H]1O[C@H](OC2=CC=C(O)C=C2)[C@H](O)[C@@H](O)[C@@H]1O",
    "molecular_weight": 272.25,
    "log_p": -1.43,
    "hbd": 5,
    "hba": 7,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "alpha-linolenic acid": {
    "name": "alpha-Linolenic acid",
    "smiles": "CC\\C=C/C\\C=C/C\\C=C/CCCCCCCC(O)=O",
    "molecular_weight": 278.44,
    "log_p": 5.66,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA"
  },
  "alpha-tocopherol succinate": {
    "name": "alpha-Tocopherol succinate",
    "smiles": "[H][C@@](C)(CCCC(C)C)CCC[C@@]([H])(C)CCC[C@]1(C)CCC2=C(C)C(OC(=O)CCC(O)=O)=C(C)C(C)=C2O1",
    "molecular_weight": 530.79,
    "log_p": 8.9,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 16,
    "approved": true,
    "source": "FDA"
  },
  "alprazolam": {
    "name": "Alprazolam",
    "smiles": "CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12",
    "molecular_weight": 308.77,
    "log_p": 3.58,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "alprostadil": {
    "name": "Alprostadil",
    "smiles": "CCCCC[C@H](O)\\C=C\\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O",
    "molecular_weight": 354.49,
    "log_p": 3.48,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "prostanoid receptor agonist",
    "disease_area": "cardiology",
    "indication": "congenital heart defects"
  },
  "altretamine": {
    "name": "Altretamine",
    "smiles": "CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C",
    "molecular_weight": 210.28,
    "log_p": 0.07,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA synthesis inhibitor",
    "disease_area": "oncology",
    "indication": "ovarian cancer"
  },
  "aluminium": {
    "name": "Aluminium",
    "smiles": "[Al]",
    "molecular_weight": 26.98,
    "log_p": -0.38,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "aluminium phosphate": {
    "name": "Aluminium phosphate",
    "smiles": "[Al+3].[O-]P([O-])([O-])=O",
    "molecular_weight": 121.95,
    "log_p": -3.21,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "aluminum acetate": {
    "name": "Aluminum acetate",
    "smiles": "[Al+3].CC([O-])=O.CC([O-])=O.CC([O-])=O",
    "molecular_weight": 204.11,
    "log_p": -4.11,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "aluminum chloride": {
    "name": "Aluminum chloride",
    "smiles": "Cl[Al](Cl)Cl",
    "molecular_weight": 133.34,
    "log_p": 1.69,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "aluminum chlorohydrate": {
    "name": "Aluminum chlorohydrate",
    "smiles": "O.[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-]",
    "molecular_weight": 192.47,
    "log_p": -5.47,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "aluminum hydroxide": {
    "name": "Aluminum hydroxide",
    "smiles": "[OH-].[OH-].[OH-].[Al+3]",
    "molecular_weight": 78.0,
    "log_p": -0.91,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "aluminum oxide": {
    "name": "Aluminum oxide",
    "smiles": "[O--].[O--].[O--].[Al+3].[Al+3]",
    "molecular_weight": 101.96,
    "log_p": -1.12,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "aluminum subacetate": {
    "name": "Aluminum subacetate",
    "smiles": "CC(=O)O[Al](O)OC(C)=O",
    "molecular_weight": 162.08,
    "log_p": -0.91,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "aluminum sulfate": {
    "name": "Aluminum sulfate",
    "smiles": "[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O",
    "molecular_weight": 342.15,
    "log_p": -4.78,
    "hbd": 0,
    "hba": 12,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "aluminum zirconium octachlorohydrex gly": {
    "name": "Aluminum zirconium octachlorohydrex gly",
    "smiles": "O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O",
    "molecular_weight": 263.75,
    "log_p": -7.33,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "alverine": {
    "name": "Alverine",
    "smiles": "CCN(CCCC1=CC=CC=C1)CCCC1=CC=CC=C1",
    "molecular_weight": 281.44,
    "log_p": 4.57,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "muscle relaxant",
    "disease_area": "gastroenterology | gastroenterology",
    "indication": "diverticular disease | irritable bowel syndrome"
  },
  "alvimopan": {
    "name": "Alvimopan",
    "smiles": "C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1",
    "molecular_weight": 424.54,
    "log_p": 3.05,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "opioid receptor antagonist",
    "disease_area": "gastroenterology",
    "indication": "postoperative ileus"
  },
  "amantadine": {
    "name": "Amantadine",
    "smiles": "NC12CC3CC(CC(C3)C1)C2",
    "molecular_weight": 151.25,
    "log_p": 1.91,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glutamate receptor antagonist",
    "disease_area": "infectious disease | neurology/psychiatry",
    "indication": "influenza A virus infection | Parkinson's Disease"
  },
  "ambenonium": {
    "name": "Ambenonium",
    "smiles": "CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC1=CC=CC=C1Cl",
    "molecular_weight": 537.58,
    "log_p": 4.64,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 14,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cholinesterase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "myasthenia gravis"
  },
  "ambrisentan": {
    "name": "Ambrisentan",
    "smiles": "COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 378.43,
    "log_p": 3.52,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "endothelin receptor antagonist",
    "disease_area": "pulmonary",
    "indication": "pulmonary arterial hypertension (PAH)"
  },
  "ambroxol": {
    "name": "Ambroxol",
    "smiles": "NC1=C(Br)C=C(Br)C=C1CN[C@H]1CC[C@H](O)CC1",
    "molecular_weight": 378.11,
    "log_p": 3.19,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "pulmonary",
    "indication": "bronchitis"
  },
  "amcinonide": {
    "name": "Amcinonide",
    "smiles": "[H][C@@]12C[C@H]3OC4(CCCC4)O[C@@]3(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 502.58,
    "log_p": 3.52,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "dermatology | Dermatology",
    "indication": "corticosteroid-responsive dermatoses | dermatitis"
  },
  "amifampridine": {
    "name": "Amifampridine",
    "smiles": "NC1=CC=NC=C1N",
    "molecular_weight": 109.13,
    "log_p": 0.25,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "potassium channel blocker",
    "disease_area": "neurology/psychiatry",
    "indication": "Lambert-Eaton myasthenic syndrome (LEMS)"
  },
  "amifostine": {
    "name": "Amifostine",
    "smiles": "NCCCNCCSP(O)(O)=O",
    "molecular_weight": 214.23,
    "log_p": -0.25,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "reducing agent",
    "disease_area": "nephrology",
    "indication": "renal toxicity"
  },
  "amikacin": {
    "name": "Amikacin",
    "smiles": "NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O",
    "molecular_weight": 585.61,
    "log_p": -8.42,
    "hbd": 13,
    "hba": 17,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-negative bacterial infections"
  },
  "amiloride": {
    "name": "Amiloride",
    "smiles": "NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N",
    "molecular_weight": 229.63,
    "log_p": -1.08,
    "hbd": 5,
    "hba": 6,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "cardiology | cardiology",
    "indication": "congestive heart failure | hypertension"
  },
  "amiloxate": {
    "name": "Amiloxate",
    "smiles": "COC1=CC=C(\\C=C\\C(=O)OCCC(C)C)C=C1",
    "molecular_weight": 248.32,
    "log_p": 3.3,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "aminobenzoic acid": {
    "name": "Aminobenzoic acid",
    "smiles": "NC1=CC=C(C=C1)C(O)=O",
    "molecular_weight": 137.14,
    "log_p": 0.97,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "aminocaproic acid": {
    "name": "Aminocaproic acid",
    "smiles": "NCCCCCC(O)=O",
    "molecular_weight": 131.17,
    "log_p": 0.59,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "aminoglutethimide": {
    "name": "Aminoglutethimide",
    "smiles": "CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1",
    "molecular_weight": 232.28,
    "log_p": 1.35,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor antagonist",
    "disease_area": "endocrinology | oncology",
    "indication": "breast cancer | Cushing's syndrome"
  },
  "aminohippuric acid": {
    "name": "Aminohippuric acid",
    "smiles": "NC1=CC=C(C=C1)C(=O)NCC(O)=O",
    "molecular_weight": 194.19,
    "log_p": 0.08,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "aminolevulinic acid": {
    "name": "Aminolevulinic acid",
    "smiles": "NCC(=O)CCC(O)=O",
    "molecular_weight": 131.13,
    "log_p": -0.62,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "aminophenazone": {
    "name": "Aminophenazone",
    "smiles": "CN(C)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1",
    "molecular_weight": 231.3,
    "log_p": 1.55,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "aminophylline": {
    "name": "Aminophylline",
    "smiles": "NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O",
    "molecular_weight": 420.43,
    "log_p": -3.18,
    "hbd": 4,
    "hba": 12,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adenosine receptor antagonist",
    "disease_area": "pulmonary | pulmonary | pulmonary",
    "indication": "asthma | bronchitis | emphysema"
  },
  "aminosalicylic acid": {
    "name": "Aminosalicylic acid",
    "smiles": "NC1=CC(O)=C(C=C1)C(O)=O",
    "molecular_weight": 153.14,
    "log_p": 0.67,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "amiodarone": {
    "name": "Amiodarone",
    "smiles": "CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2",
    "molecular_weight": 645.32,
    "log_p": 6.94,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "potassium channel blocker",
    "disease_area": "cardiology",
    "indication": "ventricular arrhythmias"
  },
  "amisulpride": {
    "name": "Amisulpride",
    "smiles": "CCN1CCCC1CNC(=O)C1=CC(=C(N)C=C1OC)S(=O)(=O)CC",
    "molecular_weight": 369.49,
    "log_p": 1.29,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry | neurology/psychiatry",
    "indication": "bipolar disorder | psychosis | schizophrenia"
  },
  "amitriptyline": {
    "name": "Amitriptyline",
    "smiles": "CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12",
    "molecular_weight": 277.41,
    "log_p": 4.17,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "norepinephrine inhibitor | norepinephrine reuptake inhibitor | serotonin\u2013norepinephrine reuptake inhibitor (SNRI) | serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "amitriptylinoxide": {
    "name": "Amitriptylinoxide",
    "smiles": "CN(C)(=O)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12",
    "molecular_weight": 293.41,
    "log_p": 4.18,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "amlexanox": {
    "name": "Amlexanox",
    "smiles": "CC(C)C1=CC2=C(OC3=NC(N)=C(C=C3C2=O)C(O)=O)C=C1",
    "molecular_weight": 298.3,
    "log_p": 2.75,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor modulator",
    "disease_area": "allergy | dental | ophthalmology | pulmonary",
    "indication": "allergic rhinitis | aphthous ulcers | asthma | conjunctivitis"
  },
  "amlodipine": {
    "name": "Amlodipine",
    "smiles": "CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC",
    "molecular_weight": 408.88,
    "log_p": 2.27,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "cardiology | cardiology | cardiology | cardiology",
    "indication": "chronic stable angina | coronary artery disease (CAD) | hypertension | vasospastic angina"
  },
  "ammonia n-13": {
    "name": "Ammonia N-13",
    "smiles": "[13NH3]",
    "molecular_weight": 16.03,
    "log_p": 0.16,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "ammonium carbonate": {
    "name": "Ammonium carbonate",
    "smiles": "[NH4+].[NH4+].[O-]C([O-])=O",
    "molecular_weight": 96.09,
    "log_p": -1.69,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "ammonium chloride": {
    "name": "Ammonium chloride",
    "smiles": "[NH4+].[Cl-]",
    "molecular_weight": 53.49,
    "log_p": -2.62,
    "hbd": 1,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "ammonium lactate": {
    "name": "Ammonium lactate",
    "smiles": "[NH4+].CC(O)C([O-])=O",
    "molecular_weight": 107.11,
    "log_p": -1.51,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "amobarbital": {
    "name": "Amobarbital",
    "smiles": "CCC1(CCC(C)C)C(=O)NC(=O)NC1=O",
    "molecular_weight": 226.28,
    "log_p": 1.18,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "amodiaquine": {
    "name": "Amodiaquine",
    "smiles": "CCN(CC)CC1=C(O)C=CC(NC2=C3C=CC(Cl)=CC3=NC=C2)=C1",
    "molecular_weight": 355.87,
    "log_p": 5.18,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor agonist",
    "disease_area": "infectious disease",
    "indication": "malaria"
  },
  "amorolfine": {
    "name": "Amorolfine",
    "smiles": "[H]C(C)(CN1C[C@]([H])(C)O[C@]([H])(C)C1)CC1=CC=C(C=C1)C(C)(C)CC",
    "molecular_weight": 317.52,
    "log_p": 4.66,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "membrane integrity inhibitor",
    "disease_area": "infectious disease",
    "indication": "onychomycosis"
  },
  "amoxapine": {
    "name": "Amoxapine",
    "smiles": "ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1",
    "molecular_weight": 313.79,
    "log_p": 3.43,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "norepinephrine reputake inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "amoxicillin": {
    "name": "Amoxicillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O",
    "molecular_weight": 365.41,
    "log_p": 0.02,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "penicillin binding protein inhibitor",
    "disease_area": "gastroenterology | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "duodenal ulcer disease | ear infections | genitourinary tract infections | gonorrhea | respiratory tract infections | skin infections | throat infections"
  },
  "amphetamine": {
    "name": "Amphetamine",
    "smiles": "CC(N)CC1=CC=CC=C1",
    "molecular_weight": 135.21,
    "log_p": 1.58,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "amphotericin b": {
    "name": "Amphotericin B",
    "smiles": "[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2",
    "molecular_weight": 924.09,
    "log_p": 0.71,
    "hbd": 12,
    "hba": 17,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "ampicillin": {
    "name": "Ampicillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O",
    "molecular_weight": 349.41,
    "log_p": 0.32,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "bacterial septicemia | endocarditis | gastrointestinal infections | meningitis | respiratory tract infections | urinary tract infections"
  },
  "amprenavir": {
    "name": "Amprenavir",
    "smiles": "CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1",
    "molecular_weight": 505.64,
    "log_p": 2.4,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HIV protease inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "amrinone": {
    "name": "Amrinone",
    "smiles": "NC1=CC(=CNC1=O)C1=CC=NC=C1",
    "molecular_weight": 187.2,
    "log_p": 1.02,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "cardiology",
    "indication": "congestive heart failure"
  },
  "amsacrine": {
    "name": "Amsacrine",
    "smiles": "COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1",
    "molecular_weight": 393.47,
    "log_p": 4.51,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "topoisomerase inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "acute lymphoblastic leukemia (ALL)"
  },
  "amyl nitrite": {
    "name": "Amyl Nitrite",
    "smiles": "CCCCCON=O",
    "molecular_weight": 117.15,
    "log_p": 1.87,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "amylmetacresol": {
    "name": "Amylmetacresol",
    "smiles": "CCCCCC1=CC=C(C)C=C1O",
    "molecular_weight": 178.27,
    "log_p": 3.43,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "amylocaine": {
    "name": "Amylocaine",
    "smiles": "CCC(C)(CN(C)C)OC(=O)C1=CC=CC=C1",
    "molecular_weight": 235.33,
    "log_p": 2.57,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "anagrelide": {
    "name": "Anagrelide",
    "smiles": "ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl",
    "molecular_weight": 256.09,
    "log_p": 1.93,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "hematologic malignancy | hematology",
    "indication": "myeloproliferative neoplasms | thrombocythemia"
  },
  "anastrozole": {
    "name": "Anastrozole",
    "smiles": "CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N",
    "molecular_weight": 293.37,
    "log_p": 2.93,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "aromatase inhibitor",
    "disease_area": "oncology",
    "indication": "breast cancer"
  },
  "anethole": {
    "name": "Anethole",
    "smiles": "COC1=CC=C(\\C=C\\C)C=C1",
    "molecular_weight": 148.2,
    "log_p": 2.73,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glutathione transferase stimulant",
    "disease_area": "",
    "indication": ""
  },
  "anethole trithione": {
    "name": "Anethole trithione",
    "smiles": "COC1=CC=C(C=C1)C1=CC(=S)SS1",
    "molecular_weight": 240.37,
    "log_p": 4.21,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "anidulafungin": {
    "name": "Anidulafungin",
    "smiles": "[H][C@]1(NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C1=O)NC(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O",
    "molecular_weight": 1140.25,
    "log_p": -0.93,
    "hbd": 14,
    "hba": 17,
    "rotatable_bonds": 14,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "fungal 1,3-beta-D-glucan synthase inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "candidemia | esophageal candidiasis | fungal infection"
  },
  "anileridine": {
    "name": "Anileridine",
    "smiles": "CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C1=CC=CC=C1",
    "molecular_weight": 352.48,
    "log_p": 3.41,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "anisindione": {
    "name": "Anisindione",
    "smiles": "COC1=CC=C(C=C1)C1C(=O)C2=CC=CC=C2C1=O",
    "molecular_weight": 252.27,
    "log_p": 2.86,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin K antagonist",
    "disease_area": "hematology",
    "indication": "deep vein thrombosis (DVT)"
  },
  "anisotropine methylbromide": {
    "name": "Anisotropine methylbromide",
    "smiles": "[Br-].CCCC(CCC)C(=O)O[C@H]1CC2CCC(C1)[N+]2(C)C",
    "molecular_weight": 362.35,
    "log_p": 0.52,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "gastroenterology",
    "indication": "peptic ulcer disease (pud)"
  },
  "antazoline": {
    "name": "Antazoline",
    "smiles": "C(N(CC1=CC=CC=C1)C1=CC=CC=C1)C1=NCCN1",
    "molecular_weight": 265.36,
    "log_p": 2.69,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antihistamine",
    "disease_area": "ophthalmology | otolaryngology",
    "indication": "conjunctivitis | nasal congestion"
  },
  "anthralin": {
    "name": "Anthralin",
    "smiles": "OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2",
    "molecular_weight": 226.23,
    "log_p": 2.23,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA synthesis inhibitor",
    "disease_area": "dermatology",
    "indication": "psoriasis"
  },
  "antipyrine": {
    "name": "Antipyrine",
    "smiles": "CN1N(C(=O)C=C1C)C1=CC=CC=C1",
    "molecular_weight": 188.23,
    "log_p": 1.48,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "antrafenine": {
    "name": "Antrafenine",
    "smiles": "FC(F)(F)C1=CC(=CC=C1)N1CCN(CCOC(=O)C2=CC=CC=C2NC2=C3C=CC(=CC3=NC=C2)C(F)(F)F)CC1",
    "molecular_weight": 588.55,
    "log_p": 7.0,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "apalutamide": {
    "name": "Apalutamide",
    "smiles": "CNC(=O)C1=CC=C(C=C1F)N1C(=S)N(C(=O)C11CCC1)C1=CC(=C(N=C1)C#N)C(F)(F)F",
    "molecular_weight": 477.44,
    "log_p": 3.53,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "androgen receptor antagonist",
    "disease_area": "oncology",
    "indication": "prostate cancer"
  },
  "apixaban": {
    "name": "Apixaban",
    "smiles": "COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O",
    "molecular_weight": 459.51,
    "log_p": 2.7,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "coagulation factor inhibitor",
    "disease_area": "cardiology | hematology | hematology | hematology | neurology/psychiatry",
    "indication": "atrial fibrillation (AF) | deep vein thrombosis (DVT) | pulmonary embolism (PE) | stroke | systemic embolism"
  },
  "apomorphine": {
    "name": "Apomorphine",
    "smiles": "[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23",
    "molecular_weight": 267.33,
    "log_p": 2.85,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "apraclonidine": {
    "name": "Apraclonidine",
    "smiles": "NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1",
    "molecular_weight": 245.11,
    "log_p": 1.95,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "ophthalmology | ophthalmology",
    "indication": "glaucoma | intraocular pressure"
  },
  "apremilast": {
    "name": "Apremilast",
    "smiles": "CCOC1=CC(=CC=C1OC)[C@@H](CS(C)(=O)=O)N1C(=O)C2=CC=CC(NC(C)=O)=C2C1=O",
    "molecular_weight": 460.51,
    "log_p": 2.43,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "dermatology | rheumatology",
    "indication": "psoriasis | psoriatic arthritis"
  },
  "aprepitant": {
    "name": "Aprepitant",
    "smiles": "C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F",
    "molecular_weight": 534.43,
    "log_p": 4.95,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "tachykinin antagonist",
    "disease_area": "gastroenterology | gastroenterology",
    "indication": "nausea | vomiting"
  },
  "apronalide": {
    "name": "Apronalide",
    "smiles": "CC(C)C(CC=C)C(=O)NC(N)=O",
    "molecular_weight": 184.24,
    "log_p": 1.03,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "arbutamine": {
    "name": "Arbutamine",
    "smiles": "O[C@@H](CNCCCCC1=CC=C(O)C=C1)C1=CC(O)=C(O)C=C1",
    "molecular_weight": 317.39,
    "log_p": 2.45,
    "hbd": 5,
    "hba": 5,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "adrenergic receptor agonist",
    "disease_area": "cardiology",
    "indication": "coronary artery disease (cad)"
  },
  "arbutin": {
    "name": "Arbutin",
    "smiles": "OC[C@H]1O[C@@H](OC2=CC=C(O)C=C2)[C@H](O)[C@@H](O)[C@@H]1O",
    "molecular_weight": 272.25,
    "log_p": -1.43,
    "hbd": 5,
    "hba": 7,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 2/Phase 3",
    "moa": "melanin inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "arformoterol": {
    "name": "Arformoterol",
    "smiles": "COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1",
    "molecular_weight": 344.41,
    "log_p": 2.22,
    "hbd": 4,
    "hba": 5,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "argatroban": {
    "name": "Argatroban",
    "smiles": "C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2",
    "molecular_weight": 508.65,
    "log_p": 0.91,
    "hbd": 6,
    "hba": 6,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "thrombin inhibitor",
    "disease_area": "hematology",
    "indication": "heparin-induced thrombocytopenia (HIT)"
  },
  "aripiprazole": {
    "name": "Aripiprazole",
    "smiles": "ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl",
    "molecular_weight": 448.39,
    "log_p": 4.86,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor agonist | serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry | neurology/psychiatry",
    "indication": "bipolar disorder | depression | schizophrenia"
  },
  "aripiprazole lauroxil": {
    "name": "Aripiprazole lauroxil",
    "smiles": "CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12",
    "molecular_weight": 660.73,
    "log_p": 8.68,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 19,
    "approved": true,
    "source": "FDA"
  },
  "armodafinil": {
    "name": "Armodafinil",
    "smiles": "NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 273.36,
    "log_p": 2.01,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "arsenic trioxide": {
    "name": "Arsenic trioxide",
    "smiles": "O=[As]O[As]=O",
    "molecular_weight": 197.84,
    "log_p": -1.07,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "artemether": {
    "name": "Artemether",
    "smiles": "[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@H](OC)[C@@H]2C)O4",
    "molecular_weight": 298.38,
    "log_p": 2.84,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antimalarial agent",
    "disease_area": "infectious disease",
    "indication": "malaria"
  },
  "artemotil": {
    "name": "Artemotil",
    "smiles": "[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@H](OCC)[C@@H]2C)O4",
    "molecular_weight": 312.41,
    "log_p": 3.23,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "infectious disease",
    "indication": "malaria"
  },
  "artenimol": {
    "name": "Artenimol",
    "smiles": "[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4",
    "molecular_weight": 284.35,
    "log_p": 2.19,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "artesunate": {
    "name": "Artesunate",
    "smiles": "[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@@H](OC(=O)CCC(O)=O)[C@@H]2C)O4",
    "molecular_weight": 384.43,
    "log_p": 2.6,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "malaria"
  },
  "articaine": {
    "name": "Articaine",
    "smiles": "CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC",
    "molecular_weight": 284.38,
    "log_p": 2.17,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "local anesthetic",
    "disease_area": "neurology/psychiatry",
    "indication": "local anesthetic"
  },
  "arzoxifene": {
    "name": "Arzoxifene",
    "smiles": "COC1=CC=C(C=C1)C1=C(OC2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2",
    "molecular_weight": 475.61,
    "log_p": 6.94,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "asciminib": {
    "name": "Asciminib",
    "smiles": "O[C@@H]1CCN(C1)C1=C(C=C(C=N1)C(=O)NC1=CC=C(OC(F)(F)Cl)C=C1)C1=CC=NN1",
    "molecular_weight": 449.85,
    "log_p": 3.46,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 2",
    "moa": "Bcr-Abl kinase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "ascorbic acid": {
    "name": "Ascorbic acid",
    "smiles": "[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO",
    "molecular_weight": 176.12,
    "log_p": -1.41,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "asenapine": {
    "name": "Asenapine",
    "smiles": "CN1CC2C(C1)C1=C(OC3=CC=C(Cl)C=C23)C=CC=C1",
    "molecular_weight": 285.77,
    "log_p": 4.26,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist | serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "bipolar disorder | schizophrenia"
  },
  "asparagine": {
    "name": "Asparagine",
    "smiles": "N[C@@H](CC(N)=O)C(O)=O",
    "molecular_weight": 132.12,
    "log_p": -1.73,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "aspartic acid": {
    "name": "Aspartic acid",
    "smiles": "N[C@@H](CC(O)=O)C(O)=O",
    "molecular_weight": 133.1,
    "log_p": -1.13,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "astemizole": {
    "name": "Astemizole",
    "smiles": "COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1",
    "molecular_weight": 458.58,
    "log_p": 5.35,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "histamine receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "asunaprevir": {
    "name": "Asunaprevir",
    "smiles": "COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2",
    "molecular_weight": 748.3,
    "log_p": 3.85,
    "hbd": 3,
    "hba": 10,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "HCV inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "ataluren": {
    "name": "Ataluren",
    "smiles": "OC(=O)C1=CC=CC(=C1)C1=NOC(=N1)C1=CC=CC=C1F",
    "molecular_weight": 284.25,
    "log_p": 3.24,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "CFTR channel agonist | dystrophin stimulant",
    "disease_area": "genetics | pulmonary",
    "indication": "cystic fibrosis | duchenne muscular dystrophy (DMD)"
  },
  "atazanavir": {
    "name": "Atazanavir",
    "smiles": "COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C",
    "molecular_weight": 704.87,
    "log_p": 4.21,
    "hbd": 5,
    "hba": 9,
    "rotatable_bonds": 14,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HIV protease inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "atenolol": {
    "name": "Atenolol",
    "smiles": "CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1",
    "molecular_weight": 266.34,
    "log_p": 0.45,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "atogepant": {
    "name": "Atogepant",
    "smiles": "C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CN=C3C[C@]4(CC3=C2)C(=O)NC2=C4C=CC=N2)C(=O)N1CC(F)(F)F)C1=C(F)C(F)=CC=C1F",
    "molecular_weight": 603.52,
    "log_p": 3.95,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "atomoxetine": {
    "name": "Atomoxetine",
    "smiles": "CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1",
    "molecular_weight": 255.36,
    "log_p": 3.72,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "norepinephrine transporter inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "attention-deficit/hyperactivity disorder (ADHD)"
  },
  "atorvastatin": {
    "name": "Atorvastatin",
    "smiles": "CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1",
    "molecular_weight": 558.65,
    "log_p": 6.31,
    "hbd": 4,
    "hba": 5,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HMGCR inhibitor",
    "disease_area": "cardiology | neurology/psychiatry",
    "indication": "heart attack | stroke"
  },
  "atosiban": {
    "name": "Atosiban",
    "smiles": "[H][C@]1(NC(=O)[C@@]([H])(NC(=O)[C@@H](CC2=CC=C(OCC)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)[C@@H](C)CC)[C@@H](C)O",
    "molecular_weight": 994.21,
    "log_p": -3.04,
    "hbd": 11,
    "hba": 15,
    "rotatable_bonds": 18,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "oxytocin receptor antagonist",
    "disease_area": "Birth | cardiology | cardiology | endocrinology | neurology/psychiatry",
    "indication": "angina pectoris | hyperlipidemia | myocardial infarction | premature labor | stroke"
  },
  "atovaquone": {
    "name": "Atovaquone",
    "smiles": "OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=CC=CC=C2C1=O",
    "molecular_weight": 366.84,
    "log_p": 5.51,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "mitochondrial electron transport inhibitor",
    "disease_area": "infectious disease",
    "indication": "pneumonia"
  },
  "atracurium besylate": {
    "name": "Atracurium besylate",
    "smiles": "[O-]S(=O)(=O)C1=CC=CC=C1.[O-]S(=O)(=O)C1=CC=CC=C1.COC1=CC2=C(C=C1OC)C(CC1=CC(OC)=C(OC)C=C1)[N+](C)(CCC(=O)OCCCCCOC(=O)CC[N+]1(C)CCC3=C(C=C(OC)C(OC)=C3)C1CC1=CC(OC)=C(OC)C=C1)CC2",
    "molecular_weight": 1243.5,
    "log_p": 9.25,
    "hbd": 0,
    "hba": 18,
    "rotatable_bonds": 26,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "critical care, neurology/psychiatry",
    "indication": "endotracheal intubation, muscle relaxant"
  },
  "atropine": {
    "name": "Atropine",
    "smiles": "CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1",
    "molecular_weight": 289.38,
    "log_p": 1.93,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "ophthalmology | ophthalmology | ophthalmology",
    "indication": "amblyopia | cycloplegia | mydriasis"
  },
  "attapulgite": {
    "name": "Attapulgite",
    "smiles": "[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[Si+4].[O-][H].[H]O[H].[H]O[H].[H]O[H].[H]O[H]",
    "molecular_weight": 412.69,
    "log_p": -6.95,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "auranofin": {
    "name": "Auranofin",
    "smiles": "CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O",
    "molecular_weight": 678.49,
    "log_p": 2.79,
    "hbd": 0,
    "hba": 10,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "NFkB pathway inhibitor",
    "disease_area": "rheumatology",
    "indication": "rheumatoid arthritis"
  },
  "aurothioglucose": {
    "name": "Aurothioglucose",
    "smiles": "OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O",
    "molecular_weight": 392.18,
    "log_p": -2.02,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PKC inhibitor",
    "disease_area": "rheumatology",
    "indication": "rheumatoid arthritis"
  },
  "avacopan": {
    "name": "Avacopan",
    "smiles": "CC1=CC=C(NC(=O)[C@H]2CCCN([C@H]2C2=CC=C(NC3CCCC3)C=C2)C(=O)C2=C(F)C=CC=C2C)C=C1C(F)(F)F",
    "molecular_weight": 581.65,
    "log_p": 8.05,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 2",
    "moa": "complement inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "avanafil": {
    "name": "Avanafil",
    "smiles": "COC1=C(Cl)C=C(CNC2=C(C=NC(=N2)N2CCC[C@H]2CO)C(=O)NCC2=NC=CC=N2)C=C1",
    "molecular_weight": 483.96,
    "log_p": 2.43,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "urology",
    "indication": "erectile dysfunction"
  },
  "avapritinib": {
    "name": "Avapritinib",
    "smiles": "CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C@@](C)(N)C3=CC=C(F)C=C3)C2=C1",
    "molecular_weight": 498.57,
    "log_p": 2.61,
    "hbd": 1,
    "hba": 10,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "KIT inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "avatrombopag": {
    "name": "Avatrombopag",
    "smiles": "OC(=O)C1CCN(CC1)C1=C(Cl)C=C(C=N1)C(=O)NC1=NC(C2=CC(Cl)=CS2)=C(S1)N1CCN(CC1)C1CCCCC1",
    "molecular_weight": 649.67,
    "log_p": 6.58,
    "hbd": 2,
    "hba": 9,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "thrombopoietin receptor agonist",
    "disease_area": "hematology",
    "indication": "thrombocytopenia"
  },
  "avibactam": {
    "name": "Avibactam",
    "smiles": "NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O",
    "molecular_weight": 265.25,
    "log_p": -1.53,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "beta lactamase inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "intra-abdominal infections | pyelonephritis | urinary tract infections"
  },
  "avobenzone": {
    "name": "Avobenzone",
    "smiles": "COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C",
    "molecular_weight": 310.39,
    "log_p": 4.45,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "topical sunscreen agent",
    "disease_area": "dermatology | dermatology",
    "indication": "cosmetic | sunscreen lotion"
  },
  "axitinib": {
    "name": "Axitinib",
    "smiles": "CNC(=O)C1=C(SC2=CC=C3C(NN=C3\\C=C\\C3=CC=CC=N3)=C2)C=CC=C1",
    "molecular_weight": 386.48,
    "log_p": 4.64,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PDGFR tyrosine kinase receptor inhibitor | VEGFR inhibitor",
    "disease_area": "oncology",
    "indication": "renal cell carcinoma (RCC)"
  },
  "azacitidine": {
    "name": "Azacitidine",
    "smiles": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",
    "molecular_weight": 244.21,
    "log_p": -3.17,
    "hbd": 4,
    "hba": 9,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA methyltransferase inhibitor",
    "disease_area": "hematologic malignancy | hematologic malignancy | hematology",
    "indication": "anemia | chronic myelomonocytic leukemia (CMMoL) | myelodysplastic diseases (MDS)"
  },
  "azatadine": {
    "name": "Azatadine",
    "smiles": "CN1CCC(CC1)=C1C2=CC=CC=C2CCC2=C1N=CC=C2",
    "molecular_weight": 290.41,
    "log_p": 3.71,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy",
    "indication": "allergic rhinitis"
  },
  "azathioprine": {
    "name": "Azathioprine",
    "smiles": "CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O",
    "molecular_weight": 277.27,
    "log_p": 1.15,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dehydrogenase inhibitor",
    "disease_area": "rheumatology | transplant",
    "indication": "renal homotransplantation | rheumatoid arthritis"
  },
  "azelaic acid": {
    "name": "Azelaic acid",
    "smiles": "OC(=O)CCCCCCCC(O)=O",
    "molecular_weight": 188.22,
    "log_p": 1.89,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "azelastine": {
    "name": "Azelastine",
    "smiles": "CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O",
    "molecular_weight": 381.91,
    "log_p": 4.3,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "ophthalmology",
    "indication": "conjunctivitis"
  },
  "azilsartan medoxomil": {
    "name": "Azilsartan medoxomil",
    "smiles": "CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1",
    "molecular_weight": 568.54,
    "log_p": 4.71,
    "hbd": 1,
    "hba": 11,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "azithromycin": {
    "name": "Azithromycin",
    "smiles": "CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O",
    "molecular_weight": 749.0,
    "log_p": 1.9,
    "hbd": 5,
    "hba": 14,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 50S ribosomal subunit inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "pelvic inflammatory disease | pneumonia"
  },
  "azlocillin": {
    "name": "Azlocillin",
    "smiles": "[H][C@](NC(=O)N1CCNC1=O)(C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])C1=CC=CC=C1",
    "molecular_weight": 461.5,
    "log_p": 0.09,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "gram-negative bacterial infections | gram-positive bacterial infections"
  },
  "aztreonam": {
    "name": "Aztreonam",
    "smiles": "C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(=O)O)\\C2=CSC([NH3+])=N2)C(=O)N1S([O-])(=O)=O",
    "molecular_weight": 435.44,
    "log_p": -2.22,
    "hbd": 3,
    "hba": 10,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "bacterial septicemia | gynecologic infections | intra-abdominal infections | respiratory tract infections | skin infections | urinary tract infections"
  },
  "bacampicillin": {
    "name": "Bacampicillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(=O)OC(C)OC(=O)OCC",
    "molecular_weight": 465.53,
    "log_p": 1.3,
    "hbd": 2,
    "hba": 9,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "gram-negative bacterial infections | gram-positive bacterial infections"
  },
  "bacitracin": {
    "name": "Bacitracin",
    "smiles": "CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC",
    "molecular_weight": 1422.72,
    "log_p": -1.68,
    "hbd": 17,
    "hba": 19,
    "rotatable_bonds": 31,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "first-aid antibiotic"
  },
  "baclofen": {
    "name": "Baclofen",
    "smiles": "NCC(CC(O)=O)C1=CC=C(Cl)C=C1",
    "molecular_weight": 213.66,
    "log_p": 1.86,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "benzodiazepine receptor agonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "multiple sclerosis | spasms"
  },
  "baloxavir marboxil": {
    "name": "Baloxavir marboxil",
    "smiles": "[H][C@@]12COCCN1C(=O)C1=C(OCOC(=O)OC)C(=O)C=CN1N2[C@H]1C2=CC=C(F)C(F)=C2CSC2=CC=CC=C12",
    "molecular_weight": 571.56,
    "log_p": 3.39,
    "hbd": 0,
    "hba": 10,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "balsalazide": {
    "name": "Balsalazide",
    "smiles": "OC(=O)CCNC(=O)C1=CC=C(C=C1)\\N=N\\C1=CC=C(O)C(=C1)C(O)=O",
    "molecular_weight": 357.32,
    "log_p": 2.71,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "gastroenterology",
    "indication": "ulcerative colitis"
  },
  "baricitinib": {
    "name": "Baricitinib",
    "smiles": "CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1",
    "molecular_weight": 371.43,
    "log_p": 1.1,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "JAK inhibitor",
    "disease_area": "rheumatology",
    "indication": "rheumatoid arthritis"
  },
  "barium sulfate": {
    "name": "Barium sulfate",
    "smiles": "[Ba++].[O-]S([O-])(=O)=O",
    "molecular_weight": 233.39,
    "log_p": -1.72,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "bazedoxifene": {
    "name": "Bazedoxifene",
    "smiles": "CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1",
    "molecular_weight": 470.61,
    "log_p": 6.33,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "selective estrogen receptor modulator (SERM)",
    "disease_area": "endocrinology | orthopedics",
    "indication": "menopause | osteoporosis"
  },
  "beclomethasone dipropionate": {
    "name": "Beclomethasone dipropionate",
    "smiles": "[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 521.05,
    "log_p": 4.09,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "bedaquiline": {
    "name": "Bedaquiline",
    "smiles": "COC1=NC2=C(C=C(Br)C=C2)C=C1[C@@H](C1=CC=CC=C1)[C@@](O)(CCN(C)C)C1=CC=CC2=C1C=CC=C2",
    "molecular_weight": 555.52,
    "log_p": 7.13,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATPase inhibitor",
    "disease_area": "infectious disease",
    "indication": "tuberculosis"
  },
  "belinostat": {
    "name": "Belinostat",
    "smiles": "ONC(=O)\\C=C\\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1",
    "molecular_weight": 318.35,
    "log_p": 2.01,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HDAC inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "peripheral T-cell lymphoma (PTCL)"
  },
  "belumosudil": {
    "name": "Belumosudil",
    "smiles": "CC(C)NC(=O)COC1=CC=CC(=C1)C1=NC2=C(C=CC=C2)C(NC2=CC=C3NN=CC3=C2)=N1",
    "molecular_weight": 452.52,
    "log_p": 4.82,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "belzutifan": {
    "name": "Belzutifan",
    "smiles": "CS(=O)(=O)C1=CC=C(OC2=CC(=CC(F)=C2)C#N)C2=C1[C@H](O)[C@H](F)[C@@H]2F",
    "molecular_weight": 383.35,
    "log_p": 3.29,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "hif modulator",
    "disease_area": "oncology",
    "indication": "renal cell carcinoma (rcc)"
  },
  "bemotrizinol": {
    "name": "Bemotrizinol",
    "smiles": "CCCCC(CC)COC1=CC(O)=C(C=C1)C1=NC(=NC(=N1)C1=CC=C(OC)C=C1)C1=C(O)C=C(OCC(CC)CCCC)C=C1",
    "molecular_weight": 627.83,
    "log_p": 9.48,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 18,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "dermatology",
    "indication": "sunscreen lotion"
  },
  "bempedoic acid": {
    "name": "Bempedoic acid",
    "smiles": "CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O",
    "molecular_weight": 344.49,
    "log_p": 4.47,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 14,
    "approved": true,
    "source": "FDA"
  },
  "benazepril": {
    "name": "Benazepril",
    "smiles": "[H][C@@]1(CCC2=CC=CC=C2N(CC(O)=O)C1=O)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC",
    "molecular_weight": 424.5,
    "log_p": 2.57,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin converting enzyme inhibitor",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "bendamustine": {
    "name": "Bendamustine",
    "smiles": "CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl",
    "molecular_weight": 358.27,
    "log_p": 3.26,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA inhibitor",
    "disease_area": "hematologic malignancy | hematologic malignancy",
    "indication": "chronic lymphocytic leukemia (CLL) | non-Hodgkin lymphoma (NHL)"
  },
  "bendazac": {
    "name": "Bendazac",
    "smiles": "OC(=O)COC1=NN(CC2=CC=CC=C2)C2=CC=CC=C12",
    "molecular_weight": 282.3,
    "log_p": 2.55,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "neurology/psychiatry | rheumatology",
    "indication": "joint pain | muscle pain"
  },
  "bendroflumethiazide": {
    "name": "Bendroflumethiazide",
    "smiles": "NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F",
    "molecular_weight": 421.42,
    "log_p": 1.63,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium/potassium/chloride transporter inhibitor",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "benfotiamine": {
    "name": "Benfotiamine",
    "smiles": "C\\C(N(CC1=CN=C(C)N=C1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)C1=CC=CC=C1",
    "molecular_weight": 466.46,
    "log_p": 2.63,
    "hbd": 3,
    "hba": 8,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antioxidant",
    "disease_area": "rheumatology",
    "indication": "lumbago"
  },
  "benorilate": {
    "name": "Benorilate",
    "smiles": "CC(=O)NC1=CC=C(OC(=O)C2=CC=CC=C2OC(C)=O)C=C1",
    "molecular_weight": 313.31,
    "log_p": 2.79,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "benoxaprofen": {
    "name": "Benoxaprofen",
    "smiles": "CC(C(O)=O)C1=CC2=C(OC(=N2)C2=CC=C(Cl)C=C2)C=C1",
    "molecular_weight": 301.73,
    "log_p": 4.34,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "benperidol": {
    "name": "Benperidol",
    "smiles": "OC1=NC2=CC=CC=C2N1C1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1",
    "molecular_weight": 381.45,
    "log_p": 4.18,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "schizophrenia"
  },
  "benserazide": {
    "name": "Benserazide",
    "smiles": "NC(CO)C(=O)NNCC1=C(O)C(O)=C(O)C=C1",
    "molecular_weight": 257.25,
    "log_p": -1.76,
    "hbd": 7,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DOPA decarboxylase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "Parkinson's Disease"
  },
  "benzatropine": {
    "name": "Benzatropine",
    "smiles": "[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(C1=CC=CC=C1)C1=CC=CC=C1)N2C",
    "molecular_weight": 307.44,
    "log_p": 4.42,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "benzethonium": {
    "name": "Benzethonium",
    "smiles": "CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1",
    "molecular_weight": 412.64,
    "log_p": 6.07,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "infectious disease",
    "indication": "first-aid antiseptic"
  },
  "benzhydrocodone": {
    "name": "Benzhydrocodone",
    "smiles": "[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CC=C2OC(=O)C1=CC=CC=C1",
    "molecular_weight": 403.48,
    "log_p": 3.72,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "benziodarone": {
    "name": "Benziodarone",
    "smiles": "CCC1=C(C(=O)C2=CC(I)=C(O)C(I)=C2)C2=CC=CC=C2O1",
    "molecular_weight": 518.09,
    "log_p": 5.14,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "benznidazole": {
    "name": "Benznidazole",
    "smiles": "[O-][N+](=O)C1=NC=CN1CC(=O)NCC1=CC=CC=C1",
    "molecular_weight": 260.25,
    "log_p": 1.11,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "Chagas disease"
  },
  "benzocaine": {
    "name": "Benzocaine",
    "smiles": "CCOC(=O)C1=CC=C(N)C=C1",
    "molecular_weight": 165.19,
    "log_p": 1.45,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "infectious disease",
    "indication": "first-aid antiseptic"
  },
  "benzoic acid": {
    "name": "Benzoic acid",
    "smiles": "OC(=O)C1=CC=CC=C1",
    "molecular_weight": 122.12,
    "log_p": 1.38,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "benzoin": {
    "name": "Benzoin",
    "smiles": "OC(C(=O)C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 212.25,
    "log_p": 2.6,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Preclinical",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "benzonatate": {
    "name": "Benzonatate",
    "smiles": "CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC",
    "molecular_weight": 603.75,
    "log_p": 2.83,
    "hbd": 1,
    "hba": 12,
    "rotatable_bonds": 32,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "local anesthetic",
    "disease_area": "pulmonary",
    "indication": "cough suppressant"
  },
  "benzoyl peroxide": {
    "name": "Benzoyl peroxide",
    "smiles": "O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 242.23,
    "log_p": 2.62,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "benzphetamine": {
    "name": "Benzphetamine",
    "smiles": "C[C@@H](CC1=CC=CC=C1)N(C)CC1=CC=CC=C1",
    "molecular_weight": 239.36,
    "log_p": 3.75,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "benzthiazide": {
    "name": "Benzthiazide",
    "smiles": "NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O",
    "molecular_weight": 431.95,
    "log_p": 2.24,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "carbonic anhydrase inhibitor",
    "disease_area": "cardiology | cardiology",
    "indication": "edema | hypertension"
  },
  "benzydamine": {
    "name": "Benzydamine",
    "smiles": "CN(C)CCCOC1=NN(CC2=CC=CC=C2)C2=CC=CC=C12",
    "molecular_weight": 309.41,
    "log_p": 3.42,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "prostanoid receptor antagonist",
    "disease_area": "dental | otolaryngology",
    "indication": "mouth inflammation | throat inflammation"
  },
  "benzyl alcohol": {
    "name": "Benzyl alcohol",
    "smiles": "OCC1=CC=CC=C1",
    "molecular_weight": 108.14,
    "log_p": 1.18,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "benzyl benzoate": {
    "name": "Benzyl benzoate",
    "smiles": "O=C(OCC1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 212.25,
    "log_p": 3.04,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "benzylparaben": {
    "name": "Benzylparaben",
    "smiles": "OC1=CC=C(C=C1)C(=O)OCC1=CC=CC=C1",
    "molecular_weight": 228.25,
    "log_p": 2.75,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "benzylpenicillin": {
    "name": "Benzylpenicillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O",
    "molecular_weight": 334.4,
    "log_p": 0.86,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "penicillin binding protein inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "bacterial septicemia | celluitis | endocarditis | meningitis | pneumonia | syphilis"
  },
  "bepotastine": {
    "name": "Bepotastine",
    "smiles": "OC(=O)CCCN1CCC(CC1)OC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1",
    "molecular_weight": 388.9,
    "log_p": 4.17,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "ophthalmology",
    "indication": "conjunctivitis"
  },
  "bepridil": {
    "name": "Bepridil",
    "smiles": "CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1",
    "molecular_weight": 366.55,
    "log_p": 4.83,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "cardiology",
    "indication": "angina pectoris"
  },
  "berberine": {
    "name": "Berberine",
    "smiles": "COC1=CC=C2C=C3C4=CC5=C(OCO5)C=C4CC[N+]3=CC2=C1OC",
    "molecular_weight": 336.37,
    "log_p": 3.1,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "LDL receptor activator",
    "disease_area": "",
    "indication": ""
  },
  "berotralstat": {
    "name": "Berotralstat",
    "smiles": "NCC1=CC(=CC=C1)N1N=C(C=C1C(=O)NC1=CC(=CC=C1F)[C@H](NCC1CC1)C1=CC=CC(=C1)C#N)C(F)(F)F",
    "molecular_weight": 562.57,
    "log_p": 5.7,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "besifloxacin": {
    "name": "Besifloxacin",
    "smiles": "N[C@@H]1CCCCN(C1)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1Cl)C(O)=O",
    "molecular_weight": 393.85,
    "log_p": 3.14,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial DNA gyrase inhibitor",
    "disease_area": "ophthalmology",
    "indication": "conjunctivitis"
  },
  "beta carotene": {
    "name": "Beta carotene",
    "smiles": "C\\C(\\C=C\\C=C(/C)\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\\C)/C=C/C=C(\\C)/C=C/C1=C(C)CCCC1(C)C",
    "molecular_weight": 536.89,
    "log_p": 12.61,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "betahistine": {
    "name": "Betahistine",
    "smiles": "CNCCC1=CC=CC=N1",
    "molecular_weight": 136.2,
    "log_p": 0.84,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor agonist | histamine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "Meniere's disease"
  },
  "betaine": {
    "name": "Betaine",
    "smiles": "C[N+](C)(C)CC([O-])=O",
    "molecular_weight": 117.15,
    "log_p": -1.56,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "nitric oxide donor",
    "disease_area": "metabolism",
    "indication": "homocystinuria"
  },
  "betamethasone": {
    "name": "Betamethasone",
    "smiles": "[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 392.47,
    "log_p": 1.9,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "dermatology",
    "indication": "corticosteroid-responsive dermatoses"
  },
  "betamethasone phosphate": {
    "name": "Betamethasone phosphate",
    "smiles": "[H][C@@]12C[C@H](C)[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 472.45,
    "log_p": 2.01,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "betaxolol": {
    "name": "Betaxolol",
    "smiles": "CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1",
    "molecular_weight": 307.43,
    "log_p": 2.39,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "ophthalmology | ophthalmology | ophthalmology",
    "indication": "glaucoma | intraocular pressure | ocular hypertension"
  },
  "betazole": {
    "name": "Betazole",
    "smiles": "NCCC1=CC=NN1",
    "molecular_weight": 111.15,
    "log_p": -0.09,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor agonist",
    "disease_area": "gastroenterology",
    "indication": "gastric hypersecretion diagnostic"
  },
  "bethanechol": {
    "name": "Bethanechol",
    "smiles": "CC(C[N+](C)(C)C)OC(N)=O",
    "molecular_weight": 161.22,
    "log_p": 0.18,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor agonist",
    "disease_area": "urology",
    "indication": "urinary retention"
  },
  "bethanidine": {
    "name": "Bethanidine",
    "smiles": "CN\\C(NCC1=CC=CC=C1)=N/C",
    "molecular_weight": 177.25,
    "log_p": 0.98,
    "hbd": 2,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "betiatide": {
    "name": "Betiatide",
    "smiles": "OC(=O)CNC(=O)CNC(=O)CNC(=O)CSC(=O)C1=CC=CC=C1",
    "molecular_weight": 367.38,
    "log_p": -1.01,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "betrixaban": {
    "name": "Betrixaban",
    "smiles": "COC1=CC=C(NC(=O)C2=CC=C(C=C2)C(=N)N(C)C)C(=C1)C(=O)NC1=CC=C(Cl)C=N1",
    "molecular_weight": 451.91,
    "log_p": 4.14,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "coagulation factor inhibitor",
    "disease_area": "hematology",
    "indication": "deep vein thrombosis (DVT)"
  },
  "betulinic acid": {
    "name": "Betulinic Acid",
    "smiles": "[H]OC(=O)[C@]12CC[C@@]([H])(C(C)=C)[C@]1([H])[C@@]1([H])CC[C@]3([H])[C@@]4(C)CC[C@]([H])(O[H])C(C)(C)[C@]4([H])CC[C@@]3(C)[C@]1(C)CC2",
    "molecular_weight": 456.71,
    "log_p": 7.09,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "bexarotene": {
    "name": "Bexarotene",
    "smiles": "CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C",
    "molecular_weight": 348.49,
    "log_p": 6.1,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "retinoid receptor agonist",
    "disease_area": "hematologic malignancy",
    "indication": "cutaneous T-cell lymphoma (CTCL)"
  },
  "bezafibrate": {
    "name": "Bezafibrate",
    "smiles": "CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O",
    "molecular_weight": 361.83,
    "log_p": 3.55,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PPAR receptor agonist",
    "disease_area": "cardiology",
    "indication": "cholesterol"
  },
  "bicalutamide": {
    "name": "Bicalutamide",
    "smiles": "CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F",
    "molecular_weight": 430.38,
    "log_p": 2.88,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "androgen receptor antagonist",
    "disease_area": "oncology",
    "indication": "prostate cancer"
  },
  "bicisate": {
    "name": "Bicisate",
    "smiles": "CCOC(=O)[C@H](CS)NCCN[C@@H](CS)C(=O)OCC",
    "molecular_weight": 324.47,
    "log_p": -0.11,
    "hbd": 4,
    "hba": 8,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA"
  },
  "bictegravir": {
    "name": "Bictegravir",
    "smiles": "OC1=C2N(C[C@H]3O[C@@H]4CC[C@@H](C4)N3C2=O)C=C(C(=O)NCC2=C(F)C=C(F)C=C2F)C1=O",
    "molecular_weight": 449.39,
    "log_p": 1.63,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HIV integrase inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "bifonazole": {
    "name": "Bifonazole",
    "smiles": "C1=CN(C=N1)C(C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC=CC=C1",
    "molecular_weight": 310.4,
    "log_p": 5.19,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sterol demethylase inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "tinea cruris | tinea pedis"
  },
  "biguanide": {
    "name": "Biguanide",
    "smiles": "NC(=N)NC(N)=N",
    "molecular_weight": 101.11,
    "log_p": -1.64,
    "hbd": 5,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "bilastine": {
    "name": "Bilastine",
    "smiles": "CCOCCN1C(=NC2=CC=CC=C12)C1CCN(CCC2=CC=C(C=C2)C(C)(C)C(O)=O)CC1",
    "molecular_weight": 463.62,
    "log_p": 4.86,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "ophthalmology",
    "indication": "conjunctivitis"
  },
  "bimatoprost": {
    "name": "Bimatoprost",
    "smiles": "CCNC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)CCC1=CC=CC=C1",
    "molecular_weight": 415.57,
    "log_p": 3.15,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "prostanoid receptor agonist",
    "disease_area": "ophthalmology | ophthalmology | ophthalmology | ophthalmology",
    "indication": "glaucoma | intraocular pressure | intraocular pressure, glaucoma, ocular hypertension | ocular hypertension"
  },
  "binimetinib": {
    "name": "Binimetinib",
    "smiles": "CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO",
    "molecular_weight": 441.23,
    "log_p": 3.01,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "MEK inhibitor",
    "disease_area": "oncology",
    "indication": "melanoma"
  },
  "bioallethrin": {
    "name": "Bioallethrin",
    "smiles": "CC(C)=CC1C(C(=O)OC2CC(=O)C(CC=C)=C2C)C1(C)C",
    "molecular_weight": 302.41,
    "log_p": 4.0,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "biotin": {
    "name": "Biotin",
    "smiles": "[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2",
    "molecular_weight": 244.32,
    "log_p": 0.8,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin B",
    "disease_area": "",
    "indication": ""
  },
  "biperiden": {
    "name": "Biperiden",
    "smiles": "OC(CCN1CCCCC1)(C1CC2CC1C=C2)C1=CC=CC=C1",
    "molecular_weight": 311.47,
    "log_p": 3.96,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "Parkinson's Disease"
  },
  "bisacodyl": {
    "name": "Bisacodyl",
    "smiles": "CC(=O)OC1=CC=C(C=C1)C(C1=CC=C(OC(C)=O)C=C1)C1=CC=CC=N1",
    "molecular_weight": 361.4,
    "log_p": 4.11,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "laxative",
    "disease_area": "gastroenterology",
    "indication": "constipation"
  },
  "bismuth subcitrate potassium": {
    "name": "Bismuth subcitrate potassium",
    "smiles": "[K+].[K+].[K+].[K+].[K+].[Bi+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O",
    "molecular_weight": 780.65,
    "log_p": -27.13,
    "hbd": 0,
    "hba": 14,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "gastroenterology",
    "indication": "duodenal ulcer disease"
  },
  "bismuth subgallate": {
    "name": "Bismuth subgallate",
    "smiles": "O[Bi]1OC2=CC(=CC(O)=C2O1)C(O)=O",
    "molecular_weight": 394.09,
    "log_p": -0.16,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "bismuth subnitrate": {
    "name": "Bismuth subnitrate",
    "smiles": "[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[O--].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O",
    "molecular_weight": 1461.98,
    "log_p": -4.57,
    "hbd": 0,
    "hba": 21,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "bismuth subsalicylate": {
    "name": "Bismuth subsalicylate",
    "smiles": "O[Bi]1OC(=O)C2=CC=CC=C2O1",
    "molecular_weight": 362.09,
    "log_p": 0.21,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "bisoctrizole": {
    "name": "Bisoctrizole",
    "smiles": "CC(C)(C)CC(C)(C)C1=CC(CC2=C(O)C(=CC(=C2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)=C(O)C(=C1)N1N=C2C=CC=CC2=N1",
    "molecular_weight": 658.89,
    "log_p": 9.58,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 2",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "bisoprolol": {
    "name": "Bisoprolol",
    "smiles": "CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1",
    "molecular_weight": 325.45,
    "log_p": 2.37,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "bisoxatin": {
    "name": "Bisoxatin",
    "smiles": "OC1=CC=C(C=C1)C1(OC2=CC=CC=C2NC1=O)C1=CC=C(O)C=C1",
    "molecular_weight": 333.34,
    "log_p": 3.37,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "bisphenol a diglycidyl ether": {
    "name": "Bisphenol A diglycidyl ether",
    "smiles": "CC(C)(C1=CC=C(OCC2CO2)C=C1)C1=CC=C(OCC2CO2)C=C1",
    "molecular_weight": 340.42,
    "log_p": 3.57,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "bithionol": {
    "name": "Bithionol",
    "smiles": "OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl",
    "molecular_weight": 356.06,
    "log_p": 5.86,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "autotaxin inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "bivalirudin": {
    "name": "Bivalirudin",
    "smiles": "CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O",
    "molecular_weight": 2180.32,
    "log_p": -8.12,
    "hbd": 28,
    "hba": 29,
    "rotatable_bonds": 66,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "thrombin inhibitor",
    "disease_area": "cardiology",
    "indication": "angina pectoris"
  },
  "bleomycin": {
    "name": "Bleomycin",
    "smiles": "[H][C@](C)(NC(=O)[C@@]([H])(NC(=O)C1=NC(=NC(N)=C1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@]([H])(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CNC=N1)[C@@H](O)[C@H](C)C(=O)N[C@]([H])(C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C)[C@@]([H])(C)O",
    "molecular_weight": 1415.58,
    "log_p": -7.7,
    "hbd": 20,
    "hba": 31,
    "rotatable_bonds": 35,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dna damage inducer | DNA synthesis inhibitor",
    "disease_area": "hematologic malignancy | hematologic malignancy | oncology | oncology | Oncology | pulmonary",
    "indication": "Hodgkin's lymphoma | non-Hodgkin lymphoma (NHL) | pancreatic cancer | pleural effusion | squamous cell carcinoma | testicular carcinoma"
  },
  "boceprevir": {
    "name": "Boceprevir",
    "smiles": "[H][C@]12CN([C@H](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C",
    "molecular_weight": 519.69,
    "log_p": 1.71,
    "hbd": 4,
    "hba": 5,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HCV inhibitor",
    "disease_area": "infectious disease",
    "indication": "hepatitis C"
  },
  "boric acid": {
    "name": "Boric acid",
    "smiles": "OB(O)O",
    "molecular_weight": 61.83,
    "log_p": -2.05,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "bortezomib": {
    "name": "Bortezomib",
    "smiles": "CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O",
    "molecular_weight": 384.25,
    "log_p": 0.36,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "NFkB pathway inhibitor | proteasome inhibitor",
    "disease_area": "hematologic malignancy | hematologic malignancy",
    "indication": "mantle cell lymphoma (MCL) | multiple myeloma"
  },
  "bortezomib d-mannitol": {
    "name": "Bortezomib D-mannitol",
    "smiles": "[H][C@@]1(OB(O[C@]1([H])[C@H](O)CO)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=NC=CN=C1)[C@H](O)CO",
    "molecular_weight": 530.39,
    "log_p": -1.13,
    "hbd": 6,
    "hba": 10,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA"
  },
  "boscalid": {
    "name": "Boscalid",
    "smiles": "ClC1=CC=C(C=C1)C1=C(NC(=O)C2=C(Cl)N=CC=C2)C=CC=C1",
    "molecular_weight": 343.21,
    "log_p": 5.31,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "bosentan": {
    "name": "Bosentan",
    "smiles": "COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1",
    "molecular_weight": 551.63,
    "log_p": 4.2,
    "hbd": 2,
    "hba": 10,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "endothelin receptor antagonist",
    "disease_area": "pulmonary",
    "indication": "pulmonary arterial hypertension (PAH)"
  },
  "bosutinib": {
    "name": "Bosutinib",
    "smiles": "COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl",
    "molecular_weight": 530.46,
    "log_p": 5.19,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "Abl kinase inhibitor | Bcr-Abl kinase inhibitor | SRC inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "chronic myeloid leukemia (CML)"
  },
  "bretylium": {
    "name": "Bretylium",
    "smiles": "CC[N+](C)(C)CC1=CC=CC=C1Br",
    "molecular_weight": 243.17,
    "log_p": 3.05,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "norepinephrine inhibitor",
    "disease_area": "cardiology | cardiology | cardiology",
    "indication": "ventricular arrhythmias | ventricular fibrillation (VF) | ventricular tachycardia (VT)"
  },
  "brexanolone": {
    "name": "Brexanolone",
    "smiles": "[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O",
    "molecular_weight": 318.5,
    "log_p": 4.6,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "brexpiprazole": {
    "name": "Brexpiprazole",
    "smiles": "O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1",
    "molecular_weight": 433.58,
    "log_p": 4.72,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor partial agonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "depression | schizophrenia"
  },
  "brigatinib": {
    "name": "Brigatinib",
    "smiles": "COC1=CC(=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)N1CCC(CC1)N1CCN(C)CC1",
    "molecular_weight": 584.11,
    "log_p": 5.09,
    "hbd": 2,
    "hba": 9,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ALK tyrosine kinase receptor inhibitor | EGFR inhibitor",
    "disease_area": "oncology",
    "indication": "non-small cell lung cancer (NSCLC)"
  },
  "brilliant blue g": {
    "name": "Brilliant blue G",
    "smiles": "[Na+].CCOC1=CC=C(NC2=CC=C(C=C2)C(=C2\\C=C/C(/C=C2C)=[N+](/CC)CC2=CC(=CC=C2)S([O-])(=O)=O)\\C2=C(C)C=C(C=C2)N(CC)CC2=CC(=CC=C2)S([O-])(=O)=O)C=C1",
    "molecular_weight": 854.04,
    "log_p": 5.97,
    "hbd": 1,
    "hba": 9,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA"
  },
  "brilliant green cation": {
    "name": "Brilliant green cation",
    "smiles": "CCN(CC)C1=CC=C(C=C1)C(C1=CC=CC=C1)=C1C=CC(C=C1)=[N+](CC)CC",
    "molecular_weight": 385.58,
    "log_p": 5.95,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "brimonidine": {
    "name": "Brimonidine",
    "smiles": "BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12",
    "molecular_weight": 292.14,
    "log_p": 1.76,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "ophthalmology | ophthalmology | ophthalmology",
    "indication": "glaucoma | intraocular pressure | ocular hypertension"
  },
  "brincidofovir": {
    "name": "Brincidofovir",
    "smiles": "CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)CN1C=CC(N)=NC1=O",
    "molecular_weight": 561.7,
    "log_p": 5.25,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 26,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "antiviral",
    "disease_area": "",
    "indication": ""
  },
  "brinzolamide": {
    "name": "Brinzolamide",
    "smiles": "CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O",
    "molecular_weight": 383.52,
    "log_p": 0.09,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "carbonic anhydrase inhibitor",
    "disease_area": "ophthalmology | ophthalmology | ophthalmology",
    "indication": "glaucoma | intraocular pressure | ocular hypertension"
  },
  "brivaracetam": {
    "name": "Brivaracetam",
    "smiles": "CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1",
    "molecular_weight": 212.29,
    "log_p": 0.9,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "brivudine": {
    "name": "Brivudine",
    "smiles": "OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(\\C=C\\Br)C(=O)NC1=O",
    "molecular_weight": 333.14,
    "log_p": -0.46,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA directed DNA polymerase inhibitor",
    "disease_area": "infectious disease",
    "indication": "shingles"
  },
  "bromazepam": {
    "name": "Bromazepam",
    "smiles": "BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1",
    "molecular_weight": 316.16,
    "log_p": 2.63,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "bromfenac": {
    "name": "Bromfenac",
    "smiles": "NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1",
    "molecular_weight": 334.17,
    "log_p": 2.89,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "bromhexine": {
    "name": "Bromhexine",
    "smiles": "CN(CC1=CC(Br)=CC(Br)=C1N)C1CCCCC1",
    "molecular_weight": 376.14,
    "log_p": 4.56,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "mucolytic agent",
    "disease_area": "pulmonary",
    "indication": "chest congestion"
  },
  "bromocriptine": {
    "name": "Bromocriptine",
    "smiles": "[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C",
    "molecular_weight": 654.61,
    "log_p": 3.19,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor agonist",
    "disease_area": "endocrinology | endocrinology | neurology/psychiatry",
    "indication": "acromegaly | hyperprolactinemia | Parkinson's Disease"
  },
  "bromodiphenhydramine": {
    "name": "Bromodiphenhydramine",
    "smiles": "CN(C)CCOC(C1=CC=CC=C1)C1=CC=C(Br)C=C1",
    "molecular_weight": 334.26,
    "log_p": 4.12,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "Allergies",
    "indication": "allergic rhinitis"
  },
  "bromothalonil": {
    "name": "Bromothalonil",
    "smiles": "BrCC(Br)(CCC#N)C#N",
    "molecular_weight": 265.94,
    "log_p": 2.34,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "bromotheophylline": {
    "name": "Bromotheophylline",
    "smiles": "CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O",
    "molecular_weight": 259.06,
    "log_p": -0.28,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "bromperidol": {
    "name": "Bromperidol",
    "smiles": "OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1",
    "molecular_weight": 420.32,
    "log_p": 4.53,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "schizophrenia"
  },
  "brompheniramine": {
    "name": "Brompheniramine",
    "smiles": "CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1",
    "molecular_weight": 319.25,
    "log_p": 3.93,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy | otolaryngology",
    "indication": "allergic rhinitis | common cold"
  },
  "bronopol": {
    "name": "Bronopol",
    "smiles": "OCC(Br)(CO)[N+]([O-])=O",
    "molecular_weight": 199.99,
    "log_p": -0.66,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "obstetrics/gynecology",
    "indication": "mastitis"
  },
  "bucetin": {
    "name": "Bucetin",
    "smiles": "CCOC1=CC=C(NC(=O)CC(C)O)C=C1",
    "molecular_weight": 223.27,
    "log_p": 1.79,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "analgesic agent",
    "disease_area": "",
    "indication": ""
  },
  "buclizine": {
    "name": "Buclizine",
    "smiles": "CC(C)(C)C1=CC=C(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)C=C1",
    "molecular_weight": 433.04,
    "log_p": 6.54,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "migraine headache"
  },
  "budesonide": {
    "name": "Budesonide",
    "smiles": "[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 430.54,
    "log_p": 2.72,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "gastroenterology",
    "indication": "Crohn's disease"
  },
  "bufexamac": {
    "name": "Bufexamac",
    "smiles": "CCCCOC1=CC=C(CC(=O)NO)C=C1",
    "molecular_weight": 223.27,
    "log_p": 1.91,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "bumadizone": {
    "name": "Bumadizone",
    "smiles": "CCCCC(C(O)=O)C(=O)N(NC1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 326.4,
    "log_p": 3.94,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "bumetanide": {
    "name": "Bumetanide",
    "smiles": "CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O",
    "molecular_weight": 364.42,
    "log_p": 3.04,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "solute carrier family member inhibitor",
    "disease_area": "cardiology | cardiology",
    "indication": "congestive heart failure | edema"
  },
  "bupivacaine": {
    "name": "Bupivacaine",
    "smiles": "CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C",
    "molecular_weight": 288.44,
    "log_p": 3.9,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "neurology/psychiatry | neurology/psychiatry | neurology/psychiatry",
    "indication": "caudal epidural block | lumbar epidural block | peripheral nerve block"
  },
  "buprenorphine": {
    "name": "Buprenorphine",
    "smiles": "CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4",
    "molecular_weight": 467.65,
    "log_p": 4.41,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "bupropion": {
    "name": "Bupropion",
    "smiles": "CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1",
    "molecular_weight": 239.75,
    "log_p": 3.3,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine reuptake inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "buserelin": {
    "name": "Buserelin",
    "smiles": "CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1",
    "molecular_weight": 1239.45,
    "log_p": -1.46,
    "hbd": 16,
    "hba": 15,
    "rotatable_bonds": 32,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "gonadotropin releasing factor hormone receptor agonist",
    "disease_area": "obstetrics/gynecology | oncology",
    "indication": "endometriosis | prostate cancer"
  },
  "buspirone": {
    "name": "Buspirone",
    "smiles": "O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1",
    "molecular_weight": 385.51,
    "log_p": 2.09,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "generalized anxiety disorder (GAD)"
  },
  "busulfan": {
    "name": "Busulfan",
    "smiles": "CS(=O)(=O)OCCCCOS(C)(=O)=O",
    "molecular_weight": 246.31,
    "log_p": -0.28,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "chronic myeloid leukemia (CML)"
  },
  "butabarbital": {
    "name": "Butabarbital",
    "smiles": "CCC(C)C1(CC)C(=O)NC(=O)NC1=O",
    "molecular_weight": 212.25,
    "log_p": 0.79,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "butacaine": {
    "name": "Butacaine",
    "smiles": "CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1",
    "molecular_weight": 306.45,
    "log_p": 3.72,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "local anesthetic",
    "disease_area": "neurology/psychiatry",
    "indication": "local anesthetic"
  },
  "butalbital": {
    "name": "Butalbital",
    "smiles": "CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O",
    "molecular_weight": 224.26,
    "log_p": 0.96,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "GABA receptor antagonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "headache | muscle relaxant"
  },
  "butamben": {
    "name": "Butamben",
    "smiles": "CCCCOC(=O)C1=CC=C(N)C=C1",
    "molecular_weight": 193.25,
    "log_p": 2.23,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "sodium channel blocker",
    "disease_area": "",
    "indication": ""
  },
  "butaperazine": {
    "name": "Butaperazine",
    "smiles": "CCCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1",
    "molecular_weight": 409.6,
    "log_p": 4.91,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "butenafine": {
    "name": "Butenafine",
    "smiles": "CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12",
    "molecular_weight": 317.48,
    "log_p": 5.77,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "fungal squalene epoxidase inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "tinea corporis | tinea cruris | tinea pedis"
  },
  "butobarbital": {
    "name": "Butobarbital",
    "smiles": "CCCCC1(CC)C(=O)NC(=O)NC1=O",
    "molecular_weight": 212.25,
    "log_p": 0.94,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "butoconazole": {
    "name": "Butoconazole",
    "smiles": "ClC1=CC=C(CCC(CN2C=CN=C2)SC2=C(Cl)C=CC=C2Cl)C=C1",
    "molecular_weight": 411.79,
    "log_p": 6.64,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "vulvovaginal candidiasis"
  },
  "butorphanol": {
    "name": "Butorphanol",
    "smiles": "[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1",
    "molecular_weight": 327.47,
    "log_p": 3.37,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "butylene glycol": {
    "name": "Butylene glycol",
    "smiles": "CC(O)CCO",
    "molecular_weight": 90.12,
    "log_p": -0.25,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "butylparaben": {
    "name": "Butylparaben",
    "smiles": "CCCCOC(=O)C1=CC=C(O)C=C1",
    "molecular_weight": 194.23,
    "log_p": 2.35,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "butylscopolamine": {
    "name": "Butylscopolamine",
    "smiles": "CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1",
    "molecular_weight": 360.47,
    "log_p": 2.23,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "cabazitaxel": {
    "name": "Cabazitaxel",
    "smiles": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C",
    "molecular_weight": 835.94,
    "log_p": 4.57,
    "hbd": 3,
    "hba": 14,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "microtubule inhibitor",
    "disease_area": "oncology",
    "indication": "prostate cancer"
  },
  "cabergoline": {
    "name": "Cabergoline",
    "smiles": "[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC",
    "molecular_weight": 451.62,
    "log_p": 3.19,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor agonist",
    "disease_area": "endocrinology",
    "indication": "hyperprolactinemia"
  },
  "cabotegravir": {
    "name": "Cabotegravir",
    "smiles": "[H][C@@]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C(O)=C3C(=O)N1[C@@H](C)CO2",
    "molecular_weight": 405.36,
    "log_p": 0.96,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "HIV integrase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "cabozantinib": {
    "name": "Cabozantinib",
    "smiles": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2",
    "molecular_weight": 501.51,
    "log_p": 5.54,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "RET tyrosine kinase inhibitor | VEGFR inhibitor",
    "disease_area": "oncology",
    "indication": "medullary thyroid cancer (MTC)"
  },
  "caffeine": {
    "name": "Caffeine",
    "smiles": "CN1C=NC2=C1C(=O)N(C)C(=O)N2C",
    "molecular_weight": 194.19,
    "log_p": -1.03,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adenosine receptor antagonist | phosphodiesterase inhibitor",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "drowsiness | fatigue"
  },
  "calcifediol": {
    "name": "Calcifediol",
    "smiles": "C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)CCC1=C",
    "molecular_weight": 400.65,
    "log_p": 6.73,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin D receptor agonist",
    "disease_area": "endocrinology",
    "indication": "hyperparathyroidism"
  },
  "calcipotriol": {
    "name": "Calcipotriol",
    "smiles": "O[C@H](\\C=C\\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)C[C@H](O)C1=C)C1CC1",
    "molecular_weight": 412.61,
    "log_p": 5.09,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin D receptor agonist",
    "disease_area": "dermatology",
    "indication": "psoriasis"
  },
  "calcitriol": {
    "name": "Calcitriol",
    "smiles": "C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)C[C@H](O)C1=C",
    "molecular_weight": 416.65,
    "log_p": 5.7,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin D receptor agonist",
    "disease_area": "endocrinology | endocrinology | orthopedics",
    "indication": "hypocalcemia | hypoparathyroidism | osteoporosis"
  },
  "calcium acetate": {
    "name": "Calcium acetate",
    "smiles": "[Ca++].CC([O-])=O.CC([O-])=O",
    "molecular_weight": 158.17,
    "log_p": -2.87,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "calcium ascorbate": {
    "name": "Calcium ascorbate",
    "smiles": "[Ca++].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-]",
    "molecular_weight": 390.31,
    "log_p": -5.59,
    "hbd": 6,
    "hba": 12,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "calcium carbimide": {
    "name": "Calcium carbimide",
    "smiles": "[Ca++].[N-]=C=[N-]",
    "molecular_weight": 80.1,
    "log_p": -0.08,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "calcium carbonate": {
    "name": "Calcium carbonate",
    "smiles": "[Ca++].[O-]C([O-])=O",
    "molecular_weight": 100.09,
    "log_p": -2.83,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "calcium chloride": {
    "name": "Calcium chloride",
    "smiles": "[Cl-].[Cl-].[Ca++]",
    "molecular_weight": 110.98,
    "log_p": -6.37,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "calcium citrate": {
    "name": "Calcium citrate",
    "smiles": "[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O",
    "molecular_weight": 498.43,
    "log_p": -11.65,
    "hbd": 2,
    "hba": 14,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "calcium glubionate anhydrous": {
    "name": "Calcium glubionate anhydrous",
    "smiles": "OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O[Ca]OC(=O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO",
    "molecular_weight": 592.51,
    "log_p": -9.7,
    "hbd": 13,
    "hba": 19,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA"
  },
  "calcium glucoheptonate": {
    "name": "Calcium glucoheptonate",
    "smiles": "[Ca++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O",
    "molecular_weight": 490.42,
    "log_p": -11.31,
    "hbd": 12,
    "hba": 16,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "calcium gluconate": {
    "name": "Calcium gluconate",
    "smiles": "[Ca++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O",
    "molecular_weight": 430.37,
    "log_p": -10.04,
    "hbd": 10,
    "hba": 14,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "calcium glycerophosphate": {
    "name": "Calcium glycerophosphate",
    "smiles": "[Ca++].OCC(CO)OP([O-])([O-])=O",
    "molecular_weight": 210.13,
    "log_p": -3.2,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "calcium lactate": {
    "name": "Calcium lactate",
    "smiles": "[Ca++].CC(O)C([O-])=O.CC(O)C([O-])=O",
    "molecular_weight": 218.22,
    "log_p": -4.15,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "calcium levulinate": {
    "name": "Calcium levulinate",
    "smiles": "[Ca++].CC(=O)CCC([O-])=O.CC(=O)CCC([O-])=O",
    "molecular_weight": 270.29,
    "log_p": -2.17,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "calcium phosphate": {
    "name": "Calcium Phosphate",
    "smiles": "[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O",
    "molecular_weight": 310.17,
    "log_p": -6.79,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "calcium phosphate dihydrate": {
    "name": "Calcium phosphate dihydrate",
    "smiles": "O.O.[Ca++].OP([O-])([O-])=O",
    "molecular_weight": 172.09,
    "log_p": -4.22,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "calcium saccharate": {
    "name": "Calcium saccharate",
    "smiles": "[Ca++].[H][C@](O)(C([O-])=O)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)C([O-])=O",
    "molecular_weight": 248.2,
    "log_p": -6.45,
    "hbd": 4,
    "hba": 8,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "calcium threonate": {
    "name": "Calcium threonate",
    "smiles": "[Ca++].OC[C@H](O)[C@@H](O)C([O-])=O.OC[C@H](O)[C@@H](O)C([O-])=O",
    "molecular_weight": 310.27,
    "log_p": -7.48,
    "hbd": 6,
    "hba": 10,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "calcium undecylenate": {
    "name": "Calcium undecylenate",
    "smiles": "[Ca++].[O-]C(=O)CCCCCCCCC=C.[O-]C(=O)CCCCCCCCC=C",
    "molecular_weight": 406.62,
    "log_p": 3.71,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 18,
    "approved": true,
    "source": "FDA"
  },
  "camphor": {
    "name": "Camphor",
    "smiles": "[H][C@@]12CC[C@@](C)(C(=O)C1)C2(C)C",
    "molecular_weight": 152.24,
    "log_p": 2.4,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "canagliflozin": {
    "name": "Canagliflozin",
    "smiles": "[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1",
    "molecular_weight": 444.52,
    "log_p": 2.97,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium/glucose cotransporter inhibitor",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "candesartan cilexetil": {
    "name": "Candesartan cilexetil",
    "smiles": "CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1",
    "molecular_weight": 610.67,
    "log_p": 6.32,
    "hbd": 1,
    "hba": 11,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "candicidin": {
    "name": "Candicidin",
    "smiles": "CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC(=O)CC(O)C(C(O)CC(OC2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\C1C)C(O)=O)C(O)CC(=O)C1=CC=C(N)C=C1",
    "molecular_weight": 1109.32,
    "log_p": 3.61,
    "hbd": 11,
    "hba": 19,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "fungal ergosterol inhibitor",
    "disease_area": "infectious disease",
    "indication": "vulvovaginal candidiasis"
  },
  "cangrelor": {
    "name": "Cangrelor",
    "smiles": "CSCCNC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC(SCCC(F)(F)F)=N1",
    "molecular_weight": 776.37,
    "log_p": 2.85,
    "hbd": 7,
    "hba": 15,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "purinergic receptor antagonist",
    "disease_area": "cardiology",
    "indication": "myocardial infarction"
  },
  "cannabidiol": {
    "name": "Cannabidiol",
    "smiles": "CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1",
    "molecular_weight": 314.47,
    "log_p": 5.85,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "canrenoic acid": {
    "name": "Canrenoic acid",
    "smiles": "[H][C@@]12CC[C@@](O)(CCC(O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C",
    "molecular_weight": 358.48,
    "log_p": 3.89,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "cantharidin": {
    "name": "Cantharidin",
    "smiles": "[H][C@]12CC[C@]([H])(O1)[C@]1(C)C(=O)OC(=O)[C@]21C",
    "molecular_weight": 196.2,
    "log_p": 0.64,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "protein phosphatase inhibitor",
    "disease_area": "dermatology",
    "indication": "blisters"
  },
  "capecitabine": {
    "name": "Capecitabine",
    "smiles": "CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",
    "molecular_weight": 359.35,
    "log_p": 0.76,
    "hbd": 3,
    "hba": 8,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA synthesis inhibitor | thymidylate synthase inhibitor",
    "disease_area": "oncology | oncology",
    "indication": "breast cancer | colorectal cancer"
  },
  "capmatinib": {
    "name": "Capmatinib",
    "smiles": "CNC(=O)C1=C(F)C=C(C=C1)C1=NN2C(CC3=CC4=C(C=C3)N=CC=C4)=CN=C2N=C1",
    "molecular_weight": 412.43,
    "log_p": 3.43,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "capreomycin": {
    "name": "Capreomycin",
    "smiles": "[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC1=O)=C/NC(N)=O.[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC1=O)=C/NC(N)=O",
    "molecular_weight": 1321.44,
    "log_p": -15.44,
    "hbd": 27,
    "hba": 27,
    "rotatable_bonds": 19,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "protein synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "tuberculosis"
  },
  "capsaicin": {
    "name": "Capsaicin",
    "smiles": "COC1=C(O)C=CC(CNC(=O)CCCC\\C=C\\C(C)C)=C1",
    "molecular_weight": 305.42,
    "log_p": 3.79,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "TRPV agonist",
    "disease_area": "neurology/psychiatry | rheumatology",
    "indication": "muscle pain | rheumatoid arthritis"
  },
  "captopril": {
    "name": "Captopril",
    "smiles": "C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O",
    "molecular_weight": 217.29,
    "log_p": 0.63,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin converting enzyme inhibitor",
    "disease_area": "cardiology | cardiology | cardiology | endocrinology | nephrology",
    "indication": "congestive heart failure | diabetes mellitus | diabetic nephropathy | hypertension | myocardial infarction"
  },
  "carbamazepine": {
    "name": "Carbamazepine",
    "smiles": "NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12",
    "molecular_weight": 236.27,
    "log_p": 3.39,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "carboxamide antiepileptic",
    "disease_area": "neurology/psychiatry",
    "indication": "seizures"
  },
  "carbamide peroxide": {
    "name": "Carbamide peroxide",
    "smiles": "OO.NC(N)=O",
    "molecular_weight": 94.07,
    "log_p": -0.96,
    "hbd": 4,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "carbamoylcholine": {
    "name": "Carbamoylcholine",
    "smiles": "C[N+](C)(C)CCOC(N)=O",
    "molecular_weight": 147.2,
    "log_p": -0.21,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "carbenicillin": {
    "name": "Carbenicillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(O)=O)C1=CC=CC=C1)C(O)=O",
    "molecular_weight": 378.41,
    "log_p": 0.49,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-negative bacterial infections"
  },
  "carbetocin": {
    "name": "Carbetocin",
    "smiles": "[H][C@]1(NC(=O)[C@H](CC2=CC=C(OC)C=C2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)CC",
    "molecular_weight": 988.18,
    "log_p": -2.5,
    "hbd": 10,
    "hba": 13,
    "rotatable_bonds": 18,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "oxytocin receptor agonist",
    "disease_area": "hematology",
    "indication": "hemorrhage"
  },
  "carbidopa": {
    "name": "Carbidopa",
    "smiles": "C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O",
    "molecular_weight": 226.23,
    "log_p": -0.05,
    "hbd": 5,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "aromatic L-amino acid decarboxylase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "Parkinson's Disease"
  },
  "carbimazole": {
    "name": "Carbimazole",
    "smiles": "CCOC(=O)N1C=CN(C)C1=S",
    "molecular_weight": 186.24,
    "log_p": 1.56,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antithyroid agent",
    "disease_area": "endocrinology",
    "indication": "hyperthyroidism"
  },
  "carbinoxamine": {
    "name": "Carbinoxamine",
    "smiles": "CN(C)CCOC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1",
    "molecular_weight": 290.79,
    "log_p": 3.4,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy | dermatology | ophthalmology | otolaryngology",
    "indication": "allergic rhinitis | conjunctivitis | dermatographism | vasomotor rhinitis"
  },
  "carbocisteine": {
    "name": "Carbocisteine",
    "smiles": "N[C@@H](CSCC(O)=O)C(O)=O",
    "molecular_weight": 179.2,
    "log_p": -0.78,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "carbocromen": {
    "name": "Carbocromen",
    "smiles": "CCOC(=O)COC1=CC2=C(C=C1)C(C)=C(CCN(CC)CC)C(=O)O2",
    "molecular_weight": 361.44,
    "log_p": 2.93,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "carbon dioxide": {
    "name": "Carbon dioxide",
    "smiles": "O=C=O",
    "molecular_weight": 44.01,
    "log_p": -0.58,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "carboplatin": {
    "name": "Carboplatin",
    "smiles": "[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]",
    "molecular_weight": 371.25,
    "log_p": 0.49,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA alkylating agent | DNA inhibitor",
    "disease_area": "oncology",
    "indication": "ovarian cancer"
  },
  "carboprost tromethamine": {
    "name": "Carboprost tromethamine",
    "smiles": "NC(CO)(CO)CO.CCCCC[C@](C)(O)\\C=C\\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(O)=O",
    "molecular_weight": 489.65,
    "log_p": 1.09,
    "hbd": 8,
    "hba": 8,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA"
  },
  "carboxin": {
    "name": "Carboxin",
    "smiles": "CC1=C(SCCO1)C(=O)NC1=CC=CC=C1",
    "molecular_weight": 235.31,
    "log_p": 2.62,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "carfilzomib": {
    "name": "Carfilzomib",
    "smiles": "CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1",
    "molecular_weight": 719.92,
    "log_p": 2.58,
    "hbd": 4,
    "hba": 8,
    "rotatable_bonds": 20,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "proteasome inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "multiple myeloma"
  },
  "carglumic acid": {
    "name": "Carglumic acid",
    "smiles": "NC(=O)N[C@@H](CCC(O)=O)C(O)=O",
    "molecular_weight": 190.16,
    "log_p": -1.03,
    "hbd": 4,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "carindacillin": {
    "name": "Carindacillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(=O)OC1=CC2=C(CCC2)C=C1)C1=CC=CC=C1)C(O)=O",
    "molecular_weight": 494.57,
    "log_p": 2.5,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "cariprazine": {
    "name": "Cariprazine",
    "smiles": "CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1",
    "molecular_weight": 427.42,
    "log_p": 4.34,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "schizophrenia"
  },
  "carisoprodol": {
    "name": "Carisoprodol",
    "smiles": "CCCC(C)(COC(N)=O)COC(=O)NC(C)C",
    "molecular_weight": 260.33,
    "log_p": 2.02,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "carmustine": {
    "name": "Carmustine",
    "smiles": "ClCCNC(=O)N(CCCl)N=O",
    "molecular_weight": 214.05,
    "log_p": 1.16,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA alkylating agent | DNA inhibitor",
    "disease_area": "hematologic malignancy | hematologic malignancy | hematologic malignancy | oncology | oncology | oncology | oncology | oncology",
    "indication": "astrocytoma | brainstem glioma | ependymoma | glioblastoma | Hodgkin's lymphoma | medulloblastoma | multiple myeloma | non-Hodgkin lymphoma (NHL)"
  },
  "carprofen": {
    "name": "Carprofen",
    "smiles": "CC(C(O)=O)C1=CC2=C(C=C1)C1=C(N2)C=CC(Cl)=C1",
    "molecular_weight": 273.72,
    "log_p": 4.16,
    "hbd": 2,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "rheumatology",
    "indication": "osteoarthritis"
  },
  "carteolol": {
    "name": "Carteolol",
    "smiles": "CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2",
    "molecular_weight": 292.38,
    "log_p": 1.7,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "ophthalmology | ophthalmology | ophthalmology",
    "indication": "glaucoma | intraocular pressure | ocular hypertension"
  },
  "carvedilol": {
    "name": "Carvedilol",
    "smiles": "COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2",
    "molecular_weight": 406.48,
    "log_p": 3.74,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology | cardiology | cardiology",
    "indication": "hypertension | myocardial infarction | myocardial infarction, hypertension"
  },
  "caspofungin": {
    "name": "Caspofungin",
    "smiles": "[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@]([H])(C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]1[C@@H](O)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@@H](C)O",
    "molecular_weight": 1093.33,
    "log_p": -3.31,
    "hbd": 16,
    "hba": 18,
    "rotatable_bonds": 23,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor | fungal 1,3-beta-D-glucan synthase inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "aspergillosis | candidemia | esophageal candidiasis | fungal infection | peritonitis"
  },
  "cedazuridine": {
    "name": "Cedazuridine",
    "smiles": "OC[C@H]1O[C@@H](N2CC[C@@H](O)NC2=O)C(F)(F)[C@@H]1O",
    "molecular_weight": 268.22,
    "log_p": -1.57,
    "hbd": 4,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "cefaclor": {
    "name": "Cefaclor",
    "smiles": "[H][C@]12SCC(Cl)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O",
    "molecular_weight": 367.81,
    "log_p": 0.62,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | otolaryngology | otolaryngology",
    "indication": "pharyngitis | pneumonia | respiratory tract infections | skin infections | tonsillitis | urinary tract infections"
  },
  "cefadroxil": {
    "name": "Cefadroxil",
    "smiles": "[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O",
    "molecular_weight": 363.4,
    "log_p": 0.15,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease, otolaryngology | otolaryngology | otolaryngology",
    "indication": "pharyngitis | skin infections | tonsillitis | urinary tract infections | urinary tract infections, skin infections, tonsillitis, pharyngitis"
  },
  "cefalotin": {
    "name": "Cefalotin",
    "smiles": "[H][C@@]1(NC(=O)CC2=CC=CS2)C(=O)N2C(C(O)=O)=C(COC(C)=O)CS[C@]12[H]",
    "molecular_weight": 396.45,
    "log_p": 0.59,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "cefamandole": {
    "name": "Cefamandole",
    "smiles": "[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O",
    "molecular_weight": 462.51,
    "log_p": -0.23,
    "hbd": 3,
    "hba": 10,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "respiratory tract infections | skin infections | urinary tract infections"
  },
  "cefamandole nafate": {
    "name": "Cefamandole nafate",
    "smiles": "[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](OC=O)C1=CC=CC=C1)C(O)=O",
    "molecular_weight": 490.52,
    "log_p": -0.04,
    "hbd": 2,
    "hba": 11,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "cefapirin": {
    "name": "Cefapirin",
    "smiles": "[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CSC1=CC=NC=C1)C(O)=O",
    "molecular_weight": 423.47,
    "log_p": 0.48,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "cefazolin": {
    "name": "Cefazolin",
    "smiles": "[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O",
    "molecular_weight": 454.52,
    "log_p": -0.64,
    "hbd": 2,
    "hba": 12,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "bacterial septicemia | bone and joint infections | endocarditis | skin infections | surgical prophylaxis | urinary tract infections"
  },
  "cefdinir": {
    "name": "Cefdinir",
    "smiles": "[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\\C1=CSC(N)=N1)C(O)=O",
    "molecular_weight": 395.42,
    "log_p": -0.17,
    "hbd": 4,
    "hba": 9,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | otolaryngology | otolaryngology | otolaryngology | otolaryngology | pulmonary",
    "indication": "bronchitis | otitis | pharyngitis | pneumonia | sinusitis | skin infections | tonsillitis"
  },
  "cefditoren": {
    "name": "Cefditoren",
    "smiles": "[H][C@]12SCC(\\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O",
    "molecular_weight": 506.59,
    "log_p": 1.29,
    "hbd": 3,
    "hba": 11,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "cefepime": {
    "name": "Cefepime",
    "smiles": "CO\\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1",
    "molecular_weight": 480.57,
    "log_p": -1.28,
    "hbd": 2,
    "hba": 10,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor | penicillin binding protein inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | Infectious disease",
    "indication": "gram-negative bacterial infections | intra-abdominal infections | pneumonia | skin infections | urinary tract infections"
  },
  "cefiderocol": {
    "name": "Cefiderocol",
    "smiles": "[H][C@]12SCC(C[N+]3(CCNC(=O)C4=C(Cl)C(O)=C(O)C=C4)CCCC3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C(O)=O)\\C1=CSC(N)=N1)C([O-])=O",
    "molecular_weight": 752.23,
    "log_p": -0.18,
    "hbd": 6,
    "hba": 14,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antibacterial",
    "disease_area": "",
    "indication": ""
  },
  "cefixime": {
    "name": "Cefixime",
    "smiles": "[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC(O)=O)\\C1=CSC(N)=N1)C(O)=O",
    "molecular_weight": 453.46,
    "log_p": -0.54,
    "hbd": 4,
    "hba": 10,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | otolaryngology | otolaryngology | otolaryngology | pulmonary",
    "indication": "bronchitis | gonorrhea | otitis | pharyngitis | tonsillitis | urinary tract infections"
  },
  "cefmenoxime": {
    "name": "Cefmenoxime",
    "smiles": "[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O",
    "molecular_weight": 511.57,
    "log_p": -0.87,
    "hbd": 3,
    "hba": 14,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-negative bacterial infections"
  },
  "cefmetazole": {
    "name": "Cefmetazole",
    "smiles": "[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSCC#N)OC)C(O)=O",
    "molecular_weight": 471.55,
    "log_p": -0.73,
    "hbd": 2,
    "hba": 12,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "skin infections | urinary tract infections"
  },
  "cefonicid": {
    "name": "Cefonicid",
    "smiles": "[H][C@]12SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O",
    "molecular_weight": 542.58,
    "log_p": -0.92,
    "hbd": 4,
    "hba": 12,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-positive bacterial infections"
  },
  "cefoperazone": {
    "name": "Cefoperazone",
    "smiles": "[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O",
    "molecular_weight": 645.68,
    "log_p": -1.11,
    "hbd": 4,
    "hba": 13,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-negative bacterial infections"
  },
  "ceforanide": {
    "name": "Ceforanide",
    "smiles": "[H][C@]12SCC(CSC3=NN=NN3CC(O)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1CN)C(O)=O",
    "molecular_weight": 519.57,
    "log_p": -0.71,
    "hbd": 4,
    "hba": 11,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "penicillin binding protein inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-negative bacterial infections"
  },
  "cefotaxime": {
    "name": "Cefotaxime",
    "smiles": "[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O",
    "molecular_weight": 455.47,
    "log_p": -0.62,
    "hbd": 3,
    "hba": 11,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "bacterial septicemia | bone and joint infections | gynecologic infections | intra-abdominal infections | meningitis | pelvic inflammatory disease | respiratory tract infections | skin infections | urinary tract infections"
  },
  "cefotetan": {
    "name": "Cefotetan",
    "smiles": "[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C1SC(S1)=C(C(N)=O)C(O)=O)OC)C(O)=O",
    "molecular_weight": 575.63,
    "log_p": -1.4,
    "hbd": 4,
    "hba": 14,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor | penicillin binding protein inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | Infectious disease",
    "indication": "bone and joint infections | chlamydia | gram-positive bacterial infections | gynecologic infections | intra-abdominal infections | respiratory tract infections | skin infections | surgical prophylaxis | urinary tract infections"
  },
  "cefotiam": {
    "name": "Cefotiam",
    "smiles": "[H][C@]12SCC(CSC3=NN=NN3CCN(C)C)=C(N1C(=O)[C@H]2NC(=O)CC1=CSC(N)=N1)C(O)=O",
    "molecular_weight": 525.64,
    "log_p": -0.65,
    "hbd": 3,
    "hba": 13,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "bacterial septicemia | bone and joint infections | respiratory tract infections | skin infections | urinary tract infections"
  },
  "cefoxitin": {
    "name": "Cefoxitin",
    "smiles": "[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O",
    "molecular_weight": 427.46,
    "log_p": 0.1,
    "hbd": 3,
    "hba": 8,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "bacterial septicemia | bone and joint infections | gynecologic infections | intra-abdominal infections | respiratory tract infections | skin infections | urinary tract infections"
  },
  "cefpiramide": {
    "name": "Cefpiramide",
    "smiles": "[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O",
    "molecular_weight": 612.65,
    "log_p": 0.33,
    "hbd": 5,
    "hba": 13,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-negative bacterial infections"
  },
  "cefpirome": {
    "name": "Cefpirome",
    "smiles": "[H][C@]12SCC(C[N+]3=C4CCCC4=CC=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C([O-])=O",
    "molecular_weight": 514.59,
    "log_p": -1.04,
    "hbd": 2,
    "hba": 10,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-negative bacterial infections"
  },
  "cefpodoxime": {
    "name": "Cefpodoxime",
    "smiles": "[H][C@]12SCC(COC)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O",
    "molecular_weight": 427.46,
    "log_p": -0.54,
    "hbd": 3,
    "hba": 10,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | otolaryngology | otolaryngology | otolaryngology | pulmonary",
    "indication": "bronchitis | gonorrhea | pharyngitis | pneumonia | sinusitis | skin infections | tonsillitis | urinary tract infections"
  },
  "cefprozil": {
    "name": "Cefprozil",
    "smiles": "[H][C@]12SCC(C=CC)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O",
    "molecular_weight": 389.43,
    "log_p": 0.71,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | otolaryngology | otolaryngology | otolaryngology | otolaryngology | pulmonary",
    "indication": "bronchitis | otitis | pharyngitis | respiratory tract infections | sinusitis | skin infections | tonsillitis"
  },
  "cefradine": {
    "name": "Cefradine",
    "smiles": "[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CCC=CC1)C(O)=O",
    "molecular_weight": 349.41,
    "log_p": 0.35,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | otolaryngology | otolaryngology | otolaryngology",
    "indication": "otitis | pharyngitis | pneumonia | respiratory tract infections | skin infections | tonsillitis | urinary tract infections"
  },
  "ceftaroline fosamil": {
    "name": "Ceftaroline fosamil",
    "smiles": "[H][C@]12SCC(SC3=NC(=CS3)C3=CC=[N+](C)C=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC)\\C1=NSC(NP(O)(O)=O)=N1)C([O-])=O",
    "molecular_weight": 684.7,
    "log_p": -0.12,
    "hbd": 4,
    "hba": 14,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA"
  },
  "ceftazidime": {
    "name": "Ceftazidime",
    "smiles": "[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1",
    "molecular_weight": 546.59,
    "log_p": -1.3,
    "hbd": 3,
    "hba": 11,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "bacterial septicemia | bone and joint infections | gynecologic infections | intra-abdominal infections | meningitis | respiratory tract infections | skin infections"
  },
  "ceftibuten": {
    "name": "Ceftibuten",
    "smiles": "[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\\C1=CSC(N)=N1)C(O)=O",
    "molecular_weight": 410.43,
    "log_p": -0.05,
    "hbd": 4,
    "hba": 8,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "otolaryngology | otolaryngology | otolaryngology | pulmonary",
    "indication": "bronchitis | otitis | pharyngitis | tonsillitis"
  },
  "ceftizoxime": {
    "name": "Ceftizoxime",
    "smiles": "[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O",
    "molecular_weight": 383.41,
    "log_p": -0.56,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "ceftobiprole": {
    "name": "Ceftobiprole",
    "smiles": "[H][C@@]1(NC(=O)C(=N/O)\\C2=NSC(N)=N2)C(=O)N2C(C(O)=O)=C(CS[C@]12[H])\\C=C1/CCN(C1=O)[C@]1([H])CCNC1",
    "molecular_weight": 534.58,
    "log_p": -1.44,
    "hbd": 5,
    "hba": 12,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "antiinfective drug",
    "disease_area": "",
    "indication": ""
  },
  "ceftobiprole medocaril": {
    "name": "Ceftobiprole medocaril",
    "smiles": "[H][C@@]1(NC(=O)C(=N/O)\\C2=NSC(N)=N2)C(=O)N2C(C(O)=O)=C(CS[C@]12[H])\\C=C1/CCN(C1=O)[C@]1([H])CCN(C1)C(=O)OCC1=C(C)OC(=O)O1",
    "molecular_weight": 690.67,
    "log_p": -0.54,
    "hbd": 4,
    "hba": 16,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "ceftolozane": {
    "name": "Ceftolozane",
    "smiles": "CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\\C1=NSC(N)=N1)C2=O)C([O-])=O",
    "molecular_weight": 666.7,
    "log_p": -3.9,
    "hbd": 7,
    "hba": 16,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "ceftriaxone": {
    "name": "Ceftriaxone",
    "smiles": "[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O",
    "molecular_weight": 554.59,
    "log_p": -1.61,
    "hbd": 4,
    "hba": 14,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | otolaryngology",
    "indication": "bacterial septicemia | bone and joint infections | gonorrhea | intra-abdominal infections | meningitis | otitis | pelvic inflammatory disease | pneumonia | skin infections | surgical prophylaxis | urinary tract infections"
  },
  "cefuroxime": {
    "name": "Cefuroxime",
    "smiles": "[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CC=CO1)C(O)=O",
    "molecular_weight": 424.39,
    "log_p": -0.54,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-negative bacterial infections"
  },
  "celecoxib": {
    "name": "Celecoxib",
    "smiles": "CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F",
    "molecular_weight": 381.38,
    "log_p": 3.51,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "endocrinology | rheumatology | rheumatology | rheumatology",
    "indication": "ankylosing spondylitis | osteoarthritis | primary dysmenorrhea (PD) | rheumatoid arthritis"
  },
  "celiprolol": {
    "name": "Celiprolol",
    "smiles": "CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(=C1)C(C)=O",
    "molecular_weight": 379.5,
    "log_p": 2.89,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "genetics",
    "indication": "Ehlers-Danlos syndrome (EDS)"
  },
  "cenobamate": {
    "name": "Cenobamate",
    "smiles": "NC(=O)O[C@@H](CN1N=CN=N1)C1=C(Cl)C=CC=C1",
    "molecular_weight": 267.68,
    "log_p": 1.16,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "GABA receptor modulator | voltage-gated sodium channel blocker",
    "disease_area": "",
    "indication": ""
  },
  "cephalexin": {
    "name": "Cephalexin",
    "smiles": "[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O",
    "molecular_weight": 347.4,
    "log_p": 0.44,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | otolaryngology",
    "indication": "bone and joint infections | genitourinary tract infections | otitis | respiratory tract infections | skin infections"
  },
  "cephaloglycin": {
    "name": "Cephaloglycin",
    "smiles": "[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O",
    "molecular_weight": 405.43,
    "log_p": -0.01,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "ceritinib": {
    "name": "Ceritinib",
    "smiles": "CC(C)OC1=C(NC2=NC=C(Cl)C(N2)=NC2=CC=CC=C2S(=O)(=O)C(C)C)C=C(C)C(=C1)C1CCNCC1",
    "molecular_weight": 558.15,
    "log_p": 5.78,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ALK tyrosine kinase receptor inhibitor",
    "disease_area": "oncology",
    "indication": "non-small cell lung cancer (NSCLC)"
  },
  "cerivastatin": {
    "name": "Cerivastatin",
    "smiles": "COCC1=C(C2=CC=C(F)C=C2)C(\\C=C\\[C@@H](O)C[C@@H](O)CC(O)=O)=C(C(C)C)N=C1C(C)C",
    "molecular_weight": 459.56,
    "log_p": 4.88,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA"
  },
  "ceruletide": {
    "name": "Ceruletide",
    "smiles": "[H][C@](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O",
    "molecular_weight": 1352.43,
    "log_p": -4.52,
    "hbd": 17,
    "hba": 19,
    "rotatable_bonds": 38,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Preclinical",
    "moa": "CCK receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "cetalkonium": {
    "name": "Cetalkonium",
    "smiles": "CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1",
    "molecular_weight": 360.65,
    "log_p": 7.74,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 17,
    "approved": true,
    "source": "FDA"
  },
  "cetirizine": {
    "name": "Cetirizine",
    "smiles": "OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1",
    "molecular_weight": 388.9,
    "log_p": 3.15,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy",
    "indication": "allergic rhinitis"
  },
  "cetrimonium": {
    "name": "Cetrimonium",
    "smiles": "CCCCCCCCCCCCCCCC[N+](C)(C)C",
    "molecular_weight": 284.55,
    "log_p": 6.17,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "dermatology",
    "indication": "cosmetic"
  },
  "cetrorelix": {
    "name": "Cetrorelix",
    "smiles": "CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O",
    "molecular_weight": 1431.06,
    "log_p": -0.51,
    "hbd": 17,
    "hba": 16,
    "rotatable_bonds": 38,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "gonadotropin releasing factor hormone receptor antagonist",
    "disease_area": "endocrinology",
    "indication": "premature luteinizing hormone surges"
  },
  "cetyl alcohol": {
    "name": "Cetyl alcohol",
    "smiles": "CCCCCCCCCCCCCCCCO",
    "molecular_weight": 242.45,
    "log_p": 5.46,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 14,
    "approved": true,
    "source": "FDA"
  },
  "cetylpyridinium": {
    "name": "Cetylpyridinium",
    "smiles": "CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1",
    "molecular_weight": 304.54,
    "log_p": 6.46,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "dental | dental",
    "indication": "gingivitis | mouth inflammation"
  },
  "cevimeline": {
    "name": "Cevimeline",
    "smiles": "CC1O[C@@]2(CS1)CN1CCC2CC1",
    "molecular_weight": 199.32,
    "log_p": 1.56,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor agonist",
    "disease_area": "rheumatology",
    "indication": "sjogren's syndrome"
  },
  "chenodeoxycholic acid": {
    "name": "Chenodeoxycholic acid",
    "smiles": "[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O",
    "molecular_weight": 392.58,
    "log_p": 4.48,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "chloral hydrate": {
    "name": "Chloral hydrate",
    "smiles": "OC(O)C(Cl)(Cl)Cl",
    "molecular_weight": 165.4,
    "log_p": 0.67,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "chlorambucil": {
    "name": "Chlorambucil",
    "smiles": "OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl",
    "molecular_weight": 304.22,
    "log_p": 3.38,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA inhibitor",
    "disease_area": "hematologic malignancy | hematologic malignancy",
    "indication": "chronic lymphocytic leukemia (CLL) | Hodgkin's lymphoma"
  },
  "chloramphenicol": {
    "name": "Chloramphenicol",
    "smiles": "OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O",
    "molecular_weight": 323.13,
    "log_p": 0.91,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 50S ribosomal subunit inhibitor",
    "disease_area": "endocrinology | infectious disease | infectious disease",
    "indication": "cholera | fever | meningitis"
  },
  "chloramphenicol palmitate": {
    "name": "Chloramphenicol palmitate",
    "smiles": "CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O",
    "molecular_weight": 561.55,
    "log_p": 6.94,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 21,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "protein synthesis inhibitor",
    "disease_area": "infectious disease, endocrinology",
    "indication": "meningitis, fever, cholera"
  },
  "chloramphenicol succinate": {
    "name": "Chloramphenicol succinate",
    "smiles": "O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O",
    "molecular_weight": 423.21,
    "log_p": 1.32,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "chlorcyclizine": {
    "name": "Chlorcyclizine",
    "smiles": "CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1",
    "molecular_weight": 300.83,
    "log_p": 3.68,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy",
    "indication": "allergic rhinitis"
  },
  "chlordiazepoxide": {
    "name": "Chlordiazepoxide",
    "smiles": "CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1",
    "molecular_weight": 299.76,
    "log_p": 2.95,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "chlorhexidine": {
    "name": "Chlorhexidine",
    "smiles": "ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1",
    "molecular_weight": 505.46,
    "log_p": 4.18,
    "hbd": 10,
    "hba": 4,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "membrane integrity inhibitor",
    "disease_area": "dental | dermatology | infectious disease",
    "indication": "cosmetic | gingivitis | skin infections"
  },
  "chloric acid": {
    "name": "Chloric acid",
    "smiles": "[H]O[Cl](=O)=O",
    "molecular_weight": 84.46,
    "log_p": -2.94,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "chlormerodrin": {
    "name": "Chlormerodrin",
    "smiles": "COC(CNC(N)=O)C[Hg]Cl",
    "molecular_weight": 367.2,
    "log_p": 0.32,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "sodium/potassium/chloride transporter inhibitor",
    "disease_area": "urology",
    "indication": "urinary frequency"
  },
  "chlormerodrin hg-197": {
    "name": "Chlormerodrin Hg-197",
    "smiles": "[Cl-].COC(C[197Hg+])CNC(N)=O",
    "molecular_weight": 363.58,
    "log_p": -3.36,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "chlormezanone": {
    "name": "Chlormezanone",
    "smiles": "CN1C(C2=CC=C(Cl)C=C2)S(=O)(=O)CCC1=O",
    "molecular_weight": 273.74,
    "log_p": 1.62,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "GABA receptor modulator",
    "disease_area": "",
    "indication": ""
  },
  "chlorobutanol": {
    "name": "Chlorobutanol",
    "smiles": "CC(C)(O)C(Cl)(Cl)Cl",
    "molecular_weight": 177.46,
    "log_p": 2.13,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "anesthetic | sedative"
  },
  "chloroform": {
    "name": "Chloroform",
    "smiles": "ClC(Cl)Cl",
    "molecular_weight": 119.38,
    "log_p": 1.99,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "chloroprocaine": {
    "name": "Chloroprocaine",
    "smiles": "CCN(CC)CCOC(=O)C1=C(Cl)C=C(N)C=C1",
    "molecular_weight": 270.76,
    "log_p": 2.42,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "neurology/psychiatry",
    "indication": "local anesthetic"
  },
  "chloroquine": {
    "name": "Chloroquine",
    "smiles": "CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12",
    "molecular_weight": 319.88,
    "log_p": 4.81,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antimalarial agent",
    "disease_area": "infectious disease | infectious disease",
    "indication": "amebiasis | malaria"
  },
  "chlorothiazide": {
    "name": "Chlorothiazide",
    "smiles": "NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1",
    "molecular_weight": 295.73,
    "log_p": 0.13,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "diuretic",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "chloroxine": {
    "name": "Chloroxine",
    "smiles": "OC1=C(Cl)C=C(Cl)C2=C1N=CC=C2",
    "molecular_weight": 214.05,
    "log_p": 3.25,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "opioid receptor antagonist",
    "disease_area": "dermatology | gastroenterology | gastroenterology | infectious disease",
    "indication": "dandruff | diarrhea | giardiasis | inflammatory bowel disease"
  },
  "chloroxylenol": {
    "name": "Chloroxylenol",
    "smiles": "CC1=CC(O)=CC(C)=C1Cl",
    "molecular_weight": 156.61,
    "log_p": 2.66,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATP synthase inhibitor",
    "disease_area": "infectious disease",
    "indication": "skin infections"
  },
  "chlorphenesin": {
    "name": "Chlorphenesin",
    "smiles": "OCC(O)COC1=CC=C(Cl)C=C1",
    "molecular_weight": 202.64,
    "log_p": 1.07,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "muscle relaxant",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "muscle relaxant | sedative"
  },
  "chlorphenesin carbamate": {
    "name": "Chlorphenesin carbamate",
    "smiles": "NC(=O)OCC(O)COC1=CC=C(Cl)C=C1",
    "molecular_weight": 245.66,
    "log_p": 1.18,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "chlorpheniramine": {
    "name": "Chlorpheniramine",
    "smiles": "CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1",
    "molecular_weight": 274.8,
    "log_p": 3.82,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "chlorpromazine": {
    "name": "Chlorpromazine",
    "smiles": "CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2",
    "molecular_weight": 318.87,
    "log_p": 4.89,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "gastroenterology | gastroenterology | hematology | infectious disease | neurology/psychiatry",
    "indication": "acute intermittent porphyria (AIP) | nausea | schizophrenia | tetanus | vomiting"
  },
  "chlorpropamide": {
    "name": "Chlorpropamide",
    "smiles": "CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1",
    "molecular_weight": 276.75,
    "log_p": 1.74,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATP channel blocker",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "chlorprothixene": {
    "name": "Chlorprothixene",
    "smiles": "CN(C)CC\\C=C1\\C2=CC=CC=C2SC2=CC=C(Cl)C=C12",
    "molecular_weight": 315.87,
    "log_p": 5.19,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "bipolar disorder | schizophrenia"
  },
  "chlorquinaldol": {
    "name": "Chlorquinaldol",
    "smiles": "CC1=NC2=C(C=C1)C(Cl)=CC(Cl)=C2O",
    "molecular_weight": 228.08,
    "log_p": 3.56,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "other antibiotic",
    "disease_area": "infectious disease",
    "indication": "fungal infection"
  },
  "chlortetracycline": {
    "name": "Chlortetracycline",
    "smiles": "[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC(Cl)=C1[C@@]3(C)O",
    "molecular_weight": 478.89,
    "log_p": 0.44,
    "hbd": 6,
    "hba": 9,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "protein synthesis inhibitor",
    "disease_area": "ophthalmology",
    "indication": "conjunctivitis"
  },
  "chlorthalidone": {
    "name": "Chlorthalidone",
    "smiles": "NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12",
    "molecular_weight": 338.77,
    "log_p": 0.92,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "carbonic anhydrase inhibitor",
    "disease_area": "cardiology | cardiology | cardiology | gastroenterology | nephrology | nephrology | rheumatology",
    "indication": "acute glomerulonephritis (AGN) | chronic renal failure | congestive heart failure | edema | hepatic cirrhosis | hypertension | nephrotic syndrome"
  },
  "chlorzoxazone": {
    "name": "Chlorzoxazone",
    "smiles": "ClC1=CC2=C(OC(=O)N2)C=C1",
    "molecular_weight": 169.57,
    "log_p": 1.77,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "muscle relaxant"
  },
  "cholecalciferol": {
    "name": "Cholecalciferol",
    "smiles": "CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)CCC1=C",
    "molecular_weight": 384.65,
    "log_p": 7.62,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "endocrinology",
    "indication": "vitamin D deficiency"
  },
  "cholesterol": {
    "name": "Cholesterol",
    "smiles": "[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)C",
    "molecular_weight": 386.66,
    "log_p": 7.39,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Preclinical",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "cholic acid": {
    "name": "Cholic Acid",
    "smiles": "[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C",
    "molecular_weight": 408.58,
    "log_p": 3.45,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "choline": {
    "name": "Choline",
    "smiles": "C[N+](C)(C)CCO",
    "molecular_weight": 104.17,
    "log_p": -0.32,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "acetylcholine precursor",
    "disease_area": "",
    "indication": ""
  },
  "choline c 11": {
    "name": "Choline C 11",
    "smiles": "[Cl-].C[N+](C)([11CH3])CCO",
    "molecular_weight": 138.63,
    "log_p": -3.31,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "choline c-11": {
    "name": "Choline C-11",
    "smiles": "C[N+](C)([11CH3])CCO",
    "molecular_weight": 103.17,
    "log_p": -0.32,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "choline magnesium trisalicylate": {
    "name": "Choline magnesium trisalicylate",
    "smiles": "[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O",
    "molecular_weight": 539.82,
    "log_p": -1.43,
    "hbd": 4,
    "hba": 10,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "choline salicylate": {
    "name": "Choline salicylate",
    "smiles": "C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O",
    "molecular_weight": 241.29,
    "log_p": -0.56,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "chromic chloride": {
    "name": "Chromic chloride",
    "smiles": "[Cl-].[Cl-].[Cl-].[Cr+3]",
    "molecular_weight": 158.36,
    "log_p": -8.99,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "chromic nitrate": {
    "name": "Chromic nitrate",
    "smiles": "[Cr+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O",
    "molecular_weight": 238.01,
    "log_p": -0.72,
    "hbd": 0,
    "hba": 9,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "chromium": {
    "name": "Chromium",
    "smiles": "[Cr]",
    "molecular_weight": 52.0,
    "log_p": -0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "chromium cr-51": {
    "name": "Chromium Cr-51",
    "smiles": "[51Cr]",
    "molecular_weight": 50.94,
    "log_p": -0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "chromium gluconate": {
    "name": "Chromium gluconate",
    "smiles": "[Cr+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O",
    "molecular_weight": 637.44,
    "log_p": -14.49,
    "hbd": 15,
    "hba": 21,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA"
  },
  "chromium nicotinate": {
    "name": "Chromium nicotinate",
    "smiles": "[Cr+3].[O-]C(=O)C1=CN=CC=C1.[O-]C(=O)C1=CN=CC=C1.[O-]C(=O)C1=CN=CC=C1",
    "molecular_weight": 418.31,
    "log_p": -1.67,
    "hbd": 0,
    "hba": 9,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "chromium picolinate": {
    "name": "Chromium picolinate",
    "smiles": "[Cr+3].[O-]C(=O)C1=NC=CC=C1.[O-]C(=O)C1=NC=CC=C1.[O-]C(=O)C1=NC=CC=C1",
    "molecular_weight": 418.31,
    "log_p": -1.67,
    "hbd": 0,
    "hba": 9,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "chromous sulfate": {
    "name": "Chromous sulfate",
    "smiles": "[Cr++].[O-]S([O-])(=O)=O",
    "molecular_weight": 148.06,
    "log_p": -1.34,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "cianidanol": {
    "name": "Cianidanol",
    "smiles": "O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC=C(O)C(O)=C1",
    "molecular_weight": 290.27,
    "log_p": 1.55,
    "hbd": 5,
    "hba": 6,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "fatty acid synthase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "ciclesonide": {
    "name": "Ciclesonide",
    "smiles": "[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C",
    "molecular_weight": 540.7,
    "log_p": 4.7,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "allergy",
    "indication": "allergic rhinitis"
  },
  "ciclopirox": {
    "name": "Ciclopirox",
    "smiles": "CC1=CC(=O)N(O)C(=C1)C1CCCCC1",
    "molecular_weight": 207.27,
    "log_p": 2.44,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "membrane integrity inhibitor",
    "disease_area": "infectious disease",
    "indication": "onychomycosis"
  },
  "cidofovir": {
    "name": "Cidofovir",
    "smiles": "NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1",
    "molecular_weight": 279.19,
    "log_p": -1.66,
    "hbd": 4,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA polymerase inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "acquired immunodeficiency syndrome (AIDS) | cytomegalovirus retinitis"
  },
  "cilastatin": {
    "name": "Cilastatin",
    "smiles": "CC1(C)C[C@@H]1C(=O)N\\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O",
    "molecular_weight": 358.46,
    "log_p": 1.43,
    "hbd": 4,
    "hba": 5,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dehydropeptidase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "cilazapril": {
    "name": "Cilazapril",
    "smiles": "CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O",
    "molecular_weight": 417.51,
    "log_p": 1.6,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin converting enzyme inhibitor",
    "disease_area": "cardiology | cardiology",
    "indication": "congestive heart failure | hypertension"
  },
  "cilostazol": {
    "name": "Cilostazol",
    "smiles": "O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2",
    "molecular_weight": 369.47,
    "log_p": 3.46,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "cardiology",
    "indication": "claudication"
  },
  "cimetidine": {
    "name": "Cimetidine",
    "smiles": "CN\\C(NCCSCC1=C(C)NC=N1)=N\\C#N",
    "molecular_weight": 252.35,
    "log_p": 0.6,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "endocrinology | gastroenterology | gastroenterology | gastroenterology | gastroenterology | hematologic malignancy",
    "indication": "aggressive systemic mastocytosis (ASM) | duodenal ulcer disease | endocrine adenoma | gastroesophageal reflux disease (GERD) | peptic ulcer disease (PUD) | Zollinger-Ellison syndrome"
  },
  "cinacalcet": {
    "name": "Cinacalcet",
    "smiles": "C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12",
    "molecular_weight": 357.42,
    "log_p": 6.14,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel activator",
    "disease_area": "endocrinology | endocrinology | nephrology | oncology",
    "indication": "chronic kidney disease (CKD) | hypercalcemia | hyperparathyroidism | parathyroid carcinoma"
  },
  "cinchocaine": {
    "name": "Cinchocaine",
    "smiles": "CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC",
    "molecular_weight": 343.47,
    "log_p": 3.49,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "neurology/psychiatry",
    "indication": "local anesthetic"
  },
  "cinnamaldehyde": {
    "name": "Cinnamaldehyde",
    "smiles": "O=C\\C=C\\C1=CC=CC=C1",
    "molecular_weight": 132.16,
    "log_p": 1.9,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Preclinical",
    "moa": "aldose reductase inhibitor | TRPV agonist",
    "disease_area": "",
    "indication": ""
  },
  "cinnamyl alcohol": {
    "name": "Cinnamyl alcohol",
    "smiles": "OC\\C=C\\C1=CC=CC=C1",
    "molecular_weight": 134.18,
    "log_p": 1.69,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "cinnarizine": {
    "name": "Cinnarizine",
    "smiles": "C(\\C=C\\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 368.52,
    "log_p": 5.11,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "cinoxacin": {
    "name": "Cinoxacin",
    "smiles": "CCN1N=C(C(O)=O)C(=O)C2=CC3=C(OCO3)C=C12",
    "molecular_weight": 262.22,
    "log_p": 0.84,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "topoisomerase inhibitor",
    "disease_area": "infectious disease",
    "indication": "urinary tract infections"
  },
  "cinoxate": {
    "name": "Cinoxate",
    "smiles": "CCOCCOC(=O)\\C=C\\C1=CC=C(OC)C=C1",
    "molecular_weight": 250.29,
    "log_p": 2.29,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "dermatology",
    "indication": "sunscreen lotion"
  },
  "ciprofibrate": {
    "name": "Ciprofibrate",
    "smiles": "CC(C)(OC1=CC=C(C=C1)C1CC1(Cl)Cl)C(O)=O",
    "molecular_weight": 289.16,
    "log_p": 3.59,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PPAR receptor agonist",
    "disease_area": "endocrinology",
    "indication": "hyperlipidemia"
  },
  "ciprofloxacin": {
    "name": "Ciprofloxacin",
    "smiles": "OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O",
    "molecular_weight": 331.35,
    "log_p": 1.58,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial DNA gyrase inhibitor",
    "disease_area": "otolaryngology",
    "indication": "otitis"
  },
  "cisapride": {
    "name": "Cisapride",
    "smiles": "CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC",
    "molecular_weight": 465.95,
    "log_p": 3.36,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "serotonin receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "cisatracurium": {
    "name": "Cisatracurium",
    "smiles": "COC1=CC2=C(C=C1OC)[C@@H](CC1=CC(OC)=C(OC)C=C1)[N@@+](C)(CCC(=O)OCCCCCOC(=O)CC[N@@+]1(C)CCC3=C(C=C(OC)C(OC)=C3)[C@H]1CC1=CC(OC)=C(OC)C=C1)CC2",
    "molecular_weight": 929.16,
    "log_p": 8.07,
    "hbd": 0,
    "hba": 12,
    "rotatable_bonds": 24,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "critical care | neurology/psychiatry",
    "indication": "endotracheal intubation | muscle relaxant"
  },
  "cisplatin": {
    "name": "Cisplatin",
    "smiles": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]",
    "molecular_weight": 300.05,
    "log_p": 1.7,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA alkylating agent | DNA synthesis inhibitor",
    "disease_area": "oncology | oncology | oncology",
    "indication": "bladder cancer | ovarian cancer | testicular carcinoma"
  },
  "citalopram": {
    "name": "Citalopram",
    "smiles": "CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1",
    "molecular_weight": 324.4,
    "log_p": 3.81,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "selective serotonin reuptake inhibitor (SSRI)",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "citicoline": {
    "name": "Citicoline",
    "smiles": "C[N+](C)(C)CCOP([O-])(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(N)=NC1=O",
    "molecular_weight": 488.33,
    "log_p": -2.23,
    "hbd": 4,
    "hba": 13,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glutathione transferase stimulant | membrane permeability enhancer",
    "disease_area": "neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | ophthalmology",
    "indication": "Alzheimer's disease | attention-deficit/hyperactivity disorder (ADHD) | glaucoma | Parkinson's Disease | senile dementia | stroke"
  },
  "citric acid": {
    "name": "Citric acid",
    "smiles": "OC(=O)CC(O)(CC(O)=O)C(O)=O",
    "molecular_weight": 192.12,
    "log_p": -1.25,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "cladribine": {
    "name": "Cladribine",
    "smiles": "NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1",
    "molecular_weight": 285.69,
    "log_p": -0.3,
    "hbd": 3,
    "hba": 8,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adenosine deaminase inhibitor | ribonucleotide reductase inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "hairy cell leukemia"
  },
  "clarithromycin": {
    "name": "Clarithromycin",
    "smiles": "[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC",
    "molecular_weight": 747.96,
    "log_p": 2.44,
    "hbd": 4,
    "hba": 14,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 50S ribosomal subunit inhibitor",
    "disease_area": "infectious disease | infectious disease | otolaryngology | otolaryngology | otolaryngology | otolaryngology | pulmonary",
    "indication": "bronchitis | otitis | pharyngitis | pneumonia | sinusitis | skin infections | tonsillitis"
  },
  "clascoterone": {
    "name": "Clascoterone",
    "smiles": "[H][C@@]12CC[C@](OC(=O)CC)(C(=O)CO)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 402.53,
    "log_p": 3.77,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "androgen receptor antagonist",
    "disease_area": "dermatology",
    "indication": "acne vulgaris (av)"
  },
  "clavulanic acid": {
    "name": "Clavulanic acid",
    "smiles": "[H][C@@]12CC(=O)N1[C@@H](C(O)=O)\\C(O2)=C\\CO",
    "molecular_weight": 199.16,
    "log_p": -1.1,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "clemastine": {
    "name": "Clemastine",
    "smiles": "CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1",
    "molecular_weight": 343.9,
    "log_p": 5.1,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy | allergy",
    "indication": "allergic rhinitis | urticaria"
  },
  "clenbuterol": {
    "name": "Clenbuterol",
    "smiles": "CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1",
    "molecular_weight": 277.19,
    "log_p": 3.0,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "pulmonary | pulmonary",
    "indication": "asthma | chronic obstructive pulmonary disease (COPD)"
  },
  "clevidipine": {
    "name": "Clevidipine",
    "smiles": "CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC",
    "molecular_weight": 456.32,
    "log_p": 4.25,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "clidinium": {
    "name": "Clidinium",
    "smiles": "C[N@@+]12CC[C@@H](CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 352.45,
    "log_p": 2.7,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "gastroenterology | gastroenterology | gastroenterology",
    "indication": "enterocolitis | irritable bowel syndrome | peptic ulcer disease (PUD)"
  },
  "clindamycin": {
    "name": "Clindamycin",
    "smiles": "[H][C@@](NC(=O)[C@@H]1C[C@@H](CCC)CN1C)([C@H](C)Cl)[C@@]1([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O",
    "molecular_weight": 424.99,
    "log_p": 0.39,
    "hbd": 4,
    "hba": 7,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "protein synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "bacterial septicemia | bone and joint infections | gynecologic infections | intra-abdominal infections | pneumonia | respiratory tract infections | skin infections"
  },
  "clioquinol": {
    "name": "Clioquinol",
    "smiles": "OC1=C(I)C=C(Cl)C2=C1N=CC=C2",
    "molecular_weight": 305.5,
    "log_p": 3.2,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "chelating agent",
    "disease_area": "",
    "indication": ""
  },
  "clobazam": {
    "name": "Clobazam",
    "smiles": "CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O",
    "molecular_weight": 300.75,
    "log_p": 3.37,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "clobetasol": {
    "name": "Clobetasol",
    "smiles": "[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 410.91,
    "log_p": 3.14,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "clobetasol propionate": {
    "name": "Clobetasol propionate",
    "smiles": "[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 466.98,
    "log_p": 4.1,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "clobetasone": {
    "name": "Clobetasone",
    "smiles": "[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]2(C)[C@@]1(O)C(=O)CCl",
    "molecular_weight": 408.9,
    "log_p": 3.35,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "clocortolone": {
    "name": "Clocortolone",
    "smiles": "[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C",
    "molecular_weight": 410.91,
    "log_p": 3.0,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "clodronic acid": {
    "name": "Clodronic acid",
    "smiles": "OP(O)(=O)C(Cl)(Cl)P(O)(O)=O",
    "molecular_weight": 244.89,
    "log_p": 0.43,
    "hbd": 4,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "clofarabine": {
    "name": "Clofarabine",
    "smiles": "[H][C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C=NC2=C(N)N=C(Cl)N=C12",
    "molecular_weight": 303.68,
    "log_p": -0.35,
    "hbd": 3,
    "hba": 8,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ribonucleotide reductase inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "acute lymphoblastic leukemia (ALL)"
  },
  "clofazimine": {
    "name": "Clofazimine",
    "smiles": "CC(C)N=C1C=C2N(C3=CC=C(Cl)C=C3)C3=C(C=CC=C3)N=C2C=C1NC1=CC=C(Cl)C=C1",
    "molecular_weight": 473.41,
    "log_p": 7.49,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "GK0582 inhibitor",
    "disease_area": "infectious disease",
    "indication": "leprosy"
  },
  "clofedanol": {
    "name": "Clofedanol",
    "smiles": "CN(C)CCC(O)(C1=CC=CC=C1)C1=CC=CC=C1Cl",
    "molecular_weight": 289.81,
    "log_p": 3.53,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "pulmonary",
    "indication": "cough suppressant"
  },
  "clofibrate": {
    "name": "Clofibrate",
    "smiles": "CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1",
    "molecular_weight": 242.7,
    "log_p": 3.06,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PPAR receptor agonist",
    "disease_area": "cardiology | endocrinology",
    "indication": "cholesterol | hyperlipidemia"
  },
  "clomifene": {
    "name": "Clomifene",
    "smiles": "CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 405.97,
    "log_p": 6.56,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "estrogen receptor antagonist",
    "disease_area": "obstetrics/gynecology",
    "indication": "infertility"
  },
  "clomipramine": {
    "name": "Clomipramine",
    "smiles": "CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2",
    "molecular_weight": 314.86,
    "log_p": 4.53,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin transporter (SERT) inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "obsessive compulsive disorder (OCD)"
  },
  "clonazepam": {
    "name": "Clonazepam",
    "smiles": "[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1",
    "molecular_weight": 315.72,
    "log_p": 3.04,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "clonidine": {
    "name": "Clonidine",
    "smiles": "ClC1=CC=CC(Cl)=C1NC1=NCCN1",
    "molecular_weight": 230.1,
    "log_p": 2.36,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "cardiology | neurology/psychiatry",
    "indication": "attention-deficit/hyperactivity disorder (ADHD) | hypertension"
  },
  "clopidogrel": {
    "name": "Clopidogrel",
    "smiles": "[H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl",
    "molecular_weight": 321.83,
    "log_p": 3.67,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "purinergic receptor antagonist",
    "disease_area": "cardiology | cardiology | cardiology | neurology/psychiatry",
    "indication": "acute coronary syndrome (ACS) | myocardial infarction | peripheral artery disease (PAD) | stroke"
  },
  "clorazepic acid": {
    "name": "Clorazepic acid",
    "smiles": "OC(=O)C1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2",
    "molecular_weight": 314.73,
    "log_p": 2.58,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "clothiapine": {
    "name": "Clothiapine",
    "smiles": "CN1CCN(CC1)C1=NC2=CC=CC=C2SC2=C1C=C(Cl)C=C2",
    "molecular_weight": 343.88,
    "log_p": 4.13,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "clotiazepam": {
    "name": "Clotiazepam",
    "smiles": "CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl",
    "molecular_weight": 318.83,
    "log_p": 3.78,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "clotrimazole": {
    "name": "Clotrimazole",
    "smiles": "ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 344.85,
    "log_p": 5.38,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cytochrome P450 inhibitor | imidazoline receptor ligand",
    "disease_area": "infectious disease | infectious disease",
    "indication": "oropharyngeal candidiasis | vulvovaginal candidiasis"
  },
  "cloxacillin": {
    "name": "Cloxacillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O",
    "molecular_weight": 435.89,
    "log_p": 2.55,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-positive bacterial infections"
  },
  "clozapine": {
    "name": "Clozapine",
    "smiles": "CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12",
    "molecular_weight": 326.83,
    "log_p": 3.72,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist | serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "schizophrenia"
  },
  "cobalt": {
    "name": "Cobalt",
    "smiles": "[Co]",
    "molecular_weight": 58.93,
    "log_p": -0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "cobalt chloride": {
    "name": "Cobalt chloride",
    "smiles": "[Cl-].[Cl-].[Co++]",
    "molecular_weight": 129.84,
    "log_p": -5.99,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "cobicistat": {
    "name": "Cobicistat",
    "smiles": "CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1",
    "molecular_weight": 776.04,
    "log_p": 6.0,
    "hbd": 3,
    "hba": 10,
    "rotatable_bonds": 19,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cytochrome P450 inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "cobimetinib": {
    "name": "Cobimetinib",
    "smiles": "OC1(CN(C1)C(=O)C1=C(NC2=C(F)C=C(I)C=C2)C(F)=C(F)C=C1)[C@@H]1CCCCN1",
    "molecular_weight": 531.32,
    "log_p": 3.78,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "MEK inhibitor",
    "disease_area": "oncology",
    "indication": "melanoma"
  },
  "cocaine": {
    "name": "Cocaine",
    "smiles": "[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C",
    "molecular_weight": 303.36,
    "log_p": 1.87,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "cocarboxylase": {
    "name": "Cocarboxylase",
    "smiles": "CC1=C(CCO[P@](O)(=O)O[P@](O)([O-])=O)SC=[N+]1CC1=CN=C(C)N=C1N",
    "molecular_weight": 424.31,
    "log_p": 0.21,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "codeine": {
    "name": "Codeine",
    "smiles": "[H][C@]12C=C[C@H](O)[C@@H]3OC4=C5C(C[C@H]1N(C)CC[C@@]235)=CC=C4OC",
    "molecular_weight": 299.37,
    "log_p": 1.5,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "coenzyme m": {
    "name": "Coenzyme M",
    "smiles": "OS(=O)(=O)CCS",
    "molecular_weight": 142.2,
    "log_p": -0.2,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "colchiceine": {
    "name": "Colchiceine",
    "smiles": "COC1=C(OC)C(OC)=C2C(CCC(NC(C)=O)C3=CC(=O)C(O)=CC=C23)=C1",
    "molecular_weight": 385.42,
    "log_p": 2.57,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "colchicine": {
    "name": "Colchicine",
    "smiles": "COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1[C@H](CC2)NC(C)=O",
    "molecular_weight": 399.44,
    "log_p": 2.87,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "microtubule inhibitor",
    "disease_area": "endocrinology | rheumatology",
    "indication": "fever | gout"
  },
  "colfosceril palmitate": {
    "name": "Colfosceril palmitate",
    "smiles": "CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC",
    "molecular_weight": 734.05,
    "log_p": 10.61,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 38,
    "approved": true,
    "source": "FDA"
  },
  "colistimethate": {
    "name": "Colistimethate",
    "smiles": "CCC(C)CCCCC(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC(C(C)O)C(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC1CCNC(=O)C(NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCNCS([O-])(=O)=O)NC1=O)C(C)O",
    "molecular_weight": 1634.9,
    "log_p": -9.77,
    "hbd": 18,
    "hba": 33,
    "rotatable_bonds": 44,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial permeability inducer",
    "disease_area": "infectious disease",
    "indication": "gram-negative bacterial infections"
  },
  "colistin": {
    "name": "Colistin",
    "smiles": "CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)C(NC(=O)[C@@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O",
    "molecular_weight": 1155.45,
    "log_p": -5.83,
    "hbd": 18,
    "hba": 18,
    "rotatable_bonds": 28,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial permeability inducer",
    "disease_area": "infectious disease",
    "indication": "gram-negative bacterial infections"
  },
  "conivaptan": {
    "name": "Conivaptan",
    "smiles": "CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C23)N1",
    "molecular_weight": 498.59,
    "log_p": 6.51,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vasopressin receptor antagonist",
    "disease_area": "endocrinology",
    "indication": "hyponatremia"
  },
  "copanlisib": {
    "name": "Copanlisib",
    "smiles": "COC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21",
    "molecular_weight": 480.53,
    "log_p": 0.66,
    "hbd": 2,
    "hba": 11,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PI3K inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "follicular lymphoma"
  },
  "copper": {
    "name": "Copper",
    "smiles": "[Cu]",
    "molecular_weight": 63.55,
    "log_p": -0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "copper cu-64": {
    "name": "Copper Cu-64",
    "smiles": "[64Cu]",
    "molecular_weight": 63.93,
    "log_p": -0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "copper gluconate": {
    "name": "Copper gluconate",
    "smiles": "[Cu++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O",
    "molecular_weight": 453.84,
    "log_p": -9.66,
    "hbd": 10,
    "hba": 14,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "copper oxodotreotide cu-64": {
    "name": "Copper oxodotreotide Cu-64",
    "smiles": "[64Cu++].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC(O)=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O",
    "molecular_weight": 1497.56,
    "log_p": -6.05,
    "hbd": 15,
    "hba": 24,
    "rotatable_bonds": 26,
    "approved": true,
    "source": "FDA"
  },
  "cortisone acetate": {
    "name": "Cortisone acetate",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 402.49,
    "log_p": 2.56,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "creatine": {
    "name": "Creatine",
    "smiles": "CN(CC(O)=O)C(N)=N",
    "molecular_weight": 131.13,
    "log_p": -1.1,
    "hbd": 3,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "crisaborole": {
    "name": "Crisaborole",
    "smiles": "OB1OCC2=C1C=CC(OC1=CC=C(C=C1)C#N)=C2",
    "molecular_weight": 251.05,
    "log_p": 1.57,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "dermatology",
    "indication": "dermatitis"
  },
  "crizotinib": {
    "name": "Crizotinib",
    "smiles": "C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl",
    "molecular_weight": 450.35,
    "log_p": 5.04,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ALK tyrosine kinase receptor inhibitor",
    "disease_area": "oncology",
    "indication": "non-small cell lung cancer (NSCLC)"
  },
  "cromoglicic acid": {
    "name": "Cromoglicic acid",
    "smiles": "OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O",
    "molecular_weight": 468.37,
    "log_p": 2.11,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "crotamiton": {
    "name": "Crotamiton",
    "smiles": "CCN(C(=O)C=CC)C1=CC=CC=C1C",
    "molecular_weight": 203.28,
    "log_p": 2.92,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antipruritic",
    "disease_area": "infectious disease",
    "indication": "scabies"
  },
  "cupric chloride": {
    "name": "Cupric Chloride",
    "smiles": "Cl[Cu]Cl",
    "molecular_weight": 134.45,
    "log_p": 1.38,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "cupric oxide": {
    "name": "Cupric oxide",
    "smiles": "[O--].[Cu++]",
    "molecular_weight": 79.55,
    "log_p": -0.12,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "cupric sulfate": {
    "name": "Cupric sulfate",
    "smiles": "[Cu++].[O-]S([O-])(=O)=O",
    "molecular_weight": 159.61,
    "log_p": -1.34,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "curcumin": {
    "name": "Curcumin",
    "smiles": "COC1=CC(\\C=C\\C(=O)CC(=O)\\C=C\\C2=CC(OC)=C(O)C=C2)=CC=C1O",
    "molecular_weight": 368.39,
    "log_p": 3.37,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor | histone acetyltransferase inhibitor | lipoxygenase inhibitor | NFkB pathway inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "cyanocobalamin": {
    "name": "Cyanocobalamin",
    "smiles": "C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\\C(C)=C1/N=C(/C=C3\\N=C(\\C(\\C)=C4\\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP([O-])(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)N1C=NC2=C1C=C(C)C(C)=C2",
    "molecular_weight": 1355.39,
    "log_p": 2.72,
    "hbd": 9,
    "hba": 21,
    "rotatable_bonds": 27,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "methylmalonyl CoA mutase stimulant | vitamin B",
    "disease_area": "gastroenterology | hematology | infectious disease",
    "indication": "anemia | celiac disease | fish tapeworm infestation"
  },
  "cyanocobalamin co-60": {
    "name": "Cyanocobalamin Co-60",
    "smiles": "[60Co+3].[C-]#N.C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)C2[N-]\\C1=C(C)/C1=N/C(=C\\C3=N\\C(=C(C)/C4=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)\\[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)/C(C)(C)[C@@H]1CCC(N)=O)OP([O-])(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)N1C=NC2=C1C=C(C)C(C)=C2",
    "molecular_weight": 1356.39,
    "log_p": 3.41,
    "hbd": 9,
    "hba": 20,
    "rotatable_bonds": 26,
    "approved": true,
    "source": "FDA"
  },
  "cyclacillin": {
    "name": "Cyclacillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1(N)CCCCC1)C(O)=O",
    "molecular_weight": 341.43,
    "log_p": 0.28,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "cyclandelate": {
    "name": "Cyclandelate",
    "smiles": "CC1CC(CC(C)(C)C1)OC(=O)C(O)C1=CC=CC=C1",
    "molecular_weight": 276.38,
    "log_p": 3.48,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "cardiology | cardiology | rheumatology",
    "indication": "arteriosclerosis | claudication | Raynaud's disease"
  },
  "cyclizine": {
    "name": "Cyclizine",
    "smiles": "CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 266.39,
    "log_p": 3.02,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor modulator",
    "disease_area": "gastroenterology | gastroenterology | neurology/psychiatry | neurology/psychiatry",
    "indication": "motion sickness | nausea | vertigo | vomiting"
  },
  "cyclobenzaprine": {
    "name": "Cyclobenzaprine",
    "smiles": "CN(C)CCC=C1C2=CC=CC=C2C=CC2=CC=CC=C12",
    "molecular_weight": 275.4,
    "log_p": 4.55,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist | serotonin receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "spasms"
  },
  "cycloguanil": {
    "name": "Cycloguanil",
    "smiles": "CC1(C)N=C(N)N=C(N)N1C1=CC=C(Cl)C=C1",
    "molecular_weight": 251.72,
    "log_p": 1.53,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "cyclopenthiazide": {
    "name": "Cyclopenthiazide",
    "smiles": "NS(=O)(=O)C1=CC2=C(NC(CC3CCCC3)NS2(=O)=O)C=C1Cl",
    "molecular_weight": 379.89,
    "log_p": 1.6,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "thiazide diuretic",
    "disease_area": "cardiology | cardiology",
    "indication": "congestive heart failure | hypertension"
  },
  "cyclopentolate": {
    "name": "Cyclopentolate",
    "smiles": "CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1",
    "molecular_weight": 291.39,
    "log_p": 2.18,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "ophthalmology | ophthalmology",
    "indication": "cycloplegia | mydriasis"
  },
  "cyclophosphamide": {
    "name": "Cyclophosphamide",
    "smiles": "ClCCN(CCCl)P1(=O)NCCCO1",
    "molecular_weight": 261.09,
    "log_p": 1.88,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA alkylating agent",
    "disease_area": "hematologic malignancy | hematologic malignancy | hematologic malignancy | hematologic malignancy | hematologic malignancy | hematologic malignancy | hematologic malignancy | hematologic malignancy | hematologic malignancy | oncology | oncology | oncology | oncology",
    "indication": "acute lymphoblastic leukemia (ALL) | acute myeloid leukemia (AML) | breast cancer | Burkitt's lymphoma | chronic lymphocytic leukemia (CLL) | chronic myeloid leukemia (CML) | Hodgkin's lymphoma | multiple myeloma | neuroblastoma | ovarian cancer | retinoblastoma | small lymphocytic lymphoma (SLL) | true histiocytic lymphoma (THL)"
  },
  "cycloserine": {
    "name": "Cycloserine",
    "smiles": "N[C@@H]1CONC1=O",
    "molecular_weight": 102.09,
    "log_p": -1.62,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "cyclosporine": {
    "name": "Cyclosporine",
    "smiles": "CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",
    "molecular_weight": 1202.63,
    "log_p": 3.27,
    "hbd": 5,
    "hba": 12,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA"
  },
  "cyclothiazide": {
    "name": "Cyclothiazide",
    "smiles": "NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2",
    "molecular_weight": 389.89,
    "log_p": 1.23,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glutamate receptor modulator",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "cycrimine": {
    "name": "Cycrimine",
    "smiles": "OC(CCN1CCCCC1)(C1CCCC1)C1=CC=CC=C1",
    "molecular_weight": 287.45,
    "log_p": 3.94,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "cyproheptadine": {
    "name": "Cyproheptadine",
    "smiles": "CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=CC=CC=C12",
    "molecular_weight": 287.41,
    "log_p": 4.7,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy | allergy | dermatology | ophthalmology | otolaryngology",
    "indication": "allergic rhinitis | conjunctivitis | dermatographism | urticaria | vasomotor rhinitis"
  },
  "cyproterone acetate": {
    "name": "Cyproterone acetate",
    "smiles": "[H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H]",
    "molecular_weight": 416.95,
    "log_p": 4.61,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "cysteamine": {
    "name": "Cysteamine",
    "smiles": "NCCS",
    "molecular_weight": 77.15,
    "log_p": -0.13,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "tissue transglutaminase inhibitor",
    "disease_area": "metabolism",
    "indication": "cystinosis"
  },
  "cysteine": {
    "name": "Cysteine",
    "smiles": "N[C@@H](CS)C(O)=O",
    "molecular_weight": 121.16,
    "log_p": -0.67,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "cystine": {
    "name": "Cystine",
    "smiles": "N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O",
    "molecular_weight": 240.31,
    "log_p": -0.81,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "cytarabine": {
    "name": "Cytarabine",
    "smiles": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",
    "molecular_weight": 243.22,
    "log_p": -2.56,
    "hbd": 4,
    "hba": 8,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ribonucleotide reductase inhibitor",
    "disease_area": "hematologic malignancy | hematologic malignancy | hematologic malignancy | hematologic malignancy",
    "indication": "acute lymphoblastic leukemia (ALL) | acute myeloid leukemia (AML) | chronic lymphocytic leukemia (CLL) | non-Hodgkin lymphoma (NHL)"
  },
  "dabigatran": {
    "name": "Dabigatran",
    "smiles": "CN1C(CNC2=CC=C(C=C2)C(N)=N)=NC2=C1C=CC(=C2)C(=O)N(CCC(O)=O)C1=NC=CC=C1",
    "molecular_weight": 471.52,
    "log_p": 2.99,
    "hbd": 4,
    "hba": 7,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "thrombin inhibitor",
    "disease_area": "hematology | hematology | hematology | neurology/psychiatry",
    "indication": "deep vein thrombosis (DVT) | pulmonary embolism (PE) | stroke | systemic embolism"
  },
  "dabigatran etexilate": {
    "name": "Dabigatran etexilate",
    "smiles": "CCCCCCOC(=O)\\N=C(\\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1",
    "molecular_weight": 627.75,
    "log_p": 5.6,
    "hbd": 2,
    "hba": 9,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA"
  },
  "dabrafenib": {
    "name": "Dabrafenib",
    "smiles": "CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1",
    "molecular_weight": 519.57,
    "log_p": 5.36,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "RAF inhibitor",
    "disease_area": "oncology",
    "indication": "melanoma"
  },
  "dacarbazine": {
    "name": "Dacarbazine",
    "smiles": "CN(C)\\N=N\\C1=C(N=CN1)C(N)=O",
    "molecular_weight": 182.19,
    "log_p": 0.07,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA alkylating agent",
    "disease_area": "hematologic malignancy | oncology",
    "indication": "Hodgkin's lymphoma | melanoma"
  },
  "daclatasvir": {
    "name": "Daclatasvir",
    "smiles": "COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C",
    "molecular_weight": 738.89,
    "log_p": 6.22,
    "hbd": 4,
    "hba": 8,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HCV inhibitor",
    "disease_area": "infectious disease",
    "indication": "hepatitis C"
  },
  "dacomitinib": {
    "name": "Dacomitinib",
    "smiles": "COC1=C(NC(=O)\\C=C\\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1",
    "molecular_weight": 469.95,
    "log_p": 5.16,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "EGFR inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "dactinomycin": {
    "name": "Dactinomycin",
    "smiles": "[H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C1=C3N=C4C(OC3=C(C)C=C1)=C(C)C(=O)C(N)=C4C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]3([H])CCCN3C(=O)[C@H](NC1=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C",
    "molecular_weight": 1255.44,
    "log_p": 0.73,
    "hbd": 5,
    "hba": 18,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "RNA polymerase inhibitor",
    "disease_area": "oncology | oncology | oncology | oncology | oncology",
    "indication": "Ewing's sarcoma | gestational trophoblastic disease (GTD) | rhabdomyosarcoma | testicular carcinoma | Wilm's tumor"
  },
  "dalfampridine": {
    "name": "Dalfampridine",
    "smiles": "NC1=CC=NC=C1",
    "molecular_weight": 94.12,
    "log_p": 0.66,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "potassium channel blocker",
    "disease_area": "neurology/psychiatry",
    "indication": "multiple sclerosis"
  },
  "dalfopristin": {
    "name": "Dalfopristin",
    "smiles": "CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@H](C(C)C)[C@H](C)\\C=C\\C(=O)NC\\C=C\\C(\\C)=C\\[C@@H](O)CC(=O)CC1=NC(=CO1)C2=O",
    "molecular_weight": 690.86,
    "log_p": 2.27,
    "hbd": 2,
    "hba": 11,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Preclinical",
    "moa": "antibacterial",
    "disease_area": "",
    "indication": ""
  },
  "d-alpha-tocopherol acetate": {
    "name": "D-alpha-Tocopherol acetate",
    "smiles": "CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(C)C(OC(C)=O)=C(C)C(C)=C2O1",
    "molecular_weight": 472.75,
    "log_p": 9.06,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA"
  },
  "danazol": {
    "name": "Danazol",
    "smiles": "[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3",
    "molecular_weight": 337.46,
    "log_p": 4.22,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "estrogen receptor antagonist | progesterone receptor agonist",
    "disease_area": "cardiology | obstetrics/gynecology",
    "indication": "angioedema | endometriosis"
  },
  "dantrolene": {
    "name": "Dantrolene",
    "smiles": "[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)\\C=N\\N1CC(=O)NC1=O",
    "molecular_weight": 314.26,
    "log_p": 1.74,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "endocrinology | neurology/psychiatry",
    "indication": "malignant hyperthermia (MH) | spasms"
  },
  "dantron": {
    "name": "Dantron",
    "smiles": "OC1=CC=CC2=C1C(=O)C1=C(C=CC=C1O)C2=O",
    "molecular_weight": 240.21,
    "log_p": 1.87,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "laxative",
    "disease_area": "",
    "indication": ""
  },
  "dapagliflozin": {
    "name": "Dapagliflozin",
    "smiles": "CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1",
    "molecular_weight": 408.88,
    "log_p": 1.84,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium/glucose cotransporter inhibitor",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "dapiprazole": {
    "name": "Dapiprazole",
    "smiles": "CC1=CC=CC=C1N1CCN(CCC2=NN=C3CCCCN23)CC1",
    "molecular_weight": 325.46,
    "log_p": 2.29,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "ophthalmology",
    "indication": "mydriasis"
  },
  "dapsone": {
    "name": "Dapsone",
    "smiles": "NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1",
    "molecular_weight": 248.31,
    "log_p": 1.68,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial antifolate",
    "disease_area": "dermatology | infectious disease",
    "indication": "dermatitis herpetiformis (DH) | leprosy"
  },
  "daptomycin": {
    "name": "Daptomycin",
    "smiles": "CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=CC=CC=C2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O",
    "molecular_weight": 1620.69,
    "log_p": -5.62,
    "hbd": 22,
    "hba": 24,
    "rotatable_bonds": 35,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "endocarditis | skin infections | skin infections, endocarditis"
  },
  "daridorexant": {
    "name": "Daridorexant",
    "smiles": "COC1=CC(C(=O)N2CCC[C@@]2(C)C2=NC3=C(N2)C=CC(Cl)=C3C)=C(C=C1)N1N=CC=N1",
    "molecular_weight": 450.93,
    "log_p": 4.27,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "darifenacin": {
    "name": "Darifenacin",
    "smiles": "NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 426.56,
    "log_p": 3.96,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "urology",
    "indication": "urinary incontinence"
  },
  "darolutamide": {
    "name": "Darolutamide",
    "smiles": "C[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)C(C)O",
    "molecular_weight": 398.85,
    "log_p": 2.67,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "androgen receptor antagonist",
    "disease_area": "oncology | oncology",
    "indication": "breast cancer | prostate cancer"
  },
  "darunavir": {
    "name": "Darunavir",
    "smiles": "[H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1",
    "molecular_weight": 547.67,
    "log_p": 2.38,
    "hbd": 3,
    "hba": 8,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HIV protease inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "dasabuvir": {
    "name": "Dasabuvir",
    "smiles": "COC1=C(C=C(C=C1C1=CC2=CC=C(NS(C)(=O)=O)C=C2C=C1)N1C=CC(=O)NC1=O)C(C)(C)C",
    "molecular_weight": 493.59,
    "log_p": 4.02,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HCV inhibitor",
    "disease_area": "infectious disease",
    "indication": "hepatitis C"
  },
  "dasatinib": {
    "name": "Dasatinib",
    "smiles": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1",
    "molecular_weight": 488.02,
    "log_p": 3.31,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "Bcr-Abl kinase inhibitor | ephrin inhibitor | KIT inhibitor | PDGFR tyrosine kinase receptor inhibitor | SRC inhibitor | tyrosine kinase inhibitor",
    "disease_area": "hematologic malignancy | hematologic malignancy",
    "indication": "acute lymphoblastic leukemia (ALL) | chronic myeloid leukemia (CML)"
  },
  "daunorubicin": {
    "name": "Daunorubicin",
    "smiles": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O",
    "molecular_weight": 527.53,
    "log_p": 1.03,
    "hbd": 5,
    "hba": 11,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "RNA synthesis inhibitor | topoisomerase inhibitor",
    "disease_area": "hematologic malignancy | hematologic malignancy",
    "indication": "acute lymphoblastic leukemia (ALL) | acute myeloid leukemia (AML)"
  },
  "debrisoquine": {
    "name": "Debrisoquine",
    "smiles": "NC(=N)N1CCC2=CC=CC=C2C1",
    "molecular_weight": 175.23,
    "log_p": 0.94,
    "hbd": 2,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "decamethonium": {
    "name": "Decamethonium",
    "smiles": "C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C",
    "molecular_weight": 258.49,
    "log_p": 3.52,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "muscle relaxant"
  },
  "decitabine": {
    "name": "Decitabine",
    "smiles": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1",
    "molecular_weight": 228.21,
    "log_p": -2.14,
    "hbd": 3,
    "hba": 8,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA methyltransferase inhibitor",
    "disease_area": "hematologic malignancy | hematologic malignancy | hematology",
    "indication": "anemia | chronic myeloid leukemia (CML) | myelodysplastic diseases (MDS)"
  },
  "deferasirox": {
    "name": "Deferasirox",
    "smiles": "OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O",
    "molecular_weight": 373.37,
    "log_p": 3.71,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "chelating agent",
    "disease_area": "hematology | hematology | hematology",
    "indication": "iron overload | thalassemia | transfusional hemosiderosis"
  },
  "deferiprone": {
    "name": "Deferiprone",
    "smiles": "CN1C=CC(=O)C(O)=C1C",
    "molecular_weight": 139.15,
    "log_p": 0.4,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "chelating agent",
    "disease_area": "hematology | hematology | hematology",
    "indication": "iron overload | thalassemia | transfusional hemosiderosis"
  },
  "deferoxamine": {
    "name": "Deferoxamine",
    "smiles": "CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN",
    "molecular_weight": 560.69,
    "log_p": 0.92,
    "hbd": 6,
    "hba": 9,
    "rotatable_bonds": 23,
    "approved": true,
    "source": "FDA"
  },
  "deflazacort": {
    "name": "Deflazacort",
    "smiles": "[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@]([H])(O)C[C@]3(C)[C@@]1(N=C(C)O2)C(=O)COC(C)=O",
    "molecular_weight": 441.52,
    "log_p": 2.56,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "rheumatology",
    "indication": "joint inflammation"
  },
  "degarelix": {
    "name": "Degarelix",
    "smiles": "CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O",
    "molecular_weight": 1632.29,
    "log_p": 1.51,
    "hbd": 17,
    "hba": 18,
    "rotatable_bonds": 41,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "gonadotropin releasing factor hormone receptor antagonist",
    "disease_area": "oncology",
    "indication": "prostate cancer"
  },
  "dehydrocholic acid": {
    "name": "Dehydrocholic acid",
    "smiles": "[H][C@@]1(CC[C@@]2([H])[C@]3([H])C(=O)C[C@]4([H])CC(=O)CC[C@]4(C)[C@@]3([H])CC(=O)[C@]12C)[C@H](C)CCC(O)=O",
    "molecular_weight": 402.53,
    "log_p": 4.07,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "delafloxacin": {
    "name": "Delafloxacin",
    "smiles": "NC1=NC(N2C=C(C(O)=O)C(=O)C3=CC(F)=C(N4CC(O)C4)C(Cl)=C23)=C(F)C=C1F",
    "molecular_weight": 440.77,
    "log_p": 1.92,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "antiinfective drug",
    "disease_area": "",
    "indication": ""
  },
  "delamanid": {
    "name": "Delamanid",
    "smiles": "C[C@]1(COC2=CC=C(C=C2)N2CCC(CC2)OC2=CC=C(OC(F)(F)F)C=C2)CN2C=C(N=C2O1)[N+]([O-])=O",
    "molecular_weight": 534.49,
    "log_p": 4.97,
    "hbd": 0,
    "hba": 9,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "tuberculosis"
  },
  "delavirdine": {
    "name": "Delavirdine",
    "smiles": "CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2",
    "molecular_weight": 456.57,
    "log_p": 2.72,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "non-nucleoside reverse transcriptase inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "demecarium": {
    "name": "Demecarium",
    "smiles": "CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C",
    "molecular_weight": 556.79,
    "log_p": 6.76,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholinesterase inhibitor",
    "disease_area": "ophthalmology | ophthalmology",
    "indication": "glaucoma | intraocular pressure"
  },
  "demeclocycline": {
    "name": "Demeclocycline",
    "smiles": "[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C([C@H]2O)C(Cl)=CC=C1O",
    "molecular_weight": 464.86,
    "log_p": 0.26,
    "hbd": 6,
    "hba": 9,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor",
    "disease_area": "endocrinology | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | ophthalmology | urology",
    "indication": "actinomycosis | anthrax | brucellosis | chancroid | cholera | conjunctivitis | fever | listeria | psittacosis | respiratory tract infections | syphilis | trachoma | tularemia | urethritis"
  },
  "deoxycholic acid": {
    "name": "Deoxycholic acid",
    "smiles": "[H][C@@]12CC[C@H]([C@H](C)CCC(O)=O)[C@@]1(C)[C@@H](O)C[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@H](O)CC[C@]12C",
    "molecular_weight": 392.58,
    "log_p": 4.48,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "dequalinium": {
    "name": "Dequalinium",
    "smiles": "CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2",
    "molecular_weight": 456.68,
    "log_p": 6.17,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PKC inhibitor",
    "disease_area": "infectious disease",
    "indication": "first-aid antiseptic"
  },
  "deserpidine": {
    "name": "Deserpidine",
    "smiles": "[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2",
    "molecular_weight": 578.66,
    "log_p": 4.16,
    "hbd": 1,
    "hba": 9,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin converting enzyme inhibitor",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "desflurane": {
    "name": "Desflurane",
    "smiles": "FC(F)OC(F)C(F)(F)F",
    "molecular_weight": 168.04,
    "log_p": 2.08,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "desipramine": {
    "name": "Desipramine",
    "smiles": "CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12",
    "molecular_weight": 266.39,
    "log_p": 3.53,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "tricyclic antidepressant",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "deslanoside": {
    "name": "Deslanoside",
    "smiles": "C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1",
    "molecular_weight": 943.09,
    "log_p": 0.04,
    "hbd": 9,
    "hba": 19,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "Na/K-ATPase inhibitor",
    "disease_area": "cardiology | cardiology",
    "indication": "cardiac arrythmia | congestive heart failure"
  },
  "desloratadine": {
    "name": "Desloratadine",
    "smiles": "ClC1=CC2=C(C=C1)C(=C1CCNCC1)C1=C(CC2)C=CC=N1",
    "molecular_weight": 310.83,
    "log_p": 4.02,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy | allergy",
    "indication": "allergic rhinitis | urticaria"
  },
  "desmopressin": {
    "name": "Desmopressin",
    "smiles": "NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O",
    "molecular_weight": 1069.24,
    "log_p": -4.13,
    "hbd": 14,
    "hba": 15,
    "rotatable_bonds": 19,
    "approved": true,
    "source": "FDA"
  },
  "desogestrel": {
    "name": "Desogestrel",
    "smiles": "[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]",
    "molecular_weight": 310.48,
    "log_p": 4.87,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "progesterone receptor agonist",
    "disease_area": "endocrinology",
    "indication": "contraceptive"
  },
  "desonide": {
    "name": "Desonide",
    "smiles": "[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 416.51,
    "log_p": 2.33,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "gastroenterology",
    "indication": "Crohn's disease"
  },
  "desoximetasone": {
    "name": "Desoximetasone",
    "smiles": "[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 376.47,
    "log_p": 2.78,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "dermatology",
    "indication": "corticosteroid-responsive dermatoses"
  },
  "desoxycorticosterone acetate": {
    "name": "Desoxycorticosterone acetate",
    "smiles": "[H][C@@]12CC[C@H](C(=O)COC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 372.51,
    "log_p": 4.27,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "desvenlafaxine": {
    "name": "Desvenlafaxine",
    "smiles": "CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1",
    "molecular_weight": 263.38,
    "log_p": 2.73,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin\u201a\u00e4\u00ecnorepinephrine reuptake inhibitor (snri) | serotonin\u2013norepinephrine reuptake inhibitor (SNRI)",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "deucravacitinib": {
    "name": "Deucravacitinib",
    "smiles": "[2H]C([2H])([2H])NC(=O)C1=C(NC2=CC=CC(C3=NN(C)C=N3)=C2OC)C=C(NC(=O)C2CC2)N=N1",
    "molecular_weight": 425.47,
    "log_p": 1.73,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "tyrosine kinase inhibitor",
    "disease_area": "gastroenterology",
    "indication": "crohn's disease"
  },
  "deutetrabenazine": {
    "name": "Deutetrabenazine",
    "smiles": "[2H]C([2H])([2H])OC1=CC2=C(C=C1OC([2H])([2H])[2H])[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2",
    "molecular_weight": 323.47,
    "log_p": 3.24,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vesicular monoamine transporter inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "huntington's disease"
  },
  "dexamethasone": {
    "name": "Dexamethasone",
    "smiles": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 392.47,
    "log_p": 1.9,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "allergy | dermatology | dermatology | endocrinology | endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology | gastroenterology | gastroenterology | hematology | neurology/psychiatry | rheumatology | rheumatology | rheumatology | rheumatology | rheumatology",
    "indication": "allergic rhinitis | anemia | dermatitis herpetiformis (DH) | enteritis | hypercalcemia | hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (dh), nephrotic syndrome, psoriasis | lupus | multiple sclerosis | nephrotic syndrome | osteoarthritis | psoriasis | psoriatic arthritis | rheumatoid arthritis | ulcerative colitis"
  },
  "dexamethasone acetate": {
    "name": "Dexamethasone acetate",
    "smiles": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 434.5,
    "log_p": 2.47,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "dexamethasone metasulfobenzoate": {
    "name": "Dexamethasone metasulfobenzoate",
    "smiles": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)C3=CC=CC(=C3)S(O)(=O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 576.64,
    "log_p": 3.01,
    "hbd": 3,
    "hba": 8,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "dexbrompheniramine": {
    "name": "Dexbrompheniramine",
    "smiles": "CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1",
    "molecular_weight": 319.25,
    "log_p": 3.93,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy",
    "indication": "allergic rhinitis"
  },
  "dexchlorpheniramine maleate": {
    "name": "Dexchlorpheniramine maleate",
    "smiles": "OC(=O)\\C=C/C(O)=O.CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1",
    "molecular_weight": 390.87,
    "log_p": 3.53,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "dexfenfluramine": {
    "name": "Dexfenfluramine",
    "smiles": "CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F",
    "molecular_weight": 231.26,
    "log_p": 3.25,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "dexibuprofen": {
    "name": "Dexibuprofen",
    "smiles": "CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O",
    "molecular_weight": 206.28,
    "log_p": 3.07,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "dexketoprofen": {
    "name": "Dexketoprofen",
    "smiles": "[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1",
    "molecular_weight": 254.28,
    "log_p": 3.11,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "dexlansoprazole": {
    "name": "Dexlansoprazole",
    "smiles": "CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1",
    "molecular_weight": 369.37,
    "log_p": 3.52,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATPase inhibitor",
    "disease_area": "gastroenterology | gastroenterology",
    "indication": "erosive esophagitis (EE) | gastroesophageal reflux disease (GERD)"
  },
  "dexmedetomidine": {
    "name": "Dexmedetomidine",
    "smiles": "C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1",
    "molecular_weight": 200.28,
    "log_p": 3.18,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "sedative"
  },
  "dexmethylphenidate": {
    "name": "Dexmethylphenidate",
    "smiles": "[H][C@@](C(=O)OC)(C1=CC=CC=C1)[C@@]1([H])CCCCN1",
    "molecular_weight": 233.31,
    "log_p": 2.09,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "dexpanthenol": {
    "name": "Dexpanthenol",
    "smiles": "CC(C)(CO)[C@@H](O)C(=O)NCCCO",
    "molecular_weight": 205.25,
    "log_p": -1.14,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "gastroenterology",
    "indication": "paralytic ileus"
  },
  "dexrazoxane": {
    "name": "Dexrazoxane",
    "smiles": "C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1",
    "molecular_weight": 268.27,
    "log_p": -2.71,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "chelating agent | topoisomerase inhibitor",
    "disease_area": "cardiology",
    "indication": "cardiomyopathy"
  },
  "dextroamphetamine": {
    "name": "Dextroamphetamine",
    "smiles": "C[C@H](N)CC1=CC=CC=C1",
    "molecular_weight": 135.21,
    "log_p": 1.58,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "dextromethorphan": {
    "name": "Dextromethorphan",
    "smiles": "[H][C@]12CCCC[C@]11CCN(C)[C@H]2CC2=C1C=C(OC)C=C2",
    "molecular_weight": 271.4,
    "log_p": 3.38,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glutamate receptor antagonist | sigma receptor agonist",
    "disease_area": "pulmonary",
    "indication": "cough suppressant"
  },
  "dextropropoxyphene": {
    "name": "Dextropropoxyphene",
    "smiles": "CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1",
    "molecular_weight": 339.48,
    "log_p": 4.28,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "dextrothyroxine": {
    "name": "Dextrothyroxine",
    "smiles": "N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O",
    "molecular_weight": 776.87,
    "log_p": 4.56,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "",
    "indication": "cholesterol"
  },
  "dezocine": {
    "name": "Dezocine",
    "smiles": "[H][C@@]12CC3=CC=C(O)C=C3[C@@](C)(CCCCC1)[C@H]2N",
    "molecular_weight": 245.37,
    "log_p": 3.11,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "d-glucose": {
    "name": "D-glucose",
    "smiles": "[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C=O",
    "molecular_weight": 180.16,
    "log_p": -3.38,
    "hbd": 5,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "diacerein": {
    "name": "Diacerein",
    "smiles": "CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O",
    "molecular_weight": 368.3,
    "log_p": 2.01,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "interleukin inhibitor",
    "disease_area": "rheumatology",
    "indication": "osteoarthritis"
  },
  "diacetyl benzoyl lathyrol": {
    "name": "Diacetyl benzoyl lathyrol",
    "smiles": "C[C@H]1C[C@@]2(OC(C)=O)[C@H]([C@H]1OC(=O)C1=CC=CC=C1)[C@@H](OC(C)=O)C(=C)CC[C@H]1[C@@H](\\C=C(C)\\C2=O)C1(C)C",
    "molecular_weight": 522.64,
    "log_p": 5.24,
    "hbd": 0,
    "hba": 7,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "diaminopropanol tetraacetic acid": {
    "name": "Diaminopropanol tetraacetic acid",
    "smiles": "OC(CN(CC(O)=O)CC(O)=O)CN(CC(O)=O)CC(O)=O",
    "molecular_weight": 322.27,
    "log_p": -2.71,
    "hbd": 5,
    "hba": 7,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "diamorphine": {
    "name": "Diamorphine",
    "smiles": "[H][C@@]12C=C[C@H](OC(C)=O)[C@@H]3OC4=C(OC(C)=O)C=CC5=C4[C@]13CCN(C)[C@@H]2C5",
    "molecular_weight": 369.42,
    "log_p": 1.99,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "diatrizoate": {
    "name": "Diatrizoate",
    "smiles": "CC(=O)NC1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I",
    "molecular_weight": 613.92,
    "log_p": 3.12,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "contrast agent",
    "disease_area": "radiology",
    "indication": "mri contrast agent"
  },
  "diazepam": {
    "name": "Diazepam",
    "smiles": "CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1",
    "molecular_weight": 284.75,
    "log_p": 3.15,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "diazolidinylurea": {
    "name": "Diazolidinylurea",
    "smiles": "OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O",
    "molecular_weight": 278.22,
    "log_p": -3.61,
    "hbd": 5,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "diazoxide": {
    "name": "Diazoxide",
    "smiles": "CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2",
    "molecular_weight": 230.68,
    "log_p": 1.87,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "potassium channel activator",
    "disease_area": "endocrinology",
    "indication": "hypoglycemia"
  },
  "dibekacin": {
    "name": "Dibekacin",
    "smiles": "NC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1",
    "molecular_weight": 451.52,
    "log_p": -5.27,
    "hbd": 9,
    "hba": 13,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-negative bacterial infections"
  },
  "dibenzepin": {
    "name": "Dibenzepin",
    "smiles": "CN(C)CCN1C2=CC=CC=C2N(C)C2=CC=CC=C2C1=O",
    "molecular_weight": 295.39,
    "log_p": 2.98,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "dichloralphenazone": {
    "name": "Dichloralphenazone",
    "smiles": "OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl.CN1N(C(=O)C=C1C)C1=CC=CC=C1",
    "molecular_weight": 519.04,
    "log_p": 2.82,
    "hbd": 4,
    "hba": 7,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "dichloroacetic acid": {
    "name": "Dichloroacetic acid",
    "smiles": "OC(=O)C(Cl)Cl",
    "molecular_weight": 128.94,
    "log_p": 0.87,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "dichlorobenzyl alcohol": {
    "name": "Dichlorobenzyl alcohol",
    "smiles": "OCC1=C(Cl)C=C(Cl)C=C1",
    "molecular_weight": 177.03,
    "log_p": 2.49,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "dichromate": {
    "name": "Dichromate",
    "smiles": "[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O",
    "molecular_weight": 215.98,
    "log_p": -2.93,
    "hbd": 0,
    "hba": 7,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "diclofenac": {
    "name": "Diclofenac",
    "smiles": "OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl",
    "molecular_weight": 296.15,
    "log_p": 4.36,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "neurology/psychiatry | rheumatology | rheumatology",
    "indication": "migraine headache | osteoarthritis | rheumatoid arthritis"
  },
  "diclofenamide": {
    "name": "Diclofenamide",
    "smiles": "NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O",
    "molecular_weight": 305.16,
    "log_p": 0.29,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "carbonic anhydrase inhibitor",
    "disease_area": "neurology/psychiatry | ophthalmology",
    "indication": "epilepsy | glaucoma"
  },
  "dicloxacillin": {
    "name": "Dicloxacillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O",
    "molecular_weight": 470.33,
    "log_p": 3.2,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-positive bacterial infections"
  },
  "dicoumarol": {
    "name": "Dicoumarol",
    "smiles": "OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2",
    "molecular_weight": 336.3,
    "log_p": 2.9,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "NADPH inhibitor",
    "disease_area": "hematology",
    "indication": "deep vein thrombosis (DVT)"
  },
  "dicyclomine": {
    "name": "Dicyclomine",
    "smiles": "CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1",
    "molecular_weight": 309.49,
    "log_p": 4.4,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "didanosine": {
    "name": "Didanosine",
    "smiles": "OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O",
    "molecular_weight": 236.23,
    "log_p": -0.21,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "nucleoside reverse transcriptase inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "didecyldimethylammonium": {
    "name": "Didecyldimethylammonium",
    "smiles": "CCCCCCCCCC[N+](C)(C)CCCCCCCCCC",
    "molecular_weight": 326.63,
    "log_p": 7.34,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 18,
    "approved": true,
    "source": "FDA"
  },
  "dienestrol": {
    "name": "Dienestrol",
    "smiles": "[H]\\C(C)=C(/C(=C(\\[H])C)/C1=CC=C(O)C=C1)\\C1=CC=C(O)C=C1",
    "molecular_weight": 266.34,
    "log_p": 4.6,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "estrogen receptor agonist",
    "disease_area": "endocrinology",
    "indication": "menopause"
  },
  "dienogest": {
    "name": "Dienogest",
    "smiles": "[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]",
    "molecular_weight": 311.43,
    "log_p": 3.84,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "progesterone receptor agonist",
    "disease_area": "endocrinology | obstetrics/gynecology",
    "indication": "contraceptive | endometriosis"
  },
  "diethylamino hydroxybenzoyl hexyl benzoate": {
    "name": "Diethylamino hydroxybenzoyl hexyl benzoate",
    "smiles": "CCCCCCOC(=O)C1=CC=CC=C1C(=O)C1=CC=C(C=C1O)N(CC)CC",
    "molecular_weight": 397.52,
    "log_p": 5.21,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA"
  },
  "diethylcarbamazine": {
    "name": "Diethylcarbamazine",
    "smiles": "CCN(CC)C(=O)N1CCN(C)CC1",
    "molecular_weight": 199.3,
    "log_p": 0.7,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "lipoxygenase inhibitor",
    "disease_area": "infectious disease",
    "indication": "filariasis"
  },
  "diethylpropion": {
    "name": "Diethylpropion",
    "smiles": "CCN(CC)C(C)C(=O)C1=CC=CC=C1",
    "molecular_weight": 205.3,
    "log_p": 2.6,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "diethylstilbestrol": {
    "name": "Diethylstilbestrol",
    "smiles": "CC\\C(=C(\\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1",
    "molecular_weight": 268.36,
    "log_p": 4.83,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "estrogen receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "diethyltoluamide": {
    "name": "Diethyltoluamide",
    "smiles": "CCN(CC)C(=O)C1=CC(C)=CC=C1",
    "molecular_weight": 191.27,
    "log_p": 2.48,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ionotropic receptor IR40a activator",
    "disease_area": "dermatology",
    "indication": "sunscreen lotion"
  },
  "difelikefalin": {
    "name": "Difelikefalin",
    "smiles": "CC(C)C[C@@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O",
    "molecular_weight": 679.86,
    "log_p": 0.83,
    "hbd": 7,
    "hba": 8,
    "rotatable_bonds": 18,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "opioid receptor agonist",
    "disease_area": "nephrology",
    "indication": "uremic pruritus"
  },
  "difenoxin": {
    "name": "Difenoxin",
    "smiles": "OC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1",
    "molecular_weight": 424.54,
    "log_p": 5.0,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "diflorasone": {
    "name": "Diflorasone",
    "smiles": "[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C",
    "molecular_weight": 410.46,
    "log_p": 1.84,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "diflunisal": {
    "name": "Diflunisal",
    "smiles": "OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1",
    "molecular_weight": 250.2,
    "log_p": 3.04,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "prostanoid receptor antagonist",
    "disease_area": "rheumatology | rheumatology",
    "indication": "osteoarthritis | rheumatoid arthritis"
  },
  "difluocortolone": {
    "name": "Difluocortolone",
    "smiles": "[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C",
    "molecular_weight": 394.46,
    "log_p": 2.73,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "difluprednate": {
    "name": "Difluprednate",
    "smiles": "[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C",
    "molecular_weight": 508.56,
    "log_p": 3.52,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "ophthalmology",
    "indication": "endogenous uveitis"
  },
  "digitoxin": {
    "name": "Digitoxin",
    "smiles": "[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1",
    "molecular_weight": 764.95,
    "log_p": 3.25,
    "hbd": 5,
    "hba": 13,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATPase inhibitor",
    "disease_area": "cardiology | cardiology",
    "indication": "cardiac arrythmia | congestive heart failure"
  },
  "digoxin": {
    "name": "Digoxin",
    "smiles": "[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1",
    "molecular_weight": 780.95,
    "log_p": 2.22,
    "hbd": 6,
    "hba": 14,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATPase inhibitor",
    "disease_area": "cardiology | cardiology",
    "indication": "atrial fibrillation (AF) | congestive heart failure"
  },
  "dihydralazine": {
    "name": "Dihydralazine",
    "smiles": "NNC1=C2C=CC=CC2=C(NN)N=N1",
    "molecular_weight": 190.21,
    "log_p": 0.2,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "dihydro-alpha-ergocryptine": {
    "name": "Dihydro-alpha-ergocryptine",
    "smiles": "[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C",
    "molecular_weight": 577.73,
    "log_p": 2.52,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "dihydrocodeine": {
    "name": "Dihydrocodeine",
    "smiles": "[H][C@@]12OC3=C4C(C[C@H]5N(C)CC[C@@]14[C@@]5([H])CC[C@@H]2O)=CC=C3OC",
    "molecular_weight": 301.39,
    "log_p": 1.73,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "dihydroergocornine": {
    "name": "Dihydroergocornine",
    "smiles": "[H][C@@]12CCCN1C(=O)[C@H](C(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C",
    "molecular_weight": 563.7,
    "log_p": 2.13,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "dihydroergocristine": {
    "name": "Dihydroergocristine",
    "smiles": "[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C",
    "molecular_weight": 611.74,
    "log_p": 2.72,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist | prolactin inhibitor",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "cerebrovascular insufficiency | senile dementia"
  },
  "dihydroergotamine": {
    "name": "Dihydroergotamine",
    "smiles": "[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O",
    "molecular_weight": 583.69,
    "log_p": 2.08,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "migraine headache"
  },
  "dihydrostreptomycin": {
    "name": "Dihydrostreptomycin",
    "smiles": "CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO",
    "molecular_weight": 583.6,
    "log_p": -7.95,
    "hbd": 15,
    "hba": 15,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "bacterial 30S ribosomal subunit inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "dihydrotachysterol": {
    "name": "Dihydrotachysterol",
    "smiles": "CC(C)[C@@H](C)\\C=C\\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1/C[C@@H](O)CC[C@@H]1C",
    "molecular_weight": 398.68,
    "log_p": 7.72,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin analog",
    "disease_area": "endocrinology | endocrinology | orthopedics",
    "indication": "hypocalcemia | osteomalacia | rickets"
  },
  "diiodohydroxyquinoline": {
    "name": "Diiodohydroxyquinoline",
    "smiles": "OC1=C2N=CC=CC2=C(I)C=C1I",
    "molecular_weight": 396.95,
    "log_p": 3.15,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "diloxanide furoate": {
    "name": "Diloxanide furoate",
    "smiles": "CN(C(=O)C(Cl)Cl)C1=CC=C(OC(=O)C2=CC=CO2)C=C1",
    "molecular_weight": 328.15,
    "log_p": 3.27,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "diltiazem": {
    "name": "Diltiazem",
    "smiles": "COC1=CC=C(C=C1)[C@@H]1SC2=C(C=CC=C2)N(CCN(C)C)C(=O)[C@@H]1OC(C)=O",
    "molecular_weight": 414.53,
    "log_p": 3.37,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "cardiology | cardiology",
    "indication": "angina pectoris | hypertension"
  },
  "dimazole": {
    "name": "Dimazole",
    "smiles": "CCN(CC)CCOC1=CC2=C(C=C1)N=C(S2)N(C)C",
    "molecular_weight": 293.44,
    "log_p": 3.08,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "dimenhydrinate": {
    "name": "Dimenhydrinate",
    "smiles": "CN1C2=C(N=C(Cl)N2)C(=O)N(C)C1=O.CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 469.97,
    "log_p": 2.97,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "gastroenterology | gastroenterology | neurology/psychiatry",
    "indication": "motion sickness | nausea | vomiting"
  },
  "dimercaprol": {
    "name": "Dimercaprol",
    "smiles": "OCC(S)CS",
    "molecular_weight": 124.23,
    "log_p": 0.21,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "chelating agent",
    "disease_area": "neurology/psychiatry",
    "indication": "metal toxicity"
  },
  "dimercaptosuccinic acid": {
    "name": "Dimercaptosuccinic acid",
    "smiles": "OC(=O)C(S)C(S)C(O)=O",
    "molecular_weight": 182.22,
    "log_p": -0.25,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "dimethyl fumarate": {
    "name": "Dimethyl fumarate",
    "smiles": "[H]\\C(=C(\\[H])C(=O)OC)C(=O)OC",
    "molecular_weight": 144.13,
    "log_p": -0.11,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "dimethyl sulfoxide": {
    "name": "Dimethyl sulfoxide",
    "smiles": "CS(C)=O",
    "molecular_weight": 78.14,
    "log_p": -0.01,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "dimetindene": {
    "name": "Dimetindene",
    "smiles": "CC(C1=C(CCN(C)C)CC2=CC=CC=C12)C1=CC=CC=N1",
    "molecular_weight": 292.43,
    "log_p": 4.15,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cholinergic receptor antagonist | histamine receptor antagonist",
    "disease_area": "allergy",
    "indication": "allergic rhinitis"
  },
  "dimetotiazine": {
    "name": "Dimetotiazine",
    "smiles": "CC(CN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(=O)(=O)N(C)C)N(C)C",
    "molecular_weight": 391.56,
    "log_p": 3.49,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "dinoprost": {
    "name": "Dinoprost",
    "smiles": "[H]\\C(CCCC(O)=O)=C(/[H])C[C@@]1([H])[C@@]([H])(O)C[C@@]([H])(O)[C@]1([H])C(\\[H])=C(/[H])[C@@]([H])(O)CCCCC",
    "molecular_weight": 354.49,
    "log_p": 3.04,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "prostacyclin analog",
    "disease_area": "obstetrics/gynecology",
    "indication": "labor induction"
  },
  "dinoprost tromethamine": {
    "name": "Dinoprost tromethamine",
    "smiles": "NC(CO)(CO)CO.CCCCC[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(O)=O",
    "molecular_weight": 475.62,
    "log_p": 0.7,
    "hbd": 8,
    "hba": 8,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA"
  },
  "dinoprostone": {
    "name": "Dinoprostone",
    "smiles": "CCCCC[C@H](O)\\C=C\\[C@H]1[C@H](O)CC(=O)[C@@H]1C\\C=C/CCCC(O)=O",
    "molecular_weight": 352.47,
    "log_p": 3.25,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "prostanoid receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "dioctyldimonium": {
    "name": "Dioctyldimonium",
    "smiles": "CCCCCCCC[N+](C)(C)CCCCCCCC",
    "molecular_weight": 270.52,
    "log_p": 5.78,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 14,
    "approved": true,
    "source": "FDA"
  },
  "diosmin": {
    "name": "Diosmin",
    "smiles": "COC1=C(O)C=C(C=C1)C1=CC(=O)C2=C(O)C=C(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)C=C2O1",
    "molecular_weight": 608.55,
    "log_p": -1.09,
    "hbd": 8,
    "hba": 15,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "aryl hydrocarbon receptor agonist | capillary stabilizing agent",
    "disease_area": "cardiology | cardiology | cardiology | dermatology | hematology",
    "indication": "chronic venous insufficiency (CVI) | deep vein thrombosis (DVT) | edema | heavy leg syndrome | statis dermatitis"
  },
  "dioxybenzone": {
    "name": "Dioxybenzone",
    "smiles": "COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1O",
    "molecular_weight": 244.25,
    "log_p": 2.34,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Preclinical",
    "moa": "topical sunscreen agent",
    "disease_area": "",
    "indication": ""
  },
  "dipentamethylenethiuram disulfide": {
    "name": "Dipentamethylenethiuram disulfide",
    "smiles": "S=C(SSC(=S)N1CCCCC1)N1CCCCC1",
    "molecular_weight": 320.57,
    "log_p": 3.91,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "diphemanil": {
    "name": "Diphemanil",
    "smiles": "C[N+]1(C)CCC(CC1)=C(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 278.42,
    "log_p": 4.36,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "spasms"
  },
  "diphenhydramine": {
    "name": "Diphenhydramine",
    "smiles": "CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 255.36,
    "log_p": 3.35,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "headache"
  },
  "diphenidol": {
    "name": "Diphenidol",
    "smiles": "OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 309.45,
    "log_p": 4.19,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "vertigo"
  },
  "diphenoxylate": {
    "name": "Diphenoxylate",
    "smiles": "CCOC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1",
    "molecular_weight": 452.6,
    "log_p": 5.48,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "diphenylguanidine": {
    "name": "Diphenylguanidine",
    "smiles": "N=C(NC1=CC=CC=C1)NC1=CC=CC=C1",
    "molecular_weight": 211.27,
    "log_p": 3.15,
    "hbd": 3,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Preclinical",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "diphenylpyraline": {
    "name": "Diphenylpyraline",
    "smiles": "CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 281.4,
    "log_p": 3.89,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine reuptake inhibitor",
    "disease_area": "allergy",
    "indication": "allergic rhinitis"
  },
  "dipivefrin": {
    "name": "Dipivefrin",
    "smiles": "CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1",
    "molecular_weight": 351.44,
    "log_p": 2.84,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "dipotassium phosphate": {
    "name": "Dipotassium phosphate",
    "smiles": "[K+].[K+].OP([O-])([O-])=O",
    "molecular_weight": 174.17,
    "log_p": -8.18,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "dipyridamole": {
    "name": "Dipyridamole",
    "smiles": "OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1",
    "molecular_weight": 504.64,
    "log_p": -0.02,
    "hbd": 4,
    "hba": 12,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "cardiology | cardiology | cardiology",
    "indication": "coronary artery disease (CAD) | hypertension | peripheral artery disease (PAD)"
  },
  "dipyrithione": {
    "name": "Dipyrithione",
    "smiles": "[O-][N+]1=CC=CC=C1SSC1=CC=CC=[N+]1[O-]",
    "molecular_weight": 252.32,
    "log_p": 1.75,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "diroximel fumarate": {
    "name": "Diroximel fumarate",
    "smiles": "COC(=O)\\C=C\\C(=O)OCCN1C(=O)CCC1=O",
    "molecular_weight": 255.23,
    "log_p": -0.59,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "disopyramide": {
    "name": "Disopyramide",
    "smiles": "CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C",
    "molecular_weight": 339.48,
    "log_p": 3.36,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "cardiology | cardiology",
    "indication": "ventricular arrhythmias | ventricular tachycardia (VT)"
  },
  "disperse blue 106": {
    "name": "Disperse Blue 106",
    "smiles": "CCN(CCO)C1=CC=C(\\N=N\\C2=NC=C(S2)N(=O)=O)C(C)=C1",
    "molecular_weight": 335.39,
    "log_p": 3.59,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "distearyldimonium": {
    "name": "Distearyldimonium",
    "smiles": "CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC",
    "molecular_weight": 551.07,
    "log_p": 13.59,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 34,
    "approved": true,
    "source": "FDA"
  },
  "disulfiram": {
    "name": "Disulfiram",
    "smiles": "CCN(CC)C(=S)SSC(=S)N(CC)CC",
    "molecular_weight": 296.55,
    "log_p": 3.62,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "aldehyde dehydrogenase inhibitor | DNA methyltransferase inhibitor | TRPV agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "abstinence from alcohol"
  },
  "ditiocarb zinc": {
    "name": "Ditiocarb zinc",
    "smiles": "[Zn++].CCN(CC)C([S-])=S.CCN(CC)C([S-])=S",
    "molecular_weight": 361.94,
    "log_p": 2.32,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "dl-alpha tocopheryl acetate": {
    "name": "DL-alpha tocopheryl acetate",
    "smiles": "CC(C)CCCC(C)CCCC(C)CCCC1(C)CCC2=C(O1)C(C)=C(C)C(OC(C)=O)=C2C",
    "molecular_weight": 472.75,
    "log_p": 9.06,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA"
  },
  "dl-alpha-tocopherol": {
    "name": "DL-alpha-Tocopherol",
    "smiles": "CC(C)CCCC(C)CCCC(C)CCCC1(C)CCC2=C(C)C(O)=C(C)C(C)=C2O1",
    "molecular_weight": 430.72,
    "log_p": 8.84,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "dl-dimyristoylphosphatidylcholine": {
    "name": "DL-dimyristoylphosphatidylcholine",
    "smiles": "CCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC",
    "molecular_weight": 677.94,
    "log_p": 9.05,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 34,
    "approved": true,
    "source": "FDA"
  },
  "dl-dimyristoylphosphatidylglycerol": {
    "name": "DL-dimyristoylphosphatidylglycerol",
    "smiles": "CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC",
    "molecular_weight": 666.87,
    "log_p": 8.33,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 34,
    "approved": true,
    "source": "FDA"
  },
  "dl-methylephedrine": {
    "name": "DL-Methylephedrine",
    "smiles": "C[C@@H]([C@H](O)C1=CC=CC=C1)N(C)C",
    "molecular_weight": 179.26,
    "log_p": 1.67,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "d-methionine": {
    "name": "D-Methionine",
    "smiles": "CSCC[C@@H](N)C(O)=O",
    "molecular_weight": 149.22,
    "log_p": 0.15,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "dobutamine": {
    "name": "Dobutamine",
    "smiles": "CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1",
    "molecular_weight": 301.39,
    "log_p": 2.96,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "cardiology",
    "indication": "congestive heart failure"
  },
  "docetaxel": {
    "name": "Docetaxel",
    "smiles": "[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1",
    "molecular_weight": 807.89,
    "log_p": 3.26,
    "hbd": 5,
    "hba": 14,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "tubulin polymerization inhibitor",
    "disease_area": "oncology | oncology | oncology | oncology | oncology",
    "indication": "breast cancer | gastric adenocarcinoma | head and neck squamous cell carcinoma (HNSCC) | non-small cell lung cancer (NSCLC) | prostate cancer"
  },
  "doconexent": {
    "name": "Doconexent",
    "smiles": "CC\\C=C/C\\C=C/C\\C=C/C\\C=C/C\\C=C/C\\C=C/CCC(O)=O",
    "molecular_weight": 328.5,
    "log_p": 6.55,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 14,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PPAR receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "docosanol": {
    "name": "Docosanol",
    "smiles": "CCCCCCCCCCCCCCCCCCCCCCO",
    "molecular_weight": 326.61,
    "log_p": 7.8,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 20,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "lipase clearing factor inhibitor",
    "disease_area": "dental",
    "indication": "cold sore"
  },
  "docusate": {
    "name": "Docusate",
    "smiles": "CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(O)(=O)=O",
    "molecular_weight": 422.58,
    "log_p": 4.15,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 16,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "laxative",
    "disease_area": "gastroenterology",
    "indication": "constipation"
  },
  "dofetilide": {
    "name": "Dofetilide",
    "smiles": "CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1",
    "molecular_weight": 441.58,
    "log_p": 1.98,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "potassium channel blocker",
    "disease_area": "",
    "indication": ""
  },
  "dolasetron": {
    "name": "Dolasetron",
    "smiles": "[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2",
    "molecular_weight": 324.38,
    "log_p": 2.52,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor antagonist",
    "disease_area": "gastroenterology | gastroenterology",
    "indication": "nausea | vomiting"
  },
  "dolutegravir": {
    "name": "Dolutegravir",
    "smiles": "[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2",
    "molecular_weight": 419.38,
    "log_p": 1.35,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HIV integrase inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "domiphen": {
    "name": "Domiphen",
    "smiles": "CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1",
    "molecular_weight": 334.57,
    "log_p": 6.06,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Preclinical",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "domperidone": {
    "name": "Domperidone",
    "smiles": "ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2",
    "molecular_weight": 425.92,
    "log_p": 3.35,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "infectious disease",
    "indication": "fescue toxicosis"
  },
  "donepezil": {
    "name": "Donepezil",
    "smiles": "COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1",
    "molecular_weight": 379.5,
    "log_p": 4.36,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholinesterase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "Alzheimer's disease"
  },
  "dopamine": {
    "name": "Dopamine",
    "smiles": "NCCC1=CC(O)=C(O)C=C1",
    "molecular_weight": 153.18,
    "log_p": 0.6,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor agonist",
    "disease_area": "cardiology | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry",
    "indication": "depression | headache | tremors | ventricular arrhythmias"
  },
  "dopexamine": {
    "name": "Dopexamine",
    "smiles": "OC1=C(O)C=C(CCNCCCCCCNCCC2=CC=CC=C2)C=C1",
    "molecular_weight": 356.51,
    "log_p": 3.62,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA"
  },
  "doravirine": {
    "name": "Doravirine",
    "smiles": "CN1C(=O)NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F",
    "molecular_weight": 425.75,
    "log_p": 2.65,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "non-nucleoside reverse transcriptase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "doripenem": {
    "name": "Doripenem",
    "smiles": "[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O",
    "molecular_weight": 420.51,
    "log_p": -1.6,
    "hbd": 5,
    "hba": 7,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "intra-abdominal infections | pyelonephritis | urinary tract infections"
  },
  "dorzolamide": {
    "name": "Dorzolamide",
    "smiles": "CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O",
    "molecular_weight": 324.45,
    "log_p": 0.61,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "carbonic anhydrase inhibitor",
    "disease_area": "ophthalmology | ophthalmology",
    "indication": "glaucoma | intraocular pressure"
  },
  "dosulepin": {
    "name": "Dosulepin",
    "smiles": "CN(C)CC\\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12",
    "molecular_weight": 295.45,
    "log_p": 4.68,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "norepinephrine reuptake inhibitor | serotonin\u2013norepinephrine reuptake inhibitor (SNRI) | tricyclic antidepressant",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "dotatate": {
    "name": "Dotatate",
    "smiles": "C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O",
    "molecular_weight": 1435.65,
    "log_p": -3.37,
    "hbd": 17,
    "hba": 22,
    "rotatable_bonds": 26,
    "approved": true,
    "source": "FDA"
  },
  "dotatate gallium ga-68": {
    "name": "Dotatate gallium Ga-68",
    "smiles": "[68Ga+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O",
    "molecular_weight": 1500.55,
    "log_p": -7.76,
    "hbd": 14,
    "hba": 25,
    "rotatable_bonds": 26,
    "approved": true,
    "source": "FDA"
  },
  "doxacurium": {
    "name": "Doxacurium",
    "smiles": "COC1=CC(CC2C3=C(OC)C(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C(OC)=C3C2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC",
    "molecular_weight": 1035.24,
    "log_p": 7.71,
    "hbd": 0,
    "hba": 16,
    "rotatable_bonds": 27,
    "approved": true,
    "source": "FDA"
  },
  "doxapram": {
    "name": "Doxapram",
    "smiles": "CCN1CC(CCN2CCOCC2)C(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 378.52,
    "log_p": 3.17,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "potassium channel blocker",
    "disease_area": "neurology/psychiatry | pulmonary | pulmonary",
    "indication": "acute hypercapnia (AHC) | central nervous system depression | respiratory depression"
  },
  "doxazosin": {
    "name": "Doxazosin",
    "smiles": "COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1",
    "molecular_weight": 451.48,
    "log_p": 1.72,
    "hbd": 1,
    "hba": 9,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology | urology",
    "indication": "benign prostatic hyperplasia (BPH) | hypertension"
  },
  "doxepin": {
    "name": "Doxepin",
    "smiles": "[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12",
    "molecular_weight": 279.38,
    "log_p": 3.96,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "anxiety | depression"
  },
  "doxercalciferol": {
    "name": "Doxercalciferol",
    "smiles": "[H][C@@]1(CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\\C=C\\[C@H](C)C(C)C",
    "molecular_weight": 412.66,
    "log_p": 6.61,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin D receptor agonist",
    "disease_area": "endocrinology | nephrology",
    "indication": "chronic kidney disease (CKD) | hyperparathyroidism"
  },
  "doxorubicin": {
    "name": "Doxorubicin",
    "smiles": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O",
    "molecular_weight": 543.53,
    "log_p": 0.0,
    "hbd": 6,
    "hba": 12,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dna polymerase inhibitor | topoisomerase inhibitor",
    "disease_area": "hematologic malignancy | hematologic malignancy | hematologic malignancy | hematologic malignancy | oncology | oncology | oncology | oncology",
    "indication": "acute lymphoblastic leukemia (ALL) | acute myeloid leukemia (AML) | bladder cancer | breast cancer | Hodgkin's lymphoma | multiple myeloma | ovarian cancer | Wilm's tumor"
  },
  "doxycycline": {
    "name": "Doxycycline",
    "smiles": "[H][C@@]12[C@@H](C)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O",
    "molecular_weight": 444.44,
    "log_p": -0.35,
    "hbd": 6,
    "hba": 9,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor | metalloproteinase inhibitor",
    "disease_area": "dental",
    "indication": "periodontitis"
  },
  "doxylamine": {
    "name": "Doxylamine",
    "smiles": "CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1",
    "molecular_weight": 270.38,
    "log_p": 2.92,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "sedative"
  },
  "drometrizole trisiloxane": {
    "name": "Drometrizole trisiloxane",
    "smiles": "CC(CC1=C(O)C(=CC(C)=C1)N1N=C2C=CC=CC2=N1)C[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C",
    "molecular_weight": 501.85,
    "log_p": 6.39,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "dronabinol": {
    "name": "Dronabinol",
    "smiles": "[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1",
    "molecular_weight": 314.47,
    "log_p": 5.74,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "dronedarone": {
    "name": "Dronedarone",
    "smiles": "CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2",
    "molecular_weight": 556.77,
    "log_p": 7.05,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 18,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology",
    "indication": "atrial fibrillation (AF)"
  },
  "droperidol": {
    "name": "Droperidol",
    "smiles": "FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=CC=CC=C12",
    "molecular_weight": 379.44,
    "log_p": 3.68,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "gastroenterology | gastroenterology",
    "indication": "nausea | vomiting"
  },
  "drospirenone": {
    "name": "Drospirenone",
    "smiles": "[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21",
    "molecular_weight": 366.5,
    "log_p": 4.31,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "mineralocorticoid receptor antagonist",
    "disease_area": "endocrinology",
    "indication": "contraceptive"
  },
  "drostanolone propionate": {
    "name": "Drostanolone propionate",
    "smiles": "[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)[C@H](C)C[C@]12C",
    "molecular_weight": 360.54,
    "log_p": 5.17,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "drotaverine": {
    "name": "Drotaverine",
    "smiles": "CCOC1=C(OCC)C=C(\\C=C2/NCCC3=CC(OCC)=C(OCC)C=C23)C=C1",
    "molecular_weight": 397.52,
    "log_p": 4.93,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "obstetrics/gynecology",
    "indication": "labor induction"
  },
  "droxidopa": {
    "name": "Droxidopa",
    "smiles": "N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O",
    "molecular_weight": 213.19,
    "log_p": -0.46,
    "hbd": 5,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "norepinephrine precursor",
    "disease_area": "cardiology | neurology/psychiatry",
    "indication": "hypertension | Parkinson's Disease"
  },
  "d-serine": {
    "name": "D-Serine",
    "smiles": "N[C@H](CO)C(O)=O",
    "molecular_weight": 105.09,
    "log_p": -1.61,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glutamate receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "duloxetine": {
    "name": "Duloxetine",
    "smiles": "CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1",
    "molecular_weight": 297.42,
    "log_p": 4.63,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "norepinephrine reuptake inhibitor | serotonin\u2013norepinephrine reuptake inhibitor (SNRI)",
    "disease_area": "neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry",
    "indication": "depression | generalized anxiety disorder (GAD) | muscle pain | peripheral neuropathy"
  },
  "dutasteride": {
    "name": "Dutasteride",
    "smiles": "[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])NC(=O)C=C[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)NC1=CC(=CC=C1C(F)(F)F)C(F)(F)F",
    "molecular_weight": 528.54,
    "log_p": 6.58,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "5 alpha reductase inhibitor",
    "disease_area": "urology",
    "indication": "benign prostatic hyperplasia (BPH)"
  },
  "duvelisib": {
    "name": "Duvelisib",
    "smiles": "C[C@H](NC1=C2N=CNC2=NC=N1)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1",
    "molecular_weight": 416.87,
    "log_p": 4.48,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PI3K inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "dyclonine": {
    "name": "Dyclonine",
    "smiles": "CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1",
    "molecular_weight": 289.42,
    "log_p": 3.92,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "neurology/psychiatry",
    "indication": "local anesthetic"
  },
  "dydrogesterone": {
    "name": "Dydrogesterone",
    "smiles": "[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C",
    "molecular_weight": 312.45,
    "log_p": 4.5,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "progesterone receptor agonist",
    "disease_area": "obstetrics/gynecology",
    "indication": "infertility"
  },
  "dyphylline": {
    "name": "Dyphylline",
    "smiles": "CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O",
    "molecular_weight": 254.25,
    "log_p": -2.21,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adenosine receptor antagonist | phosphodiesterase inhibitor",
    "disease_area": "pulmonary | pulmonary | pulmonary",
    "indication": "asthma | bronchitis | emphysema"
  },
  "ebastine": {
    "name": "Ebastine",
    "smiles": "CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 469.67,
    "log_p": 7.22,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy | allergy",
    "indication": "allergic rhinitis | urticaria"
  },
  "ecamsule": {
    "name": "Ecamsule",
    "smiles": "CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)C2=CC1=CC=C(C=C2C3CCC(CS(O)(=O)=O)(C2=O)C3(C)C)C=C1",
    "molecular_weight": 562.71,
    "log_p": 4.24,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "echothiophate": {
    "name": "Echothiophate",
    "smiles": "CCOP(=O)(OCC)SCC[N+](C)(C)C",
    "molecular_weight": 256.33,
    "log_p": 2.61,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "econazole": {
    "name": "Econazole",
    "smiles": "ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1",
    "molecular_weight": 381.69,
    "log_p": 5.8,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "lanosterol demethylase inhibitor | sterol demethylase inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "cutaneous candidiasis | tinea corporis | tinea cruris | tinea pedis | tinea versicolor"
  },
  "edaravone": {
    "name": "Edaravone",
    "smiles": "CC1=NN(C(=O)C1)C1=CC=CC=C1",
    "molecular_weight": 174.2,
    "log_p": 1.8,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "nootropic agent",
    "disease_area": "neurology/psychiatry",
    "indication": "stroke"
  },
  "edetate calcium disodium anhydrous": {
    "name": "Edetate calcium disodium anhydrous",
    "smiles": "[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O",
    "molecular_weight": 374.27,
    "log_p": -13.78,
    "hbd": 0,
    "hba": 10,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA"
  },
  "edetate disodium anhydrous": {
    "name": "Edetate disodium anhydrous",
    "smiles": "[Na+].[Na+].OC(=O)CN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O",
    "molecular_weight": 336.21,
    "log_p": -10.73,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA"
  },
  "edetic acid": {
    "name": "Edetic acid",
    "smiles": "OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O",
    "molecular_weight": 292.24,
    "log_p": -2.07,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA"
  },
  "edotreotide gallium ga-68": {
    "name": "Edotreotide gallium Ga-68",
    "smiles": "[68Ga+3].C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1",
    "molecular_weight": 1486.57,
    "log_p": -7.85,
    "hbd": 14,
    "hba": 25,
    "rotatable_bonds": 26,
    "approved": true,
    "source": "FDA"
  },
  "edoxaban": {
    "name": "Edoxaban",
    "smiles": "CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1",
    "molecular_weight": 548.07,
    "log_p": 1.29,
    "hbd": 3,
    "hba": 8,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "coagulation factor inhibitor",
    "disease_area": "cardiology | hematology | hematology | hematology | neurology/psychiatry",
    "indication": "atrial fibrillation (AF) | deep vein thrombosis (DVT) | pulmonary embolism (PE) | stroke | systemic embolism"
  },
  "edoxudine": {
    "name": "Edoxudine",
    "smiles": "CCC1=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)NC1=O",
    "molecular_weight": 256.26,
    "log_p": -1.26,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA directed DNA polymerase inhibitor",
    "disease_area": "infectious disease",
    "indication": "virus herpes simplex (HSV)"
  },
  "edrophonium": {
    "name": "Edrophonium",
    "smiles": "CC[N+](C)(C)C1=CC(O)=CC=C1",
    "molecular_weight": 166.24,
    "log_p": 1.98,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholinesterase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "myasthenia gravis"
  },
  "efavirenz": {
    "name": "Efavirenz",
    "smiles": "FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1",
    "molecular_weight": 315.68,
    "log_p": 4.07,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HIV protease inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "efinaconazole": {
    "name": "Efinaconazole",
    "smiles": "C[C@@H](N1CCC(=C)CC1)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1",
    "molecular_weight": 348.4,
    "log_p": 2.48,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "fungal lanosterol demethylase inhibitor | lanosterol demethylase inhibitor",
    "disease_area": "infectious disease | Infectious disease",
    "indication": "fungal infection | onychomycosis"
  },
  "eflornithine": {
    "name": "Eflornithine",
    "smiles": "NCCCC(N)(C(F)F)C(O)=O",
    "molecular_weight": 182.17,
    "log_p": -0.23,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ornithine decarboxylase inhibitor",
    "disease_area": "dermatology",
    "indication": "facial hair reduction"
  },
  "elagolix": {
    "name": "Elagolix",
    "smiles": "COC1=CC=CC(=C1F)C1=C(C)N(CC2=C(C=CC=C2F)C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2=CC=CC=C2)C1=O",
    "molecular_weight": 631.6,
    "log_p": 5.54,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "gonadotropin releasing factor hormone receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "elbasvir": {
    "name": "Elbasvir",
    "smiles": "[H][C@]1(CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C)C1=NC=C(N1)C1=CC2=C(C=C1)N1[C@@H](OC3=C(C=CC(=C3)C3=CN=C(N3)[C@]3([H])CCCN3C(=O)[C@@H](NC(=O)OC)C(C)C)C1=C2)C1=CC=CC=C1",
    "molecular_weight": 882.03,
    "log_p": 8.12,
    "hbd": 4,
    "hba": 10,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HCV inhibitor",
    "disease_area": "infectious disease",
    "indication": "hepatitis C"
  },
  "eletriptan": {
    "name": "Eletriptan",
    "smiles": "CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2",
    "molecular_weight": 382.53,
    "log_p": 3.82,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "migraine headache"
  },
  "elexacaftor": {
    "name": "Elexacaftor",
    "smiles": "C[C@@H]1CN(C2=NC(=CC=C2C(=O)NS(=O)(=O)C2=CN(C)N=C2C)N2C=CC(OCC(C)(C)C(F)(F)F)=N2)C(C)(C)C1",
    "molecular_weight": 597.66,
    "log_p": 4.02,
    "hbd": 1,
    "hba": 10,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cystic fibrosis transmembrane conductance regulator inhibitor",
    "disease_area": "pulmonary",
    "indication": "cystic fibrosis"
  },
  "eliglustat": {
    "name": "Eliglustat",
    "smiles": "CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C1=CC=C2OCCOC2=C1",
    "molecular_weight": 404.55,
    "log_p": 3.43,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glycosyl transferase inhibitor",
    "disease_area": "hematology",
    "indication": "Gaucher disease"
  },
  "eltrombopag": {
    "name": "Eltrombopag",
    "smiles": "CC1=NN(C(=O)\\C1=N/NC1=CC=CC(C2=CC=CC(=C2)C(O)=O)=C1O)C1=CC=C(C)C(C)=C1",
    "molecular_weight": 442.48,
    "log_p": 4.56,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "thrombopoietin receptor agonist",
    "disease_area": "hematology | hematology | hematology, infectious disease | infectious disease",
    "indication": "anemia | anemia, hepatitis c, thrombocytopenia | hepatitis C | thrombocytopenia"
  },
  "eluxadoline": {
    "name": "Eluxadoline",
    "smiles": "COC1=CC=C(CN([C@@H](C)C2=NC(=CN2)C2=CC=CC=C2)C(=O)[C@@H](N)CC2=C(C)C=C(C=C2C)C(N)=O)C=C1C(O)=O",
    "molecular_weight": 569.66,
    "log_p": 4.16,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "opioid receptor agonist | opioid receptor antagonist",
    "disease_area": "gastroenterology",
    "indication": "irritable bowel syndrome"
  },
  "elvitegravir": {
    "name": "Elvitegravir",
    "smiles": "[H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2",
    "molecular_weight": 447.89,
    "log_p": 4.28,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HIV integrase inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "emedastine": {
    "name": "Emedastine",
    "smiles": "CCOCCN1C(=NC2=CC=CC=C12)N1CCCN(C)CC1",
    "molecular_weight": 302.42,
    "log_p": 2.21,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "ophthalmology",
    "indication": "conjunctivitis"
  },
  "empagliflozin": {
    "name": "Empagliflozin",
    "smiles": "OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(Cl)C(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C1",
    "molecular_weight": 450.92,
    "log_p": 1.61,
    "hbd": 4,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium/glucose cotransporter inhibitor",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "emtricitabine": {
    "name": "Emtricitabine",
    "smiles": "NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1",
    "molecular_weight": 247.25,
    "log_p": -0.46,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "nucleoside reverse transcriptase inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "enalapril": {
    "name": "Enalapril",
    "smiles": "CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O",
    "molecular_weight": 376.45,
    "log_p": 1.6,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin converting enzyme inhibitor",
    "disease_area": "cardiology | cardiology | cardiology",
    "indication": "congestive heart failure | hypertension | left ventricular systolic dysfunction (LVSD)"
  },
  "enalaprilat": {
    "name": "Enalaprilat",
    "smiles": "[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@@]1([H])C(O)=O",
    "molecular_weight": 348.4,
    "log_p": 1.13,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin converting enzyme inhibitor",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "enasidenib": {
    "name": "Enasidenib",
    "smiles": "CC(C)(O)CNC1=NC(=NC(NC2=CC(=NC=C2)C(F)(F)F)=N1)C1=NC(=CC=C1)C(F)(F)F",
    "molecular_weight": 473.38,
    "log_p": 4.29,
    "hbd": 3,
    "hba": 8,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "isocitrate dehydrogenase inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "acute myeloid leukemia (AML)"
  },
  "encainide": {
    "name": "Encainide",
    "smiles": "COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C",
    "molecular_weight": 352.48,
    "log_p": 4.36,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "encorafenib": {
    "name": "Encorafenib",
    "smiles": "COC(=O)N[C@@H](C)CNC1=NC=CC(=N1)C1=CN(N=C1C1=CC(Cl)=CC(NS(C)(=O)=O)=C1F)C(C)C",
    "molecular_weight": 540.02,
    "log_p": 3.91,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "RAF inhibitor | serine/threonine kinase inhibitor",
    "disease_area": "oncology",
    "indication": "melanoma"
  },
  "enflurane": {
    "name": "Enflurane",
    "smiles": "FC(F)OC(F)(F)C(F)Cl",
    "molecular_weight": 184.49,
    "log_p": 2.35,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "membrane permeability inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "anesthetic"
  },
  "enoxacin": {
    "name": "Enoxacin",
    "smiles": "CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1",
    "molecular_weight": 320.32,
    "log_p": 0.66,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "topoisomerase inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "gonorrhea | urinary tract infections"
  },
  "enoximone": {
    "name": "Enoximone",
    "smiles": "CSC1=CC=C(C=C1)C(=O)C1=C(C)NC(=O)N1",
    "molecular_weight": 248.31,
    "log_p": 1.96,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "cardiology",
    "indication": "congestive heart failure"
  },
  "enprofylline": {
    "name": "Enprofylline",
    "smiles": "CCCN1C2=C(NC=N2)C(=O)NC1=O",
    "molecular_weight": 194.19,
    "log_p": -0.18,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "ensulizole": {
    "name": "Ensulizole",
    "smiles": "OS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C1=CC=CC=C1",
    "molecular_weight": 274.3,
    "log_p": 2.48,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "entacapone": {
    "name": "Entacapone",
    "smiles": "CCN(CC)C(=O)C(=C\\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\\C#N",
    "molecular_weight": 305.29,
    "log_p": 1.78,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "catechol O methyltransferase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "Parkinson's Disease"
  },
  "entecavir": {
    "name": "Entecavir",
    "smiles": "NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C",
    "molecular_weight": 277.28,
    "log_p": -0.83,
    "hbd": 4,
    "hba": 7,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA replication inhibitor | nucleoside reverse transcriptase inhibitor",
    "disease_area": "infectious disease",
    "indication": "hepatitis B"
  },
  "entrectinib": {
    "name": "Entrectinib",
    "smiles": "CN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=CC=C(CC4=CC(F)=CC(F)=C4)C=C23)C(NC2CCOCC2)=C1",
    "molecular_weight": 560.65,
    "log_p": 5.03,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ALK tyrosine kinase receptor inhibitor | proto-oncogene tyrosine protein kinase inhibitor",
    "disease_area": "oncology",
    "indication": "non-small cell lung cancer (NSCLC)"
  },
  "enzacamene": {
    "name": "Enzacamene",
    "smiles": "CC1=CC=C(\\C=C2/C3CCC(C)(C2=O)C3(C)C)C=C1",
    "molecular_weight": 254.37,
    "log_p": 4.4,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "enzalutamide": {
    "name": "Enzalutamide",
    "smiles": "CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F",
    "molecular_weight": 464.44,
    "log_p": 3.99,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "androgen receptor antagonist",
    "disease_area": "oncology",
    "indication": "prostate cancer"
  },
  "ephedrine": {
    "name": "Ephedrine",
    "smiles": "CN[C@@H](C)[C@H](O)C1=CC=CC=C1",
    "molecular_weight": 165.24,
    "log_p": 1.33,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "cardiology | endocrinology | neurology/psychiatry | pulmonary",
    "indication": "asthma | hypotension | narcolepsy | obesity"
  },
  "epicriptine": {
    "name": "Epicriptine",
    "smiles": "[H][C@@]12CCCN1C(=O)[C@]([H])([C@H](C)CC)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C",
    "molecular_weight": 577.73,
    "log_p": 2.52,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "epinastine": {
    "name": "Epinastine",
    "smiles": "NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21",
    "molecular_weight": 249.32,
    "log_p": 2.47,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "ophthalmology",
    "indication": "conjunctivitis"
  },
  "epinephrine": {
    "name": "Epinephrine",
    "smiles": "CNC[C@H](O)C1=CC(O)=C(O)C=C1",
    "molecular_weight": 183.21,
    "log_p": 0.35,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist | carbonic anhydrase activator | neurotransmitter",
    "disease_area": "allergy | cardiology | pulmonary",
    "indication": "anaphylactic shock | asthma | cardiac arrest"
  },
  "epirubicin": {
    "name": "Epirubicin",
    "smiles": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O",
    "molecular_weight": 543.53,
    "log_p": 0.0,
    "hbd": 6,
    "hba": 12,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "topoisomerase inhibitor",
    "disease_area": "oncology",
    "indication": "breast cancer"
  },
  "eplerenone": {
    "name": "Eplerenone",
    "smiles": "[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC",
    "molecular_weight": 414.5,
    "log_p": 3.12,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cytochrome P450 inhibitor",
    "disease_area": "cardiology | cardiology",
    "indication": "congestive heart failure | hypertension"
  },
  "epoprostenol": {
    "name": "Epoprostenol",
    "smiles": "[H][C@]12C[C@@H](O)[C@H](\\C=C\\[C@@H](O)CCCCC)[C@@]1([H])C\\C(O2)=C\\CCCC(O)=O",
    "molecular_weight": 352.47,
    "log_p": 3.41,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "prostacyclin analog",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "eprosartan": {
    "name": "Eprosartan",
    "smiles": "CCCCC1=NC=C(\\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O",
    "molecular_weight": 424.52,
    "log_p": 4.74,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin receptor antagonist",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "eravacycline": {
    "name": "Eravacycline",
    "smiles": "[H][C@@]12CC3=C(F)C=C(NC(=O)CN4CCCC4)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2",
    "molecular_weight": 558.56,
    "log_p": 0.29,
    "hbd": 6,
    "hba": 10,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antibacterial | bacterial 30s ribosomal subunit inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-positive bacterial infections"
  },
  "erdafitinib": {
    "name": "Erdafitinib",
    "smiles": "COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C1",
    "molecular_weight": 446.56,
    "log_p": 4.18,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "FGFR inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "erdosteine": {
    "name": "Erdosteine",
    "smiles": "OC(=O)CSCC(=O)NC1CCSC1=O",
    "molecular_weight": 249.31,
    "log_p": -0.05,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "mucolytic agent",
    "disease_area": "infectious disease | pulmonary | pulmonary | pulmonary",
    "indication": "bronchitis | chronic obstructive pulmonary disease (COPD) | cough suppressant | respiratory tract infections"
  },
  "ergocalciferol": {
    "name": "Ergocalciferol",
    "smiles": "CC(C)[C@@H](C)\\C=C\\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)CCC1=C",
    "molecular_weight": 396.66,
    "log_p": 7.64,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin analog",
    "disease_area": "endocrinology | endocrinology | orthopedics",
    "indication": "hypoparathyroidism | hypophosphatemia | rickets"
  },
  "ergometrine": {
    "name": "Ergometrine",
    "smiles": "[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](C)CO",
    "molecular_weight": 325.41,
    "log_p": 1.53,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "ergosterol": {
    "name": "Ergosterol",
    "smiles": "CC(C)[C@@H](C)\\C=C\\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",
    "molecular_weight": 396.66,
    "log_p": 7.33,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Preclinical",
    "moa": "vitamin D precursor",
    "disease_area": "",
    "indication": ""
  },
  "ergotamine": {
    "name": "Ergotamine",
    "smiles": "[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O",
    "molecular_weight": 581.67,
    "log_p": 1.99,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "migraine headache"
  },
  "eribulin": {
    "name": "Eribulin",
    "smiles": "[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@H]7O[C@@]8(C[C@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2",
    "molecular_weight": 729.91,
    "log_p": 3.44,
    "hbd": 2,
    "hba": 12,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "microtubule inhibitor",
    "disease_area": "oncology",
    "indication": "breast cancer"
  },
  "erlotinib": {
    "name": "Erlotinib",
    "smiles": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2",
    "molecular_weight": 393.44,
    "log_p": 3.41,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "EGFR inhibitor",
    "disease_area": "oncology | oncology",
    "indication": "non-small cell lung cancer (NSCLC) | pancreatic cancer"
  },
  "ertapenem": {
    "name": "Ertapenem",
    "smiles": "[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@@]([H])(C3)C(=O)NC3=CC=CC(=C3)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O",
    "molecular_weight": 475.52,
    "log_p": 0.94,
    "hbd": 5,
    "hba": 7,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "gynecologic infections | intra-abdominal infections | pneumonia | postpartum endomyometritis | skin infections | urinary tract infections"
  },
  "ertugliflozin": {
    "name": "Ertugliflozin",
    "smiles": "CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1",
    "molecular_weight": 436.89,
    "log_p": 1.36,
    "hbd": 4,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium/glucose cotransporter inhibitor",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "erythrityl tetranitrate": {
    "name": "Erythrityl tetranitrate",
    "smiles": "[O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O",
    "molecular_weight": 302.11,
    "log_p": -1.44,
    "hbd": 0,
    "hba": 12,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA"
  },
  "erythromycin": {
    "name": "Erythromycin",
    "smiles": "CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O",
    "molecular_weight": 733.94,
    "log_p": 1.79,
    "hbd": 5,
    "hba": 14,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "NFkB pathway inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "amebiasis | chlamydia | diphtheria | erythrasma | listeria | pelvic inflammatory disease | respiratory tract infections | skin infections | syphilis"
  },
  "escitalopram": {
    "name": "Escitalopram",
    "smiles": "CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1",
    "molecular_weight": 324.4,
    "log_p": 3.81,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "selective serotonin reuptake inhibitor (SSRI)",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "depression | generalized anxiety disorder (GAD)"
  },
  "esculin": {
    "name": "Esculin",
    "smiles": "OC[C@H]1O[C@@H](OC2=C(O)C=C3OC(=O)C=CC3=C2)[C@H](O)[C@@H](O)[C@@H]1O",
    "molecular_weight": 340.28,
    "log_p": -1.32,
    "hbd": 5,
    "hba": 9,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 1",
    "moa": "antioxidant",
    "disease_area": "",
    "indication": ""
  },
  "esketamine": {
    "name": "Esketamine",
    "smiles": "CN[C@@]1(CCCCC1=O)C1=CC=CC=C1Cl",
    "molecular_weight": 237.73,
    "log_p": 2.9,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "eslicarbazepine": {
    "name": "Eslicarbazepine",
    "smiles": "NC(=O)N1C2=C(C[C@H](O)C3=C1C=CC=C3)C=CC=C2",
    "molecular_weight": 254.29,
    "log_p": 2.49,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "eslicarbazepine acetate": {
    "name": "Eslicarbazepine acetate",
    "smiles": "CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12",
    "molecular_weight": 296.33,
    "log_p": 3.06,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "esmolol": {
    "name": "Esmolol",
    "smiles": "COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1",
    "molecular_weight": 295.38,
    "log_p": 1.53,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology | cardiology",
    "indication": "hypertension | ventricular tachycardia (VT)"
  },
  "esomeprazole": {
    "name": "Esomeprazole",
    "smiles": "COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1",
    "molecular_weight": 345.42,
    "log_p": 2.9,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATPase inhibitor",
    "disease_area": "gastroenterology | gastroenterology | gastroenterology",
    "indication": "gastroesophageal reflux disease (GERD) | peptic ulcer disease (PUD) | Zollinger-Ellison syndrome"
  },
  "estazolam": {
    "name": "Estazolam",
    "smiles": "ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1",
    "molecular_weight": 294.75,
    "log_p": 3.27,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "estetrol": {
    "name": "Estetrol",
    "smiles": "[H][C@@]12[C@@H](O)[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3CC[C@@]21[H]",
    "molecular_weight": 304.39,
    "log_p": 1.55,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "selective estrogen receptor modulator (SERM)",
    "disease_area": "",
    "indication": ""
  },
  "estradiol": {
    "name": "Estradiol",
    "smiles": "[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3",
    "molecular_weight": 272.39,
    "log_p": 3.61,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "estrogen receptor agonist",
    "disease_area": "endocrinology",
    "indication": "contraceptive"
  },
  "estradiol acetate": {
    "name": "Estradiol acetate",
    "smiles": "[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(C)=O)C=C3CC[C@@]21[H]",
    "molecular_weight": 314.43,
    "log_p": 3.83,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "estradiol benzoate": {
    "name": "Estradiol benzoate",
    "smiles": "[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(OC(=O)C5=CC=CC=C5)=CC=C4[C@@]3([H])CC[C@]12C",
    "molecular_weight": 376.5,
    "log_p": 5.12,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "estradiol cypionate": {
    "name": "Estradiol cypionate",
    "smiles": "[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1",
    "molecular_weight": 396.57,
    "log_p": 6.13,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "estrogen receptor agonist",
    "disease_area": "endocrinology",
    "indication": "hypoestrogenism, menopause"
  },
  "estradiol dienanthate": {
    "name": "Estradiol dienanthate",
    "smiles": "CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(OC(=O)CCCCCC)=CC=C4[C@H]3CC[C@]12C",
    "molecular_weight": 496.73,
    "log_p": 8.3,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "estradiol valerate": {
    "name": "Estradiol valerate",
    "smiles": "[H][C@@]12CC[C@H](OC(=O)CCCC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3",
    "molecular_weight": 356.51,
    "log_p": 5.35,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "estramustine": {
    "name": "Estramustine",
    "smiles": "[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H]",
    "molecular_weight": 440.41,
    "log_p": 5.18,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA alkylating agent",
    "disease_area": "oncology | Oncology",
    "indication": "breast cancer | prostate cancer"
  },
  "estramustine phosphate": {
    "name": "Estramustine phosphate",
    "smiles": "[H][C@@]12CC[C@H](OP(O)(O)=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC(=O)N(CCCl)CCCl)C=C3",
    "molecular_weight": 520.39,
    "log_p": 5.3,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "estriol": {
    "name": "Estriol",
    "smiles": "[H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3",
    "molecular_weight": 288.39,
    "log_p": 2.58,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "estrogen receptor agonist",
    "disease_area": "endocrinology | infectious disease | obstetrics/gynecology",
    "indication": "menopause | urinary tract infections | vaginal atrophy"
  },
  "estrone": {
    "name": "Estrone",
    "smiles": "[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3",
    "molecular_weight": 270.37,
    "log_p": 3.82,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "estrogenic hormone | estrogen receptor agonist",
    "disease_area": "endocrinology",
    "indication": "menopause"
  },
  "estrone sulfate": {
    "name": "Estrone sulfate",
    "smiles": "[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OS(O)(=O)=O)C=C3",
    "molecular_weight": 350.44,
    "log_p": 3.29,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "eszopiclone": {
    "name": "Eszopiclone",
    "smiles": "CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1",
    "molecular_weight": 388.82,
    "log_p": 1.57,
    "hbd": 0,
    "hba": 7,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "etacrynic acid": {
    "name": "Etacrynic acid",
    "smiles": "CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1",
    "molecular_weight": 303.14,
    "log_p": 3.61,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "etafedrine": {
    "name": "Etafedrine",
    "smiles": "CCN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1",
    "molecular_weight": 193.29,
    "log_p": 2.06,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "etelcalcetide": {
    "name": "Etelcalcetide",
    "smiles": "C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O",
    "molecular_weight": 1048.27,
    "log_p": -7.23,
    "hbd": 22,
    "hba": 16,
    "rotatable_bonds": 36,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium-sensing receptor agonist",
    "disease_area": "endocrinology",
    "indication": "hyperparathyroidism"
  },
  "ethambutol": {
    "name": "Ethambutol",
    "smiles": "CC[C@@H](CO)NCCN[C@@H](CC)CO",
    "molecular_weight": 204.31,
    "log_p": -0.29,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "tuberculosis"
  },
  "ethanol": {
    "name": "Ethanol",
    "smiles": "CCO",
    "molecular_weight": 46.07,
    "log_p": -0.0,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "ethanolamine oleate": {
    "name": "Ethanolamine oleate",
    "smiles": "NCCO.CCCCCCCC\\C=C/CCCCCCCC(O)=O",
    "molecular_weight": 343.55,
    "log_p": 5.05,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 16,
    "approved": true,
    "source": "FDA"
  },
  "ethchlorvynol": {
    "name": "Ethchlorvynol",
    "smiles": "CCC(O)(\\C=C\\Cl)C#C",
    "molecular_weight": 144.6,
    "log_p": 1.51,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "ethinamate": {
    "name": "Ethinamate",
    "smiles": "NC(=O)OC1(CCCCC1)C#C",
    "molecular_weight": 167.21,
    "log_p": 1.42,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "ethinylestradiol": {
    "name": "Ethinylestradiol",
    "smiles": "[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3",
    "molecular_weight": 296.41,
    "log_p": 3.61,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "ethionamide": {
    "name": "Ethionamide",
    "smiles": "CCC1=NC=CC(=C1)C(N)=S",
    "molecular_weight": 166.25,
    "log_p": 1.28,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "mycolic synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "tuberculosis"
  },
  "ethoheptazine": {
    "name": "Ethoheptazine",
    "smiles": "CCOC(=O)C1(CCCN(C)CC1)C1=CC=CC=C1",
    "molecular_weight": 261.36,
    "log_p": 2.6,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "ethosuximide": {
    "name": "Ethosuximide",
    "smiles": "CCC1(C)CC(=O)NC1=O",
    "molecular_weight": 141.17,
    "log_p": 0.45,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "succinimide antiepileptic",
    "disease_area": "neurology/psychiatry",
    "indication": "epilepsy"
  },
  "ethotoin": {
    "name": "Ethotoin",
    "smiles": "CCN1C(=O)NC(C1=O)C1=CC=CC=C1",
    "molecular_weight": 204.23,
    "log_p": 1.3,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "hydantoin antiepileptic",
    "disease_area": "neurology/psychiatry",
    "indication": "seizures"
  },
  "ethyl chloride": {
    "name": "Ethyl chloride",
    "smiles": "CCCl",
    "molecular_weight": 64.52,
    "log_p": 1.25,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "ethyl ferulate": {
    "name": "Ethyl ferulate",
    "smiles": "[H]\\C(=C(\\[H])C1=CC(OC)=C(O)C=C1)C(=O)OCC",
    "molecular_weight": 222.24,
    "log_p": 1.98,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "ethyl hydroxybenzoate": {
    "name": "Ethyl hydroxybenzoate",
    "smiles": "CCOC(=O)C1=CC=C(O)C=C1",
    "molecular_weight": 166.18,
    "log_p": 1.57,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "ethyl salicylate": {
    "name": "Ethyl salicylate",
    "smiles": "CCOC(=O)C1=CC=CC=C1O",
    "molecular_weight": 166.18,
    "log_p": 1.57,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "ethylenediamine": {
    "name": "Ethylenediamine",
    "smiles": "NCCN",
    "molecular_weight": 60.1,
    "log_p": -1.1,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "ethylhexyl methoxycrylene": {
    "name": "Ethylhexyl methoxycrylene",
    "smiles": "CCCCC(CC)COC(=O)C(C#N)=C(C1=CC=CC=C1)C1=CC=C(OC)C=C1",
    "molecular_weight": 391.51,
    "log_p": 5.78,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "ethynodiol diacetate": {
    "name": "Ethynodiol diacetate",
    "smiles": "[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](OC(C)=O)C=C3CC[C@@]21[H]",
    "molecular_weight": 384.52,
    "log_p": 4.43,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "etidocaine": {
    "name": "Etidocaine",
    "smiles": "CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C",
    "molecular_weight": 276.42,
    "log_p": 3.75,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "sodium channel blocker",
    "disease_area": "neurology/psychiatry",
    "indication": "anesthetic"
  },
  "etidronic acid": {
    "name": "Etidronic acid",
    "smiles": "CC(O)(P(O)(O)=O)P(O)(O)=O",
    "molecular_weight": 206.03,
    "log_p": -0.99,
    "hbd": 5,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "etilefrine": {
    "name": "Etilefrine",
    "smiles": "CCNCC(O)C1=CC=CC(O)=C1",
    "molecular_weight": 181.23,
    "log_p": 1.04,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "endocrinology | neurology/psychiatry | otolaryngology | otolaryngology | pulmonary",
    "indication": "common cold | cough suppressant | fever | headache | nasal congestion"
  },
  "etodolac": {
    "name": "Etodolac",
    "smiles": "CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1",
    "molecular_weight": 287.36,
    "log_p": 3.38,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "rheumatology | rheumatology",
    "indication": "osteoarthritis | rheumatoid arthritis"
  },
  "etofamide": {
    "name": "Etofamide",
    "smiles": "CCOCCN(CC1=CC=C(OC2=CC=C(C=C2)[N+]([O-])=O)C=C1)C(=O)C(Cl)Cl",
    "molecular_weight": 427.28,
    "log_p": 4.56,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "etomidate": {
    "name": "Etomidate",
    "smiles": "CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1",
    "molecular_weight": 244.29,
    "log_p": 2.67,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "GABA receptor modulator",
    "disease_area": "neurology/psychiatry",
    "indication": "general anaesthetic"
  },
  "etonogestrel": {
    "name": "Etonogestrel",
    "smiles": "[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]",
    "molecular_weight": 324.46,
    "log_p": 4.05,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "progesterone receptor agonist",
    "disease_area": "endocrinology",
    "indication": "contraceptive"
  },
  "etoposide": {
    "name": "Etoposide",
    "smiles": "[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O",
    "molecular_weight": 588.56,
    "log_p": 1.34,
    "hbd": 3,
    "hba": 13,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "topoisomerase inhibitor",
    "disease_area": "oncology",
    "indication": "non-small cell lung cancer (NSCLC)"
  },
  "etoricoxib": {
    "name": "Etoricoxib",
    "smiles": "CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O",
    "molecular_weight": 358.85,
    "log_p": 4.18,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "rheumatology | rheumatology | rheumatology | rheumatology | rheumatology",
    "indication": "ankylosing spondylitis | gout | osteoarthritis | psoriatic arthritis | rheumatoid arthritis"
  },
  "etravirine": {
    "name": "Etravirine",
    "smiles": "CC1=CC(=CC(C)=C1OC1=C(Br)C(N)=NC(NC2=CC=C(C=C2)C#N)=N1)C#N",
    "molecular_weight": 435.29,
    "log_p": 4.72,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "non-nucleoside reverse transcriptase inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "eugenol": {
    "name": "Eugenol",
    "smiles": "COC1=C(O)C=CC(CC=C)=C1",
    "molecular_weight": 164.2,
    "log_p": 2.13,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "androgen receptor antagonist",
    "disease_area": "dental",
    "indication": "toothache"
  },
  "everolimus": {
    "name": "Everolimus",
    "smiles": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC",
    "molecular_weight": 958.24,
    "log_p": 6.2,
    "hbd": 3,
    "hba": 14,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "mTOR inhibitor",
    "disease_area": "genetics | neurology/psychiatry | oncology | oncology | oncology | urology",
    "indication": "breast cancer | neuroendocrine tumors of pancreatic origin (PNET) | renal angiomyolipoma | renal cell carcinoma (RCC) | subependymal giant cell astrocytoma (SEGA) | tuberous sclerosis complex (TSC)"
  },
  "exametazime": {
    "name": "Exametazime",
    "smiles": "C[C@@H](NCC(C)(C)CN[C@H](C)C(\\C)=N\\O)C(\\C)=N\\O",
    "molecular_weight": 272.39,
    "log_p": 1.67,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "exemestane": {
    "name": "Exemestane",
    "smiles": "[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C",
    "molecular_weight": 296.41,
    "log_p": 4.03,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "aromatase inhibitor",
    "disease_area": "oncology",
    "indication": "breast cancer"
  },
  "ezetimibe": {
    "name": "Ezetimibe",
    "smiles": "[H][C@]1(CC[C@H](O)C2=CC=C(F)C=C2)C(=O)N(C2=CC=C(F)C=C2)[C@]1([H])C1=CC=C(O)C=C1",
    "molecular_weight": 409.43,
    "log_p": 4.89,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cholesterol inhibitor | cholesterol inhibitor, niemann-pick c1-like 1 protein antagonist | Niemann-Pick C1-like 1 protein antagonist",
    "disease_area": "endocrinology | endocrinology | endocrinology, metabolism | metabolism",
    "indication": "hypercholesterolemia | hyperlipidemia | hyperlipidemia, hypercholesterolemia, sitosterolemia | sitosterolemia"
  },
  "ezogabine": {
    "name": "Ezogabine",
    "smiles": "CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1",
    "molecular_weight": 303.34,
    "log_p": 3.59,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "famciclovir": {
    "name": "Famciclovir",
    "smiles": "CC(=O)OCC(CCN1C=NC2=CN=C(N)N=C12)COC(C)=O",
    "molecular_weight": 321.34,
    "log_p": 0.54,
    "hbd": 1,
    "hba": 9,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA polymerase inhibitor",
    "disease_area": "dental | infectious disease | infectious disease",
    "indication": "cold sore | genitial herpes | shingles"
  },
  "famotidine": {
    "name": "Famotidine",
    "smiles": "NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1",
    "molecular_weight": 337.46,
    "log_p": -0.77,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "gastroenterology",
    "indication": "heartburn"
  },
  "favipiravir": {
    "name": "Favipiravir",
    "smiles": "NC(=O)C1=NC(F)=CN=C1O",
    "molecular_weight": 157.1,
    "log_p": -0.58,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "RNA polymerase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "febuxostat": {
    "name": "Febuxostat",
    "smiles": "CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N",
    "molecular_weight": 316.38,
    "log_p": 3.72,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "xanthine oxidase inhibitor",
    "disease_area": "nephrology",
    "indication": "hyperuricemia"
  },
  "fedratinib": {
    "name": "Fedratinib",
    "smiles": "CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C",
    "molecular_weight": 524.69,
    "log_p": 4.82,
    "hbd": 3,
    "hba": 8,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "FLT3 inhibitor | JAK inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "myelofibrosis"
  },
  "felbamate": {
    "name": "Felbamate",
    "smiles": "NC(=O)OCC(COC(N)=O)C1=CC=CC=C1",
    "molecular_weight": 238.24,
    "log_p": 0.96,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glutamate receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "epilepsy"
  },
  "felodipine": {
    "name": "Felodipine",
    "smiles": "CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC",
    "molecular_weight": 384.26,
    "log_p": 3.96,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "cardiology",
    "indication": "angina pectoris | hypertension"
  },
  "fenbufen": {
    "name": "Fenbufen",
    "smiles": "OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1",
    "molecular_weight": 254.29,
    "log_p": 3.4,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "pain relief"
  },
  "fenfluramine": {
    "name": "Fenfluramine",
    "smiles": "CCNC(C)CC1=CC=CC(=C1)C(F)(F)F",
    "molecular_weight": 231.26,
    "log_p": 3.25,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "fenofibrate": {
    "name": "Fenofibrate",
    "smiles": "CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1",
    "molecular_weight": 360.84,
    "log_p": 4.68,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PPAR receptor agonist",
    "disease_area": "endocrinology | endocrinology",
    "indication": "hypercholesterolemia | hypertriglyceridemia"
  },
  "fenofibric acid": {
    "name": "Fenofibric acid",
    "smiles": "CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O",
    "molecular_weight": 318.76,
    "log_p": 3.81,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "fenoldopam": {
    "name": "Fenoldopam",
    "smiles": "OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12",
    "molecular_weight": 305.76,
    "log_p": 2.73,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor agonist",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "fenoprofen": {
    "name": "Fenoprofen",
    "smiles": "CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1",
    "molecular_weight": 242.27,
    "log_p": 3.67,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "prostaglandin inhibitor",
    "disease_area": "rheumatology | rheumatology | rheumatology",
    "indication": "osteoarthritis | rheumatoid arthritis | rheumatoid arthritis, osteoarthritis"
  },
  "fenoterol": {
    "name": "Fenoterol",
    "smiles": "CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1",
    "molecular_weight": 303.36,
    "log_p": 2.06,
    "hbd": 5,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "adrenergic receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "fenpropidin": {
    "name": "Fenpropidin",
    "smiles": "CC(CN1CCCCC1)CC1=CC=C(C=C1)C(C)(C)C",
    "molecular_weight": 273.46,
    "log_p": 4.65,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "fentanyl": {
    "name": "Fentanyl",
    "smiles": "CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1",
    "molecular_weight": 336.48,
    "log_p": 4.14,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "ferric ammonium citrate": {
    "name": "Ferric ammonium citrate",
    "smiles": "N.[Fe+3].OC(=O)CC(O)(CC(O)=O)C(O)=O",
    "molecular_weight": 265.0,
    "log_p": -1.09,
    "hbd": 5,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "ferric cation": {
    "name": "Ferric cation",
    "smiles": "[Fe+3]",
    "molecular_weight": 55.84,
    "log_p": -0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "ferric chloride": {
    "name": "Ferric chloride",
    "smiles": "Cl[Fe](Cl)Cl",
    "molecular_weight": 162.2,
    "log_p": 2.07,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "ferric derisomaltose": {
    "name": "Ferric derisomaltose",
    "smiles": "[Fe+3].OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O",
    "molecular_weight": 562.3,
    "log_p": -7.94,
    "hbd": 12,
    "hba": 16,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA"
  },
  "ferric glycerophosphate": {
    "name": "Ferric glycerophosphate",
    "smiles": "[Fe++].[Fe++].OCC(O)COP([O-])([O-])=O.OCCC(CCO)OP([O-])([O-])=O",
    "molecular_weight": 479.86,
    "log_p": -4.85,
    "hbd": 4,
    "hba": 12,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "ferric maltol": {
    "name": "Ferric maltol",
    "smiles": "[Fe+3].CC1=C([O-])C(=O)C=CO1.CC1=C([O-])C(=O)C=CO1.CC1=C([O-])C(=O)C=CO1",
    "molecular_weight": 431.15,
    "log_p": 0.06,
    "hbd": 0,
    "hba": 9,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "ferric pyrophosphate citrate": {
    "name": "Ferric pyrophosphate citrate",
    "smiles": "[Fe+3].[Fe+3].[Fe+3].[Fe+3].OP(O)(=O)OP(O)(O)=O.OP(O)(=O)OP(O)(O)=O.OP([O-])(=O)OP([O-])([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O",
    "molecular_weight": 1321.57,
    "log_p": -20.1,
    "hbd": 12,
    "hba": 33,
    "rotatable_bonds": 21,
    "approved": true,
    "source": "FDA"
  },
  "ferric sulfate": {
    "name": "Ferric sulfate",
    "smiles": "O.O.O.O.O.[Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O",
    "molecular_weight": 489.95,
    "log_p": -8.14,
    "hbd": 0,
    "hba": 12,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "ferrous ascorbate": {
    "name": "Ferrous ascorbate",
    "smiles": "[Fe++].[H][C@](O)(CO)[C@@]1([H])OC(=O)C(O)=C1O.[H][C@](O)(CO)[C@@]1([H])OC(=O)C([O-])=C1[O-]",
    "molecular_weight": 406.08,
    "log_p": -5.21,
    "hbd": 6,
    "hba": 12,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "ferrous bisglycinate": {
    "name": "Ferrous bisglycinate",
    "smiles": "[Fe++].NCC([O-])=O.NCC([O-])=O",
    "molecular_weight": 203.96,
    "log_p": -4.61,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "ferrous cysteine glycinate": {
    "name": "Ferrous cysteine glycinate",
    "smiles": "[Fe++].NCC(O)=O.[H][C@](N)(CS)C(O)=O.[H][C@](N)(C[S-])C([O-])=O",
    "molecular_weight": 371.22,
    "log_p": -4.03,
    "hbd": 6,
    "hba": 9,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "ferrous fumarate": {
    "name": "Ferrous fumarate",
    "smiles": "[Fe++].[H]\\C(=C(\\[H])C([O-])=O)C([O-])=O",
    "molecular_weight": 169.9,
    "log_p": -2.96,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "ferrous gluconate": {
    "name": "Ferrous gluconate",
    "smiles": "[Fe++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O",
    "molecular_weight": 446.14,
    "log_p": -9.66,
    "hbd": 10,
    "hba": 14,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "ferrous glycine sulfate": {
    "name": "Ferrous glycine sulfate",
    "smiles": "[Fe++].NCC([O-])=O.NCC([O-])=O.OS(O)(=O)=O",
    "molecular_weight": 302.04,
    "log_p": -5.27,
    "hbd": 4,
    "hba": 8,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "ferrous succinate": {
    "name": "Ferrous succinate",
    "smiles": "[Fe++].[O-]C(=O)CCC([O-])=O",
    "molecular_weight": 171.92,
    "log_p": -2.74,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "ferrous sulfate anhydrous": {
    "name": "Ferrous sulfate anhydrous",
    "smiles": "[Fe++].[O-]S([O-])(=O)=O",
    "molecular_weight": 151.91,
    "log_p": -1.34,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "ferumoxytol": {
    "name": "Ferumoxytol",
    "smiles": "[O--].[O--].[O--].[O--].[Fe++].[Fe+3].[Fe+3]",
    "molecular_weight": 231.53,
    "log_p": -0.48,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "fesoterodine": {
    "name": "Fesoterodine",
    "smiles": "CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C",
    "molecular_weight": 411.59,
    "log_p": 5.38,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "urology",
    "indication": "urinary incontinence"
  },
  "fexinidazole": {
    "name": "Fexinidazole",
    "smiles": "CSC1=CC=C(OCC2=NC=C(N2C)[N+]([O-])=O)C=C1",
    "molecular_weight": 279.32,
    "log_p": 2.63,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "fexofenadine": {
    "name": "Fexofenadine",
    "smiles": "CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 501.67,
    "log_p": 5.51,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy | allergy",
    "indication": "allergic rhinitis | urticaria"
  },
  "fidaxomicin": {
    "name": "Fidaxomicin",
    "smiles": "[H][C@@]1(O[C@@H]2[C@@H](CC)\\C=C(C)\\[C@@H](O)C\\C=C\\C=C(CO[C@@H]3O[C@H](C)[C@@H](OC(=O)C4=C(CC)C(Cl)=C(O)C(Cl)=C4O)[C@H](O)[C@@H]3OC)\\C(=O)O[C@@H](C\\C=C(/C)\\C=C2/C)[C@@H](C)O)OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O",
    "molecular_weight": 1058.05,
    "log_p": 6.23,
    "hbd": 7,
    "hba": 18,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "RNA polymerase inhibitor",
    "disease_area": "gastroenterology",
    "indication": "diarrhea"
  },
  "filgotinib": {
    "name": "Filgotinib",
    "smiles": "O=C(NC1=NN2C(C=CC=C2C2=CC=C(CN3CCS(=O)(=O)CC3)C=C2)=N1)C1CC1",
    "molecular_weight": 425.51,
    "log_p": 1.98,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "JAK inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "finafloxacin": {
    "name": "Finafloxacin",
    "smiles": "[H][C@]12CN(C[C@]1([H])OCCN2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1C#N)C(O)=O",
    "molecular_weight": 398.39,
    "log_p": 1.22,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial DNA gyrase inhibitor",
    "disease_area": "infectious disease | pulmonary | pulmonary",
    "indication": "chronic obstructive pulmonary disease (COPD) | cystic fibrosis | intra-abdominal infections"
  },
  "finasteride": {
    "name": "Finasteride",
    "smiles": "[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C",
    "molecular_weight": 372.55,
    "log_p": 3.81,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "5 alpha reductase inhibitor",
    "disease_area": "endocrinology",
    "indication": "androgenetic alopecia"
  },
  "finerenone": {
    "name": "Finerenone",
    "smiles": "CCOC1=NC=C(C)C2=C1[C@H](C1=CC=C(C=C1OC)C#N)C(C(N)=O)=C(C)N2",
    "molecular_weight": 378.43,
    "log_p": 2.99,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "mineralocorticoid receptor antagonist",
    "disease_area": "nephrology",
    "indication": "chronic kidney disease (ckd)"
  },
  "fingolimod": {
    "name": "Fingolimod",
    "smiles": "CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1",
    "molecular_weight": 307.48,
    "log_p": 3.2,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "immunosuppressant | sphingosine 1-phosphate receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "multiple sclerosis"
  },
  "flavin adenine dinucleotide": {
    "name": "Flavin adenine dinucleotide",
    "smiles": "CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)CO[P@](O)(=O)O[P@@](O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC3=C1N=CN=C3N)C1=NC(=O)NC(=O)C1=N2",
    "molecular_weight": 785.56,
    "log_p": -2.42,
    "hbd": 9,
    "hba": 21,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA"
  },
  "flavin mononucleotide": {
    "name": "Flavin mononucleotide",
    "smiles": "CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)C1=NC(=O)NC(=O)C1=N2",
    "molecular_weight": 456.35,
    "log_p": -1.61,
    "hbd": 6,
    "hba": 10,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "flavone": {
    "name": "Flavone",
    "smiles": "O=C1C=C(OC2=CC=CC=C12)C1=CC=CC=C1",
    "molecular_weight": 222.24,
    "log_p": 3.46,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "flavoxate": {
    "name": "Flavoxate",
    "smiles": "CC1=C(OC2=C(C=CC=C2C(=O)OCCN2CCCCC2)C1=O)C1=CC=CC=C1",
    "molecular_weight": 391.47,
    "log_p": 4.41,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "urology | urology | urology | urology",
    "indication": "interstitial cystitis (IC) | prostatitis | urethritis | urinary incontinence"
  },
  "flecainide": {
    "name": "Flecainide",
    "smiles": "FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1",
    "molecular_weight": 414.35,
    "log_p": 3.44,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "cardiology | cardiology | cardiology",
    "indication": "atrial fibrillation (AF) | ventricular arrhythmias | ventricular tachycardia (VT)"
  },
  "flibanserin": {
    "name": "Flibanserin",
    "smiles": "FC(F)(F)C1=CC(=CC=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1",
    "molecular_weight": 390.41,
    "log_p": 3.17,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "hypoactive sexual desire disorder"
  },
  "floctafenine": {
    "name": "Floctafenine",
    "smiles": "OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C=CC=C12)C(F)(F)F",
    "molecular_weight": 406.36,
    "log_p": 3.51,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "pain relief"
  },
  "florbetaben (18f)": {
    "name": "Florbetaben (18F)",
    "smiles": "CNC1=CC=C(\\C=C\\C2=CC=C(OCCOCCOCC[18F])C=C2)C=C1",
    "molecular_weight": 358.44,
    "log_p": 4.28,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "florbetapir (18f)": {
    "name": "Florbetapir (18F)",
    "smiles": "[H]N(C1=C([H])C([H])=C(\\C([H])=C(/[H])C2=C([H])N=C(OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])[18F])C([H])=C2[H])C([H])=C1[H])C([H])([H])[H]",
    "molecular_weight": 359.43,
    "log_p": 3.68,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "flortaucipir f-18": {
    "name": "Flortaucipir F-18",
    "smiles": "[18F]C1=CC=C(C=N1)C1=CC=C2C(NC3=C2C=NC=C3)=C1",
    "molecular_weight": 262.28,
    "log_p": 3.92,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "flosequinan": {
    "name": "Flosequinan",
    "smiles": "CN1C=C(C(=O)C2=C1C=C(F)C=C2)S(C)=O",
    "molecular_weight": 239.27,
    "log_p": 1.42,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "floxuridine": {
    "name": "Floxuridine",
    "smiles": "OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(F)C(=O)NC1=O",
    "molecular_weight": 246.19,
    "log_p": -1.68,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA synthesis inhibitor",
    "disease_area": "oncology",
    "indication": "colorectal cancer"
  },
  "fluciclovine (18f)": {
    "name": "Fluciclovine (18F)",
    "smiles": "N[C@]1(C[C@H]([18F])C1)C(O)=O",
    "molecular_weight": 132.12,
    "log_p": -0.1,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "pet imaging agent",
    "disease_area": "radiology",
    "indication": "pet imaging"
  },
  "fluclorolone acetonide": {
    "name": "Fluclorolone acetonide",
    "smiles": "[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(Cl)[C@@H](Cl)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO",
    "molecular_weight": 487.4,
    "log_p": 3.88,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "flucloxacillin": {
    "name": "Flucloxacillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1F)C(O)=O",
    "molecular_weight": 453.88,
    "log_p": 2.69,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "dermatology | gastroenterology | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | otolaryngology | otolaryngology",
    "indication": "bacterial septicemia | eczema | endocarditis | enteritis | gram-positive bacterial infections | meningitis | pneumonia | sinusitis | tonsillitis"
  },
  "fluconazole": {
    "name": "Fluconazole",
    "smiles": "OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1",
    "molecular_weight": 306.28,
    "log_p": 0.74,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sterol demethylase inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "esophageal candidiasis | meningitis"
  },
  "flucytosine": {
    "name": "Flucytosine",
    "smiles": "NC1=C(F)C=NC(=O)N1",
    "molecular_weight": 129.09,
    "log_p": -0.51,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "other antifungal",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "bacterial septicemia | endocarditis | meningitis | urinary tract infections"
  },
  "fludarabine": {
    "name": "Fludarabine",
    "smiles": "NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",
    "molecular_weight": 285.24,
    "log_p": -1.84,
    "hbd": 4,
    "hba": 9,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ribonucleotide reductase inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "chronic lymphocytic leukemia (CLL)"
  },
  "fludeoxyglucose (18f)": {
    "name": "Fludeoxyglucose (18F)",
    "smiles": "[H]C(=O)[C@H]([18F])[C@@H](O)[C@H](O)[C@H](O)CO",
    "molecular_weight": 181.15,
    "log_p": -2.4,
    "hbd": 4,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "fludrocortisone": {
    "name": "Fludrocortisone",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 380.46,
    "log_p": 1.87,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "flufenamic acid": {
    "name": "Flufenamic acid",
    "smiles": "OC(=O)C1=CC=CC=C1NC1=CC(=CC=C1)C(F)(F)F",
    "molecular_weight": 281.23,
    "log_p": 4.15,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "fluindione": {
    "name": "Fluindione",
    "smiles": "FC1=CC=C(C=C1)C1C(=O)C2=CC=CC=C2C1=O",
    "molecular_weight": 240.23,
    "log_p": 2.99,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "flumazenil": {
    "name": "Flumazenil",
    "smiles": "CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1",
    "molecular_weight": 303.29,
    "log_p": 1.77,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "benzodiazepine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "sedative"
  },
  "flumethasone": {
    "name": "Flumethasone",
    "smiles": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C",
    "molecular_weight": 410.46,
    "log_p": 1.84,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "dermatology | infectious disease | otolaryngology",
    "indication": "corticosteroid-responsive dermatoses | ear infections | otitis"
  },
  "flunarizine": {
    "name": "Flunarizine",
    "smiles": "FC1=CC=C(C=C1)C(N1CCN(C\\C=C\\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1",
    "molecular_weight": 404.5,
    "log_p": 5.39,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "cardiology | neurology/psychiatry | neurology/psychiatry",
    "indication": "migraine headache | peripheral artery disease (PAD) | vertigo"
  },
  "flunisolide": {
    "name": "Flunisolide",
    "smiles": "[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO",
    "molecular_weight": 434.5,
    "log_p": 2.27,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cytochrome P450 inhibitor",
    "disease_area": "allergy",
    "indication": "allergic rhinitis"
  },
  "flunitrazepam": {
    "name": "Flunitrazepam",
    "smiles": "CN1C2=C(C=C(C=C2)[N+]([O-])=O)C(=NCC1=O)C1=CC=CC=C1F",
    "molecular_weight": 313.29,
    "log_p": 2.55,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "fluocinolone acetonide": {
    "name": "Fluocinolone acetonide",
    "smiles": "[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO",
    "molecular_weight": 452.49,
    "log_p": 2.37,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "fluocinonide": {
    "name": "Fluocinonide",
    "smiles": "[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O",
    "molecular_weight": 494.53,
    "log_p": 2.94,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "dermatology | dermatology",
    "indication": "eczema | seborrheic dermatitis"
  },
  "fluocortolone": {
    "name": "Fluocortolone",
    "smiles": "[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C",
    "molecular_weight": 376.47,
    "log_p": 2.64,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "fluorescein": {
    "name": "Fluorescein",
    "smiles": "OC1=CC=C2C(OC3=CC(O)=CC=C3C22OC(=O)C3=C2C=CC=C3)=C1",
    "molecular_weight": 332.31,
    "log_p": 3.67,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "ophthalmology",
    "indication": "ophthalmology diagnostic"
  },
  "fluoride ion": {
    "name": "Fluoride ion",
    "smiles": "[F-]",
    "molecular_weight": 19.0,
    "log_p": -3.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "fluoride ion f-18": {
    "name": "Fluoride ion F-18",
    "smiles": "[18F-]",
    "molecular_weight": 18.0,
    "log_p": -3.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "fluorodopa (18f)": {
    "name": "Fluorodopa (18F)",
    "smiles": "N[C@@H](CC1=CC(O)=C(O)C=C1[18F])C(O)=O",
    "molecular_weight": 214.18,
    "log_p": 0.19,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "fluoroestradiol f-18": {
    "name": "Fluoroestradiol F-18",
    "smiles": "[H][C@@]12C[C@@H]([18F])[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3",
    "molecular_weight": 289.38,
    "log_p": 3.56,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "fluorometholone": {
    "name": "Fluorometholone",
    "smiles": "[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C",
    "molecular_weight": 376.47,
    "log_p": 2.92,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "ophthalmology",
    "indication": "eye inflammation"
  },
  "fluorouracil": {
    "name": "Fluorouracil",
    "smiles": "FC1=CNC(=O)NC1=O",
    "molecular_weight": 130.08,
    "log_p": -0.8,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "fluoxetine": {
    "name": "Fluoxetine",
    "smiles": "CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1",
    "molecular_weight": 309.33,
    "log_p": 4.44,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "selective serotonin reuptake inhibitor (SSRI)",
    "disease_area": "neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry",
    "indication": "bipolar disorder | bulimia nervosa | depression | obsessive compulsive disorder (OCD) | panic disorders"
  },
  "fluoxymesterone": {
    "name": "Fluoxymesterone",
    "smiles": "[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 336.45,
    "log_p": 3.33,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "flupentixol": {
    "name": "Flupentixol",
    "smiles": "[H]\\C(CCN1CCN(CCO)CC1)=C1/C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F",
    "molecular_weight": 434.53,
    "log_p": 4.6,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "depression | schizophrenia"
  },
  "fluphenazine": {
    "name": "Fluphenazine",
    "smiles": "OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1",
    "molecular_weight": 437.53,
    "log_p": 4.31,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "schizophrenia"
  },
  "fluprednisolone": {
    "name": "Fluprednisolone",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C",
    "molecular_weight": 378.44,
    "log_p": 1.51,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "ophthalmology",
    "indication": "contact dermatitis"
  },
  "flurandrenolide": {
    "name": "Flurandrenolide",
    "smiles": "CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",
    "molecular_weight": 436.52,
    "log_p": 2.5,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "nephrology | nephrology, infectious disease, dermatology",
    "indication": "chronic kidney disease (ckd) | chronic kidney disease (ckd), skin infections, psoriasis"
  },
  "flurazepam": {
    "name": "Flurazepam",
    "smiles": "CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F",
    "molecular_weight": 387.89,
    "log_p": 4.0,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "flurbiprofen": {
    "name": "Flurbiprofen",
    "smiles": "CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1",
    "molecular_weight": 244.27,
    "log_p": 3.68,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "fluspirilene": {
    "name": "Fluspirilene",
    "smiles": "FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1",
    "molecular_weight": 475.58,
    "log_p": 5.31,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "schizophrenia"
  },
  "flutamide": {
    "name": "Flutamide",
    "smiles": "CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F",
    "molecular_weight": 276.21,
    "log_p": 3.21,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "androgen receptor antagonist",
    "disease_area": "oncology",
    "indication": "prostate cancer"
  },
  "flutemetamol (18f)": {
    "name": "Flutemetamol (18F)",
    "smiles": "CNC1=C([18F])C=C(C=C1)C1=NC2=CC=C(O)C=C2S1",
    "molecular_weight": 273.32,
    "log_p": 3.85,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "fluticasone": {
    "name": "Fluticasone",
    "smiles": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C",
    "molecular_weight": 444.52,
    "log_p": 3.47,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "fluticasone furoate": {
    "name": "Fluticasone furoate",
    "smiles": "[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C",
    "molecular_weight": 538.58,
    "log_p": 4.93,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "pulmonary",
    "indication": "asthma"
  },
  "fluticasone propionate": {
    "name": "Fluticasone propionate",
    "smiles": "[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C",
    "molecular_weight": 500.58,
    "log_p": 4.43,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "dermatology",
    "indication": "corticosteroid-responsive dermatoses"
  },
  "fluvastatin": {
    "name": "Fluvastatin",
    "smiles": "CC(C)N1C(\\C=C\\C(O)CC(O)CC(O)=O)=C(C2=CC=CC=C12)C1=CC=C(F)C=C1",
    "molecular_weight": 411.47,
    "log_p": 4.63,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HMGCR inhibitor",
    "disease_area": "cardiology | endocrinology",
    "indication": "congenital heart defects | hypercholesterolemia"
  },
  "fluvoxamine": {
    "name": "Fluvoxamine",
    "smiles": "COCCCC\\C(=N/OCCN)C1=CC=C(C=C1)C(F)(F)F",
    "molecular_weight": 318.34,
    "log_p": 3.2,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "selective serotonin reuptake inhibitor (SSRI)",
    "disease_area": "neurology/psychiatry",
    "indication": "obsessive compulsive disorder (OCD)"
  },
  "folic acid": {
    "name": "Folic acid",
    "smiles": "NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1",
    "molecular_weight": 441.4,
    "log_p": -0.04,
    "hbd": 6,
    "hba": 9,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "fomepizole": {
    "name": "Fomepizole",
    "smiles": "CC1=CNN=C1",
    "molecular_weight": 82.11,
    "log_p": 0.72,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "alcohol dehydrogenase inhibitor",
    "disease_area": "critical care",
    "indication": "poison antidote"
  },
  "fondaparinux": {
    "name": "Fondaparinux",
    "smiles": "CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O",
    "molecular_weight": 1508.27,
    "log_p": -13.75,
    "hbd": 19,
    "hba": 39,
    "rotatable_bonds": 30,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "coagulation factor inhibitor",
    "disease_area": "hematology",
    "indication": "deep vein thrombosis (DVT)"
  },
  "formaldehyde": {
    "name": "Formaldehyde",
    "smiles": "[H]C([H])=O",
    "molecular_weight": 30.03,
    "log_p": -0.18,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "formestane": {
    "name": "Formestane",
    "smiles": "[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C",
    "molecular_weight": 302.41,
    "log_p": 3.97,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "aromatase inhibitor",
    "disease_area": "oncology",
    "indication": "breast cancer"
  },
  "formoterol": {
    "name": "Formoterol",
    "smiles": "COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1",
    "molecular_weight": 344.41,
    "log_p": 2.22,
    "hbd": 4,
    "hba": 5,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "pulmonary | pulmonary | pulmonary",
    "indication": "asthma | bronchospasm | chronic obstructive pulmonary disease (COPD)"
  },
  "fosamprenavir": {
    "name": "Fosamprenavir",
    "smiles": "CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1",
    "molecular_weight": 585.62,
    "log_p": 2.52,
    "hbd": 4,
    "hba": 8,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HIV protease inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "fosaprepitant": {
    "name": "Fosaprepitant",
    "smiles": "C[C@@H](O[C@H]1OCCN(CC2=NC(=O)N(N2)P(O)(O)=O)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F",
    "molecular_weight": 614.41,
    "log_p": 4.37,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "foscarnet": {
    "name": "Foscarnet",
    "smiles": "OC(=O)P(O)(O)=O",
    "molecular_weight": 126.0,
    "log_p": -0.16,
    "hbd": 3,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA polymerase inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "acquired immunodeficiency syndrome (AIDS) | cytomegalovirus retinitis | virus herpes simplex (HSV)"
  },
  "fosdenopterin": {
    "name": "Fosdenopterin",
    "smiles": "[H][C@@]12COP(O)(=O)O[C@]1([H])C(O)(O)[C@]1([H])NC3=C(NC(N)=NC3=O)N[C@]1([H])O2",
    "molecular_weight": 363.22,
    "log_p": -2.52,
    "hbd": 7,
    "hba": 11,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "fosfomycin": {
    "name": "Fosfomycin",
    "smiles": "C[C@@H]1O[C@@H]1P(O)(O)=O",
    "molecular_weight": 138.06,
    "log_p": -0.09,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "urinary tract infections"
  },
  "fosinopril": {
    "name": "Fosinopril",
    "smiles": "CCC(=O)O[C@@H](OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C",
    "molecular_weight": 563.67,
    "log_p": 6.12,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 14,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin converting enzyme inhibitor",
    "disease_area": "cardiology | cardiology",
    "indication": "congestive heart failure | hypertension"
  },
  "fosnetupitant": {
    "name": "Fosnetupitant",
    "smiles": "CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=CC=CC=C1C)N1CC[N+](C)(COP(O)([O-])=O)CC1",
    "molecular_weight": 688.61,
    "log_p": 5.74,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "fosphenytoin": {
    "name": "Fosphenytoin",
    "smiles": "OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 362.28,
    "log_p": 1.55,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "epilepsy | seizures"
  },
  "fospropofol": {
    "name": "Fospropofol",
    "smiles": "CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O",
    "molecular_weight": 288.28,
    "log_p": 3.38,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "fostamatinib": {
    "name": "Fostamatinib",
    "smiles": "COC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC",
    "molecular_weight": 580.47,
    "log_p": 3.09,
    "hbd": 4,
    "hba": 12,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "SYK inhibitor",
    "disease_area": "hematology",
    "indication": "chronic immune thrombocytopenia (ITP)"
  },
  "fostemsavir": {
    "name": "Fostemsavir",
    "smiles": "COC1=CN=C(N2C=NC(C)=N2)C2=C1C(=CN2COP(O)(O)=O)C(=O)C(=O)N1CCN(CC1)C(=O)C1=CC=CC=C1",
    "molecular_weight": 583.5,
    "log_p": 1.17,
    "hbd": 2,
    "hba": 11,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "antiviral",
    "disease_area": "",
    "indication": ""
  },
  "framycetin": {
    "name": "Framycetin",
    "smiles": "NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O",
    "molecular_weight": 614.65,
    "log_p": -8.9,
    "hbd": 13,
    "hba": 19,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "frovatriptan": {
    "name": "Frovatriptan",
    "smiles": "CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O",
    "molecular_weight": 243.31,
    "log_p": 1.34,
    "hbd": 3,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "migraine headache"
  },
  "fructose": {
    "name": "Fructose",
    "smiles": "OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O",
    "molecular_weight": 180.16,
    "log_p": -3.22,
    "hbd": 5,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "fulvestrant": {
    "name": "Fulvestrant",
    "smiles": "[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]",
    "molecular_weight": 606.78,
    "log_p": 8.68,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 14,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "estrogen receptor antagonist",
    "disease_area": "oncology",
    "indication": "breast cancer"
  },
  "furosemide": {
    "name": "Furosemide",
    "smiles": "NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O",
    "molecular_weight": 330.75,
    "log_p": 1.89,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "diuretic",
    "disease_area": "cardiology | cardiology | cardiology | rheumatology",
    "indication": "congestive heart failure | edema | hypertension | nephrotic syndrome"
  },
  "fursultiamine": {
    "name": "Fursultiamine",
    "smiles": "C\\C(N(CC1=C(N)N=C(C)N=C1)C=O)=C(\\CCO)SSCC1CCCO1",
    "molecular_weight": 398.55,
    "log_p": 2.5,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin B",
    "disease_area": "metabolism",
    "indication": "thiamine deficiency"
  },
  "fusafungine": {
    "name": "Fusafungine",
    "smiles": "[H]C1(OC(=O)[C@]([H])(C(C)C)N(C)C(=O)C([H])(OC(=O)[C@]([H])(C(C)C)N(C)C(=O)C([H])(OC(=O)[C@]([H])(C(C)C)N(C)C1=O)C(C)C)C(C)C)C(C)C",
    "molecular_weight": 639.83,
    "log_p": 3.15,
    "hbd": 0,
    "hba": 9,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "fusidic acid": {
    "name": "Fusidic acid",
    "smiles": "[H][C@@]12C[C@@H](O)[C@@]3([H])[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@]4([H])CC[C@]3(C)[C@@]1(C)C[C@H](OC(C)=O)\\C2=C(\\CCC=C(C)C)C(O)=O",
    "molecular_weight": 516.72,
    "log_p": 5.67,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30s ribosomal subunit inhibitor",
    "disease_area": "dermatology",
    "indication": "acne vulgaris (av)"
  },
  "futibatinib": {
    "name": "Futibatinib",
    "smiles": "COC1=CC(=CC(OC)=C1)C#CC1=NN([C@H]2CCN(C2)C(=O)C=C)C2=C1C(N)=NC=N2",
    "molecular_weight": 418.46,
    "log_p": 1.78,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "FGFR inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "gabapentin": {
    "name": "Gabapentin",
    "smiles": "NCC1(CC(O)=O)CCCCC1",
    "molecular_weight": 171.24,
    "log_p": 1.37,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "infectious disease | infectious disease | neurology/psychiatry | neurology/psychiatry",
    "indication": "restless leg syndrome | seizures | shingles | virus herpes simplex (HSV)"
  },
  "gabapentin enacarbil": {
    "name": "Gabapentin enacarbil",
    "smiles": "CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1",
    "molecular_weight": 329.39,
    "log_p": 2.68,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "gadobenic acid": {
    "name": "Gadobenic acid",
    "smiles": "[Gd+3].OC(=O)CN(CCN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)C(COCC1=CC=CC=C1)C(O)=O",
    "molecular_weight": 667.73,
    "log_p": -5.1,
    "hbd": 2,
    "hba": 12,
    "rotatable_bonds": 20,
    "approved": true,
    "source": "FDA"
  },
  "gadobutrol": {
    "name": "Gadobutrol",
    "smiles": "OC[C@H](O)[C@H](CO)[N+]12CC[N+]3(CC([O-])=O)CC[N+]4(CC([O-])=O)CC[N+](CC([O-])=O)(CC1)[Gd-]234",
    "molecular_weight": 604.72,
    "log_p": -7.91,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "radiopaque medium",
    "disease_area": "radiology",
    "indication": "MRI contrast agent"
  },
  "gadodiamide": {
    "name": "Gadodiamide",
    "smiles": "[Gd+3].CNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NC)CC([O-])=O)CC([O-])=O",
    "molecular_weight": 573.66,
    "log_p": -7.37,
    "hbd": 2,
    "hba": 11,
    "rotatable_bonds": 16,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "radiopaque medium",
    "disease_area": "radiology",
    "indication": "MRI contrast agent"
  },
  "gadofosveset trisodium": {
    "name": "Gadofosveset trisodium",
    "smiles": "[Na+].[Na+].[Na+].[Gd+3].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)C[C@H](COP([O-])(=O)OC1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1)N(CC([O-])=O)CC([O-])=O",
    "molecular_weight": 957.87,
    "log_p": -14.55,
    "hbd": 0,
    "hba": 17,
    "rotatable_bonds": 23,
    "approved": true,
    "source": "FDA"
  },
  "gadolinium": {
    "name": "Gadolinium",
    "smiles": "[Gd]",
    "molecular_weight": 157.25,
    "log_p": 0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "gadopentetic acid": {
    "name": "Gadopentetic acid",
    "smiles": "[Gd+3].OC(=O)CN(CCN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O)CC([O-])=O",
    "molecular_weight": 547.58,
    "log_p": -6.69,
    "hbd": 2,
    "hba": 11,
    "rotatable_bonds": 16,
    "approved": true,
    "source": "FDA"
  },
  "gadopiclenol": {
    "name": "Gadopiclenol",
    "smiles": "[Gd+3].OCC(O)CNC(=O)CCC(N1CCN(CC2=CC=CC(CN(CC1)C(CCC(=O)NCC(O)CO)C([O-])=O)=N2)C(CCC(=O)NCC(O)CO)C([O-])=O)C([O-])=O",
    "molecular_weight": 970.1,
    "log_p": -8.89,
    "hbd": 9,
    "hba": 19,
    "rotatable_bonds": 24,
    "approved": true,
    "source": "FDA"
  },
  "gadoteric acid": {
    "name": "Gadoteric acid",
    "smiles": "[Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1",
    "molecular_weight": 558.65,
    "log_p": -6.46,
    "hbd": 1,
    "hba": 11,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "gadoteridol": {
    "name": "Gadoteridol",
    "smiles": "[Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1",
    "molecular_weight": 558.69,
    "log_p": -6.16,
    "hbd": 1,
    "hba": 11,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "radiopaque medium",
    "disease_area": "radiology",
    "indication": "MRI contrast agent"
  },
  "gadoversetamide": {
    "name": "Gadoversetamide",
    "smiles": "[Gd+3].COCCNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NCCOC)CC([O-])=O)CC([O-])=O",
    "molecular_weight": 661.77,
    "log_p": -7.33,
    "hbd": 2,
    "hba": 13,
    "rotatable_bonds": 22,
    "approved": true,
    "source": "FDA"
  },
  "gadoxetic acid": {
    "name": "Gadoxetic acid",
    "smiles": "[Gd+3].[H][C@@](CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)(CC1=CC=C(OCC)C=C1)N(CC(O)=O)CC(O)=O",
    "molecular_weight": 681.75,
    "log_p": -4.68,
    "hbd": 2,
    "hba": 12,
    "rotatable_bonds": 20,
    "approved": true,
    "source": "FDA"
  },
  "galactose": {
    "name": "Galactose",
    "smiles": "[H]C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO",
    "molecular_weight": 180.16,
    "log_p": -3.38,
    "hbd": 5,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "galantamine": {
    "name": "Galantamine",
    "smiles": "[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3",
    "molecular_weight": 287.36,
    "log_p": 1.85,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholinesterase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "senile dementia"
  },
  "gallamine triethiodide": {
    "name": "Gallamine triethiodide",
    "smiles": "[I-].[I-].[I-].CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC",
    "molecular_weight": 891.54,
    "log_p": -3.54,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 21,
    "approved": true,
    "source": "FDA"
  },
  "gallium chloride ga-67": {
    "name": "Gallium chloride Ga-67",
    "smiles": "[Cl-].[Cl-].[Cl-].[67Ga+3]",
    "molecular_weight": 173.29,
    "log_p": -9.37,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "gallium citrate ga-67": {
    "name": "Gallium citrate Ga-67",
    "smiles": "[67Ga+3].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O",
    "molecular_weight": 256.03,
    "log_p": -5.63,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "gallium ga-68 gozetotide": {
    "name": "Gallium Ga-68 gozetotide",
    "smiles": "[68Ga+3].OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)CCCCCNC(=O)CCC1=CC(CN(CCN(CC([O-])=O)CC2=C(O)C=CC(CCC([O-])=O)=C2)CC([O-])=O)=C(O)C=C1)C(O)=O)C(O)=O",
    "molecular_weight": 1011.91,
    "log_p": -2.83,
    "hbd": 9,
    "hba": 16,
    "rotatable_bonds": 35,
    "approved": true,
    "source": "FDA"
  },
  "gallium nitrate": {
    "name": "Gallium nitrate",
    "smiles": "[Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O",
    "molecular_weight": 255.73,
    "log_p": -1.1,
    "hbd": 0,
    "hba": 9,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "gallium-68 psma": {
    "name": "Gallium-68 PSMA",
    "smiles": "OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)CCCCCNC(=O)CCC1=CC=C(O)C(CN(CCN(CC(O)=O)CC2=CC(CCC(O)=O)=CC=C2O)CC(O)=O)=C1)C(O)=O)C(O)=O",
    "molecular_weight": 947.01,
    "log_p": 1.55,
    "hbd": 12,
    "hba": 13,
    "rotatable_bonds": 35,
    "approved": true,
    "source": "FDA"
  },
  "gamma-aminobutyric acid": {
    "name": "gamma-Aminobutyric acid",
    "smiles": "NCCCC(O)=O",
    "molecular_weight": 103.12,
    "log_p": -0.19,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "gamma-hydroxybutyric acid": {
    "name": "gamma-Hydroxybutyric acid",
    "smiles": "OCCCC(O)=O",
    "molecular_weight": 104.1,
    "log_p": -0.16,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "gamolenic acid": {
    "name": "Gamolenic acid",
    "smiles": "CCCCC\\C=C/C\\C=C/C\\C=C/CCCCC(O)=O",
    "molecular_weight": 278.44,
    "log_p": 5.66,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA"
  },
  "ganaxolone": {
    "name": "Ganaxolone",
    "smiles": "[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@](C)(O)CC[C@]12C",
    "molecular_weight": 332.53,
    "log_p": 4.99,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "GABA receptor modulator",
    "disease_area": "",
    "indication": ""
  },
  "ganciclovir": {
    "name": "Ganciclovir",
    "smiles": "NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1",
    "molecular_weight": 255.23,
    "log_p": -1.97,
    "hbd": 4,
    "hba": 8,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA polymerase inhibitor",
    "disease_area": "infectious disease",
    "indication": "cytomegalovirus (CMV)"
  },
  "ganirelix": {
    "name": "Ganirelix",
    "smiles": "CCNC(NCC)=NCCCC[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O",
    "molecular_weight": 1570.35,
    "log_p": 2.27,
    "hbd": 16,
    "hba": 16,
    "rotatable_bonds": 44,
    "approved": true,
    "source": "FDA"
  },
  "gatifloxacin": {
    "name": "Gatifloxacin",
    "smiles": "COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1",
    "molecular_weight": 375.4,
    "log_p": 1.98,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "bacterial DNA gyrase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "gaxilose": {
    "name": "Gaxilose",
    "smiles": "OC[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C=O",
    "molecular_weight": 312.27,
    "log_p": -4.92,
    "hbd": 7,
    "hba": 10,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "gefitinib": {
    "name": "Gefitinib",
    "smiles": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1",
    "molecular_weight": 446.91,
    "log_p": 4.28,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "EGFR inhibitor",
    "disease_area": "oncology",
    "indication": "non-small cell lung cancer (NSCLC)"
  },
  "gemcitabine": {
    "name": "Gemcitabine",
    "smiles": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F",
    "molecular_weight": 263.2,
    "log_p": -1.29,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ribonucleotide reductase inhibitor",
    "disease_area": "oncology | oncology | oncology | oncology",
    "indication": "breast cancer | non-small cell lung cancer (NSCLC) | ovarian cancer | pancreatic cancer"
  },
  "gemeprost": {
    "name": "Gemeprost",
    "smiles": "CCCCC(C)(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\\C=C\\C(=O)OC",
    "molecular_weight": 394.55,
    "log_p": 3.98,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "gemfibrozil": {
    "name": "Gemfibrozil",
    "smiles": "CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1",
    "molecular_weight": 250.34,
    "log_p": 3.57,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "lipoprotein lipase activator",
    "disease_area": "cardiology | endocrinology",
    "indication": "coronary heart disease | hyperlipidemia"
  },
  "gemifloxacin": {
    "name": "Gemifloxacin",
    "smiles": "CO\\N=C1/CN(CC1CN)C1=NC2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O",
    "molecular_weight": 389.39,
    "log_p": 0.97,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial DNA gyrase inhibitor",
    "disease_area": "infectious disease | pulmonary",
    "indication": "bronchitis | pneumonia"
  },
  "gentamicin": {
    "name": "Gentamicin",
    "smiles": "[H][C@@]1(CN)CC[C@@H](N)[C@@H](O[C@]2([H])[C@@H](N)C[C@@H](N)[C@H](O[C@@]3([H])OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1.[H][C@]1(CC[C@@H](N)[C@@H](O[C@]2([H])[C@@H](N)C[C@@H](N)[C@H](O[C@@]3([H])OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1)C(C)N.[H][C@]1(CC[C@@H](N)[C@@H](O[C@]2([H])[C@@H](N)C[C@@H](N)[C@H](O[C@@]3([H])OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1)C(C)NC",
    "molecular_weight": 1390.73,
    "log_p": -10.89,
    "hbd": 24,
    "hba": 36,
    "rotatable_bonds": 19,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30s ribosomal subunit inhibitor",
    "disease_area": "Infectious disease",
    "indication": "gram-negative bacterial infections"
  },
  "gentian violet cation": {
    "name": "Gentian violet cation",
    "smiles": "CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C",
    "molecular_weight": 372.54,
    "log_p": 4.46,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "geraniol": {
    "name": "Geraniol",
    "smiles": "CC(C)=CCC\\C(C)=C\\CO",
    "molecular_weight": 154.25,
    "log_p": 2.67,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "gestonorone caproate": {
    "name": "Gestonorone caproate",
    "smiles": "[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]",
    "molecular_weight": 414.59,
    "log_p": 5.58,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "gestrinone": {
    "name": "Gestrinone",
    "smiles": "[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]",
    "molecular_weight": 308.42,
    "log_p": 3.72,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "progesterone receptor antagonist",
    "disease_area": "obstetrics/gynecology",
    "indication": "endometriosis"
  },
  "gilteritinib": {
    "name": "Gilteritinib",
    "smiles": "CCC1=C(NC2CCOCC2)N=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)C(=N1)C(N)=O",
    "molecular_weight": 552.72,
    "log_p": 2.7,
    "hbd": 3,
    "hba": 10,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "FLT3 inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "gimeracil": {
    "name": "Gimeracil",
    "smiles": "OC1=CC(=O)NC=C1Cl",
    "molecular_weight": 145.54,
    "log_p": 0.73,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dihydropyrimidine dehydrogenase inhibitor",
    "disease_area": "oncology",
    "indication": "gastric adenocarcinoma"
  },
  "glasdegib": {
    "name": "Glasdegib",
    "smiles": "CN1CC[C@H](C[C@@H]1C1=NC2=CC=CC=C2N1)NC(=O)NC1=CC=C(C=C1)C#N",
    "molecular_weight": 374.45,
    "log_p": 3.39,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "hedgehog pathway inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "acute myeloid leukemia (AML)"
  },
  "glecaprevir": {
    "name": "Glecaprevir",
    "smiles": "[H][C@@]12CN(C(=O)[C@@]([H])(NC(=O)O[C@]3([H])CCC[C@@]3([H])OC\\C=C\\C(F)(F)C3=NC4=C(C=CC=C4)N=C3O1)C(C)(C)C)[C@@]([H])(C2)C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1",
    "molecular_weight": 838.88,
    "log_p": 3.86,
    "hbd": 3,
    "hba": 11,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serine protease inhibitor",
    "disease_area": "infectious disease",
    "indication": "hepatitis C"
  },
  "gliclazide": {
    "name": "Gliclazide",
    "smiles": "[H][C@@]12CCC[C@]1([H])CN(C2)NC(=O)NS(=O)(=O)C1=CC=C(C)C=C1",
    "molecular_weight": 323.42,
    "log_p": 1.63,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATP channel blocker | insulin secretagogue",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "glimepiride": {
    "name": "Glimepiride",
    "smiles": "CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O",
    "molecular_weight": 490.63,
    "log_p": 3.07,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "insulin secretagogue",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "glipizide": {
    "name": "Glipizide",
    "smiles": "CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1",
    "molecular_weight": 445.55,
    "log_p": 2.08,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sulfonylurea",
    "disease_area": "endocrinology | endocrinology",
    "indication": "diabetes mellitus | hyperglycemia"
  },
  "gliquidone": {
    "name": "Gliquidone",
    "smiles": "COC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C2=O",
    "molecular_weight": 527.64,
    "log_p": 3.52,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sulfonylurea",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "gluconic acid": {
    "name": "Gluconic Acid",
    "smiles": "OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O",
    "molecular_weight": 196.16,
    "log_p": -3.49,
    "hbd": 6,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "gluconolactone": {
    "name": "Gluconolactone",
    "smiles": "OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O",
    "molecular_weight": 178.14,
    "log_p": -3.01,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "glucosamine": {
    "name": "Glucosamine",
    "smiles": "N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O",
    "molecular_weight": 179.17,
    "log_p": -3.25,
    "hbd": 5,
    "hba": 6,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glycosylated protein precursor",
    "disease_area": "neurology/psychiatry | neurology/psychiatry | rheumatology | rheumatology",
    "indication": "backache | joint pain | muscle pain | rheumatoid arthritis"
  },
  "glutamic acid": {
    "name": "Glutamic acid",
    "smiles": "N[C@@H](CCC(O)=O)C(O)=O",
    "molecular_weight": 147.13,
    "log_p": -0.74,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "glutathione": {
    "name": "Glutathione",
    "smiles": "N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O",
    "molecular_weight": 307.33,
    "log_p": -2.21,
    "hbd": 6,
    "hba": 6,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "antioxidant",
    "disease_area": "",
    "indication": ""
  },
  "glutathione disulfide": {
    "name": "Glutathione disulfide",
    "smiles": "N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O",
    "molecular_weight": 612.64,
    "log_p": -3.88,
    "hbd": 10,
    "hba": 12,
    "rotatable_bonds": 21,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glutathione reductase (nadph) activators",
    "disease_area": "ophthalmology",
    "indication": "ocular hypertension"
  },
  "glutethimide": {
    "name": "Glutethimide",
    "smiles": "CCC1(CCC(=O)NC1=O)C1=CC=CC=C1",
    "molecular_weight": 217.27,
    "log_p": 1.77,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "glyburide": {
    "name": "Glyburide",
    "smiles": "COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1",
    "molecular_weight": 494.01,
    "log_p": 3.64,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATP channel blocker | insulin secretagogue | sulfonylurea",
    "disease_area": "endocrinology | endocrinology",
    "indication": "diabetes mellitus | hyperglycemia"
  },
  "glycerin": {
    "name": "Glycerin",
    "smiles": "OCC(O)CO",
    "molecular_weight": 92.09,
    "log_p": -1.67,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "glycerol phenylbutyrate": {
    "name": "Glycerol phenylbutyrate",
    "smiles": "O=C(CCCC1=CC=CC=C1)OCC(COC(=O)CCCC1=CC=CC=C1)OC(=O)CCCC1=CC=CC=C1",
    "molecular_weight": 530.66,
    "log_p": 6.05,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 17,
    "approved": true,
    "source": "FDA"
  },
  "glycine": {
    "name": "Glycine",
    "smiles": "NCC(O)=O",
    "molecular_weight": 75.07,
    "log_p": -0.97,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "glycol salicylate": {
    "name": "Glycol salicylate",
    "smiles": "OCCOC(=O)C1=CC=CC=C1O",
    "molecular_weight": 182.17,
    "log_p": 0.54,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "prostaglandin inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "muscle pain"
  },
  "glycolic acid": {
    "name": "Glycolic acid",
    "smiles": "OCC(O)=O",
    "molecular_weight": 76.05,
    "log_p": -0.94,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "glycopyrronium": {
    "name": "Glycopyrronium",
    "smiles": "C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1",
    "molecular_weight": 318.44,
    "log_p": 2.46,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "glycyrrhizic acid": {
    "name": "Glycyrrhizic acid",
    "smiles": "[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O[C@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)C(O)=O)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O",
    "molecular_weight": 822.94,
    "log_p": 2.25,
    "hbd": 8,
    "hba": 13,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "glymidine": {
    "name": "Glymidine",
    "smiles": "COCCOC1=CN=C(NS(=O)(=O)C2=CC=CC=C2)N=C1",
    "molecular_weight": 309.35,
    "log_p": 1.3,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "gonadorelin": {
    "name": "Gonadorelin",
    "smiles": "CC(C)CC(NC(=O)CNC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=CC=CC=C12)NC(=O)C(CC1=CN=CN1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O",
    "molecular_weight": 1182.31,
    "log_p": -4.39,
    "hbd": 16,
    "hba": 15,
    "rotatable_bonds": 31,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "gonadotropin releasing factor hormone receptor agonist",
    "disease_area": "obstetrics/gynecology | obstetrics/gynecology",
    "indication": "cystic ovaries | reproductive synchrony"
  },
  "goserelin": {
    "name": "Goserelin",
    "smiles": "CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O",
    "molecular_weight": 1269.43,
    "log_p": -3.11,
    "hbd": 17,
    "hba": 16,
    "rotatable_bonds": 31,
    "approved": true,
    "source": "FDA"
  },
  "gramicidin d": {
    "name": "Gramicidin D",
    "smiles": "CC(C)C[C@@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCCO",
    "molecular_weight": 1811.25,
    "log_p": 4.87,
    "hbd": 20,
    "hba": 16,
    "rotatable_bonds": 51,
    "approved": true,
    "source": "FDA"
  },
  "granisetron": {
    "name": "Granisetron",
    "smiles": "CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2",
    "molecular_weight": 312.42,
    "log_p": 2.32,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor antagonist",
    "disease_area": "gastroenterology | gastroenterology",
    "indication": "nausea | vomiting"
  },
  "grazoprevir": {
    "name": "Grazoprevir",
    "smiles": "COC1=CC2=NC3=C(CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)O3)C(C)(C)C)N=C2C=C1",
    "molecular_weight": 766.92,
    "log_p": 3.3,
    "hbd": 3,
    "hba": 11,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HCV inhibitor",
    "disease_area": "infectious disease",
    "indication": "hepatitis C"
  },
  "grepafloxacin": {
    "name": "Grepafloxacin",
    "smiles": "CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O",
    "molecular_weight": 359.4,
    "log_p": 2.28,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "bacterial dna gyrase inhibitor",
    "disease_area": "infectious disease",
    "indication": "gonorrhea"
  },
  "griseofulvin": {
    "name": "Griseofulvin",
    "smiles": "COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC",
    "molecular_weight": 352.77,
    "log_p": 2.81,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "tubulin polymerization inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "ringworm | tinea pedis"
  },
  "guaiacol": {
    "name": "Guaiacol",
    "smiles": "COC1=C(O)C=CC=C1",
    "molecular_weight": 124.14,
    "log_p": 1.4,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "local anesthetic",
    "disease_area": "pulmonary",
    "indication": "cough suppressant"
  },
  "guaifenesin": {
    "name": "Guaifenesin",
    "smiles": "COC1=CC=CC=C1OCC(O)CO",
    "molecular_weight": 198.22,
    "log_p": 0.43,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "expectorant",
    "disease_area": "pulmonary",
    "indication": "cough suppressant"
  },
  "guanabenz": {
    "name": "Guanabenz",
    "smiles": "NC(N)=NN=CC1=C(Cl)C=CC=C1Cl",
    "molecular_weight": 231.09,
    "log_p": 1.6,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "guanadrel": {
    "name": "Guanadrel",
    "smiles": "NC(N)=NCC1COC2(CCCCC2)O1",
    "molecular_weight": 213.28,
    "log_p": 0.34,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic inhibitor",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "guanethidine": {
    "name": "Guanethidine",
    "smiles": "NC(N)=NCCN1CCCCCCC1",
    "molecular_weight": 198.31,
    "log_p": 0.53,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic inhibitor",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "guanfacine": {
    "name": "Guanfacine",
    "smiles": "NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl",
    "molecular_weight": 246.1,
    "log_p": 1.55,
    "hbd": 3,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "guanidine": {
    "name": "Guanidine",
    "smiles": "NC(N)=N",
    "molecular_weight": 59.07,
    "log_p": -1.16,
    "hbd": 3,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HSP inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "Lambert-Eaton myasthenic syndrome (LEMS)"
  },
  "guanoxan": {
    "name": "Guanoxan",
    "smiles": "NC(=N)NCC1COC2=C(O1)C=CC=C2",
    "molecular_weight": 207.23,
    "log_p": 0.31,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "halazepam": {
    "name": "Halazepam",
    "smiles": "FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1",
    "molecular_weight": 352.74,
    "log_p": 4.09,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "halcinonide": {
    "name": "Halcinonide",
    "smiles": "[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 454.97,
    "log_p": 3.89,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "dermatology",
    "indication": "corticosteroid-responsive dermatoses"
  },
  "halofantrine": {
    "name": "Halofantrine",
    "smiles": "CCCCN(CCCC)CCC(O)C1=C2C=CC(=CC2=C2C=C(Cl)C=C(Cl)C2=C1)C(F)(F)F",
    "molecular_weight": 500.43,
    "log_p": 8.64,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antimalarial agent",
    "disease_area": "infectious disease",
    "indication": "malaria"
  },
  "haloperidol": {
    "name": "Haloperidol",
    "smiles": "OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1",
    "molecular_weight": 375.87,
    "log_p": 4.43,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "schizophrenia | Tourette's disorder"
  },
  "haloprogin": {
    "name": "Haloprogin",
    "smiles": "ClC1=CC(Cl)=C(Cl)C=C1OCC#CI",
    "molecular_weight": 361.39,
    "log_p": 4.42,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "other antifungal",
    "disease_area": "infectious disease",
    "indication": "tinea pedis"
  },
  "halothane": {
    "name": "Halothane",
    "smiles": "[H]C(Cl)(Br)C(F)(F)F",
    "molecular_weight": 197.38,
    "log_p": 2.51,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glutamate receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "general anaesthetic"
  },
  "helium": {
    "name": "Helium",
    "smiles": "[He]",
    "molecular_weight": 4.0,
    "log_p": 0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "hesperidin": {
    "name": "Hesperidin",
    "smiles": "COC1=CC=C(C=C1O)[C@@H]1CC(=O)C2=C(O1)C=C(O[C@@H]1O[C@H](CO[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]1O)C=C2O",
    "molecular_weight": 610.57,
    "log_p": -1.16,
    "hbd": 8,
    "hba": 15,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "flavanone glycoside",
    "disease_area": "",
    "indication": ""
  },
  "hetacillin": {
    "name": "Hetacillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2N1C(=O)[C@H](NC1(C)C)C1=CC=CC=C1)C(O)=O",
    "molecular_weight": 389.48,
    "log_p": 1.41,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "bacterial cell wall synthesis inhibitor | penicillin binding protein inhibitor",
    "disease_area": "Infectious disease | obstetrics/gynecology",
    "indication": "gram-positive bacterial infections | mastitis"
  },
  "hexachlorophene": {
    "name": "Hexachlorophene",
    "smiles": "OC1=C(CC2=C(O)C(Cl)=CC(Cl)=C2Cl)C(Cl)=C(Cl)C=C1Cl",
    "molecular_weight": 406.91,
    "log_p": 6.61,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "potassium channel activator",
    "disease_area": "infectious disease",
    "indication": "gram-positive bacterial infections"
  },
  "hexafluronium": {
    "name": "Hexafluronium",
    "smiles": "C[N+](C)(CCCCCC[N+](C)(C)C1C2=C(C=CC=C2)C2=C1C=CC=C2)C1C2=C(C=CC=C2)C2=C1C=CC=C2",
    "molecular_weight": 502.75,
    "log_p": 8.24,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "hexamidine": {
    "name": "Hexamidine",
    "smiles": "NC(=N)C1=CC=C(OCCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1",
    "molecular_weight": 354.45,
    "log_p": 3.27,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA"
  },
  "hexaminolevulinate": {
    "name": "Hexaminolevulinate",
    "smiles": "[H]N([H])CC(=O)CCC(=O)OCCCCCC",
    "molecular_weight": 215.29,
    "log_p": 1.42,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "radiology",
    "indication": "diagnostic agent"
  },
  "hexetidine": {
    "name": "Hexetidine",
    "smiles": "CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1",
    "molecular_weight": 339.61,
    "log_p": 4.71,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "local anesthetic",
    "disease_area": "dental | gastroenterology | infectious disease | otolaryngology | otolaryngology",
    "indication": "gingivitis | laryngitis | meningitis | pharyngitis | ulcerative colitis"
  },
  "hexobendine": {
    "name": "Hexobendine",
    "smiles": "COC1=CC(=CC(OC)=C1OC)C(=O)OCCCN(C)CCN(C)CCCOC(=O)C1=CC(OC)=C(OC)C(OC)=C1",
    "molecular_weight": 592.69,
    "log_p": 3.4,
    "hbd": 0,
    "hba": 12,
    "rotatable_bonds": 19,
    "approved": true,
    "source": "FDA"
  },
  "hexocyclium": {
    "name": "Hexocyclium",
    "smiles": "C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1",
    "molecular_weight": 317.5,
    "log_p": 2.85,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "hexylcaine": {
    "name": "Hexylcaine",
    "smiles": "CC(CNC1CCCCC1)OC(=O)C1=CC=CC=C1",
    "molecular_weight": 261.37,
    "log_p": 3.15,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "neurology/psychiatry",
    "indication": "local anesthetic"
  },
  "hexylresorcinol": {
    "name": "Hexylresorcinol",
    "smiles": "CCCCCCC1=C(O)C=C(O)C=C1",
    "molecular_weight": 194.27,
    "log_p": 3.22,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "local anesthetic",
    "disease_area": "infectious disease | infectious disease",
    "indication": "first-aid antiseptic | skin infections"
  },
  "histamine": {
    "name": "Histamine",
    "smiles": "NCCC1=CNC=N1",
    "molecular_weight": 111.15,
    "log_p": -0.09,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor agonist",
    "disease_area": "allergy",
    "indication": "allergic rhinitis"
  },
  "histrelin": {
    "name": "Histrelin",
    "smiles": "CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CN(CC2=CC=CC=C2)C=N1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1",
    "molecular_weight": 1443.63,
    "log_p": -0.61,
    "hbd": 18,
    "hba": 18,
    "rotatable_bonds": 34,
    "approved": true,
    "source": "FDA"
  },
  "homatropine": {
    "name": "Homatropine",
    "smiles": "[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)C1=CC=CC=C1)N2C",
    "molecular_weight": 275.35,
    "log_p": 1.89,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "ophthalmology | ophthalmology",
    "indication": "pupil dilation | uveal tract inflammation"
  },
  "homatropine methylbromide": {
    "name": "Homatropine methylbromide",
    "smiles": "[Br-].C[N+]1(C)C2CCC1CC(C2)OC(=O)C(O)C1=CC=CC=C1",
    "molecular_weight": 370.29,
    "log_p": -0.96,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "ophthalmology",
    "indication": "uveal tract inflammation"
  },
  "homosalate": {
    "name": "Homosalate",
    "smiles": "CC1CC(CC(C)(C)C1)OC(=O)C1=C(O)C=CC=C1",
    "molecular_weight": 262.35,
    "log_p": 3.76,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Preclinical",
    "moa": "HSP inducer",
    "disease_area": "",
    "indication": ""
  },
  "huperzine a": {
    "name": "Huperzine A",
    "smiles": "[H][C@@]12CC3=C(C=CC(=O)N3)[C@@](N)(CC(C)=C1)\\C2=C\\C",
    "molecular_weight": 242.32,
    "log_p": 2.0,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "hyaluronic acid": {
    "name": "Hyaluronic acid",
    "smiles": "CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O",
    "molecular_weight": 776.65,
    "log_p": -9.28,
    "hbd": 14,
    "hba": 21,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "hydralazine": {
    "name": "Hydralazine",
    "smiles": "NNC1=NN=CC2=CC=CC=C12",
    "molecular_weight": 160.18,
    "log_p": 0.92,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "myeloperoxidase inhibitor | vasodilator",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "hydrochlorothiazide": {
    "name": "Hydrochlorothiazide",
    "smiles": "NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1",
    "molecular_weight": 297.75,
    "log_p": -0.35,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "thiazide diuretic",
    "disease_area": "cardiology | cardiology",
    "indication": "congestive heart failure | hypertension"
  },
  "hydrocodone": {
    "name": "Hydrocodone",
    "smiles": "[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O",
    "molecular_weight": 299.37,
    "log_p": 1.93,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "hydrocortamate": {
    "name": "Hydrocortamate",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)COC(=O)CN(CC)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 475.63,
    "log_p": 2.67,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "hydrocortisone": {
    "name": "Hydrocortisone",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 362.47,
    "log_p": 1.78,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "dermatology | dermatology | dermatology | neurology/psychiatry",
    "indication": "eczema | itching | psoriasis | seborrheic dermatitis"
  },
  "hydrocortisone acetate": {
    "name": "Hydrocortisone acetate",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 404.5,
    "log_p": 2.35,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "dermatology",
    "indication": "corticosteroid-responsive dermatoses"
  },
  "hydrocortisone butyrate": {
    "name": "Hydrocortisone butyrate",
    "smiles": "[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 432.56,
    "log_p": 3.13,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "hydrocortisone cypionate": {
    "name": "Hydrocortisone cypionate",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC3CCCC3)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 486.65,
    "log_p": 4.3,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "hydrocortisone phosphate": {
    "name": "Hydrocortisone phosphate",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 442.45,
    "log_p": 1.9,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "hydrocortisone probutate": {
    "name": "Hydrocortisone probutate",
    "smiles": "[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 488.62,
    "log_p": 4.09,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "hydrocortisone succinate": {
    "name": "Hydrocortisone succinate",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 462.54,
    "log_p": 2.2,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "hydrocortisone valerate": {
    "name": "Hydrocortisone valerate",
    "smiles": "[H][C@@]12CC[C@](OC(=O)CCCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 446.58,
    "log_p": 3.52,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "dermatology",
    "indication": "corticosteroid-responsive dermatoses"
  },
  "hydroflumethiazide": {
    "name": "Hydroflumethiazide",
    "smiles": "NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F",
    "molecular_weight": 331.3,
    "log_p": 0.01,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium/potassium/chloride transporter inhibitor",
    "disease_area": "cardiology | cardiology | cardiology | gastroenterology | nephrology | nephrology | rheumatology",
    "indication": "acute glomerulonephritis (AGN) | chronic renal failure | congestive heart failure | edema | hepatic cirrhosis | hypertension | nephrotic syndrome"
  },
  "hydrogen fluoride": {
    "name": "Hydrogen fluoride",
    "smiles": "F",
    "molecular_weight": 20.01,
    "log_p": 0.15,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "hydrogen peroxide": {
    "name": "Hydrogen peroxide",
    "smiles": "OO",
    "molecular_weight": 34.01,
    "log_p": 0.02,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "hydromorphone": {
    "name": "Hydromorphone",
    "smiles": "[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O",
    "molecular_weight": 285.34,
    "log_p": 1.63,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "hydroquinone": {
    "name": "Hydroquinone",
    "smiles": "OC1=CC=C(O)C=C1",
    "molecular_weight": 110.11,
    "log_p": 1.1,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "melanin inhibitor",
    "disease_area": "dermatology",
    "indication": "dyschromia"
  },
  "hydrotalcite": {
    "name": "Hydrotalcite",
    "smiles": "O.O.O.O.O.O.O.O.O.O.O.O.[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[O-]C([O-])=O",
    "molecular_weight": 619.97,
    "log_p": -16.46,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "hydroxocobalamin": {
    "name": "Hydroxocobalamin",
    "smiles": "[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]",
    "molecular_weight": 1346.38,
    "log_p": -0.22,
    "hbd": 10,
    "hba": 17,
    "rotatable_bonds": 16,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin B",
    "disease_area": "",
    "indication": ""
  },
  "hydroxyamphetamine": {
    "name": "Hydroxyamphetamine",
    "smiles": "CC(N)CC1=CC=C(O)C=C1",
    "molecular_weight": 151.21,
    "log_p": 1.28,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "trace amine associated receptor agonist",
    "disease_area": "ophthalmology",
    "indication": "mydriasis"
  },
  "hydroxychloroquine": {
    "name": "Hydroxychloroquine",
    "smiles": "CCN(CCO)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1",
    "molecular_weight": 335.88,
    "log_p": 3.78,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antimalarial agent",
    "disease_area": "infectious disease",
    "indication": "malaria"
  },
  "hydroxycitronellal": {
    "name": "Hydroxycitronellal",
    "smiles": "[H]C(=O)CC(C)CCCC(C)(C)O",
    "molecular_weight": 172.27,
    "log_p": 2.15,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "hydroxyethyl cellulose": {
    "name": "Hydroxyethyl cellulose",
    "smiles": "CC(O)COCC1OC(OC2C(COCC(C)O)OC(OCC(C)O)C(OCC(C)O)C2OCC(C)O)C(OCC(C)O)C(OCC(C)O)C1OCC(C)O",
    "molecular_weight": 806.94,
    "log_p": -2.16,
    "hbd": 8,
    "hba": 19,
    "rotatable_bonds": 28,
    "approved": true,
    "source": "FDA"
  },
  "hydroxyprogesterone caproate": {
    "name": "Hydroxyprogesterone caproate",
    "smiles": "[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 428.61,
    "log_p": 5.97,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "progesterone receptor agonist",
    "disease_area": "obstetrics/gynecology",
    "indication": "spontaneous preterm birth"
  },
  "hydroxystilbamidine": {
    "name": "Hydroxystilbamidine",
    "smiles": "NC(=N)C1=CC=C(\\C=C\\C2=C(O)C=C(C=C2)C(N)=N)C=C1",
    "molecular_weight": 280.33,
    "log_p": 2.13,
    "hbd": 5,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "hydroxyurea": {
    "name": "Hydroxyurea",
    "smiles": "NC(=O)NO",
    "molecular_weight": 76.05,
    "log_p": -0.96,
    "hbd": 3,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ribonucleotide reductase inhibitor",
    "disease_area": "hematologic malignancy | oncology",
    "indication": "chronic myeloid leukemia (CML) | head and neck squamous cell carcinoma (HNSCC)"
  },
  "hydroxyzine": {
    "name": "Hydroxyzine",
    "smiles": "OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1",
    "molecular_weight": 374.91,
    "log_p": 3.06,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antihistamine",
    "disease_area": "allergy | dermatology | neurology/psychiatry | neurology/psychiatry",
    "indication": "anxiety | dermatosis | itching | urticaria"
  },
  "hyoscyamine": {
    "name": "Hyoscyamine",
    "smiles": "CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1",
    "molecular_weight": 289.38,
    "log_p": 1.93,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "allergy | gastroenterology | gastroenterology | gastroenterology | gastroenterology | gastroenterology | neurology/psychiatry | urology",
    "indication": "acute abdominal visceral spasm | allergic rhinitis | enterocolitis | interstitial cystitis (IC) | irritable bowel syndrome | peptic ulcer disease (PUD) | tremors | ulcerative colitis"
  },
  "hypochlorite": {
    "name": "Hypochlorite",
    "smiles": "[O-]Cl",
    "molecular_weight": 51.45,
    "log_p": -0.5,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "ibandronate": {
    "name": "Ibandronate",
    "smiles": "CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O",
    "molecular_weight": 319.23,
    "log_p": 0.5,
    "hbd": 5,
    "hba": 4,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bone resorption inhibitor",
    "disease_area": "orthopedics",
    "indication": "osteoporosis"
  },
  "ibrexafungerp": {
    "name": "Ibrexafungerp",
    "smiles": "[H][C@]12CC[C@@]3([H])[C@@]4(C)COC[C@@]3(C[C@H]([C@@H]4OC[C@](C)(N)C(C)(C)C)N3N=CN=C3C3=CC=NC=C3)C1=CC[C@@]1(C)[C@H](C(O)=O)[C@](C)(CC[C@]21C)[C@H](C)C(C)C",
    "molecular_weight": 730.05,
    "log_p": 8.62,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "ibrutinib": {
    "name": "Ibrutinib",
    "smiles": "NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1",
    "molecular_weight": 440.51,
    "log_p": 4.22,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "Bruton's tyrosine kinase (BTK) inhibitor",
    "disease_area": "hematologic malignancy | hematologic malignancy | hematologic malignancy",
    "indication": "chronic lymphocytic leukemia (CLL) | mantle cell lymphoma (MCL) | Waldenstrom's macroglobulinemia (WM)"
  },
  "ibuprofen": {
    "name": "Ibuprofen",
    "smiles": "CC(C)CC1=CC=C(C=C1)C(C)C(O)=O",
    "molecular_weight": 206.28,
    "log_p": 3.07,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "dental | endocrinology | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | obstetrics/gynecology | otolaryngology | rheumatology",
    "indication": "backache | common cold | fever | headache | menstrual pain | muscle pain | rheumatoid arthritis | toothache"
  },
  "ibutilide": {
    "name": "Ibutilide",
    "smiles": "CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1",
    "molecular_weight": 384.59,
    "log_p": 4.16,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 14,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "potassium channel blocker",
    "disease_area": "cardiology",
    "indication": "atrial fibrillation (AF)"
  },
  "icatibant": {
    "name": "Icatibant",
    "smiles": "[H][C@]12C[C@]([H])(N(C(=O)[C@@]3([H])CC4=C(CN3C(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=CS3)NC(=O)CNC(=O)[C@]3([H])C[C@@H](O)CN3C(=O)[C@@H]3CCCN3C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](N)CCCNC(N)=N)C=CC=C4)[C@@]1([H])CCCC2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O",
    "molecular_weight": 1304.55,
    "log_p": -4.39,
    "hbd": 18,
    "hba": 17,
    "rotatable_bonds": 30,
    "approved": true,
    "source": "FDA"
  },
  "icosapent": {
    "name": "Icosapent",
    "smiles": "CC\\C=C/C\\C=C/C\\C=C/C\\C=C/C\\C=C/CCCC(O)=O",
    "molecular_weight": 302.46,
    "log_p": 5.99,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "platelet aggregation inhibitor",
    "disease_area": "endocrinology",
    "indication": "hypertriglyceridemia"
  },
  "icosapent ethyl": {
    "name": "Icosapent ethyl",
    "smiles": "CCOC(=O)CCC\\C=C/C\\C=C/C\\C=C/C\\C=C/C\\C=C/CC",
    "molecular_weight": 330.51,
    "log_p": 6.47,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 14,
    "approved": true,
    "source": "FDA"
  },
  "idarubicin": {
    "name": "Idarubicin",
    "smiles": "C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O",
    "molecular_weight": 497.5,
    "log_p": 1.02,
    "hbd": 5,
    "hba": 10,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "topoisomerase inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "acute myeloid leukemia (AML)"
  },
  "idebenone": {
    "name": "Idebenone",
    "smiles": "COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O",
    "molecular_weight": 338.44,
    "log_p": 3.46,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel modulator",
    "disease_area": "neurology/psychiatry | neurology/psychiatry | ophthalmology",
    "indication": "Alzheimer's disease | Friedreich's ataxia | Leber hereditary optic neuropathy (LHON)"
  },
  "idelalisib": {
    "name": "Idelalisib",
    "smiles": "[H][C@@](CC)(NC1=NC=NC2=C1N=CN2)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1",
    "molecular_weight": 415.43,
    "log_p": 3.75,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PI3K inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "chronic lymphocytic leukemia (CLL)"
  },
  "idoxuridine": {
    "name": "Idoxuridine",
    "smiles": "OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(I)C(=O)NC1=O",
    "molecular_weight": 354.1,
    "log_p": -1.22,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA directed DNA polymerase inhibitor | DNA synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "virus herpes simplex (HSV)"
  },
  "ifosfamide": {
    "name": "Ifosfamide",
    "smiles": "ClCCNP1(=O)OCCCN1CCCl",
    "molecular_weight": 261.09,
    "log_p": 1.88,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA alkylating agent",
    "disease_area": "oncology | urology",
    "indication": "hemorrhagic cystitis | testicular carcinoma"
  },
  "iloperidone": {
    "name": "Iloperidone",
    "smiles": "COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O",
    "molecular_weight": 426.49,
    "log_p": 4.83,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist | serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "schizophrenia"
  },
  "iloprost": {
    "name": "Iloprost",
    "smiles": "[H][C@]12C[C@@H](O)[C@H](\\C=C\\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\\C(C2)=C\\CCCC(O)=O",
    "molecular_weight": 360.49,
    "log_p": 3.54,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "platelet aggregation inhibitor | prostanoid receptor agonist",
    "disease_area": "pulmonary",
    "indication": "pulmonary arterial hypertension (PAH)"
  },
  "imatinib": {
    "name": "Imatinib",
    "smiles": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1",
    "molecular_weight": 493.62,
    "log_p": 4.59,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "Bcr-Abl kinase inhibitor | KIT inhibitor | PDGFR tyrosine kinase receptor inhibitor",
    "disease_area": "hematologic malignancy | hematologic malignancy | hematologic malignancy | hematologic malignancy | hematologic malignancy | hematologic malignancy | oncology | oncology",
    "indication": "acute lymphoblastic leukemia (ALL) | aggressive systemic mastocytosis (ASM) | chronic eosinophilic leukemia (CEL) | chronic myeloid leukemia (CML) | dermatofibrosarcoma protuberans (DFSP) | gastrointestinal stromal tumors (GIST) | hypereosinophilic syndrome (HES) | myelodysplastic diseases (MDS)"
  },
  "imidurea": {
    "name": "Imidurea",
    "smiles": "OCN1C(NC(=O)NCNC(=O)NC2N(CO)C(=O)NC2=O)C(=O)NC1=O",
    "molecular_weight": 388.3,
    "log_p": -4.8,
    "hbd": 8,
    "hba": 8,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Preclinical",
    "moa": "other antibiotic",
    "disease_area": "",
    "indication": ""
  },
  "imipenem": {
    "name": "Imipenem",
    "smiles": "[H][C@]12CC(SCC\\N=C\\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O",
    "molecular_weight": 299.35,
    "log_p": -0.39,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "bacterial septicemia | bone and joint infections | endocarditis | gynecologic infections | intra-abdominal infections | pneumonia | skin infections | urinary tract infections"
  },
  "imipramine": {
    "name": "Imipramine",
    "smiles": "CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12",
    "molecular_weight": 280.42,
    "log_p": 3.88,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "norepinephrine reputake inhibitor | serotonin reuptake inhibitor",
    "disease_area": "neurology/psychiatry | urology",
    "indication": "depression | nocturnal enuresis"
  },
  "imiquimod": {
    "name": "Imiquimod",
    "smiles": "CC(C)CN1C=NC2=C1C1=C(C=CC=C1)N=C2N",
    "molecular_weight": 240.31,
    "log_p": 2.82,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "interferon inducer | toll-like receptor agonist",
    "disease_area": "dermatology | infectious disease | oncology",
    "indication": "actinic keratosis (AK) | basal cell carcinoma (BCC) | genital warts"
  },
  "indacaterol": {
    "name": "Indacaterol",
    "smiles": "CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1",
    "molecular_weight": 392.5,
    "log_p": 3.15,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "pulmonary",
    "indication": "chronic obstructive pulmonary disease (COPD)"
  },
  "indapamide": {
    "name": "Indapamide",
    "smiles": "CC1CC2=CC=CC=C2N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O",
    "molecular_weight": 365.84,
    "log_p": 2.08,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "thiazide diuretic",
    "disease_area": "cardiology | cardiology",
    "indication": "congestive heart failure | hypertension"
  },
  "indecainide": {
    "name": "Indecainide",
    "smiles": "CC(C)NCCCC1(C(N)=O)C2=CC=CC=C2C2=CC=CC=C12",
    "molecular_weight": 308.43,
    "log_p": 3.22,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "indigotindisulfonic acid": {
    "name": "Indigotindisulfonic acid",
    "smiles": "OS(=O)(=O)C1=CC2=C(N\\C(C2=O)=C2\\NC3=C(C=C(C=C3)S(O)(=O)=O)C2=O)C=C1",
    "molecular_weight": 422.4,
    "log_p": 1.31,
    "hbd": 4,
    "hba": 8,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "indinavir": {
    "name": "Indinavir",
    "smiles": "CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12",
    "molecular_weight": 613.8,
    "log_p": 2.87,
    "hbd": 4,
    "hba": 7,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HIV protease inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "indium in-111 chloride": {
    "name": "Indium In-111 chloride",
    "smiles": "Cl[111In](Cl)Cl",
    "molecular_weight": 217.26,
    "log_p": 1.69,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "indium in-111 oxyquinoline": {
    "name": "Indium In-111 oxyquinoline",
    "smiles": "[111In+3].[O-]C1=CC=CC2=C1N=CC=C2.[O-]C1=CC=CC2=C1N=CC=C2.[O-]C1=CC=CC2=C1N=CC=C2",
    "molecular_weight": 543.36,
    "log_p": 3.54,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "indium in-111 pentetate": {
    "name": "Indium In-111 pentetate",
    "smiles": "[111In+3].OC(=O)CN(CCN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)CC(O)=O",
    "molecular_weight": 501.23,
    "log_p": -7.07,
    "hbd": 2,
    "hba": 11,
    "rotatable_bonds": 16,
    "approved": true,
    "source": "FDA"
  },
  "indium in-111 pentetreotide": {
    "name": "Indium In-111 pentetreotide",
    "smiles": "[111In+3].CC(O)C(CO)N=C(O)C1CSSCC(N=C(O)C(CC2=CC=CC=C2)N=C([O-])CN(CCN(CCC(C(O)=O)C(O)=O)CC([O-])=O)CC([O-])=O)C(O)=NC(CC2=CC=CC=C2)C(O)=NC(CC2=CNC3=CC=CC=C23)C(O)=NC(CCCCN)C([O-])=NC(C(C)O)C(O)=N1",
    "molecular_weight": 1472.43,
    "log_p": -1.42,
    "hbd": 13,
    "hba": 24,
    "rotatable_bonds": 32,
    "approved": true,
    "source": "FDA"
  },
  "indocyanine green": {
    "name": "Indocyanine green",
    "smiles": "[Na+].CC1(C)\\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS([O-])(=O)=O)C3=CC=C4C=CC=CC4=C3C2(C)C)N(CCCCS([O-])(=O)=O)C2=CC=C3C=CC=CC3=C12",
    "molecular_weight": 774.98,
    "log_p": 5.37,
    "hbd": 0,
    "hba": 7,
    "rotatable_bonds": 14,
    "approved": true,
    "source": "FDA"
  },
  "indocyanine green acid form": {
    "name": "Indocyanine green acid form",
    "smiles": "CC1(C)\\C(=C\\C=C\\C=C\\C=C\\C2=[N+](CCCCS(O)(=O)=O)C3=C(C4=CC=CC=C4C=C3)C2(C)C)N(CCCCS(O)(=O)=O)C2=C1C1=CC=CC=C1C=C2",
    "molecular_weight": 754.01,
    "log_p": 9.06,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 14,
    "approved": true,
    "source": "FDA"
  },
  "indomethacin": {
    "name": "Indomethacin",
    "smiles": "COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O",
    "molecular_weight": 357.79,
    "log_p": 3.93,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "orthopedics | rheumatology | rheumatology | rheumatology | rheumatology",
    "indication": "ankylosing spondylitis | bursitis | osteoarthritis | rheumatoid arthritis | tendinitis"
  },
  "indoramin": {
    "name": "Indoramin",
    "smiles": "O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C1=CC=CC=C1",
    "molecular_weight": 347.46,
    "log_p": 3.6,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology | urology",
    "indication": "benign prostatic hyperplasia (BPH) | hypertension"
  },
  "infigratinib": {
    "name": "Infigratinib",
    "smiles": "CCN1CCN(CC1)C1=CC=C(NC2=CC(=NC=N2)N(C)C(=O)NC2=C(Cl)C(OC)=CC(OC)=C2Cl)C=C1",
    "molecular_weight": 560.49,
    "log_p": 5.35,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "ingenol mebutate": {
    "name": "Ingenol mebutate",
    "smiles": "[H][C@@]12C[C@@H](C)[C@]34C=C(C)[C@H](OC(=O)C(\\C)=C/C)[C@@]3(O)[C@H](O)C(CO)=C[C@@]([H])(C4=O)[C@]1([H])C2(C)C",
    "molecular_weight": 430.54,
    "log_p": 2.33,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "inosine pranobex": {
    "name": "Inosine pranobex",
    "smiles": "C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CNC2=O",
    "molecular_weight": 1115.25,
    "log_p": 1.55,
    "hbd": 13,
    "hba": 20,
    "rotatable_bonds": 14,
    "approved": true,
    "source": "FDA"
  },
  "inositol": {
    "name": "Inositol",
    "smiles": "O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O",
    "molecular_weight": 180.16,
    "log_p": -3.83,
    "hbd": 6,
    "hba": 6,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "insulin sensitizer",
    "disease_area": "obstetrics/gynecology",
    "indication": "polycystic ovary syndrom (PCOS)"
  },
  "inositol nicotinate": {
    "name": "Inositol nicotinate",
    "smiles": "O=C(O[C@H]1[C@H](OC(=O)C2=CC=CN=C2)[C@@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@@H]1OC(=O)C1=CC=CN=C1)C1=CC=CN=C1",
    "molecular_weight": 810.73,
    "log_p": 3.72,
    "hbd": 0,
    "hba": 18,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "iobenguane": {
    "name": "Iobenguane",
    "smiles": "NC(N)=NCC1=CC(I)=CC=C1",
    "molecular_weight": 275.09,
    "log_p": 1.06,
    "hbd": 2,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antineoplastic agent",
    "disease_area": "cardiology | endocrinology | oncology",
    "indication": "congestive heart failure | neuroblastoma | pheochromocytoma"
  },
  "iobenguane sulfate i-123": {
    "name": "Iobenguane sulfate I-123",
    "smiles": "OS(O)(=O)=O.NC(=N)NCC1=CC([123I])=CC=C1.NC(=N)NCC1=CC([123I])=CC=C1",
    "molecular_weight": 640.27,
    "log_p": 1.9,
    "hbd": 8,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "iobitridol": {
    "name": "Iobitridol",
    "smiles": "CN(CC(O)CO)C(=O)C1=C(I)C(C(=O)N(C)CC(O)CO)=C(I)C(NC(=O)C(CO)CO)=C1I",
    "molecular_weight": 835.17,
    "log_p": -1.11,
    "hbd": 7,
    "hba": 9,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "iocetamic acid": {
    "name": "Iocetamic acid",
    "smiles": "CC(CN(C(C)=O)C1=C(I)C=C(I)C(N)=C1I)C(O)=O",
    "molecular_weight": 613.96,
    "log_p": 3.16,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "iodide": {
    "name": "Iodide",
    "smiles": "[I-]",
    "molecular_weight": 126.9,
    "log_p": -3.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "iodide i-123": {
    "name": "Iodide I-123",
    "smiles": "[123I-]",
    "molecular_weight": 122.91,
    "log_p": -3.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "iodide i-131": {
    "name": "Iodide I-131",
    "smiles": "[131I-]",
    "molecular_weight": 130.91,
    "log_p": -3.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "iodine": {
    "name": "Iodine",
    "smiles": "II",
    "molecular_weight": 253.81,
    "log_p": 1.77,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "iodipamide": {
    "name": "Iodipamide",
    "smiles": "OC(=O)C1=C(I)C(NC(=O)CCCCC(=O)NC2=C(I)C=C(I)C(C(O)=O)=C2I)=C(I)C=C1I",
    "molecular_weight": 1139.76,
    "log_p": 6.85,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "radiopaque medium",
    "disease_area": "radiology",
    "indication": "contrast agent"
  },
  "iodixanol": {
    "name": "Iodixanol",
    "smiles": "CC(=O)N(CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I",
    "molecular_weight": 1550.19,
    "log_p": -1.59,
    "hbd": 13,
    "hba": 15,
    "rotatable_bonds": 22,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "radiopaque medium",
    "disease_area": "radiology",
    "indication": "contrast agent"
  },
  "iodoform": {
    "name": "Iodoform",
    "smiles": "[H]C(I)(I)I",
    "molecular_weight": 393.73,
    "log_p": 2.58,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "iodohippurate sodium i-123": {
    "name": "Iodohippurate sodium I-123",
    "smiles": "[Na+].[O-]C(=O)CNC(=O)C1=CC=CC=C1[123I]",
    "molecular_weight": 323.05,
    "log_p": -3.23,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "iodohippurate sodium i-131": {
    "name": "Iodohippurate sodium I-131",
    "smiles": "[Na+].[O-]C(=O)CNC(=O)C1=C([131I])C=CC=C1",
    "molecular_weight": 331.06,
    "log_p": -3.23,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "iofetamine i-123": {
    "name": "Iofetamine I-123",
    "smiles": "CC(C)NC(C)CC1=CC=C([123I])C=C1",
    "molecular_weight": 299.19,
    "log_p": 3.22,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "ioflupane i-123": {
    "name": "Ioflupane I-123",
    "smiles": "[H][C@]12CC[C@]([H])([C@H]([C@H](C1)C1=CC=C([123I])C=C1)C(=O)OC)N2CCCF",
    "molecular_weight": 427.29,
    "log_p": 3.76,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "iohexol": {
    "name": "Iohexol",
    "smiles": "CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I",
    "molecular_weight": 821.14,
    "log_p": -1.63,
    "hbd": 8,
    "hba": 9,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "radiopaque medium",
    "disease_area": "radiology",
    "indication": "contrast agent"
  },
  "iomeprol": {
    "name": "Iomeprol",
    "smiles": "CN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I",
    "molecular_weight": 777.09,
    "log_p": -1.38,
    "hbd": 7,
    "hba": 8,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "iopamidol": {
    "name": "Iopamidol",
    "smiles": "C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I",
    "molecular_weight": 777.09,
    "log_p": -1.01,
    "hbd": 8,
    "hba": 8,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "radiopaque medium",
    "disease_area": "radiology",
    "indication": "contrast agent"
  },
  "iopanoic acid": {
    "name": "Iopanoic acid",
    "smiles": "CCC(CC1=C(I)C(N)=C(I)C=C1I)C(O)=O",
    "molecular_weight": 570.93,
    "log_p": 3.74,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "iophendylate": {
    "name": "Iophendylate",
    "smiles": "CCOC(=O)CCCCCCCCC(C)C1=CC=CC=C1I",
    "molecular_weight": 416.34,
    "log_p": 6.08,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA"
  },
  "iopodic acid": {
    "name": "Iopodic acid",
    "smiles": "CN(C)C=NC1=C(I)C=C(I)C(CCC(O)=O)=C1I",
    "molecular_weight": 597.96,
    "log_p": 3.74,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "iopromide": {
    "name": "Iopromide",
    "smiles": "COCC(=O)NC1=C(I)C(C(=O)N(C)CC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I",
    "molecular_weight": 791.12,
    "log_p": -0.41,
    "hbd": 6,
    "hba": 8,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "radiopaque medium",
    "disease_area": "radiology",
    "indication": "contrast agent"
  },
  "iothalamic acid": {
    "name": "Iothalamic acid",
    "smiles": "CNC(=O)C1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I",
    "molecular_weight": 613.92,
    "log_p": 2.52,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "iotrolan": {
    "name": "Iotrolan",
    "smiles": "CN(C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I",
    "molecular_weight": 1626.24,
    "log_p": -3.89,
    "hbd": 16,
    "hba": 18,
    "rotatable_bonds": 24,
    "approved": true,
    "source": "FDA"
  },
  "ioversol": {
    "name": "Ioversol",
    "smiles": "OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I",
    "molecular_weight": 807.11,
    "log_p": -2.02,
    "hbd": 8,
    "hba": 9,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "radiopaque medium",
    "disease_area": "radiology",
    "indication": "contrast agent"
  },
  "ioxaglic acid": {
    "name": "Ioxaglic acid",
    "smiles": "CNC(=O)C1=C(I)C(C(=O)NCC(=O)NC2=C(I)C(C(O)=O)=C(I)C(C(=O)NCCO)=C2I)=C(I)C(N(C)C(C)=O)=C1I",
    "molecular_weight": 1268.88,
    "log_p": 3.45,
    "hbd": 6,
    "hba": 7,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "ioxilan": {
    "name": "Ioxilan",
    "smiles": "CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCCO)=C1I",
    "molecular_weight": 791.12,
    "log_p": -0.99,
    "hbd": 7,
    "hba": 8,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "radiopaque medium",
    "disease_area": "radiology",
    "indication": "angiography"
  },
  "ioxitalamic acid": {
    "name": "Ioxitalamic acid",
    "smiles": "CC(=O)NC1=C(I)C(C(O)=O)=C(I)C(C(=O)NCCO)=C1I",
    "molecular_weight": 643.94,
    "log_p": 1.88,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "ipratropium": {
    "name": "Ipratropium",
    "smiles": "[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N+]2(C)C(C)C",
    "molecular_weight": 332.46,
    "log_p": 2.85,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "pulmonary | pulmonary | pulmonary | pulmonary",
    "indication": "bronchitis | bronchospasm | chronic obstructive pulmonary disease (COPD) | emphysema"
  },
  "irbesartan": {
    "name": "Irbesartan",
    "smiles": "CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1",
    "molecular_weight": 428.54,
    "log_p": 4.78,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin receptor antagonist",
    "disease_area": "cardiology | nephrology",
    "indication": "diabetic nephropathy | hypertension"
  },
  "irinotecan": {
    "name": "Irinotecan",
    "smiles": "CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12",
    "molecular_weight": 586.69,
    "log_p": 4.09,
    "hbd": 1,
    "hba": 9,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "topoisomerase inhibitor",
    "disease_area": "oncology",
    "indication": "colorectal cancer"
  },
  "iron": {
    "name": "Iron",
    "smiles": "[Fe]",
    "molecular_weight": 55.84,
    "log_p": -0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "iron sucrose": {
    "name": "Iron sucrose",
    "smiles": "O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O",
    "molecular_weight": 866.55,
    "log_p": -15.0,
    "hbd": 8,
    "hba": 12,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "isavuconazole": {
    "name": "Isavuconazole",
    "smiles": "C[C@@H](C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=C(F)C=CC(F)=C1",
    "molecular_weight": 437.48,
    "log_p": 4.24,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cytochrome P450 inhibitor | fungal lanosterol demethylase inhibitor",
    "disease_area": "Infectious disease",
    "indication": "fungal infection"
  },
  "isavuconazonium": {
    "name": "Isavuconazonium",
    "smiles": "[H]C(C)(OC(=O)N(C)C1=C(COC(=O)CNC)C=CC=N1)[N+]1=CN(C[C@](O)(C2=C(F)C=CC(F)=C2)[C@@]([H])(C)C2=NC(=CS2)C2=CC=C(C=C2)C#N)N=C1",
    "molecular_weight": 717.78,
    "log_p": 4.58,
    "hbd": 2,
    "hba": 12,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA"
  },
  "isoaminile": {
    "name": "Isoaminile",
    "smiles": "CC(C)[C@@](C[C@H](C)N(C)C)(C#N)C1=CC=CC=C1",
    "molecular_weight": 244.38,
    "log_p": 3.44,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "isocarboxazid": {
    "name": "Isocarboxazid",
    "smiles": "CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1",
    "molecular_weight": 231.26,
    "log_p": 1.42,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "monoamine oxidase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "isoconazole": {
    "name": "Isoconazole",
    "smiles": "ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC1=C(Cl)C=CC=C1Cl",
    "molecular_weight": 416.14,
    "log_p": 6.45,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "fungal lanosterol demethylase inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-positive bacterial infections"
  },
  "isoetharine": {
    "name": "Isoetharine",
    "smiles": "CCC(NC(C)C)C(O)C1=CC(O)=C(O)C=C1",
    "molecular_weight": 239.31,
    "log_p": 1.91,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "pulmonary | pulmonary",
    "indication": "asthma | bronchospasm"
  },
  "isoeugenol": {
    "name": "Isoeugenol",
    "smiles": "COC1=CC(C=CC)=CC=C1O",
    "molecular_weight": 164.2,
    "log_p": 2.43,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "isoflurane": {
    "name": "Isoflurane",
    "smiles": "FC(F)OC(Cl)C(F)(F)F",
    "molecular_weight": 184.49,
    "log_p": 2.35,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "inhaled anaesthetic",
    "disease_area": "neurology/psychiatry",
    "indication": "general anaesthetic"
  },
  "isoflurophate": {
    "name": "Isoflurophate",
    "smiles": "CC(C)OP(F)(=O)OC(C)C",
    "molecular_weight": 184.15,
    "log_p": 2.91,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cholinesterase inhibitor",
    "disease_area": "ophthalmology",
    "indication": "glaucoma"
  },
  "isometheptene": {
    "name": "Isometheptene",
    "smiles": "CNC(C)CCC=C(C)C",
    "molecular_weight": 141.26,
    "log_p": 2.34,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "isoniazid": {
    "name": "Isoniazid",
    "smiles": "NNC(=O)C1=CC=NC=C1",
    "molecular_weight": 137.14,
    "log_p": -0.31,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "FABI inhibitor",
    "disease_area": "infectious disease",
    "indication": "tuberculosis"
  },
  "isoprenaline": {
    "name": "Isoprenaline",
    "smiles": "CC(C)NCC(O)C1=CC(O)=C(O)C=C1",
    "molecular_weight": 211.26,
    "log_p": 1.13,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "cardiology | cardiology | pulmonary",
    "indication": "asthma | bradycardia | heart block"
  },
  "isopropamide": {
    "name": "Isopropamide",
    "smiles": "CC(C)[N+](C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C",
    "molecular_weight": 353.53,
    "log_p": 4.11,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "isopropyl alcohol": {
    "name": "Isopropyl alcohol",
    "smiles": "CC(C)O",
    "molecular_weight": 60.1,
    "log_p": 0.39,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "isopropyl myristate": {
    "name": "Isopropyl myristate",
    "smiles": "CCCCCCCCCCCCCC(=O)OC(C)C",
    "molecular_weight": 270.46,
    "log_p": 5.64,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA"
  },
  "isosorbide": {
    "name": "Isosorbide",
    "smiles": "[H][C@]1(O)CO[C@]2([H])[C@]([H])(O)CO[C@]12[H]",
    "molecular_weight": 146.14,
    "log_p": -1.49,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "nitric oxide stimulant",
    "disease_area": "cardiology | cardiology",
    "indication": "angina pectoris | coronary artery disease (CAD)"
  },
  "isosorbide dinitrate": {
    "name": "Isosorbide dinitrate",
    "smiles": "[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O",
    "molecular_weight": 236.14,
    "log_p": -1.06,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "isosorbide mononitrate": {
    "name": "Isosorbide mononitrate",
    "smiles": "[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O",
    "molecular_weight": 191.14,
    "log_p": -1.28,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "isosulfan blue": {
    "name": "Isosulfan blue",
    "smiles": "CCN(CC)C1=CC=C(C=C1)C(=C1C=CC(C=C1)=[N+](CC)CC)C1=CC(=CC=C1S(O)(=O)=O)S(O)(=O)=O",
    "molecular_weight": 545.7,
    "log_p": 4.45,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "isotretinoin": {
    "name": "Isotretinoin",
    "smiles": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\\C(O)=O",
    "molecular_weight": 300.44,
    "log_p": 5.6,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "retinoid receptor agonist",
    "disease_area": "dermatology",
    "indication": "acne vulgaris (AV)"
  },
  "isoxaflutole": {
    "name": "Isoxaflutole",
    "smiles": "[H]C1=NOC(=C1C(=O)C1=C(C([H])=C(C([H])=C1[H])C(F)(F)F)S(=O)(=O)C([H])([H])[H])C1([H])C([H])([H])C1([H])[H]",
    "molecular_weight": 359.33,
    "log_p": 3.21,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "isoxicam": {
    "name": "Isoxicam",
    "smiles": "CN1C(C(=O)NC2=NOC(C)=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O",
    "molecular_weight": 335.34,
    "log_p": 1.48,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "isoxsuprine": {
    "name": "Isoxsuprine",
    "smiles": "C[C@H](COC1=CC=CC=C1)N[C@H](C)[C@@H](O)C1=CC=C(O)C=C1",
    "molecular_weight": 301.39,
    "log_p": 2.87,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "cardiology | rheumatology | rheumatology",
    "indication": "arteriosclerosis | Buerger's disease | Raynaud's disease"
  },
  "isradipine": {
    "name": "Isradipine",
    "smiles": "COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C",
    "molecular_weight": 371.39,
    "log_p": 2.58,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "istradefylline": {
    "name": "Istradefylline",
    "smiles": "[H]\\C(=C(\\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC",
    "molecular_weight": 384.44,
    "log_p": 2.12,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adenosine receptor antagonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "dyskinesia | Parkinson's Disease"
  },
  "itraconazole": {
    "name": "Itraconazole",
    "smiles": "CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1",
    "molecular_weight": 705.65,
    "log_p": 5.58,
    "hbd": 0,
    "hba": 12,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cytochrome P450 inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "aspergillosis | blastomycosis | histoplasmosis | onychomycosis | onychomycosis, histoplasmosis, blastomycosis, aspergillosis"
  },
  "ivabradine": {
    "name": "Ivabradine",
    "smiles": "COC1=C(OC)C=C2[C@@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1",
    "molecular_weight": 468.59,
    "log_p": 3.31,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HCN channel blocker | potassium channel blocker | sodium channel blocker",
    "disease_area": "cardiology",
    "indication": "angina pectoris"
  },
  "ivacaftor": {
    "name": "Ivacaftor",
    "smiles": "CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C",
    "molecular_weight": 392.5,
    "log_p": 5.08,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "CFTR channel potentiator",
    "disease_area": "pulmonary",
    "indication": "cystic fibrosis"
  },
  "ivermectin": {
    "name": "Ivermectin",
    "smiles": "[H][C@@]12OC\\C3=C/C=C/[C@H](C)[C@H](O[C@H]4C[C@H](OC)[C@@H](O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\\C(C)=C\\C[C@]4([H])C[C@@]([H])(C[C@]5(CC[C@H](C)[C@]([H])(O5)C(C)C)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O.[H][C@@]12OC\\C3=C/C=C/[C@H](C)[C@H](O[C@H]4C[C@H](OC)[C@@H](O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\\C(C)=C\\C[C@]4([H])C[C@@]([H])(C[C@]5(CC[C@H](C)[C@]([H])(O5)[C@@H](C)CC)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O",
    "molecular_weight": 1736.18,
    "log_p": 10.81,
    "hbd": 6,
    "hba": 28,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "benzodiazepine receptor agonist",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "cattle grubs | gastrointestinal roundworms | horn flies | lice | lungworms | mites"
  },
  "ivosidenib": {
    "name": "Ivosidenib",
    "smiles": "[H][C@@](N(C(=O)[C@]1([H])CCC(=O)N1C1=NC=CC(=C1)C#N)C1=CC(F)=CN=C1)(C(=O)NC1CC(F)(F)C1)C1=C(Cl)C=CC=C1",
    "molecular_weight": 582.97,
    "log_p": 4.32,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "isocitrate dehydrogenase inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "acute myeloid leukemia (AML)"
  },
  "ixabepilone": {
    "name": "Ixabepilone",
    "smiles": "[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\\C)=C\\C1=CSC(C)=N1",
    "molecular_weight": 506.71,
    "log_p": 4.05,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "microtubule stabilizing agent",
    "disease_area": "oncology",
    "indication": "breast cancer"
  },
  "ixazomib": {
    "name": "Ixazomib",
    "smiles": "CC(C)C[C@H](NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl)B(O)O",
    "molecular_weight": 361.03,
    "log_p": 1.27,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "proteasome inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "multiple myeloma"
  },
  "kanamycin": {
    "name": "Kanamycin",
    "smiles": "NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O",
    "molecular_weight": 484.5,
    "log_p": -7.29,
    "hbd": 11,
    "hba": 15,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-negative bacterial infections"
  },
  "kaolin": {
    "name": "Kaolin",
    "smiles": "O.O.[Al+3].[Al+3].[O-][Si]([O-])([O-])O[Si]([O-])([O-])[O-]",
    "molecular_weight": 258.16,
    "log_p": -10.37,
    "hbd": 0,
    "hba": 7,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "kappadione": {
    "name": "Kappadione",
    "smiles": "[Na+].[Na+].[Na+].[Na+].CC1=C(OP([O-])([O-])=O)C2=CC=CC=C2C(OP([O-])([O-])=O)=C1",
    "molecular_weight": 422.09,
    "log_p": -12.42,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "kava": {
    "name": "Kava",
    "smiles": "COC1=CC(=O)OC(C1)\\C=C\\C1=CCCC=C1",
    "molecular_weight": 232.28,
    "log_p": 2.66,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "ketamine": {
    "name": "Ketamine",
    "smiles": "CNC1(CCCCC1=O)C1=CC=CC=C1Cl",
    "molecular_weight": 237.73,
    "log_p": 2.9,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "ketazolam": {
    "name": "Ketazolam",
    "smiles": "CN1C2=C(C=C(Cl)C=C2)C2(OC(C)=CC(=O)N2CC1=O)C1=CC=CC=C1",
    "molecular_weight": 368.82,
    "log_p": 3.28,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "ketoconazole": {
    "name": "Ketoconazole",
    "smiles": "CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1",
    "molecular_weight": 531.44,
    "log_p": 4.21,
    "hbd": 0,
    "hba": 7,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sterol demethylase inhibitor",
    "disease_area": "dermatology",
    "indication": "seborrheic dermatitis"
  },
  "ketoprofen": {
    "name": "Ketoprofen",
    "smiles": "CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1",
    "molecular_weight": 254.28,
    "log_p": 3.11,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "rheumatology | rheumatology",
    "indication": "osteoarthritis | rheumatoid arthritis"
  },
  "ketorolac": {
    "name": "Ketorolac",
    "smiles": "OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1",
    "molecular_weight": 255.27,
    "log_p": 2.29,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "pain relief"
  },
  "ketotifen": {
    "name": "Ketotifen",
    "smiles": "CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=CC=CC=C12",
    "molecular_weight": 309.43,
    "log_p": 4.01,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor agonist | histamine receptor antagonist | leukotriene receptor antagonist | phosphodiesterase inhibitor",
    "disease_area": "neurology/psychiatry | pulmonary",
    "indication": "asthma | itching"
  },
  "kinetin": {
    "name": "Kinetin",
    "smiles": "C(NC1=NC=NC2=C1NC=N2)C1=CC=CO1",
    "molecular_weight": 215.22,
    "log_p": 1.56,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cell division inducer",
    "disease_area": "dermatology",
    "indication": "sunburn"
  },
  "krypton kr 81m": {
    "name": "Krypton Kr 81m",
    "smiles": "[81Kr]",
    "molecular_weight": 80.92,
    "log_p": 0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "labetalol": {
    "name": "Labetalol",
    "smiles": "CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1",
    "molecular_weight": 328.41,
    "log_p": 2.14,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "lacidipine": {
    "name": "Lacidipine",
    "smiles": "CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1\\C=C\\C(=O)OC(C)(C)C)C(=O)OCC",
    "molecular_weight": 455.55,
    "log_p": 4.4,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "lacosamide": {
    "name": "Lacosamide",
    "smiles": "COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1",
    "molecular_weight": 250.3,
    "log_p": 0.45,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "lactic acid": {
    "name": "Lactic acid",
    "smiles": "CC(O)C(O)=O",
    "molecular_weight": 90.08,
    "log_p": -0.55,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "lactitol": {
    "name": "Lactitol",
    "smiles": "OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO",
    "molecular_weight": 344.31,
    "log_p": -5.76,
    "hbd": 9,
    "hba": 11,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "lactose": {
    "name": "Lactose",
    "smiles": "OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O",
    "molecular_weight": 342.3,
    "log_p": -5.4,
    "hbd": 8,
    "hba": 11,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "lactulose": {
    "name": "Lactulose",
    "smiles": "OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O",
    "molecular_weight": 342.3,
    "log_p": -5.4,
    "hbd": 8,
    "hba": 11,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "laxative",
    "disease_area": "gastroenterology",
    "indication": "portal-systemic encephalopathy (PSE)"
  },
  "lamivudine": {
    "name": "Lamivudine",
    "smiles": "NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1",
    "molecular_weight": 229.26,
    "log_p": -0.59,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "nucleoside reverse transcriptase inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "acquired immunodeficiency syndrome (AIDS) | hepatitis B | human immunodeficiency virus (HIV-1) | human immunodeficiency virus (hiv-1), acquired immunodeficiency syndrome (aids), hepatitis b"
  },
  "lamotrigine": {
    "name": "Lamotrigine",
    "smiles": "NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1",
    "molecular_weight": 256.1,
    "log_p": 2.01,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor antagonist | sodium channel blocker",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "bipolar disorder | epilepsy"
  },
  "lanreotide": {
    "name": "Lanreotide",
    "smiles": "[H]N([H])CCCCC1N([H])C(=O)C(CC2=CN([H])C3=CC=CC=C23)N([H])C(=O)C(CC2=CC=C(O)C=C2)N([H])C(=O)C(CSSCC(N([H])C(=O)C(N([H])C1=O)C(C)C)C(=O)N([H])C(C(C)O)C(=O)N([H])[H])N([H])C(=O)C(CC1=CC2=CC=CC=C2C=C1)N([H])[H]",
    "molecular_weight": 1096.35,
    "log_p": 0.82,
    "hbd": 13,
    "hba": 14,
    "rotatable_bonds": 17,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "somatostatin receptor agonist",
    "disease_area": "endocrinology",
    "indication": "acromegaly"
  },
  "lansoprazole": {
    "name": "Lansoprazole",
    "smiles": "CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1",
    "molecular_weight": 369.37,
    "log_p": 3.52,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATPase inhibitor",
    "disease_area": "gastroenterology",
    "indication": "heartburn"
  },
  "lanthanum carbonate": {
    "name": "Lanthanum carbonate",
    "smiles": "[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O",
    "molecular_weight": 457.84,
    "log_p": -7.34,
    "hbd": 0,
    "hba": 9,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "lapatinib": {
    "name": "Lapatinib",
    "smiles": "CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1",
    "molecular_weight": 581.07,
    "log_p": 6.14,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "EGFR inhibitor",
    "disease_area": "oncology",
    "indication": "breast cancer"
  },
  "lapyrium": {
    "name": "Lapyrium",
    "smiles": "CCCCCCCCCCCC(=O)OCCNC(=O)C[N+]1=CC=CC=C1",
    "molecular_weight": 363.52,
    "log_p": 3.55,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA"
  },
  "laropiprant": {
    "name": "Laropiprant",
    "smiles": "CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1",
    "molecular_weight": 435.9,
    "log_p": 4.39,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "prostanoid receptor antagonist",
    "disease_area": "cardiology",
    "indication": "cholesterol"
  },
  "larotrectinib": {
    "name": "Larotrectinib",
    "smiles": "O[C@H]1CCN(C1)C(=O)NC1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=C(F)C=CC(F)=C1",
    "molecular_weight": 428.44,
    "log_p": 2.95,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "alk tyrosine kinase receptor inhibitor | tropomyosin receptor kinase inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "myeloproliferative neoplasms"
  },
  "lasmiditan": {
    "name": "Lasmiditan",
    "smiles": "CN1CCC(CC1)C(=O)C1=CC=CC(NC(=O)C2=C(F)C=C(F)C=C2F)=N1",
    "molecular_weight": 377.37,
    "log_p": 3.28,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "lasofoxifene": {
    "name": "Lasofoxifene",
    "smiles": "[H][C@@]1(CCC2=CC(O)=CC=C2[C@@]1([H])C1=CC=C(OCCN2CCCC2)C=C1)C1=CC=CC=C1",
    "molecular_weight": 413.56,
    "log_p": 5.73,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 2",
    "moa": "selective estrogen receptor modulator (SERM)",
    "disease_area": "oncology | orthopedics",
    "indication": "breast cancer | osteoporosis"
  },
  "latamoxef": {
    "name": "Latamoxef",
    "smiles": "[H][C@]12OCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C(C(O)=O)C1=CC=C(O)C=C1)OC)C(O)=O",
    "molecular_weight": 520.48,
    "log_p": -1.13,
    "hbd": 4,
    "hba": 12,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "latanoprost": {
    "name": "Latanoprost",
    "smiles": "CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1",
    "molecular_weight": 432.6,
    "log_p": 4.19,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "prostanoid receptor agonist",
    "disease_area": "ophthalmology | ophthalmology",
    "indication": "glaucoma | ocular hypertension"
  },
  "latanoprostene bunod": {
    "name": "Latanoprostene bunod",
    "smiles": "O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(=O)OCCCCO[N+]([O-])=O)CCC1=CC=CC=C1",
    "molecular_weight": 507.62,
    "log_p": 3.77,
    "hbd": 3,
    "hba": 8,
    "rotatable_bonds": 18,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "prostanoid receptor agonist",
    "disease_area": "ophthalmology",
    "indication": "intraocular pressure"
  },
  "lauric acid": {
    "name": "Lauric acid",
    "smiles": "CCCCCCCCCCCC(O)=O",
    "molecular_weight": 200.32,
    "log_p": 3.99,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "laurocapram": {
    "name": "Laurocapram",
    "smiles": "CCCCCCCCCCCCN1CCCCCC1=O",
    "molecular_weight": 281.48,
    "log_p": 5.31,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "ledipasvir": {
    "name": "Ledipasvir",
    "smiles": "COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1C1=NC(=CN1)C1=CC=C2C3=CC=C(C=C3C(F)(F)C2=C1)C1=CC=C2NC(=NC2=C1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C",
    "molecular_weight": 889.02,
    "log_p": 8.61,
    "hbd": 4,
    "hba": 8,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HCV inhibitor",
    "disease_area": "infectious disease",
    "indication": "hepatitis C"
  },
  "lefamulin": {
    "name": "Lefamulin",
    "smiles": "[H][C@@]12C(=O)CC[C@]11CCC(C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O",
    "molecular_weight": 507.74,
    "log_p": 3.87,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 50s ribosomal subunit inhibitor",
    "disease_area": "infectious disease",
    "indication": "pneumonia"
  },
  "leflunomide": {
    "name": "Leflunomide",
    "smiles": "CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F",
    "molecular_weight": 270.21,
    "log_p": 3.25,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dihydroorotate dehydrogenase inhibitor | PDGFR tyrosine kinase receptor inhibitor",
    "disease_area": "rheumatology",
    "indication": "rheumatoid arthritis"
  },
  "lemborexant": {
    "name": "Lemborexant",
    "smiles": "CC1=NC=C(OC[C@]2(C[C@H]2C(=O)NC2=NC=C(F)C=C2)C2=CC=CC(F)=C2)C(C)=N1",
    "molecular_weight": 410.42,
    "log_p": 3.74,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "orexin receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "lenalidomide": {
    "name": "Lenalidomide",
    "smiles": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O",
    "molecular_weight": 259.26,
    "log_p": 0.03,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "anticancer agent",
    "disease_area": "hematologic malignancy | hematologic malignancy | hematologic malignancy",
    "indication": "mantle cell lymphoma (MCL) | multiple myeloma | myelodysplastic diseases (MDS)"
  },
  "lenvatinib": {
    "name": "Lenvatinib",
    "smiles": "COC1=C(C=C2C(OC3=CC=C(NC(=O)NC4CC4)C(Cl)=C3)=CC=NC2=C1)C(N)=O",
    "molecular_weight": 426.86,
    "log_p": 4.07,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "FGFR inhibitor | KIT inhibitor | PDGFR tyrosine kinase receptor inhibitor | VEGFR inhibitor",
    "disease_area": "oncology",
    "indication": "thyroid cancer"
  },
  "lercanidipine": {
    "name": "Lercanidipine",
    "smiles": "COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 611.74,
    "log_p": 6.48,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "lesinurad": {
    "name": "Lesinurad",
    "smiles": "OC(=O)CSC1=NN=C(Br)N1C1=CC=C(C2CC2)C2=C1C=CC=C2",
    "molecular_weight": 404.29,
    "log_p": 4.24,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "uric acid diuretic",
    "disease_area": "rheumatology",
    "indication": "gout"
  },
  "letermovir": {
    "name": "Letermovir",
    "smiles": "COC1=CC=CC(=C1)N1CCN(CC1)C1=NC2=C(C=CC=C2F)[C@H](CC(O)=O)N1C1=CC(=CC=C1OC)C(F)(F)F",
    "molecular_weight": 572.56,
    "log_p": 5.71,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "CMV terminase inhibitor",
    "disease_area": "infectious disease",
    "indication": "cytomegalovirus (CMV)"
  },
  "letrozole": {
    "name": "Letrozole",
    "smiles": "N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N",
    "molecular_weight": 285.31,
    "log_p": 2.66,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "aromatase inhibitor",
    "disease_area": "oncology",
    "indication": "breast cancer"
  },
  "leucovorin": {
    "name": "Leucovorin",
    "smiles": "[H]C(=O)N1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)NC(N)=N2",
    "molecular_weight": 473.45,
    "log_p": -0.73,
    "hbd": 7,
    "hba": 9,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "folate receptor ligand",
    "disease_area": "oncology",
    "indication": "osteosarcoma"
  },
  "leuprolide": {
    "name": "Leuprolide",
    "smiles": "CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1",
    "molecular_weight": 1209.42,
    "log_p": -1.23,
    "hbd": 16,
    "hba": 14,
    "rotatable_bonds": 32,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "gonadotropin releasing factor hormone receptor agonist",
    "disease_area": "oncology",
    "indication": "prostate cancer"
  },
  "levacetylmethadol": {
    "name": "Levacetylmethadol",
    "smiles": "CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 353.51,
    "log_p": 4.65,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "levallorphan": {
    "name": "Levallorphan",
    "smiles": "[H][C@@]12CCCC[C@@]11CCN(CC=C)[C@@H]2CC2=C1C=C(O)C=C2",
    "molecular_weight": 283.41,
    "log_p": 3.64,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "opioid receptor antagonist",
    "disease_area": "pulmonary",
    "indication": "respiratory depression"
  },
  "levamisole": {
    "name": "Levamisole",
    "smiles": "C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1",
    "molecular_weight": 204.3,
    "log_p": 2.15,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "acetylcholine receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "levamlodipine": {
    "name": "Levamlodipine",
    "smiles": "CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC",
    "molecular_weight": 408.88,
    "log_p": 2.27,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "levetiracetam": {
    "name": "Levetiracetam",
    "smiles": "CC[C@H](N1CCCC1=O)C(N)=O",
    "molecular_weight": 170.21,
    "log_p": -0.13,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "neurology/psychiatry",
    "indication": "seizures"
  },
  "levmetamfetamine": {
    "name": "Levmetamfetamine",
    "smiles": "CN[C@H](C)CC1=CC=CC=C1",
    "molecular_weight": 149.24,
    "log_p": 1.84,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "levobetaxolol": {
    "name": "Levobetaxolol",
    "smiles": "CC(C)NC[C@H](O)COC1=CC=C(CCOCC2CC2)C=C1",
    "molecular_weight": 307.43,
    "log_p": 2.39,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "ophthalmology | ophthalmology",
    "indication": "glaucoma | intraocular pressure"
  },
  "levobunolol": {
    "name": "Levobunolol",
    "smiles": "CC(C)(C)NC[C@H](O)COC1=CC=CC2=C1CCCC2=O",
    "molecular_weight": 291.39,
    "log_p": 2.33,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "ophthalmology | ophthalmology",
    "indication": "glaucoma | ocular hypertension"
  },
  "levobupivacaine": {
    "name": "Levobupivacaine",
    "smiles": "CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C",
    "molecular_weight": 288.44,
    "log_p": 3.9,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "voltage-gated potassium channel blocker",
    "disease_area": "Anesthesia",
    "indication": "local anesthetic"
  },
  "levocabastine": {
    "name": "Levocabastine",
    "smiles": "C[C@@H]1CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@H]1CC[C@](CC1)(C#N)C1=CC=C(F)C=C1",
    "molecular_weight": 420.53,
    "log_p": 4.89,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "ophthalmology",
    "indication": "conjunctivitis"
  },
  "levocarnitine": {
    "name": "Levocarnitine",
    "smiles": "C[N+](C)(C)C[C@H](O)CC([O-])=O",
    "molecular_weight": 161.2,
    "log_p": -1.81,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "endocrinology",
    "indication": "carnitine deficiency"
  },
  "levocetirizine": {
    "name": "Levocetirizine",
    "smiles": "OC(=O)COCCN1CCN(CC1)[C@H](C1=CC=CC=C1)C1=CC=C(Cl)C=C1",
    "molecular_weight": 388.9,
    "log_p": 3.15,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy | allergy",
    "indication": "allergic rhinitis | urticaria"
  },
  "levodopa": {
    "name": "Levodopa",
    "smiles": "N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O",
    "molecular_weight": 197.19,
    "log_p": 0.05,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine analog | dopamine precursor",
    "disease_area": "neurology/psychiatry",
    "indication": "Parkinson's Disease"
  },
  "levofloxacin": {
    "name": "Levofloxacin",
    "smiles": "C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1",
    "molecular_weight": 361.37,
    "log_p": 1.54,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial DNA gyrase inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | otolaryngology | pulmonary | urology",
    "indication": "anthrax | bronchitis | plague | pneumonia | prostatitis | pyelonephritis | sinusitis | skin infections | urinary tract infections"
  },
  "levoketoconazole": {
    "name": "Levoketoconazole",
    "smiles": "CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1",
    "molecular_weight": 531.44,
    "log_p": 4.21,
    "hbd": 0,
    "hba": 7,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "levoleucovorin": {
    "name": "Levoleucovorin",
    "smiles": "NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1",
    "molecular_weight": 473.45,
    "log_p": -0.73,
    "hbd": 7,
    "hba": 9,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "levomefolic acid": {
    "name": "Levomefolic acid",
    "smiles": "CN1[C@@H](CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)N=C(N)N2",
    "molecular_weight": 459.46,
    "log_p": -0.26,
    "hbd": 7,
    "hba": 9,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "levomenol": {
    "name": "Levomenol",
    "smiles": "[H][C@@]1(CCC(C)=CC1)[C@@](C)(O)CCC=C(C)C",
    "molecular_weight": 222.37,
    "log_p": 4.23,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "infectious disease | neurology/psychiatry",
    "indication": "skin infections | spasms"
  },
  "levomenthol": {
    "name": "Levomenthol",
    "smiles": "CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O",
    "molecular_weight": 156.27,
    "log_p": 2.44,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "neurology/psychiatry",
    "indication": "pain relief"
  },
  "levomilnacipran": {
    "name": "Levomilnacipran",
    "smiles": "CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1",
    "molecular_weight": 246.35,
    "log_p": 1.77,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "levonordefrin": {
    "name": "Levonordefrin",
    "smiles": "C[C@H](N)[C@H](O)C1=CC(O)=C(O)C=C1",
    "molecular_weight": 183.21,
    "log_p": 0.48,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vasodilator",
    "disease_area": "hematology",
    "indication": "hemorrhage"
  },
  "levonorgestrel": {
    "name": "Levonorgestrel",
    "smiles": "[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]",
    "molecular_weight": 312.45,
    "log_p": 3.88,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "estrogen receptor agonist | glucocorticoid receptor antagonist | progesterone receptor agonist | progesterone receptor antagonist",
    "disease_area": "endocrinology",
    "indication": "contraceptive"
  },
  "levorphanol": {
    "name": "Levorphanol",
    "smiles": "[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2",
    "molecular_weight": 257.38,
    "log_p": 3.08,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "levosalbutamol": {
    "name": "Levosalbutamol",
    "smiles": "CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1",
    "molecular_weight": 239.31,
    "log_p": 1.31,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "levosimendan": {
    "name": "Levosimendan",
    "smiles": "C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1",
    "molecular_weight": 280.29,
    "log_p": 1.36,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium sensitizer",
    "disease_area": "cardiology",
    "indication": "congestive heart failure"
  },
  "levothyroxine": {
    "name": "Levothyroxine",
    "smiles": "N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O",
    "molecular_weight": 776.87,
    "log_p": 4.56,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "thyroid hormone stimulant",
    "disease_area": "endocrinology",
    "indication": "myxedema coma"
  },
  "l-glutamine": {
    "name": "L-Glutamine",
    "smiles": "N[C@@H](CCC(N)=O)C(O)=O",
    "molecular_weight": 146.15,
    "log_p": -1.34,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "dental | gastroenterology | gastroenterology | gastroenterology | gastroenterology | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | rheumatology",
    "indication": "anxiety | Crohn's disease | diarrhea | insomnia | joint pain | mucositis | muscle pain | peptic ulcer disease (PUD) | ulcerative colitis"
  },
  "lidocaine": {
    "name": "Lidocaine",
    "smiles": "CCN(CC)CC(=O)NC1=C(C)C=CC=C1C",
    "molecular_weight": 234.34,
    "log_p": 2.58,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor agonist",
    "disease_area": "dermatology | hematology | neurology/psychiatry",
    "indication": "eczema | hemorrhage | itching"
  },
  "lidoflazine": {
    "name": "Lidoflazine",
    "smiles": "CC1=CC=CC(C)=C1NC(=O)CN1CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1",
    "molecular_weight": 491.63,
    "log_p": 5.75,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "cardiology",
    "indication": "coronary artery disease (CAD)"
  },
  "lifitegrast": {
    "name": "Lifitegrast",
    "smiles": "CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C3=CC=C4C=COC4=C3)C=C2Cl)C(O)=O)=CC=C1",
    "molecular_weight": 615.49,
    "log_p": 4.77,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "lymphocyte function-associated antigen negative modulator",
    "disease_area": "ophthalmology",
    "indication": "dry eye syndrome"
  },
  "light green sf yellowish": {
    "name": "Light green SF yellowish",
    "smiles": "[Na+].[Na+].CCN(CC1=CC(=CC=C1)S([O-])(=O)=O)C1=CC=C(C=C1)C(C1=CC=C(C=C1)S([O-])(=O)=O)=C1C=CC(C=C1)=[N+](CC)CC1=CC(=CC=C1)S([O-])(=O)=O",
    "molecular_weight": 792.87,
    "log_p": -0.97,
    "hbd": 0,
    "hba": 10,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "linaclotide": {
    "name": "Linaclotide",
    "smiles": "[H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O",
    "molecular_weight": 1526.77,
    "log_p": -5.94,
    "hbd": 19,
    "hba": 26,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "guanylate cyclase activator",
    "disease_area": "gastroenterology | gastroenterology | gastroenterology",
    "indication": "constipation | irritable bowel syndrome | irritable bowel syndrome, constipation"
  },
  "linagliptin": {
    "name": "Linagliptin",
    "smiles": "CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1",
    "molecular_weight": 472.55,
    "log_p": 1.15,
    "hbd": 1,
    "hba": 10,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dipeptidyl peptidase inhibitor",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "lincomycin": {
    "name": "Lincomycin",
    "smiles": "[H][C@]1(C[C@@H](CCC)CN1C)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O",
    "molecular_weight": 406.55,
    "log_p": -0.86,
    "hbd": 5,
    "hba": 8,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor",
    "disease_area": "gastroenterology",
    "indication": "enteritis"
  },
  "lindane": {
    "name": "Lindane",
    "smiles": "Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl",
    "molecular_weight": 290.83,
    "log_p": 3.64,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "infectious disease",
    "indication": "scabies"
  },
  "linezolid": {
    "name": "Linezolid",
    "smiles": "CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1",
    "molecular_weight": 337.35,
    "log_p": 1.12,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 50S ribosomal subunit inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "pneumonia | skin infections"
  },
  "linoleic acid": {
    "name": "Linoleic acid",
    "smiles": "CCCCC\\C=C/C\\C=C/CCCCCCCC(O)=O",
    "molecular_weight": 280.45,
    "log_p": 5.88,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 14,
    "approved": true,
    "source": "FDA"
  },
  "linzagolix": {
    "name": "Linzagolix",
    "smiles": "COC1=C(COC2=C(OC)C=C(F)C(=C2)N2C(=O)NC3=CSC(C(O)=O)=C3C2=O)C(F)=C(F)C=C1",
    "molecular_weight": 508.43,
    "log_p": 3.45,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "liothyronine": {
    "name": "Liothyronine",
    "smiles": "N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O",
    "molecular_weight": 650.98,
    "log_p": 3.95,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "thyroid hormone stimulant",
    "disease_area": "endocrinology | endocrinology",
    "indication": "hypothyroidism | myxedema coma"
  },
  "liotrix": {
    "name": "Liotrix",
    "smiles": "[Na+].[Na+].N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C([O-])=O.N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C([O-])=O",
    "molecular_weight": 1471.81,
    "log_p": -0.15,
    "hbd": 4,
    "hba": 10,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "lipoic acid": {
    "name": "Lipoic acid",
    "smiles": "OC(=O)CCCC[C@@H]1CCSS1",
    "molecular_weight": 206.33,
    "log_p": 2.79,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "lisdexamfetamine": {
    "name": "Lisdexamfetamine",
    "smiles": "C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN",
    "molecular_weight": 263.38,
    "log_p": 1.19,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "lisinopril": {
    "name": "Lisinopril",
    "smiles": "NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O",
    "molecular_weight": 405.5,
    "log_p": 1.24,
    "hbd": 4,
    "hba": 5,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin converting enzyme inhibitor",
    "disease_area": "cardiology | cardiology | endocrinology",
    "indication": "congestive heart failure | diabetes mellitus | hypertension"
  },
  "lisuride": {
    "name": "Lisuride",
    "smiles": "[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC",
    "molecular_weight": 338.46,
    "log_p": 2.84,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "Parkinson's Disease"
  },
  "lithium carbonate": {
    "name": "Lithium carbonate",
    "smiles": "[Li+].[Li+].[O-]C([O-])=O",
    "molecular_weight": 73.89,
    "log_p": -8.44,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "lithium citrate": {
    "name": "Lithium citrate",
    "smiles": "[Li+].[Li+].[Li+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O",
    "molecular_weight": 209.92,
    "log_p": -14.24,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "lithium hydroxide": {
    "name": "Lithium hydroxide",
    "smiles": "[Li+].[OH-]",
    "molecular_weight": 23.95,
    "log_p": -3.17,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "l-lactic acid": {
    "name": "L-Lactic acid",
    "smiles": "C[C@H](O)C(O)=O",
    "molecular_weight": 90.08,
    "log_p": -0.55,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "lodoxamide": {
    "name": "Lodoxamide",
    "smiles": "OC(=O)C(=O)NC1=CC(=CC(NC(=O)C(O)=O)=C1Cl)C#N",
    "molecular_weight": 311.64,
    "log_p": 0.26,
    "hbd": 4,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "ophthalmology",
    "indication": "vernal keratoconjunctivitis (VKC)"
  },
  "lofexidine": {
    "name": "Lofexidine",
    "smiles": "CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1",
    "molecular_weight": 259.14,
    "log_p": 2.76,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "opioid withdrawal"
  },
  "lomefloxacin": {
    "name": "Lomefloxacin",
    "smiles": "CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCNC(C)C3)C(F)=C12",
    "molecular_weight": 351.35,
    "log_p": 1.8,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial DNA gyrase inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "respiratory tract infections | urinary tract infections"
  },
  "lomitapide": {
    "name": "Lomitapide",
    "smiles": "FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12",
    "molecular_weight": 693.73,
    "log_p": 8.38,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "microsomal trigylceride transfer protein inhibitor",
    "disease_area": "endocrinology",
    "indication": "hypercholesterolemia"
  },
  "lomustine": {
    "name": "Lomustine",
    "smiles": "ClCCN(N=O)C(=O)NC1CCCCC1",
    "molecular_weight": 233.7,
    "log_p": 2.25,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA synthesis inhibitor",
    "disease_area": "hematologic malignancy | oncology",
    "indication": "brain tumors | Hodgkin's lymphoma"
  },
  "lonafarnib": {
    "name": "Lonafarnib",
    "smiles": "NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2C3=C(CCC4=C2C(Br)=CC(Cl)=C4)C=C(Br)C=N3)CC1",
    "molecular_weight": 638.83,
    "log_p": 5.91,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "farnesyltransferase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "loperamide": {
    "name": "Loperamide",
    "smiles": "CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 477.05,
    "log_p": 5.09,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "opioid receptor agonist",
    "disease_area": "gastroenterology",
    "indication": "diarrhea"
  },
  "lopinavir": {
    "name": "Lopinavir",
    "smiles": "CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1",
    "molecular_weight": 628.81,
    "log_p": 4.33,
    "hbd": 4,
    "hba": 5,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HIV protease inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "loracarbef": {
    "name": "Loracarbef",
    "smiles": "N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1",
    "molecular_weight": 349.77,
    "log_p": 0.71,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | otolaryngology | pulmonary",
    "indication": "bronchitis | ear infections | laryngitis | pneumonia | skin infections | urinary tract infections"
  },
  "loratadine": {
    "name": "Loratadine",
    "smiles": "CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2",
    "molecular_weight": 382.89,
    "log_p": 4.89,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy | neurology/psychiatry",
    "indication": "allergic rhinitis | itching"
  },
  "lorazepam": {
    "name": "Lorazepam",
    "smiles": "OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2",
    "molecular_weight": 321.16,
    "log_p": 3.1,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "lorcaserin": {
    "name": "Lorcaserin",
    "smiles": "C[C@H]1CNCCC2=CC=C(Cl)C=C12",
    "molecular_weight": 195.69,
    "log_p": 2.59,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "lorlatinib": {
    "name": "Lorlatinib",
    "smiles": "C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2",
    "molecular_weight": 406.42,
    "log_p": 2.8,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ALK tyrosine kinase receptor inhibitor",
    "disease_area": "oncology",
    "indication": "non-small cell lung cancer (NSCLC)"
  },
  "lormetazepam": {
    "name": "Lormetazepam",
    "smiles": "CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1Cl",
    "molecular_weight": 335.19,
    "log_p": 3.13,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "lornoxicam": {
    "name": "Lornoxicam",
    "smiles": "CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=C(Cl)S2)S1(=O)=O",
    "molecular_weight": 371.83,
    "log_p": 2.3,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "neurology/psychiatry | rheumatology",
    "indication": "osteoarthritis | sciata"
  },
  "lorpiprazole": {
    "name": "Lorpiprazole",
    "smiles": "[H][C@@]12CCC[C@]1([H])C1=NN=C(CCN3CCN(CC3)C3=CC=CC(=C3)C(F)(F)F)N1C2",
    "molecular_weight": 405.47,
    "log_p": 3.56,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "losartan": {
    "name": "Losartan",
    "smiles": "CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1",
    "molecular_weight": 422.92,
    "log_p": 4.27,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin receptor antagonist",
    "disease_area": "cardiology | nephrology",
    "indication": "diabetic nephropathy | hypertension"
  },
  "loteprednol": {
    "name": "Loteprednol",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 394.9,
    "log_p": 2.74,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist | phospholipase inhibitor",
    "disease_area": "ophthalmology",
    "indication": "conjunctivitis"
  },
  "loteprednol etabonate": {
    "name": "Loteprednol etabonate",
    "smiles": "[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 466.96,
    "log_p": 3.92,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "lovastatin": {
    "name": "Lovastatin",
    "smiles": "[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC",
    "molecular_weight": 404.55,
    "log_p": 4.2,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HMGCR inhibitor",
    "disease_area": "cardiology | cardiology | endocrinology",
    "indication": "coronary heart disease | hypercholesterolemia | myocardial infarction"
  },
  "loxapine": {
    "name": "Loxapine",
    "smiles": "CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2",
    "molecular_weight": 327.82,
    "log_p": 3.77,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist | serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "schizophrenia"
  },
  "loxoprofen": {
    "name": "Loxoprofen",
    "smiles": "CC(C(O)=O)C1=CC=C(CC2CCCC2=O)C=C1",
    "molecular_weight": 246.31,
    "log_p": 2.79,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor | prostanoid receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "pain relief"
  },
  "lubiprostone": {
    "name": "Lubiprostone",
    "smiles": "[H][C@@]12CC(=O)[C@H](CCCCCCC(O)=O)[C@@]1([H])CC[C@@](O)(O2)C(F)(F)CCCC",
    "molecular_weight": 390.47,
    "log_p": 4.31,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "chloride channel activator",
    "disease_area": "gastroenterology | gastroenterology",
    "indication": "constipation | irritable bowel syndrome"
  },
  "luliconazole": {
    "name": "Luliconazole",
    "smiles": "ClC1=CC(Cl)=C(C=C1)[C@@H]1CS\\C(S1)=C(\\C#N)N1C=CN=C1",
    "molecular_weight": 354.29,
    "log_p": 5.06,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sterol demethylase inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "tinea corporis | tinea cruris | tinea pedis"
  },
  "lumacaftor": {
    "name": "Lumacaftor",
    "smiles": "CC1=CC=C(NC(=O)C2(CC2)C2=CC=C3OC(F)(F)OC3=C2)N=C1C1=CC(=CC=C1)C(O)=O",
    "molecular_weight": 452.41,
    "log_p": 4.75,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "CFTR channel agonist",
    "disease_area": "pulmonary",
    "indication": "cystic fibrosis"
  },
  "lumateperone": {
    "name": "Lumateperone",
    "smiles": "[H][C@]12CCN(CCCC(=O)C3=CC=C(F)C=C3)C[C@@]1([H])C1=CC=CC3=C1N2CCN3C",
    "molecular_weight": 393.51,
    "log_p": 3.92,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor modulator | serotonin receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "lumefantrine": {
    "name": "Lumefantrine",
    "smiles": "CCCCN(CCCC)CC(O)C1=C2C(=CC(Cl)=C1)\\C(=C/C1=CC=C(Cl)C=C1)C1=C2C=CC(Cl)=C1",
    "molecular_weight": 528.95,
    "log_p": 9.15,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antimalarial agent",
    "disease_area": "infectious disease",
    "indication": "malaria"
  },
  "lumefantrine co-artemether": {
    "name": "Lumefantrine co-artemether",
    "smiles": "[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@]4(C)OO[C@@]13[C@]([H])(O[C@H](OC)[C@@H]2C)O4.CCCCN(CCCC)CC(O)C1=CC(Cl)=CC2=C1C1=CC=C(Cl)C=C1\\C2=C\\C1=CC=C(Cl)C=C1.CCCCN(CCCC)CC(O)C1=CC(Cl)=CC2=C1C1=CC=C(Cl)C=C1\\C2=C\\C1=CC=C(Cl)C=C1.CCCCN(CCCC)CC(O)C1=CC(Cl)=CC2=C1C1=CC=C(Cl)C=C1\\C2=C\\C1=CC=C(Cl)C=C1.CCCCN(CCCC)CC(O)C1=CC(Cl)=CC2=C1C1=CC=C(Cl)C=C1\\C2=C\\C1=CC=C(Cl)C=C1.CCCCN(CCCC)CC(O)C1=CC(Cl)=CC2=C1C1=CC=C(Cl)C=C1\\C2=C\\C1=CC=C(Cl)C=C1.CCCCN(CCCC)CC(O)C1=CC(Cl)=CC2=C1C1=CC=C(Cl)C=C1\\C2=C\\C1=CC=C(Cl)C=C1",
    "molecular_weight": 3472.08,
    "log_p": 57.75,
    "hbd": 6,
    "hba": 17,
    "rotatable_bonds": 61,
    "approved": true,
    "source": "FDA"
  },
  "lumiracoxib": {
    "name": "Lumiracoxib",
    "smiles": "CC1=CC=C(NC2=C(Cl)C=CC=C2F)C(CC(O)=O)=C1",
    "molecular_weight": 293.73,
    "log_p": 4.16,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "lurasidone": {
    "name": "Lurasidone",
    "smiles": "[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O",
    "molecular_weight": 492.69,
    "log_p": 4.26,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist | serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "schizophrenia"
  },
  "lurbinectedin": {
    "name": "Lurbinectedin",
    "smiles": "[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4NC4=CC=C(OC)C=C54)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@@]2([H])N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31",
    "molecular_weight": 784.89,
    "log_p": 4.19,
    "hbd": 4,
    "hba": 14,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "DNA binding agent",
    "disease_area": "",
    "indication": ""
  },
  "lusutrombopag": {
    "name": "Lusutrombopag",
    "smiles": "CCCCCCO[C@@H](C)C1=C(OC)C(=CC=C1)C1=CSC(NC(=O)C2=CC(Cl)=C(\\C=C(/C)C(O)=O)C(Cl)=C2)=N1",
    "molecular_weight": 591.56,
    "log_p": 8.52,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "thrombopoietin receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "lutein": {
    "name": "Lutein",
    "smiles": "C\\C(\\C=C\\C=C(/C)\\C=C\\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\\C)/C=C/C=C(\\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C",
    "molecular_weight": 568.89,
    "log_p": 10.4,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antioxidant",
    "disease_area": "ophthalmology | ophthalmology | ophthalmology",
    "indication": "cataracts | macular degeneration | retinitis pigmentosa (RP)"
  },
  "lutetium lu 177 dotatate": {
    "name": "Lutetium Lu 177 dotatate",
    "smiles": "[177Lu+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O",
    "molecular_weight": 1609.57,
    "log_p": -7.38,
    "hbd": 14,
    "hba": 25,
    "rotatable_bonds": 26,
    "approved": true,
    "source": "FDA"
  },
  "lutetium lu-177": {
    "name": "Lutetium Lu-177",
    "smiles": "[177Lu]",
    "molecular_weight": 176.94,
    "log_p": 0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "lutetium lu-177 vipivotide tetraxetan": {
    "name": "Lutetium Lu-177 vipivotide tetraxetan",
    "smiles": "[177Lu+3].OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@H](CC1=CC2=CC=CC=C2C=C1)NC(=O)[C@H]1CC[C@H](CNC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)CC1)C(O)=O)C(O)=O",
    "molecular_weight": 1216.07,
    "log_p": -4.38,
    "hbd": 8,
    "hba": 17,
    "rotatable_bonds": 27,
    "approved": true,
    "source": "FDA"
  },
  "lycopene": {
    "name": "Lycopene",
    "smiles": "CC(C)=CCC\\C(C)=C\\C=C\\C(\\C)=C\\C=C\\C(\\C)=C\\C=C\\C=C(/C)\\C=C\\C=C(/C)\\C=C\\C=C(/C)CCC=C(C)C",
    "molecular_weight": 536.89,
    "log_p": 12.94,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 16,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "free radical scavenger",
    "disease_area": "",
    "indication": ""
  },
  "lymecycline": {
    "name": "Lymecycline",
    "smiles": "[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)=C(O)[C@H]2N(C)C",
    "molecular_weight": 602.64,
    "log_p": -0.45,
    "hbd": 9,
    "hba": 12,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 50S ribosomal subunit inhibitor",
    "disease_area": "dermatology",
    "indication": "acne vulgaris (AV)"
  },
  "lynestrenol": {
    "name": "Lynestrenol",
    "smiles": "C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",
    "molecular_weight": 284.44,
    "log_p": 4.31,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "progestogen hormone",
    "disease_area": "endocrinology",
    "indication": "contraceptive"
  },
  "lypressin": {
    "name": "Lypressin",
    "smiles": "[H]N([H])C(=O)C[C@]1([H])NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](N)CSSC[C@H](NC1=O)C(=O)N1CCC[C@H]1C(=O)NC([H])(CCCCN)C(=O)NCC(N)=O",
    "molecular_weight": 1056.24,
    "log_p": -4.33,
    "hbd": 13,
    "hba": 16,
    "rotatable_bonds": 19,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vasopressin receptor agonist",
    "disease_area": "endocrinology",
    "indication": "central diabetes insipidus"
  },
  "lysine": {
    "name": "Lysine",
    "smiles": "NCCCC[C@H](N)C(O)=O",
    "molecular_weight": 146.19,
    "log_p": -0.47,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "macimorelin": {
    "name": "Macimorelin",
    "smiles": "CC(C)(N)C(=O)N[C@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@H](CC1=CNC2=CC=CC=C12)NC=O",
    "molecular_weight": 474.57,
    "log_p": 1.84,
    "hbd": 6,
    "hba": 4,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ghrelin receptor agonist",
    "disease_area": "endocrinology",
    "indication": "cachexia"
  },
  "macitentan": {
    "name": "Macitentan",
    "smiles": "CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1",
    "molecular_weight": 588.28,
    "log_p": 3.57,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "endothelin receptor antagonist",
    "disease_area": "endocrinology",
    "indication": "contraceptive"
  },
  "mafenide": {
    "name": "Mafenide",
    "smiles": "NCC1=CC=C(C=C1)S(N)(=O)=O",
    "molecular_weight": 186.24,
    "log_p": -0.21,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "carbonic anhydrase inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "first-aid antibiotic | skin infections"
  },
  "magaldrate": {
    "name": "Magaldrate",
    "smiles": "O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O",
    "molecular_weight": 1115.32,
    "log_p": -14.69,
    "hbd": 0,
    "hba": 39,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "magnesium": {
    "name": "Magnesium",
    "smiles": "[MgH2]",
    "molecular_weight": 26.32,
    "log_p": -0.92,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "magnesium acetate": {
    "name": "Magnesium acetate",
    "smiles": "[Mg++].CC([O-])=O.CC([O-])=O",
    "molecular_weight": 142.39,
    "log_p": -2.87,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "magnesium acetate tetrahydrate": {
    "name": "Magnesium acetate tetrahydrate",
    "smiles": "O.O.O.O.[Mg++].CC([O-])=O.CC([O-])=O",
    "molecular_weight": 214.45,
    "log_p": -6.17,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "magnesium ascorbate": {
    "name": "Magnesium ascorbate",
    "smiles": "[Mg++].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO.[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO",
    "molecular_weight": 374.54,
    "log_p": -5.59,
    "hbd": 6,
    "hba": 12,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "magnesium carbonate": {
    "name": "Magnesium carbonate",
    "smiles": "[Mg++].[O-]C([O-])=O",
    "molecular_weight": 84.31,
    "log_p": -2.83,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "magnesium cation": {
    "name": "Magnesium cation",
    "smiles": "[Mg++]",
    "molecular_weight": 24.3,
    "log_p": -0.38,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "magnesium chloride": {
    "name": "Magnesium chloride",
    "smiles": "[Mg++].[Cl-].[Cl-]",
    "molecular_weight": 95.21,
    "log_p": -6.37,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "magnesium citrate": {
    "name": "Magnesium citrate",
    "smiles": "[Mg++].[Mg++].[Mg++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O",
    "molecular_weight": 451.11,
    "log_p": -11.65,
    "hbd": 2,
    "hba": 14,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "magnesium gluconate": {
    "name": "Magnesium gluconate",
    "smiles": "O.O.[Mg++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O",
    "molecular_weight": 450.63,
    "log_p": -11.69,
    "hbd": 10,
    "hba": 14,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "magnesium glycinate": {
    "name": "Magnesium glycinate",
    "smiles": "[Mg++].NCC([O-])=O.NCC([O-])=O",
    "molecular_weight": 172.42,
    "log_p": -4.99,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "magnesium hydroxide": {
    "name": "Magnesium hydroxide",
    "smiles": "[OH-].[OH-].[Mg++]",
    "molecular_weight": 58.32,
    "log_p": -0.73,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "magnesium malate": {
    "name": "Magnesium malate",
    "smiles": "[Mg++].OC(CC([O-])=O)C([O-])=O",
    "molecular_weight": 156.38,
    "log_p": -4.14,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "magnesium oxide": {
    "name": "Magnesium oxide",
    "smiles": "[O--].[Mg++]",
    "molecular_weight": 40.3,
    "log_p": -0.5,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "magnesium silicate": {
    "name": "Magnesium silicate",
    "smiles": "[O--].[O--].[O--].[Mg++].[Si+4]",
    "molecular_weight": 100.39,
    "log_p": -1.12,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "magnesium sulfate": {
    "name": "Magnesium sulfate",
    "smiles": "[Mg++].[O-]S([O-])(=O)=O",
    "molecular_weight": 120.37,
    "log_p": -1.72,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "magnesium trisilicate": {
    "name": "Magnesium trisilicate",
    "smiles": "[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O",
    "molecular_weight": 260.86,
    "log_p": -7.03,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "malathion": {
    "name": "Malathion",
    "smiles": "CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC",
    "molecular_weight": 330.36,
    "log_p": 2.12,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cholinesterase inhibitor",
    "disease_area": "infectious disease",
    "indication": "lice"
  },
  "mandelic acid": {
    "name": "Mandelic acid",
    "smiles": "OC(C(O)=O)C1=CC=CC=C1",
    "molecular_weight": 152.15,
    "log_p": 0.8,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "mangafodipir": {
    "name": "Mangafodipir",
    "smiles": "[Mn++].CC1=C(O)C(CN(CCN(CC([O-])=O)CC2=CC(COP(O)(O)=O)=NC(C)=C2O)CC([O-])=O)=CC(COP(O)(O)=O)=N1",
    "molecular_weight": 691.38,
    "log_p": -2.48,
    "hbd": 6,
    "hba": 14,
    "rotatable_bonds": 17,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "contrast agent",
    "disease_area": "radiology",
    "indication": "contrast agent"
  },
  "manganese": {
    "name": "Manganese",
    "smiles": "[Mn++]",
    "molecular_weight": 54.94,
    "log_p": -0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "manganese citrate": {
    "name": "Manganese citrate",
    "smiles": "[Mn++].[Mn++].[Mn++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O",
    "molecular_weight": 543.01,
    "log_p": -10.51,
    "hbd": 2,
    "hba": 14,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "manganese gluconate": {
    "name": "Manganese gluconate",
    "smiles": "[Mn++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O",
    "molecular_weight": 445.23,
    "log_p": -9.66,
    "hbd": 10,
    "hba": 14,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "manidipine": {
    "name": "Manidipine",
    "smiles": "COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 610.71,
    "log_p": 4.95,
    "hbd": 1,
    "hba": 9,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "mannitol": {
    "name": "Mannitol",
    "smiles": "OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO",
    "molecular_weight": 182.17,
    "log_p": -3.59,
    "hbd": 6,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "mannitol busulfan": {
    "name": "Mannitol busulfan",
    "smiles": "CS(=O)(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)COS(C)(=O)=O",
    "molecular_weight": 338.36,
    "log_p": -3.62,
    "hbd": 4,
    "hba": 10,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "maprotiline": {
    "name": "Maprotiline",
    "smiles": "CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21",
    "molecular_weight": 277.41,
    "log_p": 4.21,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "norepinephrine reputake inhibitor | tricyclic antidepressant",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "depression | dysthymic disorder"
  },
  "maralixibat": {
    "name": "Maralixibat",
    "smiles": "CCCCC1(CCCC)CS(=O)(=O)C2=CC=C(C=C2[C@H]([C@H]1O)C1=CC=C(OCC2=CC=C(C[N+]34CCN(CC3)CC4)C=C2)C=C1)N(C)C",
    "molecular_weight": 674.97,
    "log_p": 6.62,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA"
  },
  "maraviroc": {
    "name": "Maraviroc",
    "smiles": "CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1",
    "molecular_weight": 513.68,
    "log_p": 5.95,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "CC chemokine receptor antagonist",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "maribavir": {
    "name": "Maribavir",
    "smiles": "CC(C)NC1=NC2=CC(Cl)=C(Cl)C=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O",
    "molecular_weight": 376.24,
    "log_p": 1.77,
    "hbd": 4,
    "hba": 7,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "cytomegalovirus inhibitor | protein kinase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "masoprocol": {
    "name": "Masoprocol",
    "smiles": "C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1",
    "molecular_weight": 302.37,
    "log_p": 3.57,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "lipoxygenase inhibitor",
    "disease_area": "dermatology",
    "indication": "actinic keratosis (AK)"
  },
  "mavacamten": {
    "name": "Mavacamten",
    "smiles": "CC(C)N1C(=O)NC(N[C@@H](C)C2=CC=CC=C2)=CC1=O",
    "molecular_weight": 273.34,
    "log_p": 2.29,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "myosin inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "mazindol": {
    "name": "Mazindol",
    "smiles": "OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1",
    "molecular_weight": 284.75,
    "log_p": 2.61,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "mebendazole": {
    "name": "Mebendazole",
    "smiles": "COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C1=CC=CC=C1",
    "molecular_weight": 295.3,
    "log_p": 2.97,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "tubulin polymerization inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "ascariasis | hookworm | pinworm | whipworm"
  },
  "mebeverine": {
    "name": "Mebeverine",
    "smiles": "CCN(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)C(C)CC1=CC=C(OC)C=C1",
    "molecular_weight": 429.56,
    "log_p": 4.6,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "gastroenterology",
    "indication": "irritable bowel syndrome"
  },
  "mebrofenin": {
    "name": "Mebrofenin",
    "smiles": "CC1=CC(C)=C(Br)C(C)=C1NC(=O)CN(CC(O)=O)CC(O)=O",
    "molecular_weight": 387.23,
    "log_p": 1.78,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "radiology",
    "indication": "diagnostic agent"
  },
  "mebutamate": {
    "name": "Mebutamate",
    "smiles": "CCC(C)C(C)(COC(N)=O)COC(N)=O",
    "molecular_weight": 232.28,
    "log_p": 1.23,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "mecamylamine": {
    "name": "Mecamylamine",
    "smiles": "CNC1(C)C2CCC(C2)C1(C)C",
    "molecular_weight": 167.3,
    "log_p": 2.42,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "mechlorethamine": {
    "name": "Mechlorethamine",
    "smiles": "CN(CCCl)CCCl",
    "molecular_weight": 156.06,
    "log_p": 1.4,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "meclizine": {
    "name": "Meclizine",
    "smiles": "CC1=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=CC=C1",
    "molecular_weight": 390.96,
    "log_p": 5.56,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "constitutive androstane receptor (CAR) agonist",
    "disease_area": "gastroenterology | gastroenterology | neurology/psychiatry",
    "indication": "motion sickness | nausea | vomiting"
  },
  "meclofenamic acid": {
    "name": "Meclofenamic acid",
    "smiles": "CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1",
    "molecular_weight": 296.15,
    "log_p": 4.74,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "mecobalamin": {
    "name": "Mecobalamin",
    "smiles": "C1(CC[C@@]2([C@@H](CC(N)=O)[C@@]3([C@@]4([N+]5=C([C@H]([C@@]4(CC(N)=O)C)CCC(N)=O)C(C)=C4[N+]6=C(C=C7[N+]8=C([C@H](C7(C)C)CCC(N)=O)C(C)=C2N3[Co-3]568([N+]2=CN([C@H]3O[C@@H]([C@@H](OP(O[C@@H](CN1)C)([O-])=O)[C@H]3O)CO)C1=CC(C)=C(C=C21)C)C)[C@H]([C@@]4(CC(N)=O)C)CCC(N)=O)C)[H])C)=O",
    "molecular_weight": 1344.4,
    "log_p": 0.92,
    "hbd": 9,
    "hba": 16,
    "rotatable_bonds": 16,
    "approved": true,
    "source": "FDA"
  },
  "medifoxamine": {
    "name": "Medifoxamine",
    "smiles": "CN(C)CC(OC1=CC=CC=C1)OC1=CC=CC=C1",
    "molecular_weight": 257.33,
    "log_p": 3.03,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "medrogestone": {
    "name": "Medrogestone",
    "smiles": "[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C",
    "molecular_weight": 340.51,
    "log_p": 5.28,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "medronic acid": {
    "name": "Medronic acid",
    "smiles": "OP(O)(=O)CP(O)(O)=O",
    "molecular_weight": 176.0,
    "log_p": -0.7,
    "hbd": 4,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "medroxyprogesterone acetate": {
    "name": "Medroxyprogesterone acetate",
    "smiles": "[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C",
    "molecular_weight": 386.53,
    "log_p": 4.66,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "progesterone receptor agonist",
    "disease_area": "endocrinology",
    "indication": "contraceptive"
  },
  "medrysone": {
    "name": "Medrysone",
    "smiles": "[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C",
    "molecular_weight": 344.5,
    "log_p": 3.94,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "ophthalmology | ophthalmology | ophthalmology",
    "indication": "conjunctivitis | conjunctivitis, episcleritis | episcleritis"
  },
  "mefenamic acid": {
    "name": "Mefenamic acid",
    "smiles": "CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1",
    "molecular_weight": 241.29,
    "log_p": 3.75,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "mefloquine": {
    "name": "Mefloquine",
    "smiles": "OC(C1CCCCN1)C1=CC(=NC2=C1C=CC=C2C(F)(F)F)C(F)(F)F",
    "molecular_weight": 378.32,
    "log_p": 4.45,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adenosine receptor antagonist | hemoglobin antagonist | protein synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "malaria"
  },
  "megestrol acetate": {
    "name": "Megestrol acetate",
    "smiles": "[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C",
    "molecular_weight": 384.52,
    "log_p": 4.58,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "meglumine": {
    "name": "Meglumine",
    "smiles": "CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO",
    "molecular_weight": 195.21,
    "log_p": -3.36,
    "hbd": 6,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "excipient",
    "disease_area": "",
    "indication": ""
  },
  "melatonin": {
    "name": "Melatonin",
    "smiles": "COC1=CC2=C(NC=C2CCNC(C)=O)C=C1",
    "molecular_weight": 232.28,
    "log_p": 1.86,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "melatonin receptor agonist | nitric oxide synthase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "sleep cycle support"
  },
  "meloxicam": {
    "name": "Meloxicam",
    "smiles": "CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O",
    "molecular_weight": 351.41,
    "log_p": 1.95,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "rheumatology | rheumatology | rheumatology",
    "indication": "osteoarthritis | osteoarthritis, rheumatoid arthritis | rheumatoid arthritis"
  },
  "melphalan": {
    "name": "Melphalan",
    "smiles": "N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O",
    "molecular_weight": 305.2,
    "log_p": 1.93,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA alkylating agent | DNA inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "multiple myeloma"
  },
  "melphalan flufenamide": {
    "name": "Melphalan flufenamide",
    "smiles": "CCOC(=O)[C@H](CC1=CC=C(F)C=C1)NC(=O)[C@@H](N)CC1=CC=C(C=C1)N(CCCl)CCCl",
    "molecular_weight": 498.43,
    "log_p": 3.27,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dna alkylating agent",
    "disease_area": "hematologic malignancy",
    "indication": "multiple myeloma"
  },
  "memantine": {
    "name": "Memantine",
    "smiles": "CC12CC3CC(C)(C1)CC(N)(C3)C2",
    "molecular_weight": 179.31,
    "log_p": 2.69,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glutamate receptor antagonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "Alzheimer's disease | senile dementia"
  },
  "menadiol diphosphate": {
    "name": "Menadiol diphosphate",
    "smiles": "CC1=C(OP(O)(O)=O)C2=CC=CC=C2C(OP(O)(O)=O)=C1",
    "molecular_weight": 334.16,
    "log_p": 2.09,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "menadione": {
    "name": "Menadione",
    "smiles": "CC1=CC(=O)C2=CC=CC=C2C1=O",
    "molecular_weight": 172.18,
    "log_p": 2.01,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "mitochondrial DNA polymerase inhibitor | phosphatase inhibitor",
    "disease_area": "dermatology | gastroenterology | gastroenterology | neurology/psychiatry | rheumatology",
    "indication": "diarrhea | headache | rheumatoid arthritis | ulcerative colitis | varicose veins"
  },
  "menthol": {
    "name": "Menthol",
    "smiles": "CC(C)C1CCC(C)CC1O",
    "molecular_weight": 156.27,
    "log_p": 2.44,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "menthyl salicylate": {
    "name": "Menthyl salicylate",
    "smiles": "CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C1=CC=CC=C1O",
    "molecular_weight": 276.38,
    "log_p": 4.01,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "mepenzolate": {
    "name": "Mepenzolate",
    "smiles": "C[N+]1(C)CCCC(C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 340.44,
    "log_p": 2.7,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "gastroenterology",
    "indication": "peptic ulcer disease (PUD)"
  },
  "meperidine": {
    "name": "Meperidine",
    "smiles": "CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1",
    "molecular_weight": 247.34,
    "log_p": 2.21,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "mephenesin": {
    "name": "Mephenesin",
    "smiles": "CC1=CC=CC=C1OCC(O)CO",
    "molecular_weight": 182.22,
    "log_p": 0.73,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "muscle relaxant",
    "disease_area": "neurology/psychiatry",
    "indication": "muscle relaxant"
  },
  "mephentermine": {
    "name": "Mephentermine",
    "smiles": "CNC(C)(C)CC1=CC=CC=C1",
    "molecular_weight": 163.26,
    "log_p": 2.23,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "cardiology",
    "indication": "hypotension"
  },
  "mephenytoin": {
    "name": "Mephenytoin",
    "smiles": "CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1",
    "molecular_weight": 218.26,
    "log_p": 1.47,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "hydantoin antiepileptic",
    "disease_area": "neurology/psychiatry",
    "indication": "seizures"
  },
  "mepivacaine": {
    "name": "Mepivacaine",
    "smiles": "CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C",
    "molecular_weight": 246.35,
    "log_p": 2.73,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "potassium channel blocker | sodium channel blocker",
    "disease_area": "neurology/psychiatry",
    "indication": "local anesthetic"
  },
  "meprednisone": {
    "name": "Meprednisone",
    "smiles": "[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3([H])C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO",
    "molecular_weight": 372.46,
    "log_p": 2.01,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "meprobamate": {
    "name": "Meprobamate",
    "smiles": "CCCC(C)(COC(N)=O)COC(N)=O",
    "molecular_weight": 218.25,
    "log_p": 0.98,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "mepyramine": {
    "name": "Mepyramine",
    "smiles": "COC1=CC=C(CN(CCN(C)C)C2=NC=CC=C2)C=C1",
    "molecular_weight": 285.39,
    "log_p": 2.66,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "obstetrics/gynecology | otolaryngology",
    "indication": "common cold | menstrual pain"
  },
  "mequinol": {
    "name": "Mequinol",
    "smiles": "COC1=CC=C(O)C=C1",
    "molecular_weight": 124.14,
    "log_p": 1.4,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "dermatology",
    "indication": "skin depigmentation"
  },
  "meradimate": {
    "name": "Meradimate",
    "smiles": "CC(C)C1CCC(C)CC1OC(=O)C1=CC=CC=C1N",
    "molecular_weight": 275.39,
    "log_p": 3.89,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "mercaptopurine": {
    "name": "Mercaptopurine",
    "smiles": "S=C1N=CNC2=C1NC=N2",
    "molecular_weight": 152.18,
    "log_p": 1.02,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "immunosuppressant | protein synthesis inhibitor | purine antagonist",
    "disease_area": "hematologic malignancy",
    "indication": "acute lymphoblastic leukemia (ALL)"
  },
  "meropenem": {
    "name": "Meropenem",
    "smiles": "[H][C@]1([C@@H](C)O)C(=O)N2C(C(O)=O)=C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)[C@H](C)[C@]12[H]",
    "molecular_weight": 383.47,
    "log_p": -0.31,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "intra-abdominal infections | meningitis | skin infections"
  },
  "mesalazine": {
    "name": "Mesalazine",
    "smiles": "NC1=CC(C(O)=O)=C(O)C=C1",
    "molecular_weight": 153.14,
    "log_p": 0.67,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor | lipoxygenase inhibitor | prostanoid receptor antagonist",
    "disease_area": "gastroenterology | gastroenterology",
    "indication": "inflammatory bowel disease | ulcerative colitis"
  },
  "mesoridazine": {
    "name": "Mesoridazine",
    "smiles": "CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2",
    "molecular_weight": 386.59,
    "log_p": 4.9,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "schizophrenia"
  },
  "mestranol": {
    "name": "Mestranol",
    "smiles": "[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC)C=C3",
    "molecular_weight": 310.44,
    "log_p": 3.92,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "estrogen receptor agonist",
    "disease_area": "endocrinology",
    "indication": "contraceptive"
  },
  "metacycline": {
    "name": "Metacycline",
    "smiles": "[H][C@@]12[C@@H](O)[C@]3([H])C(=C)C4=C(C(O)=CC=C4)C(=O)C3=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C",
    "molecular_weight": 442.42,
    "log_p": -0.44,
    "hbd": 6,
    "hba": 9,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "metamfetamine": {
    "name": "Metamfetamine",
    "smiles": "CN[C@@H](C)CC1=CC=CC=C1",
    "molecular_weight": 149.24,
    "log_p": 1.84,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "metamizole": {
    "name": "Metamizole",
    "smiles": "CN(CS(O)(=O)=O)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1",
    "molecular_weight": 311.36,
    "log_p": 0.77,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "cyclooxygenase inhibitor | opioid receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "metaraminol": {
    "name": "Metaraminol",
    "smiles": "C[C@H](N)[C@H](O)C1=CC(O)=CC=C1",
    "molecular_weight": 167.21,
    "log_p": 0.77,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "cardiology",
    "indication": "hypotension"
  },
  "metaxalone": {
    "name": "Metaxalone",
    "smiles": "CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1",
    "molecular_weight": 221.26,
    "log_p": 1.79,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "muscle relaxant",
    "disease_area": "neurology/psychiatry",
    "indication": "muscle pain"
  },
  "metergoline": {
    "name": "Metergoline",
    "smiles": "[H][C@@]12CC3=CN(C)C4=CC=CC(=C34)[C@@]1([H])C[C@@H](CNC(=O)OCC1=CC=CC=C1)CN2C",
    "molecular_weight": 403.53,
    "log_p": 4.06,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor agonist | dopamine receptor agonist, serotonin receptor antagonist | serotonin receptor antagonist",
    "disease_area": "endocrinology | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry, endocrinology",
    "indication": "anxiety | hyperprolactinemia | seasonal affective disorder | seasonal affective disorder, anxiety, hyperprolactinemia"
  },
  "metformin": {
    "name": "Metformin",
    "smiles": "CN(C)C(=N)NC(N)=N",
    "molecular_weight": 129.17,
    "log_p": -1.03,
    "hbd": 4,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "insulin sensitizer",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "methacholine": {
    "name": "Methacholine",
    "smiles": "CC(C[N+](C)(C)C)OC(C)=O",
    "molecular_weight": 160.24,
    "log_p": 0.64,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor agonist",
    "disease_area": "pulmonary",
    "indication": "bronchial hyperresponsiveness diagnostic"
  },
  "methadone": {
    "name": "Methadone",
    "smiles": "CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 309.45,
    "log_p": 4.29,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "methantheline": {
    "name": "Methantheline",
    "smiles": "CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12",
    "molecular_weight": 340.44,
    "log_p": 3.95,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "gastroenterology | gastroenterology | gastroenterology | neurology/psychiatry | urology",
    "indication": "dyskinesia | irritable bowel syndrome | neurogenic bladder | pancreatitis | peptic ulcer disease (PUD)"
  },
  "methazolamide": {
    "name": "Methazolamide",
    "smiles": "CN1N=C(S\\C1=N\\C(C)=O)S(N)(=O)=O",
    "molecular_weight": 236.28,
    "log_p": -1.42,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "carbonic anhydrase inhibitor",
    "disease_area": "ophthalmology | ophthalmology | ophthalmology",
    "indication": "glaucoma | glaucoma, intraocular pressure | intraocular pressure"
  },
  "methdilazine": {
    "name": "Methdilazine",
    "smiles": "CN1CCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1",
    "molecular_weight": 296.44,
    "log_p": 4.24,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "methenamine": {
    "name": "Methenamine",
    "smiles": "C1N2CN3CN1CN(C2)C3",
    "molecular_weight": 140.19,
    "log_p": -1.02,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial DNA inhibitor",
    "disease_area": "infectious disease",
    "indication": "urinary tract infections"
  },
  "methimazole": {
    "name": "Methimazole",
    "smiles": "CN1C=CNC1=S",
    "molecular_weight": 114.17,
    "log_p": 1.08,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antithyroid agent",
    "disease_area": "endocrinology",
    "indication": "hyperthyroidism"
  },
  "methionine": {
    "name": "Methionine",
    "smiles": "CSCC[C@H](N)C(O)=O",
    "molecular_weight": 149.22,
    "log_p": 0.15,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "methocarbamol": {
    "name": "Methocarbamol",
    "smiles": "COC1=C(OCC(O)COC(N)=O)C=CC=C1",
    "molecular_weight": 241.24,
    "log_p": 0.53,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "muscle relaxant",
    "disease_area": "neurology/psychiatry",
    "indication": "muscle relaxant"
  },
  "methohexital": {
    "name": "Methohexital",
    "smiles": "CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O",
    "molecular_weight": 262.31,
    "log_p": 1.31,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "methotrexate": {
    "name": "Methotrexate",
    "smiles": "CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O",
    "molecular_weight": 454.45,
    "log_p": 0.27,
    "hbd": 5,
    "hba": 10,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dihydrofolate reductase inhibitor",
    "disease_area": "dermatology | hematologic malignancy | oncology | oncology | rheumatology",
    "indication": "acute lymphoblastic leukemia (ALL) | gestational choriocarcinoma | hydatidiform mole | psoriasis | rheumatoid arthritis"
  },
  "methotrimeprazine": {
    "name": "Methotrimeprazine",
    "smiles": "COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1",
    "molecular_weight": 328.48,
    "log_p": 4.5,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "methoxamine": {
    "name": "Methoxamine",
    "smiles": "COC1=CC(C(O)C(C)N)=C(OC)C=C1",
    "molecular_weight": 211.26,
    "log_p": 1.08,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "cardiology",
    "indication": "hypotension"
  },
  "methoxsalen": {
    "name": "Methoxsalen",
    "smiles": "COC1=C2OC(=O)C=CC2=CC2=C1OC=C2",
    "molecular_weight": 216.19,
    "log_p": 2.55,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA synthesis inhibitor",
    "disease_area": "dermatology",
    "indication": "psoriasis"
  },
  "methoxyflurane": {
    "name": "Methoxyflurane",
    "smiles": "COC(F)(F)C(Cl)Cl",
    "molecular_weight": 164.97,
    "log_p": 2.03,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "membrane permeability inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "general anaesthetic"
  },
  "methoxyphenamine": {
    "name": "Methoxyphenamine",
    "smiles": "CNC(C)CC1=CC=CC=C1OC",
    "molecular_weight": 179.26,
    "log_p": 1.85,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "pulmonary",
    "indication": "asthma"
  },
  "methscopolamine": {
    "name": "Methscopolamine",
    "smiles": "C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1",
    "molecular_weight": 318.39,
    "log_p": 1.06,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "gastroenterology",
    "indication": "peptic ulcer disease (PUD)"
  },
  "methscopolamine bromide": {
    "name": "Methscopolamine bromide",
    "smiles": "[Br-].[H][C@@]12O[C@]1([H])[C@H]1C[C@H](C[C@@H]2[N+]1(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1",
    "molecular_weight": 398.3,
    "log_p": -1.93,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "gastroenterology",
    "indication": "peptic ulcer disease (pud)"
  },
  "methsuximide": {
    "name": "Methsuximide",
    "smiles": "CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1",
    "molecular_weight": 203.24,
    "log_p": 1.33,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "T-type calcium channel blocker",
    "disease_area": "neurology/psychiatry",
    "indication": "seizures"
  },
  "methyl aminolevulinate": {
    "name": "Methyl aminolevulinate",
    "smiles": "COC(=O)CCC(=O)CN",
    "molecular_weight": 145.16,
    "log_p": -0.53,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "methyl nicotinate": {
    "name": "Methyl nicotinate",
    "smiles": "COC(=O)C1=CN=CC=C1",
    "molecular_weight": 137.14,
    "log_p": 0.87,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "methyl salicylate": {
    "name": "Methyl salicylate",
    "smiles": "COC(=O)C1=CC=CC=C1O",
    "molecular_weight": 152.15,
    "log_p": 1.18,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "methylchloroisothiazolinone": {
    "name": "Methylchloroisothiazolinone",
    "smiles": "CN1SC(Cl)=CC1=O",
    "molecular_weight": 149.6,
    "log_p": 1.1,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "methyldopa": {
    "name": "Methyldopa",
    "smiles": "C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O",
    "molecular_weight": 211.22,
    "log_p": 0.44,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "methylene blue": {
    "name": "Methylene blue",
    "smiles": "[Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1",
    "molecular_weight": 319.86,
    "log_p": 0.87,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "methylergometrine": {
    "name": "Methylergometrine",
    "smiles": "[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO",
    "molecular_weight": 339.44,
    "log_p": 1.92,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist | serotonin receptor antagonist",
    "disease_area": "hematology | neurology/psychiatry",
    "indication": "migraine headache | postpartum hemorrhage (PPH)"
  },
  "methylnaltrexone": {
    "name": "Methylnaltrexone",
    "smiles": "C[N@+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35",
    "molecular_weight": 356.44,
    "log_p": 1.67,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "opioid receptor antagonist",
    "disease_area": "gastroenterology",
    "indication": "constipation"
  },
  "methylparaben": {
    "name": "Methylparaben",
    "smiles": "COC(=O)C1=CC=C(O)C=C1",
    "molecular_weight": 152.15,
    "log_p": 1.18,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "other antifungal",
    "disease_area": "dermatology",
    "indication": "cosmetic"
  },
  "methylphenidate": {
    "name": "Methylphenidate",
    "smiles": "COC(=O)C(C1CCCCN1)C1=CC=CC=C1",
    "molecular_weight": 233.31,
    "log_p": 2.09,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "methylphenobarbital": {
    "name": "Methylphenobarbital",
    "smiles": "CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1",
    "molecular_weight": 246.27,
    "log_p": 1.04,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "methylprednisolone": {
    "name": "Methylprednisolone",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C",
    "molecular_weight": 374.48,
    "log_p": 1.8,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "allergy | dermatology | dermatology | endocrinology | endocrinology | gastroenterology | gastroenterology | hematology | infectious disease | neurology/psychiatry | rheumatology | rheumatology | rheumatology | rheumatology",
    "indication": "allergic rhinitis | anemia | ankylosing spondylitis | bursitis | enteritis | hypercalcemia | multiple sclerosis | mycosis | osteoarthritis | psoriasis | psoriatic arthritis | seborrheic dermatitis | thyroiditis | ulcerative colitis"
  },
  "methylprednisolone aceponate": {
    "name": "Methylprednisolone aceponate",
    "smiles": "[H][C@@]12CC[C@](OC(=O)CC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C",
    "molecular_weight": 472.58,
    "log_p": 3.34,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "methylprednisolone hemisuccinate": {
    "name": "Methylprednisolone hemisuccinate",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C",
    "molecular_weight": 474.55,
    "log_p": 2.22,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "methylprednisone": {
    "name": "Methylprednisone",
    "smiles": "C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)CC(=O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12",
    "molecular_weight": 372.46,
    "log_p": 2.01,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "methyltestosterone": {
    "name": "Methyltestosterone",
    "smiles": "[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 302.46,
    "log_p": 4.27,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "methyprylon": {
    "name": "Methyprylon",
    "smiles": "CCC1(CC)C(=O)NCC(C)C1=O",
    "molecular_weight": 183.25,
    "log_p": 1.13,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "methysergide": {
    "name": "Methysergide",
    "smiles": "[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO",
    "molecular_weight": 353.47,
    "log_p": 1.94,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "headache"
  },
  "meticillin": {
    "name": "Meticillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OC)C=CC=C1OC)C(O)=O",
    "molecular_weight": 380.42,
    "log_p": 0.95,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "meticrane": {
    "name": "Meticrane",
    "smiles": "CC1=CC2=C(C=C1S(N)(=O)=O)S(=O)(=O)CCC2",
    "molecular_weight": 275.35,
    "log_p": 0.36,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "diuretic",
    "disease_area": "cardiology",
    "indication": "edema"
  },
  "metipranolol": {
    "name": "Metipranolol",
    "smiles": "CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1",
    "molecular_weight": 309.41,
    "log_p": 2.27,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "metixene": {
    "name": "Metixene",
    "smiles": "CN1CCCC(CC2C3=CC=CC=C3SC3=CC=CC=C23)C1",
    "molecular_weight": 309.48,
    "log_p": 5.02,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "Parkinson's Disease"
  },
  "metoclopramide": {
    "name": "Metoclopramide",
    "smiles": "CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC",
    "molecular_weight": 299.8,
    "log_p": 2.0,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist | serotonin receptor antagonist",
    "disease_area": "gastroenterology | gastroenterology | gastroenterology",
    "indication": "gastroparesis | nausea | vomiting"
  },
  "metocurine": {
    "name": "Metocurine",
    "smiles": "[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CC[N+]1(C)C)C2=C6)=C(OC)C=C5)=CC(OC)=C4OC)C=C3",
    "molecular_weight": 652.83,
    "log_p": 7.45,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "muscle relaxant"
  },
  "metocurine iodide": {
    "name": "Metocurine iodide",
    "smiles": "[I-].[I-].[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CC[N+]1(C)C)C2=C6)=C(OC)C=C5)=CC(OC)=C4OC)C=C3",
    "molecular_weight": 906.64,
    "log_p": 1.46,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "metolazone": {
    "name": "Metolazone",
    "smiles": "CC1NC2=CC(Cl)=C(C=C2C(=O)N1C1=CC=CC=C1C)S(N)(=O)=O",
    "molecular_weight": 365.84,
    "log_p": 2.71,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "carbonic anhydrase inhibitor",
    "disease_area": "cardiology | cardiology",
    "indication": "edema | hypertension"
  },
  "metoprolol": {
    "name": "Metoprolol",
    "smiles": "COCCC1=CC=C(OCC(O)CNC(C)C)C=C1",
    "molecular_weight": 267.37,
    "log_p": 1.61,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology | cardiology | cardiology",
    "indication": "angina pectoris | hypertension | myocardial infarction"
  },
  "metrizoic acid": {
    "name": "Metrizoic acid",
    "smiles": "CN(C(C)=O)C1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I",
    "molecular_weight": 627.94,
    "log_p": 3.14,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "metronidazole": {
    "name": "Metronidazole",
    "smiles": "CC1=NC=C(N1CCO)[N+]([O-])=O",
    "molecular_weight": 171.16,
    "log_p": 0.09,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA inhibitor",
    "disease_area": "dermatology",
    "indication": "rosacea"
  },
  "metyrapone": {
    "name": "Metyrapone",
    "smiles": "CC(C)(C(=O)C1=CN=CC=C1)C1=CC=CN=C1",
    "molecular_weight": 226.28,
    "log_p": 2.64,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cytochrome P450 inhibitor",
    "disease_area": "nephrology",
    "indication": "adrenal diagnostic agent"
  },
  "metyrosine": {
    "name": "Metyrosine",
    "smiles": "C[C@](N)(CC1=CC=C(O)C=C1)C(O)=O",
    "molecular_weight": 195.22,
    "log_p": 0.74,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "mexiletine": {
    "name": "Mexiletine",
    "smiles": "CC(N)COC1=C(C)C=CC=C1C",
    "molecular_weight": 179.26,
    "log_p": 2.03,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "cardiology | cardiology",
    "indication": "ventricular arrhythmias | ventricular tachycardia (VT)"
  },
  "mezlocillin": {
    "name": "Mezlocillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(C1=O)S(C)(=O)=O)C1=CC=CC=C1)C(O)=O",
    "molecular_weight": 539.59,
    "log_p": -0.23,
    "hbd": 3,
    "hba": 8,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "gram-negative bacterial infections | gram-positive bacterial infections"
  },
  "mianserin": {
    "name": "Mianserin",
    "smiles": "CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21",
    "molecular_weight": 264.37,
    "log_p": 3.08,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "micafungin": {
    "name": "Micafungin",
    "smiles": "CCCCCOC1=CC=C(C=C1)C1=CC(=NO1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC(OS(O)(=O)=O)=C(O)C=C1)[C@H](O)CC(N)=O",
    "molecular_weight": 1270.29,
    "log_p": -3.9,
    "hbd": 16,
    "hba": 23,
    "rotatable_bonds": 18,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "fungal 1,3-beta-D-glucan synthase inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "candidemia | candidemia, peritonitis, esophageal candidiasis | esophageal candidiasis | peritonitis"
  },
  "miconazole": {
    "name": "Miconazole",
    "smiles": "ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1",
    "molecular_weight": 416.14,
    "log_p": 6.45,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | neurology/psychiatry",
    "indication": "itching | yeast infection"
  },
  "micronomicin": {
    "name": "Micronomicin",
    "smiles": "CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1",
    "molecular_weight": 463.58,
    "log_p": -3.72,
    "hbd": 8,
    "hba": 12,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "protein synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-negative bacterial infections"
  },
  "midazolam": {
    "name": "Midazolam",
    "smiles": "CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12",
    "molecular_weight": 325.77,
    "log_p": 4.32,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "midodrine": {
    "name": "Midodrine",
    "smiles": "COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1",
    "molecular_weight": 254.29,
    "log_p": -0.19,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "cardiology",
    "indication": "hypotension"
  },
  "midostaurin": {
    "name": "Midostaurin",
    "smiles": "CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O)N(C)C(=O)C1=CC=CC=C1",
    "molecular_weight": 570.65,
    "log_p": 5.91,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "FLT3 inhibitor | KIT inhibitor | PKC inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "acute myeloid leukemia (AML)"
  },
  "mifamurtide": {
    "name": "Mifamurtide",
    "smiles": "O.[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC",
    "molecular_weight": 1277.52,
    "log_p": 1.15,
    "hbd": 9,
    "hba": 19,
    "rotatable_bonds": 56,
    "approved": true,
    "source": "FDA"
  },
  "mifepristone": {
    "name": "Mifepristone",
    "smiles": "[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]",
    "molecular_weight": 429.6,
    "log_p": 5.41,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor antagonist | progesterone receptor antagonist",
    "disease_area": "endocrinology | endocrinology",
    "indication": "diabetes mellitus | hyperglycemia"
  },
  "migalastat": {
    "name": "Migalastat",
    "smiles": "OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O",
    "molecular_weight": 163.17,
    "log_p": -2.97,
    "hbd": 5,
    "hba": 5,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "alpha-galactosidase a inhibitor",
    "disease_area": "endocrinology",
    "indication": "fabry disease"
  },
  "miglitol": {
    "name": "Miglitol",
    "smiles": "OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO",
    "molecular_weight": 207.23,
    "log_p": -3.26,
    "hbd": 5,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucosidase inhibitor",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "miglustat": {
    "name": "Miglustat",
    "smiles": "CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO",
    "molecular_weight": 219.28,
    "log_p": -1.45,
    "hbd": 4,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glycosyl transferase inhibitor",
    "disease_area": "hematology",
    "indication": "Gaucher disease"
  },
  "milnacipran": {
    "name": "Milnacipran",
    "smiles": "CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1",
    "molecular_weight": 246.35,
    "log_p": 1.77,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin\u2013norepinephrine reuptake inhibitor (SNRI)",
    "disease_area": "rheumatology",
    "indication": "fibromyalgia"
  },
  "milrinone": {
    "name": "Milrinone",
    "smiles": "CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1",
    "molecular_weight": 211.22,
    "log_p": 1.62,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "cardiology",
    "indication": "congestive heart failure"
  },
  "miltefosine": {
    "name": "Miltefosine",
    "smiles": "CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C",
    "molecular_weight": 407.58,
    "log_p": 5.68,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 20,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "membrane integrity inhibitor",
    "disease_area": "infectious disease",
    "indication": "leishmaniasis"
  },
  "minaprine": {
    "name": "Minaprine",
    "smiles": "CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1",
    "molecular_weight": 298.39,
    "log_p": 2.2,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "serotonin reuptake inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "minocycline": {
    "name": "Minocycline",
    "smiles": "[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2",
    "molecular_weight": 457.48,
    "log_p": 0.19,
    "hbd": 5,
    "hba": 9,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor | ribosomal protein inhibitor",
    "disease_area": "endocrinology | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | neurology/psychiatry | ophthalmology | urology",
    "indication": "brucellosis | chancroid | cholera | conjunctivitis | fever | psittacosis | respiratory tract infections | stroke | trachoma | tularemia | urethritis"
  },
  "minoxidil": {
    "name": "Minoxidil",
    "smiles": "NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1",
    "molecular_weight": 209.25,
    "log_p": -0.13,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "KATP activator | Kir6 channel (KATP) activator | vasodilator",
    "disease_area": "endocrinology",
    "indication": "androgenetic alopecia"
  },
  "mirabegron": {
    "name": "Mirabegron",
    "smiles": "NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1",
    "molecular_weight": 396.52,
    "log_p": 2.77,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "urology",
    "indication": "urinary incontinence"
  },
  "mirtazapine": {
    "name": "Mirtazapine",
    "smiles": "CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1",
    "molecular_weight": 265.36,
    "log_p": 2.48,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist | serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "misoprostol": {
    "name": "Misoprostol",
    "smiles": "CCCCC(C)(O)C\\C=C\\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC",
    "molecular_weight": 382.54,
    "log_p": 3.95,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "prostanoid receptor agonist",
    "disease_area": "gastroenterology",
    "indication": "duodenal ulcer disease"
  },
  "mitapivat": {
    "name": "Mitapivat",
    "smiles": "O=C(N1CCN(CC2CC2)CC1)C1=CC=C(NS(=O)(=O)C2=CC=CC3=C2N=CC=C3)C=C1",
    "molecular_weight": 450.56,
    "log_p": 3.2,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Preclinical",
    "moa": "pyruvate kinase isozyme activator",
    "disease_area": "",
    "indication": ""
  },
  "mitomycin": {
    "name": "Mitomycin",
    "smiles": "[H][C@]12CN3C4=C([C@@H](COC(N)=O)[C@@]3(OC)[C@@]1([H])N2)C(=O)C(N)=C(C)C4=O",
    "molecular_weight": 334.33,
    "log_p": -1.65,
    "hbd": 3,
    "hba": 8,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "mitotane": {
    "name": "Mitotane",
    "smiles": "ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl",
    "molecular_weight": 320.05,
    "log_p": 5.93,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antineoplastic agent",
    "disease_area": "oncology",
    "indication": "adrenal cortical carcinoma"
  },
  "mitoxantrone": {
    "name": "Mitoxantrone",
    "smiles": "OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O",
    "molecular_weight": 444.49,
    "log_p": -0.14,
    "hbd": 8,
    "hba": 10,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "topoisomerase inhibitor",
    "disease_area": "hematologic malignancy | neurology/psychiatry | oncology",
    "indication": "acute myeloid leukemia (AML) | multiple sclerosis | prostate cancer"
  },
  "mivacurium": {
    "name": "Mivacurium",
    "smiles": "COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\\C=C\\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC",
    "molecular_weight": 1029.28,
    "log_p": 9.03,
    "hbd": 0,
    "hba": 14,
    "rotatable_bonds": 28,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "critical care | neurology/psychiatry",
    "indication": "endotracheal intubation | muscle relaxant"
  },
  "mizolastine": {
    "name": "Mizolastine",
    "smiles": "CN(C1CCN(CC1)C1=NC2=C(C=CC=C2)N1CC1=CC=C(F)C=C1)C1=NC=CC(=O)N1",
    "molecular_weight": 432.5,
    "log_p": 3.41,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy | allergy",
    "indication": "allergic rhinitis | urticaria"
  },
  "mobocertinib": {
    "name": "Mobocertinib",
    "smiles": "COC1=C(NC2=NC=C(C(=O)OC(C)C)C(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C",
    "molecular_weight": 585.71,
    "log_p": 5.08,
    "hbd": 2,
    "hba": 10,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 2",
    "moa": "egfr inhibitor",
    "disease_area": "oncology",
    "indication": "non-small cell lung cancer (nsclc)"
  },
  "moclobemide": {
    "name": "Moclobemide",
    "smiles": "ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1",
    "molecular_weight": 268.74,
    "log_p": 1.4,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "monoamine oxidase inhibitor",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "anxiety | depression"
  },
  "modafinil": {
    "name": "Modafinil",
    "smiles": "NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 273.36,
    "log_p": 2.01,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "moexipril": {
    "name": "Moexipril",
    "smiles": "CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[C@H]1C(O)=O",
    "molecular_weight": 498.58,
    "log_p": 2.58,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin converting enzyme inhibitor",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "molindone": {
    "name": "Molindone",
    "smiles": "CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2",
    "molecular_weight": 276.38,
    "log_p": 1.96,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "schizophrenia"
  },
  "molsidomine": {
    "name": "Molsidomine",
    "smiles": "CCOC(=O)[N-]C1=C[N+](=NO1)N1CCOCC1",
    "molecular_weight": 242.23,
    "log_p": 0.09,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "guanylate cyclase stimulant",
    "disease_area": "cardiology",
    "indication": "coronary artery disease (CAD)"
  },
  "molybdenum": {
    "name": "Molybdenum",
    "smiles": "[Mo]",
    "molecular_weight": 95.94,
    "log_p": -0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "mometasone furoate": {
    "name": "Mometasone furoate",
    "smiles": "[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 521.44,
    "log_p": 4.87,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "monobenzone": {
    "name": "Monobenzone",
    "smiles": "OC1=CC=C(OCC2=CC=CC=C2)C=C1",
    "molecular_weight": 200.24,
    "log_p": 2.97,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "melanin inhibitor",
    "disease_area": "dermatology",
    "indication": "skin depigmentation"
  },
  "monomethyl fumarate": {
    "name": "Monomethyl fumarate",
    "smiles": "COC(=O)\\C=C\\C(O)=O",
    "molecular_weight": 130.1,
    "log_p": -0.2,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "monopotassium phosphate": {
    "name": "Monopotassium phosphate",
    "smiles": "[K+].OP(O)([O-])=O",
    "molecular_weight": 136.08,
    "log_p": -4.56,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "montelukast": {
    "name": "Montelukast",
    "smiles": "OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(\\C=C\\C2=NC3=C(C=CC(Cl)=C3)C=C2)=C1",
    "molecular_weight": 586.2,
    "log_p": 8.95,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "leukotriene receptor antagonist",
    "disease_area": "allergy | pulmonary | pulmonary",
    "indication": "allergic rhinitis | asthma | exercise-induced bronchoconstriction (EIB)"
  },
  "moricizine": {
    "name": "Moricizine",
    "smiles": "CCOC(=O)NC1=CC2=C(SC3=CC=CC=C3N2C(=O)CCN2CCOCC2)C=C1",
    "molecular_weight": 427.53,
    "log_p": 4.11,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "morphine": {
    "name": "Morphine",
    "smiles": "[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O",
    "molecular_weight": 285.34,
    "log_p": 1.2,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "morpholinylmercaptobenzothiazole": {
    "name": "Morpholinylmercaptobenzothiazole",
    "smiles": "C1CN(CCO1)SC1=NC2=CC=CC=C2S1",
    "molecular_weight": 252.36,
    "log_p": 2.64,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "moxidectin": {
    "name": "Moxidectin",
    "smiles": "[H][C@@]12OC\\C3=C/C=C/[C@H](C)C\\C(C)=C\\C[C@]4([H])C[C@@]([H])(C[C@]5(C\\C(=N/OC)[C@H](C)[C@H](O5)C(\\C)=C\\C(C)C)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O",
    "molecular_weight": 639.83,
    "log_p": 5.73,
    "hbd": 2,
    "hba": 9,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "chloride channel antagonist",
    "disease_area": "infectious disease",
    "indication": "gastrointestinal parasites"
  },
  "moxifloxacin": {
    "name": "Moxifloxacin",
    "smiles": "[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O",
    "molecular_weight": 401.44,
    "log_p": 2.37,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial DNA gyrase inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | otolaryngology | pulmonary",
    "indication": "bronchitis | intra-abdominal infections | pneumonia | sinusitis | skin infections"
  },
  "moxisylyte": {
    "name": "Moxisylyte",
    "smiles": "CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1",
    "molecular_weight": 279.38,
    "log_p": 2.98,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "moxonidine": {
    "name": "Moxonidine",
    "smiles": "COC1=NC(C)=NC(Cl)=C1NC1=NCCN1",
    "molecular_weight": 241.68,
    "log_p": 0.82,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "imidazoline receptor agonist",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "mupirocin": {
    "name": "Mupirocin",
    "smiles": "C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\\C(C)=C\\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O",
    "molecular_weight": 500.63,
    "log_p": 2.59,
    "hbd": 4,
    "hba": 8,
    "rotatable_bonds": 16,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "isoleucyl-tRNA synthetase inhibitor",
    "disease_area": "infectious disease",
    "indication": "impetigo"
  },
  "muzolimine": {
    "name": "Muzolimine",
    "smiles": "CC(N1N=C(N)CC1=O)C1=CC(Cl)=C(Cl)C=C1",
    "molecular_weight": 272.13,
    "log_p": 2.56,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "mycophenolate mofetil": {
    "name": "Mycophenolate mofetil",
    "smiles": "COC1=C(C\\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C",
    "molecular_weight": 433.5,
    "log_p": 2.52,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "mycophenolic acid": {
    "name": "Mycophenolic acid",
    "smiles": "COC1=C(C\\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C",
    "molecular_weight": 320.34,
    "log_p": 2.73,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "nabilone": {
    "name": "Nabilone",
    "smiles": "[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC",
    "molecular_weight": 372.55,
    "log_p": 6.26,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "nabumetone": {
    "name": "Nabumetone",
    "smiles": "COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2",
    "molecular_weight": 228.29,
    "log_p": 3.37,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "rheumatology | rheumatology",
    "indication": "osteoarthritis | rheumatoid arthritis"
  },
  "n-acetylglucosamine": {
    "name": "N-Acetylglucosamine",
    "smiles": "[H]C(=O)[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@H](O)CO",
    "molecular_weight": 221.21,
    "log_p": -3.23,
    "hbd": 5,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "n-acetyltyrosine": {
    "name": "N-acetyltyrosine",
    "smiles": "CC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O",
    "molecular_weight": 223.23,
    "log_p": 0.52,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "nadh": {
    "name": "NADH",
    "smiles": "NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C(N)N=CN=C23)[C@@H](O)[C@H]1O",
    "molecular_weight": 665.45,
    "log_p": -2.69,
    "hbd": 8,
    "hba": 18,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA"
  },
  "nadolol": {
    "name": "Nadolol",
    "smiles": "CC(C)(C)NCC(O)COC1=CC=CC2=C1C[C@H](O)[C@H](O)C2",
    "molecular_weight": 309.41,
    "log_p": 0.63,
    "hbd": 4,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology | cardiology",
    "indication": "angina pectoris | hypertension"
  },
  "nafarelin": {
    "name": "Nafarelin",
    "smiles": "CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O",
    "molecular_weight": 1322.5,
    "log_p": -1.41,
    "hbd": 17,
    "hba": 15,
    "rotatable_bonds": 33,
    "approved": true,
    "source": "FDA"
  },
  "nafcillin": {
    "name": "Nafcillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O",
    "molecular_weight": 414.48,
    "log_p": 2.48,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-positive bacterial infections"
  },
  "naftazone": {
    "name": "Naftazone",
    "smiles": "NC(=O)N\\N=C1/C=CC2=CC=CC=C2C1=O",
    "molecular_weight": 215.21,
    "log_p": 0.92,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "naftifine": {
    "name": "Naftifine",
    "smiles": "CN(CC=CC1=CC=CC=C1)CC1=CC=CC2=CC=CC=C12",
    "molecular_weight": 287.41,
    "log_p": 4.99,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "fungal squalene epoxidase inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "tinea corporis | tinea cruris | tinea pedis"
  },
  "nalbuphine": {
    "name": "Nalbuphine",
    "smiles": "O[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CCC2)[C@H]1O5",
    "molecular_weight": 357.45,
    "log_p": 1.71,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "opioid receptor agonist | opioid receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "pain relief"
  },
  "naldemedine": {
    "name": "Naldemedine",
    "smiles": "[H][C@@]12OC3=C4C(C[C@@]5([H])N(CC6CC6)CC[C@@]14[C@@]5(O)CC(C(=O)NC(C)(C)C1=NC(=NO1)C1=CC=CC=C1)=C2O)=CC=C3O",
    "molecular_weight": 570.65,
    "log_p": 3.48,
    "hbd": 4,
    "hba": 9,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "opioid receptor antagonist",
    "disease_area": "gastroenterology",
    "indication": "constipation"
  },
  "nalidixic acid": {
    "name": "Nalidixic acid",
    "smiles": "CCN1C=C(C(O)=O)C(=O)C2=C1N=C(C)C=C2",
    "molecular_weight": 232.24,
    "log_p": 1.42,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "nalmefene": {
    "name": "Nalmefene",
    "smiles": "OC1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](OC1=C24)C(=C)CC[C@@]35O",
    "molecular_weight": 339.44,
    "log_p": 2.51,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "opioid receptor antagonist",
    "disease_area": "pulmonary",
    "indication": "respiratory depression"
  },
  "naloxegol": {
    "name": "Naloxegol",
    "smiles": "COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5",
    "molecular_weight": 651.79,
    "log_p": 1.86,
    "hbd": 2,
    "hba": 12,
    "rotatable_bonds": 24,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "opioid receptor antagonist",
    "disease_area": "gastroenterology",
    "indication": "constipation"
  },
  "naloxone": {
    "name": "Naloxone",
    "smiles": "OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O",
    "molecular_weight": 327.38,
    "log_p": 1.3,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "opioid receptor antagonist",
    "disease_area": "pulmonary",
    "indication": "respiratory depression"
  },
  "naltrexone": {
    "name": "Naltrexone",
    "smiles": "[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O",
    "molecular_weight": 341.41,
    "log_p": 1.53,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "opioid receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "abstinence from alcohol"
  },
  "nandrolone decanoate": {
    "name": "Nandrolone decanoate",
    "smiles": "[H][C@@]12CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]",
    "molecular_weight": 428.66,
    "log_p": 7.18,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "nandrolone phenpropionate": {
    "name": "Nandrolone phenpropionate",
    "smiles": "[H][C@@]12CC[C@H](OC(=O)CCC3=CC=CC=C3)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]",
    "molecular_weight": 406.57,
    "log_p": 5.67,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "naphazoline": {
    "name": "Naphazoline",
    "smiles": "C(C1=NCCN1)C1=CC=CC2=CC=CC=C12",
    "molecular_weight": 210.28,
    "log_p": 2.38,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "ophthalmology",
    "indication": "eye irritation"
  },
  "naproxen": {
    "name": "Naproxen",
    "smiles": "COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O",
    "molecular_weight": 230.26,
    "log_p": 3.04,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "dental | endocrinology | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | otolaryngology | rheumatology",
    "indication": "backache | common cold | fever | headache | muscle pain | pain relief | rheumatoid arthritis | toothache"
  },
  "naratriptan": {
    "name": "Naratriptan",
    "smiles": "CNS(=O)(=O)CCC1=CC2=C(NC=C2C2CCN(C)CC2)C=C1",
    "molecular_weight": 335.47,
    "log_p": 2.07,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "migraine headache"
  },
  "natamycin": {
    "name": "Natamycin",
    "smiles": "[H][C@@]12C[C@H](O)C[C@]3(O)C[C@H](O)[C@@H](C(O)=O)[C@]([H])(C[C@@H](O[C@]4([H])O[C@H](C)[C@@H](O)[C@H](N)[C@@H]4O)\\C=C\\C=C\\C=C\\C=C\\C[C@@H](C)OC(=O)\\C=C\\[C@@]1([H])O2)O3",
    "molecular_weight": 665.73,
    "log_p": 0.12,
    "hbd": 7,
    "hba": 13,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "fungal ergosterol inhibitor",
    "disease_area": "infectious disease | ophthalmology | ophthalmology",
    "indication": "blepharitis | conjunctivitis | fungal keratosis"
  },
  "nateglinide": {
    "name": "Nateglinide",
    "smiles": "CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](CC1=CC=CC=C1)C(O)=O",
    "molecular_weight": 317.43,
    "log_p": 3.26,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "insulin secretagogue",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "n-cyclohexyl-n'-phenyl-1,4-phenylenediamine": {
    "name": "N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine",
    "smiles": "C1CCC(CC1)NC1=CC=C(NC2=CC=CC=C2)C=C1",
    "molecular_weight": 266.39,
    "log_p": 5.17,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "nebivolol": {
    "name": "Nebivolol",
    "smiles": "OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2",
    "molecular_weight": 405.44,
    "log_p": 2.36,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "nedaplatin": {
    "name": "Nedaplatin",
    "smiles": "[H][N]([H])([H])[Pt]1(OCC(=O)O1)[N]([H])([H])[H]",
    "molecular_weight": 303.18,
    "log_p": -0.2,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA inhibitor",
    "disease_area": "oncology | oncology | oncology | oncology",
    "indication": "esophageal cancer | non-small cell lung cancer (NSCLC) | non-small cell lung cancer (nsclc), small cell lung cancer, esophageal cancer | small cell lung cancer"
  },
  "nedocromil": {
    "name": "Nedocromil",
    "smiles": "CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O",
    "molecular_weight": 371.35,
    "log_p": 2.48,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "neurology/psychiatry | ophthalmology",
    "indication": "conjunctivitis | itching"
  },
  "nefazodone": {
    "name": "Nefazodone",
    "smiles": "CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1",
    "molecular_weight": 470.02,
    "log_p": 3.55,
    "hbd": 0,
    "hba": 7,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "adrenergic inhibitor | norepinephrine reuptake inhibitor | serotonin receptor antagonist | serotonin reuptake inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "nefopam": {
    "name": "Nefopam",
    "smiles": "CN1CCOC(C2=CC=CC=C2)C2=CC=CC=C2C1",
    "molecular_weight": 253.34,
    "log_p": 3.24,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "pain relief"
  },
  "nelarabine": {
    "name": "Nelarabine",
    "smiles": "COC1=NC(N)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",
    "molecular_weight": 297.27,
    "log_p": -1.97,
    "hbd": 4,
    "hba": 10,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA synthesis inhibitor | T cell inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "acute lymphoblastic leukemia (ALL)"
  },
  "nelfinavir": {
    "name": "Nelfinavir",
    "smiles": "[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C",
    "molecular_weight": 567.8,
    "log_p": 4.75,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HIV protease inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "neon": {
    "name": "Neon",
    "smiles": "[Ne]",
    "molecular_weight": 20.18,
    "log_p": 0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "neostigmine": {
    "name": "Neostigmine",
    "smiles": "CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C",
    "molecular_weight": 223.3,
    "log_p": 1.94,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholinesterase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "myasthenia gravis"
  },
  "nepafenac": {
    "name": "Nepafenac",
    "smiles": "NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N",
    "molecular_weight": 254.29,
    "log_p": 1.53,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "ophthalmology",
    "indication": "eye inflammation"
  },
  "neratinib": {
    "name": "Neratinib",
    "smiles": "CCOC1=C(NC(=O)\\C=C\\CN(C)C)C=C2C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C(C=NC2=C1)C#N",
    "molecular_weight": 557.05,
    "log_p": 5.93,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "EGFR inhibitor",
    "disease_area": "oncology",
    "indication": "breast cancer"
  },
  "netarsudil": {
    "name": "Netarsudil",
    "smiles": "CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1",
    "molecular_weight": 453.54,
    "log_p": 4.89,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "rho associated kinase inhibitor",
    "disease_area": "ophthalmology",
    "indication": "ocular hypertension"
  },
  "netilmicin": {
    "name": "Netilmicin",
    "smiles": "CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O",
    "molecular_weight": 475.59,
    "log_p": -3.2,
    "hbd": 8,
    "hba": 12,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "protein synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-negative bacterial infections"
  },
  "netupitant": {
    "name": "Netupitant",
    "smiles": "CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=CC=CC=C1C)N1CCN(C)CC1",
    "molecular_weight": 578.6,
    "log_p": 6.79,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "neurokinin receptor antagonist | tachykinin antagonist",
    "disease_area": "gastroenterology | gastroenterology",
    "indication": "nausea | vomiting"
  },
  "nevirapine": {
    "name": "Nevirapine",
    "smiles": "CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1",
    "molecular_weight": 266.3,
    "log_p": 2.65,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "non-nucleoside reverse transcriptase inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "niacin": {
    "name": "Niacin",
    "smiles": "OC(=O)C1=CN=CC=C1",
    "molecular_weight": 123.11,
    "log_p": 0.78,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "NAD precursor | vitamin B",
    "disease_area": "endocrinology",
    "indication": "hypertriglyceridemia"
  },
  "niacinamide ascorbate": {
    "name": "Niacinamide ascorbate",
    "smiles": "NC(=O)C1=CN=CC=C1.[H]C(O)(CO)[C@@]1([H])OC(=O)C(O)=C1O",
    "molecular_weight": 298.25,
    "log_p": -1.23,
    "hbd": 5,
    "hba": 8,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "nialamide": {
    "name": "Nialamide",
    "smiles": "O=C(CCNNC(=O)C1=CC=NC=C1)NCC1=CC=CC=C1",
    "molecular_weight": 298.35,
    "log_p": 1.02,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "monoamine oxidase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "nicardipine": {
    "name": "Nicardipine",
    "smiles": "COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1",
    "molecular_weight": 479.53,
    "log_p": 3.68,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "cardiology | cardiology",
    "indication": "chronic stable angina | hypertension"
  },
  "nicergoline": {
    "name": "Nicergoline",
    "smiles": "[H][C@@]12CC3=CN(C)C4=CC=CC(=C34)[C@]1(C[C@@H](COC(=O)C1=CN=CC(Br)=C1)CN2C)OC",
    "molecular_weight": 484.39,
    "log_p": 3.91,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology | hematology | neurology/psychiatry | rheumatology",
    "indication": "atherosclerosis | migraine headache | Raynaud's disease | thrombosis"
  },
  "nickel sulfate": {
    "name": "Nickel sulfate",
    "smiles": "[Ni++].[O-]S([O-])(=O)=O",
    "molecular_weight": 154.76,
    "log_p": -1.34,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "niclosamide": {
    "name": "Niclosamide",
    "smiles": "OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O",
    "molecular_weight": 327.12,
    "log_p": 3.86,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA replication inhibitor | STAT inhibitor",
    "disease_area": "infectious disease",
    "indication": "tapeworm"
  },
  "nicoboxil": {
    "name": "Nicoboxil",
    "smiles": "CCCCOCCOC(=O)C1=CN=CC=C1",
    "molecular_weight": 223.27,
    "log_p": 2.06,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "nicorandil": {
    "name": "Nicorandil",
    "smiles": "[O-][N+](=O)OCCNC(=O)C1=CC=CN=C1",
    "molecular_weight": 211.18,
    "log_p": 0.02,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "nitric oxide donor | potassium channel activator",
    "disease_area": "cardiology",
    "indication": "angina pectoris"
  },
  "nicotinamide": {
    "name": "Nicotinamide",
    "smiles": "NC(=O)C1=CC=CN=C1",
    "molecular_weight": 122.13,
    "log_p": 0.18,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "protein synthesis stimulant",
    "disease_area": "dermatology",
    "indication": "acne vulgaris (AV)"
  },
  "nicotine": {
    "name": "Nicotine",
    "smiles": "CN1CCC[C@H]1C1=CN=CC=C1",
    "molecular_weight": 162.24,
    "log_p": 1.85,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "smoking cessation"
  },
  "nifedipine": {
    "name": "Nifedipine",
    "smiles": "COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC",
    "molecular_weight": 346.34,
    "log_p": 2.18,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "cardiology | cardiology",
    "indication": "chronic stable angina | vasospastic angina"
  },
  "nifurtimox": {
    "name": "Nifurtimox",
    "smiles": "CC1CS(=O)(=O)CCN1\\N=C\\C1=CC=C(O1)[N+]([O-])=O",
    "molecular_weight": 287.3,
    "log_p": 0.64,
    "hbd": 0,
    "hba": 7,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "African trypanosomiasis | Chagas disease | chagas disease, african trypanosomiasis"
  },
  "nilotinib": {
    "name": "Nilotinib",
    "smiles": "CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F",
    "molecular_weight": 529.53,
    "log_p": 6.36,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "Abl kinase inhibitor | Bcr-Abl kinase inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "chronic myeloid leukemia (CML)"
  },
  "nilutamide": {
    "name": "Nilutamide",
    "smiles": "CC1(C)NC(=O)N(C1=O)C1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F",
    "molecular_weight": 317.22,
    "log_p": 2.45,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "androgen receptor antagonist",
    "disease_area": "oncology",
    "indication": "prostate cancer"
  },
  "nilvadipine": {
    "name": "Nilvadipine",
    "smiles": "COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N",
    "molecular_weight": 385.38,
    "log_p": 2.46,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "cardiology | cardiology",
    "indication": "cerebral artery occlusion | hypertension"
  },
  "nimesulide": {
    "name": "Nimesulide",
    "smiles": "CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O",
    "molecular_weight": 308.32,
    "log_p": 2.76,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "obstetrics/gynecology | rheumatology",
    "indication": "menstrual pain | osteoarthritis"
  },
  "nimodipine": {
    "name": "Nimodipine",
    "smiles": "COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C",
    "molecular_weight": 418.45,
    "log_p": 2.97,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "hematology",
    "indication": "hemorrhage"
  },
  "nintedanib": {
    "name": "Nintedanib",
    "smiles": "COC(=O)C1=CC=C2C(NC(=O)\\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1",
    "molecular_weight": 539.64,
    "log_p": 3.62,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "FGFR inhibitor | PDGFR tyrosine kinase receptor inhibitor | VEGFR inhibitor",
    "disease_area": "pulmonary",
    "indication": "idiopathic pulmonary fibrosis (IPF)"
  },
  "niraparib": {
    "name": "Niraparib",
    "smiles": "NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1",
    "molecular_weight": 320.4,
    "log_p": 2.59,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PARP inhibitor",
    "disease_area": "oncology",
    "indication": "primary peritoneal cancer (PPC)"
  },
  "nirmatrelvir": {
    "name": "Nirmatrelvir",
    "smiles": "[H][C@]12CN([C@H](C(=O)N[C@@H](C[C@]3([H])CCNC3=O)C#N)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)C(F)(F)F)C(C)(C)C",
    "molecular_weight": 499.53,
    "log_p": 1.1,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "nisoldipine": {
    "name": "Nisoldipine",
    "smiles": "COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C",
    "molecular_weight": 388.42,
    "log_p": 3.2,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "nitazoxanide": {
    "name": "Nitazoxanide",
    "smiles": "CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O",
    "molecular_weight": 307.29,
    "log_p": 2.23,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "pyruvate ferredoxin oxidoreductase inhibitor",
    "disease_area": "gastroenterology",
    "indication": "diarrhea"
  },
  "nitisinone": {
    "name": "Nitisinone",
    "smiles": "[O-][N+](=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C1C(=O)CCCC1=O",
    "molecular_weight": 329.23,
    "log_p": 2.73,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "hydroxyphenylpyruvate dioxygenase inhibitor",
    "disease_area": "metabolism",
    "indication": "tyrosinemia"
  },
  "nitrazepam": {
    "name": "Nitrazepam",
    "smiles": "[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1",
    "molecular_weight": 281.27,
    "log_p": 2.38,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "nitrendipine": {
    "name": "Nitrendipine",
    "smiles": "CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC",
    "molecular_weight": 360.37,
    "log_p": 2.57,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "nitric oxide": {
    "name": "Nitric Oxide",
    "smiles": "[N]=O",
    "molecular_weight": 30.01,
    "log_p": -0.45,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "nitrite": {
    "name": "Nitrite",
    "smiles": "[O-]N=O",
    "molecular_weight": 46.01,
    "log_p": 0.25,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "nitrofural": {
    "name": "Nitrofural",
    "smiles": "NC(=O)N\\N=C\\C1=CC=C(O1)[N+]([O-])=O",
    "molecular_weight": 198.14,
    "log_p": 0.19,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "nitrofurantoin": {
    "name": "Nitrofurantoin",
    "smiles": "[O-][N+](=O)C1=CC=C(O1)\\C=N\\N1CC(=O)NC1=O",
    "molecular_weight": 238.16,
    "log_p": 0.07,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "pyelonephritis | urinary tract infections"
  },
  "nitrogen": {
    "name": "Nitrogen",
    "smiles": "N#N",
    "molecular_weight": 28.01,
    "log_p": 0.03,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "nitroglycerin": {
    "name": "Nitroglycerin",
    "smiles": "[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O",
    "molecular_weight": 227.08,
    "log_p": -1.02,
    "hbd": 0,
    "hba": 9,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "nitroprusside": {
    "name": "Nitroprusside",
    "smiles": "O=N[Fe--](C#N)(C#N)(C#N)(C#N)C#N",
    "molecular_weight": 215.94,
    "log_p": 0.3,
    "hbd": 0,
    "hba": 7,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "nitrous acid": {
    "name": "Nitrous acid",
    "smiles": "ON=O",
    "molecular_weight": 47.01,
    "log_p": 0.14,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "nitrous oxide": {
    "name": "Nitrous oxide",
    "smiles": "[N-]=[N+]=O",
    "molecular_weight": 44.01,
    "log_p": -0.16,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "nizatidine": {
    "name": "Nizatidine",
    "smiles": "CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O",
    "molecular_weight": 331.47,
    "log_p": 1.32,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "gastroenterology | gastroenterology | gastroenterology | gastroenterology",
    "indication": "duodenal ulcer disease | erosive esophagitis (EE) | gastroesophageal reflux disease (GERD) | ulcerative esophagitis (UE)"
  },
  "nomegestrol": {
    "name": "Nomegestrol",
    "smiles": "CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C",
    "molecular_weight": 328.45,
    "log_p": 3.61,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "nomegestrol acetate": {
    "name": "Nomegestrol acetate",
    "smiles": "[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C(C)=C[C@@]21[H]",
    "molecular_weight": 370.49,
    "log_p": 4.19,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "nomifensine": {
    "name": "Nomifensine",
    "smiles": "CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2",
    "molecular_weight": 238.33,
    "log_p": 2.85,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine reuptake inhibitor | noradrenaline uptake inhibitor",
    "disease_area": "Antidepressant",
    "indication": "depression"
  },
  "nonoxynol-9": {
    "name": "Nonoxynol-9",
    "smiles": "CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1",
    "molecular_weight": 616.83,
    "log_p": 4.48,
    "hbd": 1,
    "hba": 10,
    "rotatable_bonds": 35,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "membrane integrity inhibitor",
    "disease_area": "endocrinology",
    "indication": "contraceptive"
  },
  "norelgestromin": {
    "name": "Norelgestromin",
    "smiles": "[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(C=C3CC[C@@]21[H])=NO",
    "molecular_weight": 327.47,
    "log_p": 4.14,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "endocrinology",
    "indication": "contraceptive"
  },
  "norepinephrine": {
    "name": "Norepinephrine",
    "smiles": "NC[C@H](O)C1=CC(O)=C(O)C=C1",
    "molecular_weight": 169.18,
    "log_p": 0.09,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "allergy | cardiology | neurology/psychiatry | neurology/psychiatry",
    "indication": "headache | hypertension | seasonal affective disorder | urticaria"
  },
  "norethisterone": {
    "name": "Norethisterone",
    "smiles": "[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]",
    "molecular_weight": 298.43,
    "log_p": 3.49,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "norethynodrel": {
    "name": "Norethynodrel",
    "smiles": "[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])CC(=O)CC3",
    "molecular_weight": 298.43,
    "log_p": 3.64,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "norfloxacin": {
    "name": "Norfloxacin",
    "smiles": "CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1",
    "molecular_weight": 319.34,
    "log_p": 1.27,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial DNA gyrase inhibitor",
    "disease_area": "infectious disease | infectious disease | urology",
    "indication": "gonorrhea | prostatitis | urinary tract infections"
  },
  "norflurane": {
    "name": "Norflurane",
    "smiles": "FCC(F)(F)F",
    "molecular_weight": 102.03,
    "log_p": 1.52,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "norgestimate": {
    "name": "Norgestimate",
    "smiles": "[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\\C(C=C3CC[C@@]21[H])=N/O",
    "molecular_weight": 369.51,
    "log_p": 4.71,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "progesterone receptor agonist",
    "disease_area": "endocrinology",
    "indication": "contraceptive"
  },
  "norgestrel": {
    "name": "Norgestrel",
    "smiles": "CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C",
    "molecular_weight": 312.45,
    "log_p": 3.88,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "progesterone receptor agonist",
    "disease_area": "endocrinology",
    "indication": "contraceptive"
  },
  "normethadone": {
    "name": "Normethadone",
    "smiles": "CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 295.43,
    "log_p": 3.9,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "nortriptyline": {
    "name": "Nortriptyline",
    "smiles": "CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12",
    "molecular_weight": 263.38,
    "log_p": 3.83,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "tricyclic antidepressant",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "noscapine": {
    "name": "Noscapine",
    "smiles": "[H][C@@]1(OC(=O)C2=C1C=CC(OC)=C2OC)[C@]1([H])N(C)CCC2=CC3=C(OCO3)C(OC)=C12",
    "molecular_weight": 413.43,
    "log_p": 2.88,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bradykinin receptor antagonist | tubulin polymerization inhibitor",
    "disease_area": "pulmonary",
    "indication": "cough suppressant"
  },
  "novobiocin": {
    "name": "Novobiocin",
    "smiles": "CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=C(C)C3=C(C=C2)C(O)=C(NC(=O)C2=CC=C(O)C(CC=C(C)C)=C2)C(=O)O3)OC1(C)C",
    "molecular_weight": 612.63,
    "log_p": 3.63,
    "hbd": 5,
    "hba": 11,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial DNA gyrase inhibitor",
    "disease_area": "obstetrics/gynecology",
    "indication": "mastitis"
  },
  "noxytiolin": {
    "name": "Noxytiolin",
    "smiles": "CNC(=S)NCO",
    "molecular_weight": 120.18,
    "log_p": -0.97,
    "hbd": 3,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "nylidrin": {
    "name": "Nylidrin",
    "smiles": "CC(CCC1=CC=CC=C1)NC(C)C(O)C1=CC=C(O)C=C1",
    "molecular_weight": 299.41,
    "log_p": 3.43,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "nystatin": {
    "name": "Nystatin",
    "smiles": "[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\\C=C\\C=C\\C=C\\C=C\\CC\\C=C\\C=C\\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2",
    "molecular_weight": 926.11,
    "log_p": 0.94,
    "hbd": 12,
    "hba": 17,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "fungal ergosterol inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "esophageal candidiasis | esophageal candidiasis, skin infections, yeast infection | skin infections | yeast infection"
  },
  "obeticholic acid": {
    "name": "Obeticholic acid",
    "smiles": "[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O",
    "molecular_weight": 420.63,
    "log_p": 5.11,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "octasulfur": {
    "name": "Octasulfur",
    "smiles": "S1SSSSSSS1",
    "molecular_weight": 256.54,
    "log_p": 5.19,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "octinoxate": {
    "name": "Octinoxate",
    "smiles": "[H]\\C(=C(\\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC",
    "molecular_weight": 290.4,
    "log_p": 4.47,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "dermatology",
    "indication": "sunscreen lotion"
  },
  "octisalate": {
    "name": "Octisalate",
    "smiles": "CCCCC(CC)COC(=O)C1=C(O)C=CC=C1",
    "molecular_weight": 250.34,
    "log_p": 3.77,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "dermatology",
    "indication": "sunscreen lotion"
  },
  "octocrylene": {
    "name": "Octocrylene",
    "smiles": "CCCCC(CC)COC(=O)C(C#N)=C(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 361.49,
    "log_p": 5.77,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "dermatology",
    "indication": "sunscreen lotion"
  },
  "odevixibat": {
    "name": "Odevixibat",
    "smiles": "CCCCC1(CCCC)CN(C2=CC=CC=C2)C2=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C3=CC=C(O)C=C3)C=C2S(=O)(=O)N1",
    "molecular_weight": 740.95,
    "log_p": 5.88,
    "hbd": 5,
    "hba": 9,
    "rotatable_bonds": 17,
    "approved": true,
    "source": "FDA"
  },
  "ofloxacin": {
    "name": "Ofloxacin",
    "smiles": "CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1",
    "molecular_weight": 361.37,
    "log_p": 1.54,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial DNA gyrase inhibitor",
    "disease_area": "endocrinology | gastroenterology | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | otolaryngology",
    "indication": "bone and joint infections | diarrhea | fever | intra-abdominal infections | respiratory tract infections | sinusitis | skin infections | urinary tract infections"
  },
  "oftasceine": {
    "name": "Oftasceine",
    "smiles": "OC(=O)CN(CC(O)=O)CC1=CC2=C(OC3=CC(O)=C(CN(CC(O)=O)CC(O)=O)C=C3C22OC(=O)C3=CC=CC=C23)C=C1O",
    "molecular_weight": 622.54,
    "log_p": 1.61,
    "hbd": 6,
    "hba": 11,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "olanzapine": {
    "name": "Olanzapine",
    "smiles": "CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2",
    "molecular_weight": 312.44,
    "log_p": 3.44,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist | serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "bipolar disorder | schizophrenia"
  },
  "olaparib": {
    "name": "Olaparib",
    "smiles": "FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1",
    "molecular_weight": 434.47,
    "log_p": 2.35,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PARP inhibitor",
    "disease_area": "oncology",
    "indication": "ovarian cancer"
  },
  "oleic acid": {
    "name": "Oleic Acid",
    "smiles": "CCCCCCCC\\C=C\\CCCCCCCC(O)=O",
    "molecular_weight": 282.47,
    "log_p": 6.11,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA"
  },
  "oliceridine": {
    "name": "Oliceridine",
    "smiles": "COC1=C(CNCC[C@]2(CCOC3(CCCC3)C2)C2=NC=CC=C2)SC=C1",
    "molecular_weight": 386.56,
    "log_p": 4.69,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "olmesartan": {
    "name": "Olmesartan",
    "smiles": "CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O",
    "molecular_weight": 446.51,
    "log_p": 3.66,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin receptor antagonist",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "olodaterol": {
    "name": "Olodaterol",
    "smiles": "COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1",
    "molecular_weight": 386.45,
    "log_p": 2.38,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "olopatadine": {
    "name": "Olopatadine",
    "smiles": "CN(C)CC\\C=C1\\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2",
    "molecular_weight": 337.42,
    "log_p": 3.59,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "ophthalmology",
    "indication": "conjunctivitis"
  },
  "olsalazine": {
    "name": "Olsalazine",
    "smiles": "OC(=O)C1=CC(=CC=C1O)\\N=N\\C1=CC=C(O)C(=C1)C(O)=O",
    "molecular_weight": 302.24,
    "log_p": 2.91,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "gastroenterology",
    "indication": "ulcerative colitis"
  },
  "olutasidenib": {
    "name": "Olutasidenib",
    "smiles": "C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=CC(Cl)=C2",
    "molecular_weight": 354.8,
    "log_p": 2.92,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 1/Phase 2",
    "moa": "isocitrate dehydrogenase inhibitor",
    "disease_area": "oncology",
    "indication": "glioma"
  },
  "omacetaxine mepesuccinate": {
    "name": "Omacetaxine mepesuccinate",
    "smiles": "[H][C@@]1(OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)C(OC)=C[C@]23CCCN2CCC2=CC4=C(OCO4)C=C2[C@]13[H]",
    "molecular_weight": 545.63,
    "log_p": 2.58,
    "hbd": 2,
    "hba": 10,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "omadacycline": {
    "name": "Omadacycline",
    "smiles": "[H][C@@]12CC3=C(C=C(CNCC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C",
    "molecular_weight": 556.66,
    "log_p": 1.32,
    "hbd": 6,
    "hba": 10,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor",
    "disease_area": "infectious disease",
    "indication": "pneumonia"
  },
  "ombitasvir": {
    "name": "Ombitasvir",
    "smiles": "COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1",
    "molecular_weight": 894.13,
    "log_p": 7.69,
    "hbd": 4,
    "hba": 9,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HCV inhibitor",
    "disease_area": "infectious disease",
    "indication": "hepatitis C"
  },
  "omeprazole": {
    "name": "Omeprazole",
    "smiles": "COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C",
    "molecular_weight": 345.42,
    "log_p": 2.9,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATPase inhibitor",
    "disease_area": "gastroenterology",
    "indication": "heartburn"
  },
  "omidenepag isopropyl": {
    "name": "Omidenepag isopropyl",
    "smiles": "CC(C)OC(=O)CNC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=N1",
    "molecular_weight": 520.62,
    "log_p": 3.42,
    "hbd": 1,
    "hba": 9,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA"
  },
  "ondansetron": {
    "name": "Ondansetron",
    "smiles": "CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2",
    "molecular_weight": 293.37,
    "log_p": 3.13,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "5-ht3 receptor antagonist | serotonin receptor antagonist",
    "disease_area": "Alcoholism | gastroenterology | gastroenterology",
    "indication": "abstinence from alcohol | nausea | vomiting"
  },
  "opicapone": {
    "name": "Opicapone",
    "smiles": "CC1=C(C2=NOC(=N2)C2=CC(=C(O)C(O)=C2)[N+]([O-])=O)C(Cl)=[N+]([O-])C(C)=C1Cl",
    "molecular_weight": 413.17,
    "log_p": 3.28,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "catechol O methyltransferase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "orciprenaline": {
    "name": "Orciprenaline",
    "smiles": "CC(C)NCC(O)C1=CC(O)=CC(O)=C1",
    "molecular_weight": 211.26,
    "log_p": 1.13,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "oritavancin": {
    "name": "Oritavancin",
    "smiles": "CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(NCC5=CC=C(C=C5)C5=CC=C(Cl)C=C5)[C@@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2",
    "molecular_weight": 1793.13,
    "log_p": 4.5,
    "hbd": 20,
    "hba": 28,
    "rotatable_bonds": 19,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "skin infections"
  },
  "orlistat": {
    "name": "Orlistat",
    "smiles": "CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O",
    "molecular_weight": 495.75,
    "log_p": 6.88,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 23,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "lipase inhibitor",
    "disease_area": "endocrinology",
    "indication": "weight-loss aid"
  },
  "ornithine": {
    "name": "Ornithine",
    "smiles": "NCCC[C@H](N)C(O)=O",
    "molecular_weight": 132.16,
    "log_p": -0.86,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "NFkB pathway modulator",
    "disease_area": "",
    "indication": ""
  },
  "orphenadrine": {
    "name": "Orphenadrine",
    "smiles": "CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C",
    "molecular_weight": 269.39,
    "log_p": 3.66,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "muscle pain"
  },
  "oseltamivir": {
    "name": "Oseltamivir",
    "smiles": "CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1",
    "molecular_weight": 312.41,
    "log_p": 1.29,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "osilodrostat": {
    "name": "Osilodrostat",
    "smiles": "FC1=C(C=CC(=C1)C#N)[C@H]1CCC2=CN=CN12",
    "molecular_weight": 227.24,
    "log_p": 2.43,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cytochrome P450 inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "osimertinib": {
    "name": "Osimertinib",
    "smiles": "COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C",
    "molecular_weight": 499.62,
    "log_p": 4.51,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "EGFR inhibitor",
    "disease_area": "oncology",
    "indication": "non-small cell lung cancer (NSCLC)"
  },
  "ospemifene": {
    "name": "Ospemifene",
    "smiles": "OCCOC1=CC=C(C=C1)C(=C(\\CCCl)C1=CC=CC=C1)\\C1=CC=CC=C1",
    "molecular_weight": 378.9,
    "log_p": 5.65,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "selective estrogen receptor modulator (SERM)",
    "disease_area": "endocrinology | obstetrics/gynecology | obstetrics/gynecology",
    "indication": "dyspareunia | menopause | vaginal atrophy"
  },
  "oteracil": {
    "name": "Oteracil",
    "smiles": "OC(=O)C1=NC(=O)NC(=O)N1",
    "molecular_weight": 157.09,
    "log_p": -1.84,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "oteseconazole": {
    "name": "Oteseconazole",
    "smiles": "O[C@@](CN1C=NN=N1)(C1=CC=C(F)C=C1F)C(F)(F)C1=CC=C(C=N1)C1=CC=C(OCC(F)(F)F)C=C1",
    "molecular_weight": 527.4,
    "log_p": 4.63,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "other antifungal",
    "disease_area": "infectious disease",
    "indication": "vulvovaginal candidiasis"
  },
  "ouabain": {
    "name": "Ouabain",
    "smiles": "[H][C@@]12CC[C@]3(O)C[C@H](C[C@@H](O)[C@]3(CO)[C@@]1([H])[C@H](O)C[C@]1(C)[C@H](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O",
    "molecular_weight": 584.66,
    "log_p": -1.51,
    "hbd": 8,
    "hba": 12,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATPase inhibitor",
    "disease_area": "cardiology | cardiology",
    "indication": "cardiac arrythmia | hypertension"
  },
  "oxacillin": {
    "name": "Oxacillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O",
    "molecular_weight": 401.44,
    "log_p": 1.9,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "staphylococcal infections"
  },
  "oxaliplatin": {
    "name": "Oxaliplatin",
    "smiles": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1",
    "molecular_weight": 397.29,
    "log_p": -0.79,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA inhibitor",
    "disease_area": "oncology",
    "indication": "colorectal cancer"
  },
  "oxamniquine": {
    "name": "Oxamniquine",
    "smiles": "CC(C)NCC1CCC2=CC(CO)=C(C=C2N1)[N+]([O-])=O",
    "molecular_weight": 279.34,
    "log_p": 1.81,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "dna inhibitor",
    "disease_area": "infectious disease",
    "indication": "schistosomiasis"
  },
  "oxandrolone": {
    "name": "Oxandrolone",
    "smiles": "[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)OC[C@]12C",
    "molecular_weight": 306.45,
    "log_p": 3.54,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "oxaprozin": {
    "name": "Oxaprozin",
    "smiles": "OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 293.32,
    "log_p": 4.03,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "rheumatology | rheumatology",
    "indication": "osteoarthritis | rheumatoid arthritis"
  },
  "oxatomide": {
    "name": "Oxatomide",
    "smiles": "O=C1NC2=C(C=CC=C2)N1CCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 426.56,
    "log_p": 4.13,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy",
    "indication": "allergic rhinitis"
  },
  "oxazepam": {
    "name": "Oxazepam",
    "smiles": "OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2",
    "molecular_weight": 286.72,
    "log_p": 2.45,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "oxcarbazepine": {
    "name": "Oxcarbazepine",
    "smiles": "NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2",
    "molecular_weight": 252.27,
    "log_p": 2.64,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "neurology/psychiatry",
    "indication": "seizures"
  },
  "oxeladin": {
    "name": "Oxeladin",
    "smiles": "CCN(CC)CCOCCOC(=O)C(CC)(CC)C1=CC=CC=C1",
    "molecular_weight": 335.49,
    "log_p": 3.65,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "oxetacaine": {
    "name": "Oxetacaine",
    "smiles": "CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)CC1=CC=CC=C1)C(C)(C)CC1=CC=CC=C1",
    "molecular_weight": 467.65,
    "log_p": 3.24,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "oxiconazole": {
    "name": "Oxiconazole",
    "smiles": "ClC1=CC(Cl)=C(CO\\N=C(/CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1",
    "molecular_weight": 429.13,
    "log_p": 6.12,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "tinea corporis | tinea cruris | tinea pedis"
  },
  "oxidronic acid": {
    "name": "Oxidronic acid",
    "smiles": "OC(P(O)(O)=O)P(O)(O)=O",
    "molecular_weight": 192.0,
    "log_p": -1.38,
    "hbd": 5,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "oxilofrine": {
    "name": "Oxilofrine",
    "smiles": "[H][C@@](C)(NC)[C@]([H])(O)C1=CC=C(O)C=C1",
    "molecular_weight": 181.23,
    "log_p": 1.03,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "oxitriptan": {
    "name": "Oxitriptan",
    "smiles": "N[C@@H](CC1=CNC2=C1C=C(O)C=C2)C(O)=O",
    "molecular_weight": 220.23,
    "log_p": 0.83,
    "hbd": 4,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "oxolamine": {
    "name": "Oxolamine",
    "smiles": "CCN(CC)CCC1=NC(=NO1)C1=CC=CC=C1",
    "molecular_weight": 245.33,
    "log_p": 2.62,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antitussive",
    "disease_area": "pulmonary",
    "indication": "cough suppressant"
  },
  "oxprenolol": {
    "name": "Oxprenolol",
    "smiles": "CC(C)NCC(O)COC1=CC=CC=C1OCC=C",
    "molecular_weight": 265.35,
    "log_p": 1.99,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology | cardiology | cardiology",
    "indication": "angina pectoris | cardiac arrythmia | hypertension"
  },
  "oxtriphylline": {
    "name": "Oxtriphylline",
    "smiles": "C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O",
    "molecular_weight": 283.33,
    "log_p": -1.73,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "oxybenzone": {
    "name": "Oxybenzone",
    "smiles": "COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1",
    "molecular_weight": 228.25,
    "log_p": 2.63,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "lipase inhibitor",
    "disease_area": "dermatology",
    "indication": "sunscreen lotion"
  },
  "oxybuprocaine": {
    "name": "Oxybuprocaine",
    "smiles": "CCCCOC1=CC(=CC=C1N)C(=O)OCCN(CC)CC",
    "molecular_weight": 308.42,
    "log_p": 2.95,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "local anesthetic",
    "disease_area": "neurology/psychiatry",
    "indication": "local anesthetic"
  },
  "oxybutynin": {
    "name": "Oxybutynin",
    "smiles": "CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1",
    "molecular_weight": 357.49,
    "log_p": 3.34,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "urology",
    "indication": "urinary incontinence"
  },
  "oxycodone": {
    "name": "Oxycodone",
    "smiles": "COC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5C",
    "molecular_weight": 315.37,
    "log_p": 1.05,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "oxygen": {
    "name": "Oxygen",
    "smiles": "O=O",
    "molecular_weight": 32.0,
    "log_p": 0.07,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "oxymetazoline": {
    "name": "Oxymetazoline",
    "smiles": "CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C",
    "molecular_weight": 260.38,
    "log_p": 2.85,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "otolaryngology",
    "indication": "nasal congestion"
  },
  "oxymetholone": {
    "name": "Oxymetholone",
    "smiles": "[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)\\C(C[C@]12C)=C/O",
    "molecular_weight": 332.48,
    "log_p": 4.4,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "oxymorphone": {
    "name": "Oxymorphone",
    "smiles": "[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O",
    "molecular_weight": 301.34,
    "log_p": 0.75,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "oxyphenbutazone": {
    "name": "Oxyphenbutazone",
    "smiles": "CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1",
    "molecular_weight": 324.38,
    "log_p": 3.49,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "oxyphencyclimine": {
    "name": "Oxyphencyclimine",
    "smiles": "CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1",
    "molecular_weight": 344.46,
    "log_p": 2.73,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cholinergic receptor antagonist",
    "disease_area": "gastroenterology",
    "indication": "peptic ulcer disease (PUD)"
  },
  "oxyphenisatin acetate": {
    "name": "Oxyphenisatin acetate",
    "smiles": "CC(=O)OC1=CC=C(C=C1)C1(C(=O)NC2=CC=CC=C12)C1=CC=C(OC(C)=O)C=C1",
    "molecular_weight": 401.42,
    "log_p": 3.82,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "oxyphenonium": {
    "name": "Oxyphenonium",
    "smiles": "CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1",
    "molecular_weight": 348.51,
    "log_p": 3.48,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cholinergic receptor antagonist",
    "disease_area": "gastroenterology",
    "indication": "peptic ulcer disease (PUD)"
  },
  "oxyquinoline": {
    "name": "Oxyquinoline",
    "smiles": "OC1=CC=CC2=C1N=CC=C2",
    "molecular_weight": 145.16,
    "log_p": 1.94,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "chelating agent",
    "disease_area": "dermatology",
    "indication": "cosmetic"
  },
  "oxytetracycline": {
    "name": "Oxytetracycline",
    "smiles": "[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C",
    "molecular_weight": 460.44,
    "log_p": -1.24,
    "hbd": 7,
    "hba": 10,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | Infectious disease | Infectious disease, infectious disease, urology | urology",
    "indication": "chlamydia | ear infections | first-aid antibiotic | first-aid antibiotic, chlamydia, urinary tract infections, skin infections, ear infections, gonorrhea, urethritis, lyme disease | gonorrhea | Lyme disease | skin infections | urethritis | urinary tract infections"
  },
  "ozanimod": {
    "name": "Ozanimod",
    "smiles": "CC(C)OC1=C(C=C(C=C1)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1)C#N",
    "molecular_weight": 404.47,
    "log_p": 3.63,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "sphingosine 1-phosphate receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "ozenoxacin": {
    "name": "Ozenoxacin",
    "smiles": "CNC1=NC=C(C=C1C)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1C)C(O)=O",
    "molecular_weight": 363.42,
    "log_p": 3.76,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "antiinfective drug",
    "disease_area": "",
    "indication": ""
  },
  "paclitaxel": {
    "name": "Paclitaxel",
    "smiles": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C",
    "molecular_weight": 853.92,
    "log_p": 3.74,
    "hbd": 4,
    "hba": 14,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "tubulin polymerization inhibitor",
    "disease_area": "oncology | oncology | oncology",
    "indication": "breast cancer | non-small cell lung cancer (NSCLC) | ovarian cancer"
  },
  "pacritinib": {
    "name": "Pacritinib",
    "smiles": "C(CN1CCCC1)OC1=CC=C2NC3=NC=CC(=N3)C3=CC(COC\\C=C\\COCC1=C2)=CC=C3",
    "molecular_weight": 472.59,
    "log_p": 4.96,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "FLT3 inhibitor | JAK inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "padeliporfin": {
    "name": "Padeliporfin",
    "smiles": "[Pd++].[H][C@]1(C)\\C2=C\\C3=C(C(C)=O)C(C)=C([N-]3)\\C=C3/N=C(/C(/CC(=O)OC)=C4\\[N-]\\C(=C/C(=N2)[C@]1([H])CC)C(C)=C4C(=O)NCCS(O)(=O)=O)[C@@]([H])(CCC(O)=O)[C@]3([H])C",
    "molecular_weight": 840.26,
    "log_p": 4.77,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA"
  },
  "padimate o": {
    "name": "Padimate O",
    "smiles": "CCCCC(CC)COC(=O)C1=CC=C(C=C1)N(C)C",
    "molecular_weight": 277.41,
    "log_p": 4.13,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "dermatology",
    "indication": "sunscreen lotion"
  },
  "pafolacianine": {
    "name": "Pafolacianine",
    "smiles": "CC1(C)\\C(=C/C=C2\\CCCC(\\C=C\\C3=[N+](CCCCS(O)(=O)=O)C4=C(C=C(C=C4)S([O-])(=O)=O)C3(C)C)=C2OC2=CC=C(C[C@H](NC(=O)C3=CC=C(NCC4=CN=C5N=C(N)NC(=O)C5=N4)C=C3)C(O)=O)C=C2)N(CCCCS(O)(=O)=O)C2=C1C=C(C=C2)S(O)(=O)=O",
    "molecular_weight": 1326.52,
    "log_p": 6.88,
    "hbd": 8,
    "hba": 19,
    "rotatable_bonds": 25,
    "approved": true,
    "source": "FDA"
  },
  "palbociclib": {
    "name": "Palbociclib",
    "smiles": "CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O",
    "molecular_weight": 447.54,
    "log_p": 2.97,
    "hbd": 2,
    "hba": 9,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "CDK inhibitor",
    "disease_area": "oncology",
    "indication": "breast cancer"
  },
  "paliperidone": {
    "name": "Paliperidone",
    "smiles": "CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1",
    "molecular_weight": 426.49,
    "log_p": 3.08,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist | serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "schizophrenia"
  },
  "palmitic acid": {
    "name": "Palmitic Acid",
    "smiles": "CCCCCCCCCCCCCCCC(O)=O",
    "molecular_weight": 256.43,
    "log_p": 5.55,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 14,
    "approved": true,
    "source": "FDA"
  },
  "palonosetron": {
    "name": "Palonosetron",
    "smiles": "[H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2",
    "molecular_weight": 296.41,
    "log_p": 2.66,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor antagonist",
    "disease_area": "gastroenterology | gastroenterology",
    "indication": "nausea | vomiting"
  },
  "palovarotene": {
    "name": "Palovarotene",
    "smiles": "CC1(C)CCC(C)(C)C2=C1C=C(CN1C=CC=N1)C(\\C=C\\C1=CC=C(C=C1)C(O)=O)=C2",
    "molecular_weight": 414.55,
    "log_p": 6.15,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "retinoid receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "pamidronic acid": {
    "name": "Pamidronic acid",
    "smiles": "NCCC(O)(P(O)(O)=O)P(O)(O)=O",
    "molecular_weight": 235.07,
    "log_p": -1.66,
    "hbd": 6,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "pancuronium": {
    "name": "Pancuronium",
    "smiles": "[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1",
    "molecular_weight": 572.88,
    "log_p": 6.11,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "critical care | neurology/psychiatry",
    "indication": "endotracheal intubation | muscle relaxant"
  },
  "panobinostat": {
    "name": "Panobinostat",
    "smiles": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1",
    "molecular_weight": 349.43,
    "log_p": 3.33,
    "hbd": 4,
    "hba": 3,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HDAC inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "multiple myeloma"
  },
  "pantethine": {
    "name": "Pantethine",
    "smiles": "CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO",
    "molecular_weight": 554.73,
    "log_p": -1.63,
    "hbd": 8,
    "hba": 10,
    "rotatable_bonds": 19,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "coenzyme A precursor",
    "disease_area": "",
    "indication": ""
  },
  "panthenol": {
    "name": "Panthenol",
    "smiles": "CC(C)(CO)C(O)C(=O)NCCCO",
    "molecular_weight": 205.25,
    "log_p": -1.14,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "pantoprazole": {
    "name": "Pantoprazole",
    "smiles": "COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1",
    "molecular_weight": 383.38,
    "log_p": 2.88,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATPase inhibitor",
    "disease_area": "gastroenterology | gastroenterology | gastroenterology | gastroenterology",
    "indication": "erosive esophagitis (EE) | gastroesophageal reflux disease (GERD) | gastroesophageal reflux disease (gerd), erosive esophagitis (ee), zollinger-ellison syndrome | Zollinger-Ellison syndrome"
  },
  "pantothenic acid": {
    "name": "Pantothenic acid",
    "smiles": "CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O",
    "molecular_weight": 219.24,
    "log_p": -1.04,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "papaverine": {
    "name": "Papaverine",
    "smiles": "COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1",
    "molecular_weight": 339.39,
    "log_p": 3.86,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "cardiology | cardiology | cardiology | gastroenterology | hematology",
    "indication": "angina pectoris | colitis | myocardial infarction | pulmonary embolism (PE) | vascular spasm"
  },
  "parachlorophenol": {
    "name": "Parachlorophenol",
    "smiles": "OC1=CC=C(Cl)C=C1",
    "molecular_weight": 128.56,
    "log_p": 2.05,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antiinfective drug",
    "disease_area": "infectious disease",
    "indication": "first-aid antiseptic"
  },
  "paraldehyde": {
    "name": "Paraldehyde",
    "smiles": "CC1OC(C)OC(C)O1",
    "molecular_weight": 132.16,
    "log_p": 1.09,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "paramethadione": {
    "name": "Paramethadione",
    "smiles": "CCC1(C)OC(=O)N(C)C1=O",
    "molecular_weight": 157.17,
    "log_p": 0.76,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "anticonvulsant",
    "disease_area": "neurology/psychiatry",
    "indication": "seizures"
  },
  "paramethasone acetate": {
    "name": "Paramethasone acetate",
    "smiles": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C",
    "molecular_weight": 434.5,
    "log_p": 2.32,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "parecoxib": {
    "name": "Parecoxib",
    "smiles": "CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C1=C(C)ON=C1C1=CC=CC=C1",
    "molecular_weight": 370.43,
    "log_p": 3.53,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "pain relief"
  },
  "pargyline": {
    "name": "Pargyline",
    "smiles": "CN(CC#C)CC1=CC=CC=C1",
    "molecular_weight": 159.23,
    "log_p": 1.75,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "monoamine oxidase inhibitor",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "paricalcitol": {
    "name": "Paricalcitol",
    "smiles": "[H][C@@]1(CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)\\C=C\\[C@H](C)C(C)(C)O",
    "molecular_weight": 416.65,
    "log_p": 5.56,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin D receptor agonist",
    "disease_area": "endocrinology | nephrology",
    "indication": "chronic kidney disease (CKD) | hyperthyroidism"
  },
  "paritaprevir": {
    "name": "Paritaprevir",
    "smiles": "[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1",
    "molecular_weight": 765.89,
    "log_p": 3.64,
    "hbd": 3,
    "hba": 10,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HCV inhibitor",
    "disease_area": "infectious disease",
    "indication": "hepatitis C"
  },
  "paromomycin": {
    "name": "Paromomycin",
    "smiles": "NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O",
    "molecular_weight": 615.63,
    "log_p": -8.86,
    "hbd": 13,
    "hba": 19,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor",
    "disease_area": "infectious disease",
    "indication": "amebiasis"
  },
  "paroxetine": {
    "name": "Paroxetine",
    "smiles": "FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1",
    "molecular_weight": 329.37,
    "log_p": 3.33,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "selective serotonin reuptake inhibitor (SSRI)",
    "disease_area": "neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry",
    "indication": "depression | generalized anxiety disorder (GAD) | obsessive compulsive disorder (OCD) | panic disorders | posttraumatic stress disorder | social anxiety disorder"
  },
  "parthenolide": {
    "name": "Parthenolide",
    "smiles": "C\\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1",
    "molecular_weight": 248.32,
    "log_p": 2.76,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 1",
    "moa": "NFkB pathway inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "pasireotide": {
    "name": "Pasireotide",
    "smiles": "NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1",
    "molecular_weight": 1047.23,
    "log_p": 3.37,
    "hbd": 9,
    "hba": 11,
    "rotatable_bonds": 17,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "somatostatin receptor agonist",
    "disease_area": "endocrinology | endocrinology",
    "indication": "acromegaly | Cushing's syndrome"
  },
  "patent blue": {
    "name": "Patent Blue",
    "smiles": "CCN(CC)C1=CC=C(C=C1)C(=C1C=CC(C=C1)=[N+](CC)CC)C1=C(C=C(C(O)=C1)S(O)(=O)=O)S(O)(=O)=O",
    "molecular_weight": 561.7,
    "log_p": 4.15,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "pazopanib": {
    "name": "Pazopanib",
    "smiles": "CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1",
    "molecular_weight": 437.53,
    "log_p": 3.14,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "KIT inhibitor | PDGFR tyrosine kinase receptor inhibitor | VEGFR inhibitor",
    "disease_area": "oncology | oncology",
    "indication": "renal cell carcinoma (RCC) | soft tissue sarcoma (STS)"
  },
  "pbt-434": {
    "name": "PBT-434",
    "smiles": "CCNCC1=NC2=C(C(Cl)=CC(Cl)=C2O)C(=O)N1C",
    "molecular_weight": 302.16,
    "log_p": 2.06,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "pefloxacin": {
    "name": "Pefloxacin",
    "smiles": "CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCN(C)CC1",
    "molecular_weight": 333.36,
    "log_p": 1.61,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial DNA gyrase inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | urology",
    "indication": "gastrointestinal infections | gonorrhea | urethritis | urinary tract infections"
  },
  "pemetrexed": {
    "name": "Pemetrexed",
    "smiles": "NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1",
    "molecular_weight": 427.42,
    "log_p": 0.67,
    "hbd": 6,
    "hba": 6,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dihydrofolate reductase inhibitor | thymidylate synthase inhibitor",
    "disease_area": "oncology | oncology",
    "indication": "mesothelioma | non-small cell lung cancer (NSCLC)"
  },
  "pemigatinib": {
    "name": "Pemigatinib",
    "smiles": "CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C1=C(F)C(OC)=CC(OC)=C1F",
    "molecular_weight": 487.51,
    "log_p": 3.66,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "fgfr inhibitor",
    "disease_area": "oncology",
    "indication": "colorectal cancer"
  },
  "pemirolast": {
    "name": "Pemirolast",
    "smiles": "CC1=CC=CN2C(=O)C(=CN=C12)C1=NNN=N1",
    "molecular_weight": 228.22,
    "log_p": 0.18,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "mediator release inhibitor",
    "disease_area": "pulmonary",
    "indication": "asthma"
  },
  "pemoline": {
    "name": "Pemoline",
    "smiles": "NC1=NC(=O)C(O1)C1=CC=CC=C1",
    "molecular_weight": 176.17,
    "log_p": 0.6,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "penbutolol": {
    "name": "Penbutolol",
    "smiles": "CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1",
    "molecular_weight": 291.44,
    "log_p": 3.47,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "penciclovir": {
    "name": "Penciclovir",
    "smiles": "NC1=NC(=O)C2=C(N1)N(CCC(CO)CO)C=N2",
    "molecular_weight": 253.26,
    "log_p": -1.31,
    "hbd": 4,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA directed DNA polymerase inhibitor",
    "disease_area": "dental",
    "indication": "cold sore"
  },
  "penicillamine": {
    "name": "Penicillamine",
    "smiles": "[H][C@](N)(C(O)=O)C(C)(C)S",
    "molecular_weight": 149.22,
    "log_p": 0.11,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "pentaerythritol tetranitrate": {
    "name": "Pentaerythritol tetranitrate",
    "smiles": "[O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O",
    "molecular_weight": 316.13,
    "log_p": -1.19,
    "hbd": 0,
    "hba": 12,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "pentafluoropropane": {
    "name": "Pentafluoropropane",
    "smiles": "FC(F)CC(F)(F)F",
    "molecular_weight": 134.05,
    "log_p": 2.2,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "pentagastrin": {
    "name": "Pentagastrin",
    "smiles": "CSCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O",
    "molecular_weight": 767.91,
    "log_p": 1.52,
    "hbd": 8,
    "hba": 9,
    "rotatable_bonds": 20,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "CCK receptor agonist",
    "disease_area": "gastroenterology | gastroenterology",
    "indication": "anacidity diagnostic | gastric hypersecretion diagnostic"
  },
  "pentamidine": {
    "name": "Pentamidine",
    "smiles": "NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1",
    "molecular_weight": 340.43,
    "log_p": 2.88,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "anti-pneumocystis agent",
    "disease_area": "infectious disease",
    "indication": "pneumonia"
  },
  "pentazocine": {
    "name": "Pentazocine",
    "smiles": "CC1C2CC3=C(C=C(O)C=C3)C1(C)CCN2CC=C(C)C",
    "molecular_weight": 285.43,
    "log_p": 3.88,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "pentetic acid": {
    "name": "Pentetic acid",
    "smiles": "OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O",
    "molecular_weight": 393.35,
    "log_p": -2.68,
    "hbd": 5,
    "hba": 8,
    "rotatable_bonds": 16,
    "approved": true,
    "source": "FDA"
  },
  "pentetreotide": {
    "name": "Pentetreotide",
    "smiles": "C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN(CCN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)CC(O)=O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](CC2=CNC3=CC=CC=C23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1",
    "molecular_weight": 1394.6,
    "log_p": -3.4,
    "hbd": 17,
    "hba": 21,
    "rotatable_bonds": 34,
    "approved": true,
    "source": "FDA"
  },
  "pentobarbital": {
    "name": "Pentobarbital",
    "smiles": "CCCC(C)C1(CC)C(=O)NC(=O)NC1=O",
    "molecular_weight": 226.28,
    "log_p": 1.18,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "pentolinium": {
    "name": "Pentolinium",
    "smiles": "C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1",
    "molecular_weight": 240.43,
    "log_p": 2.64,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cholinergic receptor antagonist",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "pentosan polysulfate": {
    "name": "Pentosan polysulfate",
    "smiles": "O[C@@H]1CO[C@@H](O[C@@H]2CO[C@@H](O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O",
    "molecular_weight": 602.5,
    "log_p": -4.81,
    "hbd": 6,
    "hba": 17,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "pentostatin": {
    "name": "Pentostatin",
    "smiles": "OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1N=CNC[C@H]2O",
    "molecular_weight": 268.27,
    "log_p": -1.18,
    "hbd": 4,
    "hba": 8,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adenosine deaminase inhibitor | adenosine deaminase inhibitor, ribonucleotide reductase inhibitor | ribonucleotide reductase inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "hairy cell leukemia"
  },
  "pentoxifylline": {
    "name": "Pentoxifylline",
    "smiles": "CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C",
    "molecular_weight": 278.31,
    "log_p": 0.19,
    "hbd": 0,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "cardiology",
    "indication": "claudication"
  },
  "pentoxyverine": {
    "name": "Pentoxyverine",
    "smiles": "CCN(CC)CCOCCOC(=O)C1(CCCC1)C1=CC=CC=C1",
    "molecular_weight": 333.47,
    "log_p": 3.4,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "peramivir": {
    "name": "Peramivir",
    "smiles": "[H][C@@]1([C@@H](NC(C)=O)C(CC)CC)[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O",
    "molecular_weight": 328.41,
    "log_p": -0.14,
    "hbd": 6,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "neuraminidase inhibitor",
    "disease_area": "infectious disease",
    "indication": "influenza A virus infection"
  },
  "perampanel": {
    "name": "Perampanel",
    "smiles": "O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 349.39,
    "log_p": 4.44,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "perazine": {
    "name": "Perazine",
    "smiles": "CN1CCN(CCCN2C3=CC=CC=C3SC3=CC=CC=C23)CC1",
    "molecular_weight": 339.51,
    "log_p": 3.93,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "perboric acid": {
    "name": "Perboric acid",
    "smiles": "OOB=O",
    "molecular_weight": 59.82,
    "log_p": -0.56,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "perflexane": {
    "name": "Perflexane",
    "smiles": "FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F",
    "molecular_weight": 338.04,
    "log_p": 4.65,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "perflubutane": {
    "name": "Perflubutane",
    "smiles": "FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F",
    "molecular_weight": 238.02,
    "log_p": 3.38,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "perflutren": {
    "name": "Perflutren",
    "smiles": "FC(F)(F)C(F)(F)C(F)(F)F",
    "molecular_weight": 188.02,
    "log_p": 2.75,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "pergolide": {
    "name": "Pergolide",
    "smiles": "[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC",
    "molecular_weight": 314.5,
    "log_p": 4.27,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "dopamine receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "perhexiline": {
    "name": "Perhexiline",
    "smiles": "C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1",
    "molecular_weight": 277.5,
    "log_p": 5.3,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "carnitine palmitoyltransferase inhibitor",
    "disease_area": "cardiology",
    "indication": "angina pectoris"
  },
  "periciazine": {
    "name": "Periciazine",
    "smiles": "OC1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C#N)CC1",
    "molecular_weight": 365.5,
    "log_p": 4.01,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "psychosis"
  },
  "perindopril": {
    "name": "Perindopril",
    "smiles": "[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O",
    "molecular_weight": 368.47,
    "log_p": 1.94,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin converting enzyme inhibitor",
    "disease_area": "cardiology | cardiology | cardiology",
    "indication": "coronary artery disease (CAD) | hypertension | myocardial infarction"
  },
  "permethrin": {
    "name": "Permethrin",
    "smiles": "CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC(OC2=CC=CC=C2)=CC=C1",
    "molecular_weight": 391.29,
    "log_p": 6.11,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "infectious disease",
    "indication": "lice"
  },
  "perphenazine": {
    "name": "Perphenazine",
    "smiles": "OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1",
    "molecular_weight": 403.98,
    "log_p": 3.94,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "gastroenterology | gastroenterology | neurology/psychiatry",
    "indication": "nausea | schizophrenia | vomiting"
  },
  "pexidartinib": {
    "name": "Pexidartinib",
    "smiles": "FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1",
    "molecular_weight": 417.82,
    "log_p": 5.23,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "tyrosine kinase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "phenacemide": {
    "name": "Phenacemide",
    "smiles": "NC(=O)NC(=O)CC1=CC=CC=C1",
    "molecular_weight": 178.19,
    "log_p": 0.42,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "epilepsy | seizures"
  },
  "phenazopyridine": {
    "name": "Phenazopyridine",
    "smiles": "NC1=NC(N)=C(C=C1)\\N=N\\C1=CC=CC=C1",
    "molecular_weight": 213.24,
    "log_p": 2.66,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "local anesthetic",
    "disease_area": "infectious disease",
    "indication": "urinary tract infections"
  },
  "phendimetrazine": {
    "name": "Phendimetrazine",
    "smiles": "C[C@H]1[C@@H](OCCN1C)C1=CC=CC=C1",
    "molecular_weight": 191.27,
    "log_p": 2.08,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "phenelzine": {
    "name": "Phenelzine",
    "smiles": "NNCCC1=CC=CC=C1",
    "molecular_weight": 136.2,
    "log_p": 0.69,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "monoamine oxidase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "pheneticillin": {
    "name": "Pheneticillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C)OC1=CC=CC=C1)C(O)=O",
    "molecular_weight": 364.42,
    "log_p": 1.09,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "phenformin": {
    "name": "Phenformin",
    "smiles": "NC(=N)NC(=N)NCCC1=CC=CC=C1",
    "molecular_weight": 205.27,
    "log_p": 0.24,
    "hbd": 5,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "AMPK activator",
    "disease_area": "",
    "indication": ""
  },
  "phenindamine": {
    "name": "Phenindamine",
    "smiles": "CN1CCC2=C(C1)C(C1=CC=CC=C21)C1=CC=CC=C1",
    "molecular_weight": 261.37,
    "log_p": 3.92,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy | otolaryngology",
    "indication": "allergic rhinitis | common cold"
  },
  "phenindione": {
    "name": "Phenindione",
    "smiles": "O=C1C(C(=O)C2=CC=CC=C12)C1=CC=CC=C1",
    "molecular_weight": 222.24,
    "log_p": 2.85,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin K antagonist",
    "disease_area": "hematology",
    "indication": "deep vein thrombosis (DVT)"
  },
  "pheniramine": {
    "name": "Pheniramine",
    "smiles": "CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=N1",
    "molecular_weight": 240.35,
    "log_p": 3.17,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy | allergy",
    "indication": "allergic rhinitis | urticaria"
  },
  "phenmetrazine": {
    "name": "Phenmetrazine",
    "smiles": "CC1NCCOC1C1=CC=CC=C1",
    "molecular_weight": 177.25,
    "log_p": 1.74,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "phenobarbital": {
    "name": "Phenobarbital",
    "smiles": "CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1",
    "molecular_weight": 232.24,
    "log_p": 0.7,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "phenol": {
    "name": "Phenol",
    "smiles": "OC1=CC=CC=C1",
    "molecular_weight": 94.11,
    "log_p": 1.39,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Preclinical",
    "moa": "",
    "disease_area": "otolaryngology",
    "indication": "pharyngitis"
  },
  "phenolphthalein": {
    "name": "Phenolphthalein",
    "smiles": "OC1=CC=C(C=C1)C1(OC(=O)C2=CC=CC=C12)C1=CC=C(O)C=C1",
    "molecular_weight": 318.33,
    "log_p": 3.56,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "indicator dye",
    "disease_area": "",
    "indication": ""
  },
  "phenoxybenzamine": {
    "name": "Phenoxybenzamine",
    "smiles": "CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1",
    "molecular_weight": 303.83,
    "log_p": 4.19,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology | endocrinology",
    "indication": "hypertension | pheochromocytoma"
  },
  "phenoxymethylpenicillin": {
    "name": "Phenoxymethylpenicillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O",
    "molecular_weight": 350.4,
    "log_p": 0.7,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "phenprocoumon": {
    "name": "Phenprocoumon",
    "smiles": "CCC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2",
    "molecular_weight": 280.32,
    "log_p": 4.04,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin K antagonist",
    "disease_area": "hematology | hematology",
    "indication": "pulmonary embolism (PE) | thrombosis"
  },
  "phensuximide": {
    "name": "Phensuximide",
    "smiles": "CN1C(=O)CC(C1=O)C1=CC=CC=C1",
    "molecular_weight": 189.21,
    "log_p": 1.16,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "succinimide antiepileptic",
    "disease_area": "neurology/psychiatry",
    "indication": "seizures"
  },
  "phentermine": {
    "name": "Phentermine",
    "smiles": "CC(C)(N)CC1=CC=CC=C1",
    "molecular_weight": 149.24,
    "log_p": 1.97,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "phentolamine": {
    "name": "Phentolamine",
    "smiles": "CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1",
    "molecular_weight": 281.36,
    "log_p": 2.84,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology | endocrinology",
    "indication": "hypertension | pheochromocytoma"
  },
  "phenyl aminosalicylate": {
    "name": "Phenyl aminosalicylate",
    "smiles": "NC1=CC(O)=C(C=C1)C(=O)OC1=CC=CC=C1",
    "molecular_weight": 229.23,
    "log_p": 2.19,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "phenyl salicylate": {
    "name": "Phenyl salicylate",
    "smiles": "OC1=CC=CC=C1C(=O)OC1=CC=CC=C1",
    "molecular_weight": 214.22,
    "log_p": 2.61,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "phenylacetic acid": {
    "name": "Phenylacetic acid",
    "smiles": "OC(=O)CC1=CC=CC=C1",
    "molecular_weight": 136.15,
    "log_p": 1.31,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "phenylalanine": {
    "name": "Phenylalanine",
    "smiles": "N[C@@H](CC1=CC=CC=C1)C(O)=O",
    "molecular_weight": 165.19,
    "log_p": 0.64,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "phenylbutazone": {
    "name": "Phenylbutazone",
    "smiles": "CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 308.38,
    "log_p": 3.79,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "cyclooxygenase inhibitor | prostanoid receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "phenylbutyric acid": {
    "name": "Phenylbutyric acid",
    "smiles": "OC(=O)CCCC1=CC=CC=C1",
    "molecular_weight": 164.2,
    "log_p": 2.09,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "phenylephrine": {
    "name": "Phenylephrine",
    "smiles": "CNC[C@H](O)C1=CC(O)=CC=C1",
    "molecular_weight": 167.21,
    "log_p": 0.65,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "cardiology | gastroenterology | otolaryngology",
    "indication": "hemorrhoids | hypotension | nasal congestion"
  },
  "phenylethyl resorcinol": {
    "name": "Phenylethyl resorcinol",
    "smiles": "CC(C1=CC=CC=C1)C1=CC=C(O)C=C1O",
    "molecular_weight": 214.26,
    "log_p": 3.25,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "phenylpropanolamine": {
    "name": "Phenylpropanolamine",
    "smiles": "CC(N)C(O)C1=CC=CC=C1",
    "molecular_weight": 151.21,
    "log_p": 1.07,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "phenyltoloxamine": {
    "name": "Phenyltoloxamine",
    "smiles": "CN(C)CCOC1=CC=CC=C1CC1=CC=CC=C1",
    "molecular_weight": 255.36,
    "log_p": 3.22,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "phenytoin": {
    "name": "Phenytoin",
    "smiles": "O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 252.27,
    "log_p": 1.77,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "hydantoin antiepileptic",
    "disease_area": "neurology/psychiatry",
    "indication": "seizures"
  },
  "phloxine b": {
    "name": "Phloxine B",
    "smiles": "[Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C1C=C(Br)C([O-])=C2Br",
    "molecular_weight": 829.64,
    "log_p": 1.67,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "pholcodine": {
    "name": "Pholcodine",
    "smiles": "[H][C@@]12OC3=C(OCCN4CCOCC4)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O",
    "molecular_weight": 398.5,
    "log_p": 1.2,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "phosphoric acid": {
    "name": "Phosphoric acid",
    "smiles": "OP(O)(O)=O",
    "molecular_weight": 97.99,
    "log_p": -0.93,
    "hbd": 3,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "phosphorus": {
    "name": "Phosphorus",
    "smiles": "[P]",
    "molecular_weight": 30.97,
    "log_p": 0.86,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "phthalylsulfathiazole": {
    "name": "Phthalylsulfathiazole",
    "smiles": "OC(=O)C1=CC=CC=C1C(=O)NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1",
    "molecular_weight": 403.44,
    "log_p": 2.89,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dihydropteroate synthetase inhibitor",
    "disease_area": "gastroenterology | infectious disease",
    "indication": "colitis | dysentry"
  },
  "phylloquinone": {
    "name": "Phylloquinone",
    "smiles": "CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\\C(C)=C\\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O",
    "molecular_weight": 450.71,
    "log_p": 9.16,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 14,
    "approved": true,
    "source": "FDA"
  },
  "physostigmine": {
    "name": "Physostigmine",
    "smiles": "[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC)=C1)N2C",
    "molecular_weight": 275.35,
    "log_p": 1.77,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholinesterase inhibitor | cholinesterase inhibitor",
    "disease_area": "cardiology | gastroenterology | neurology/psychiatry | ophthalmology",
    "indication": "Alzheimer's disease | gastroparesis | glaucoma | hypotension"
  },
  "pibrentasvir": {
    "name": "Pibrentasvir",
    "smiles": "CO[C@H](C)[C@H](NC(=O)OC)C(=O)N1CCC[C@H]1C1=NC2=C(N1)C=C(F)C(=C2)[C@H]1CC[C@@H](N1C1=CC(F)=C(N2CCC(CC2)C2=CC=C(F)C=C2)C(F)=C1)C1=CC2=C(NC(=N2)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)C=C1F",
    "molecular_weight": 1113.2,
    "log_p": 9.45,
    "hbd": 4,
    "hba": 12,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antiviral",
    "disease_area": "infectious disease",
    "indication": "hepatitis c"
  },
  "picosulfuric acid": {
    "name": "Picosulfuric acid",
    "smiles": "OS(=O)(=O)OC1=CC=C(C=C1)C(C1=CC=C(OS(O)(=O)=O)C=C1)C1=CC=CC=N1",
    "molecular_weight": 437.45,
    "log_p": 2.63,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "pidolic acid": {
    "name": "Pidolic acid",
    "smiles": "OC(=O)[C@@H]1CCC(=O)N1",
    "molecular_weight": 129.12,
    "log_p": -0.65,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "piflufolastat f 18": {
    "name": "Piflufolastat F 18",
    "smiles": "OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)C1=CC=C([18F])N=C1)C(O)=O)C(O)=O",
    "molecular_weight": 441.4,
    "log_p": 0.19,
    "hbd": 6,
    "hba": 6,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA"
  },
  "pilocarpine": {
    "name": "Pilocarpine",
    "smiles": "CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O",
    "molecular_weight": 208.26,
    "log_p": 1.16,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor agonist",
    "disease_area": "cardiology | ophthalmology",
    "indication": "glaucoma | hypertension"
  },
  "pimavanserin": {
    "name": "Pimavanserin",
    "smiles": "CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C2CCN(C)CC2)C=C1",
    "molecular_weight": 427.56,
    "log_p": 4.67,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor inverse agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "Parkinson's Disease"
  },
  "pimecrolimus": {
    "name": "Pimecrolimus",
    "smiles": "[H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\\C(C)=C\\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OC",
    "molecular_weight": 810.47,
    "log_p": 5.72,
    "hbd": 2,
    "hba": 11,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcineurin inhibitor",
    "disease_area": "dermatology",
    "indication": "eczema"
  },
  "pimethixene": {
    "name": "Pimethixene",
    "smiles": "CN1CCC(CC1)=C1C2=CC=CC=C2SC2=CC=CC=C12",
    "molecular_weight": 293.44,
    "log_p": 4.68,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antihistamine",
    "disease_area": "allergy | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry",
    "indication": "allergic rhinitis | anxiety | attention-deficit/hyperactivity disorder (ADHD) | sleep cycle support"
  },
  "pimozide": {
    "name": "Pimozide",
    "smiles": "FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1",
    "molecular_weight": 461.56,
    "log_p": 5.86,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "Tourette's disorder"
  },
  "pinacidil": {
    "name": "Pinacidil",
    "smiles": "CC(N\\C(NC#N)=N\\C1=CC=NC=C1)C(C)(C)C",
    "molecular_weight": 245.33,
    "log_p": 2.16,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATP channel activator | potassium channel activator",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "pinaverium": {
    "name": "Pinaverium",
    "smiles": "COC1=C(OC)C=C(C[N+]2(CCOCCC3CCC4CC3C4(C)C)CCOCC2)C(Br)=C1",
    "molecular_weight": 511.52,
    "log_p": 5.29,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "T-type calcium channel blocker",
    "disease_area": "gastroenterology",
    "indication": "irritable bowel syndrome"
  },
  "pindolol": {
    "name": "Pindolol",
    "smiles": "CC(C)NCC(O)COC1=CC=CC2=C1C=CN2",
    "molecular_weight": 248.33,
    "log_p": 1.91,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "pioglitazone": {
    "name": "Pioglitazone",
    "smiles": "CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1",
    "molecular_weight": 356.45,
    "log_p": 3.16,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "insulin sensitizer | PPAR receptor agonist",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "pipecuronium": {
    "name": "Pipecuronium",
    "smiles": "[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1",
    "molecular_weight": 602.9,
    "log_p": 3.63,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "neuromuscular blocker",
    "disease_area": "neurology/psychiatry",
    "indication": "anesthetic"
  },
  "piperacillin": {
    "name": "Piperacillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O",
    "molecular_weight": 517.56,
    "log_p": -0.24,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "intra-abdominal infections | pelvic inflammatory disease | pneumonia | skin infections"
  },
  "piperaquine": {
    "name": "Piperaquine",
    "smiles": "ClC1=CC2=C(C=C1)C(=CC=N2)N1CCN(CCCN2CCN(CC2)C2=CC=NC3=C2C=CC(Cl)=C3)CC1",
    "molecular_weight": 535.52,
    "log_p": 5.42,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "piperazine": {
    "name": "Piperazine",
    "smiles": "C1CNCCN1",
    "molecular_weight": 86.14,
    "log_p": -0.82,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "benzodiazepine receptor agonist",
    "disease_area": "infectious disease",
    "indication": "gastrointestinal roundworms"
  },
  "piperonyl butoxide": {
    "name": "Piperonyl butoxide",
    "smiles": "CCCCOCCOCCOCC1=CC2=C(OCO2)C=C1CCC",
    "molecular_weight": 338.44,
    "log_p": 3.72,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA"
  },
  "pipobroman": {
    "name": "Pipobroman",
    "smiles": "BrCCC(=O)N1CCN(CC1)C(=O)CCBr",
    "molecular_weight": 356.06,
    "log_p": 1.23,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA alkylating agent",
    "disease_area": "hematology | hematology",
    "indication": "polycythemia vera | thrombocythemia"
  },
  "pipotiazine": {
    "name": "Pipotiazine",
    "smiles": "CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCC(CCO)CC2)C=C1",
    "molecular_weight": 475.68,
    "log_p": 4.02,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "schizophrenia"
  },
  "pipradrol": {
    "name": "Pipradrol",
    "smiles": "[H]N1CCCCC1C(O)(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 267.37,
    "log_p": 3.06,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "piracetam": {
    "name": "Piracetam",
    "smiles": "NC(=O)CN1CCCC1=O",
    "molecular_weight": 142.16,
    "log_p": -0.91,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "senile dementia"
  },
  "pirbuterol": {
    "name": "Pirbuterol",
    "smiles": "CC(C)(C)NCC(O)C1=NC(CO)=C(O)C=C1",
    "molecular_weight": 240.3,
    "log_p": 0.7,
    "hbd": 4,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "adrenergic receptor agonist",
    "disease_area": "pulmonary",
    "indication": "bronchospasm"
  },
  "pirenzepine": {
    "name": "Pirenzepine",
    "smiles": "CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1",
    "molecular_weight": 351.41,
    "log_p": 1.56,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "gastroenterology",
    "indication": "peptic ulcer disease (PUD)"
  },
  "piretanide": {
    "name": "Piretanide",
    "smiles": "NS(=O)(=O)C1=CC(=CC(N2CCCC2)=C1OC1=CC=CC=C1)C(O)=O",
    "molecular_weight": 362.41,
    "log_p": 2.42,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "cardiology | cardiology",
    "indication": "edema | hypertension"
  },
  "pirfenidone": {
    "name": "Pirfenidone",
    "smiles": "CC1=CN(C(=O)C=C1)C1=CC=CC=C1",
    "molecular_weight": 185.23,
    "log_p": 2.15,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "TGF beta receptor inhibitor",
    "disease_area": "pulmonary",
    "indication": "idiopathic pulmonary fibrosis (IPF)"
  },
  "piritramide": {
    "name": "Piritramide",
    "smiles": "NC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)N1CCCCC1",
    "molecular_weight": 430.6,
    "log_p": 3.69,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "piroxicam": {
    "name": "Piroxicam",
    "smiles": "CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O",
    "molecular_weight": 331.35,
    "log_p": 1.58,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "rheumatology | rheumatology | rheumatology",
    "indication": "osteoarthritis | osteoarthritis, rheumatoid arthritis | rheumatoid arthritis"
  },
  "pitavastatin": {
    "name": "Pitavastatin",
    "smiles": "O[C@H](C[C@H](O)\\C=C\\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC(O)=O",
    "molecular_weight": 421.47,
    "log_p": 4.52,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HMGCR inhibitor",
    "disease_area": "endocrinology",
    "indication": "hyperlipidemia"
  },
  "pitolisant": {
    "name": "Pitolisant",
    "smiles": "ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1",
    "molecular_weight": 295.85,
    "log_p": 4.17,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "pivampicillin": {
    "name": "Pivampicillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(=O)OCOC(=O)C(C)(C)C",
    "molecular_weight": 463.56,
    "log_p": 1.32,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease | pulmonary",
    "indication": "bronchitis | gynecologic infections | pneumonia"
  },
  "pivmecillinam": {
    "name": "Pivmecillinam",
    "smiles": "[H]C(=N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)C(C)(C)C)C(C)(C)S[C@]12[H])N1CCCCCC1",
    "molecular_weight": 439.58,
    "log_p": 2.41,
    "hbd": 0,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "gram-negative bacterial infections | urinary tract infections"
  },
  "pixantrone": {
    "name": "Pixantrone",
    "smiles": "NCCNC1=CC=C(NCCN)C2=C1C(=O)C1=C(C=NC=C1)C2=O",
    "molecular_weight": 325.37,
    "log_p": 0.6,
    "hbd": 4,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "topoisomerase inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "non-Hodgkin lymphoma (NHL)"
  },
  "pizotifen": {
    "name": "Pizotifen",
    "smiles": "CN1CCC(CC1)=C1C2=C(CCC3=CC=CC=C13)SC=C2",
    "molecular_weight": 295.45,
    "log_p": 4.37,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "migraine headache"
  },
  "plazomicin": {
    "name": "Plazomicin",
    "smiles": "CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H]2O)NC(=O)[C@@H](O)CCN)OC[C@]1(C)O",
    "molecular_weight": 592.69,
    "log_p": -5.36,
    "hbd": 11,
    "hba": 15,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA"
  },
  "plecanatide": {
    "name": "Plecanatide",
    "smiles": "[H][C@@]12CSSC[C@H](NC(=O)CNC(=O)[C@@]([H])(NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC2=O)C(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O",
    "molecular_weight": 1681.91,
    "log_p": -8.15,
    "hbd": 23,
    "hba": 27,
    "rotatable_bonds": 28,
    "approved": true,
    "source": "FDA"
  },
  "plerixafor": {
    "name": "Plerixafor",
    "smiles": "C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1",
    "molecular_weight": 502.8,
    "log_p": 0.42,
    "hbd": 6,
    "hba": 8,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "CC chemokine receptor antagonist",
    "disease_area": "hematologic malignancy | hematologic malignancy",
    "indication": "multiple myeloma | non-Hodgkin lymphoma (NHL)"
  },
  "plicamycin": {
    "name": "Plicamycin",
    "smiles": "CO[C@@H]([C@@H]1CC2=CC3=CC(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)=C(C)C(O)=C3C(O)=C2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O",
    "molecular_weight": 1085.16,
    "log_p": -0.25,
    "hbd": 11,
    "hba": 24,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "alcohol dehydrogenase inhibitor",
    "disease_area": "endocrinology | endocrinology | oncology",
    "indication": "hypercalcemia | Paget's disease | testicular carcinoma"
  },
  "p-nitrobiphenyl": {
    "name": "P-nitrobiphenyl",
    "smiles": "O=N(=O)C1=CC=C(C=C1)C1=CC=CC=C1",
    "molecular_weight": 199.21,
    "log_p": 3.26,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "podofilox": {
    "name": "Podofilox",
    "smiles": "[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(OC)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@@H]2O",
    "molecular_weight": 414.41,
    "log_p": 2.41,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "podophyllin": {
    "name": "Podophyllin",
    "smiles": "COC1=CC(=CC(OC)=C1OC)C1C2C(COC2=O)C(O)C2=CC3=C(OCO3)C=C12.COC1=CC(=CC(OC)=C1OC)C1C2C(COC2=O)C(O)C2=CC3=C(OCO3)C=C12.COC1=CC(=CC(OC)=C1OC)C1C(C(CO)C(O)C2=CC3=C(OCO3)C=C12)C(O)=O.COC1=CC(=CC(OC)=C1OC)C1C(C(CO)C(O)C2=CC3=C(OCO3)C=C12)C(O)=O",
    "molecular_weight": 1693.67,
    "log_p": 8.68,
    "hbd": 8,
    "hba": 32,
    "rotatable_bonds": 20,
    "approved": true,
    "source": "FDA"
  },
  "polidocanol": {
    "name": "Polidocanol",
    "smiles": "CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO",
    "molecular_weight": 582.82,
    "log_p": 4.05,
    "hbd": 1,
    "hba": 10,
    "rotatable_bonds": 37,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "local anesthetic",
    "disease_area": "dermatology",
    "indication": "varicose veins"
  },
  "polydatin": {
    "name": "Polydatin",
    "smiles": "OC[C@H]1O[C@@H](OC2=CC(\\C=C\\C3=CC=C(O)C=C3)=CC(O)=C2)[C@H](O)[C@@H](O)[C@@H]1O",
    "molecular_weight": 390.39,
    "log_p": 0.45,
    "hbd": 6,
    "hba": 8,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 2",
    "moa": "ICAM1 expression inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "polymyxin b": {
    "name": "Polymyxin B",
    "smiles": "[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O",
    "molecular_weight": 1203.5,
    "log_p": -5.24,
    "hbd": 18,
    "hba": 18,
    "rotatable_bonds": 29,
    "approved": true,
    "source": "FDA"
  },
  "polythiazide": {
    "name": "Polythiazide",
    "smiles": "CN1C(CSCC(F)(F)F)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O",
    "molecular_weight": 439.89,
    "log_p": 1.66,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium/chloride cotransporter inhibitor",
    "disease_area": "cardiology | cardiology | cardiology | gastroenterology | nephrology | nephrology | rheumatology",
    "indication": "acute glomerulonephritis (AGN) | chronic renal failure | congestive heart failure | edema | hepatic cirrhosis | hypertension | nephrotic syndrome"
  },
  "pomalidomide": {
    "name": "Pomalidomide",
    "smiles": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O",
    "molecular_weight": 273.25,
    "log_p": -0.33,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiogenesis inhibitor | tumor necrosis factor production inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "multiple myeloma"
  },
  "ponatinib": {
    "name": "Ponatinib",
    "smiles": "CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1",
    "molecular_weight": 532.57,
    "log_p": 4.46,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "Bcr-Abl kinase inhibitor | FLT3 inhibitor | PDGFR tyrosine kinase receptor inhibitor",
    "disease_area": "hematologic malignancy | hematologic malignancy",
    "indication": "acute lymphoblastic leukemia (ALL) | chronic myeloid leukemia (CML)"
  },
  "ponesimod": {
    "name": "Ponesimod",
    "smiles": "CCC\\N=C1/S\\C(=C/C2=CC=C(OC[C@H](O)CO)C(Cl)=C2)C(=O)N1C1=CC=CC=C1C",
    "molecular_weight": 460.98,
    "log_p": 4.27,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "sphingosine 1-phosphate receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "posaconazole": {
    "name": "Posaconazole",
    "smiles": "CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=NC=N3)(C2)C2=C(F)C=C(F)C=C2)C=C1",
    "molecular_weight": 700.79,
    "log_p": 4.57,
    "hbd": 1,
    "hba": 12,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sterol demethylase inhibitor",
    "disease_area": "infectious disease",
    "indication": "oropharyngeal candidiasis"
  },
  "potassium": {
    "name": "Potassium",
    "smiles": "[KH]",
    "molecular_weight": 40.11,
    "log_p": -0.65,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "potassium acetate": {
    "name": "Potassium acetate",
    "smiles": "[K+].CC([O-])=O",
    "molecular_weight": 98.14,
    "log_p": -4.24,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "potassium alum": {
    "name": "Potassium alum",
    "smiles": "[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O",
    "molecular_weight": 258.21,
    "log_p": -6.05,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "potassium aspartate": {
    "name": "Potassium aspartate",
    "smiles": "[H+].[H+].O.[K+].[K+].N[C@@H](CC([O-])=O)C([O-])=O.N[C@@H](CC([O-])=O)C([O-])=O",
    "molecular_weight": 360.4,
    "log_p": -14.18,
    "hbd": 2,
    "hba": 10,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "potassium bicarbonate": {
    "name": "Potassium bicarbonate",
    "smiles": "[K+].OC([O-])=O",
    "molecular_weight": 100.11,
    "log_p": -4.11,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "potassium carbonate": {
    "name": "Potassium carbonate",
    "smiles": "[K+].[K+].[O-]C([O-])=O",
    "molecular_weight": 138.2,
    "log_p": -8.44,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "potassium cation": {
    "name": "Potassium cation",
    "smiles": "[K+]",
    "molecular_weight": 39.1,
    "log_p": -3.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "potassium chloride": {
    "name": "Potassium chloride",
    "smiles": "[Cl-].[K+]",
    "molecular_weight": 74.55,
    "log_p": -5.99,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "potassium citrate": {
    "name": "Potassium citrate",
    "smiles": "[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O",
    "molecular_weight": 306.39,
    "log_p": -14.24,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "potassium gluconate": {
    "name": "Potassium gluconate",
    "smiles": "[K+].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O",
    "molecular_weight": 234.25,
    "log_p": -7.82,
    "hbd": 5,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "potassium hydroxide": {
    "name": "Potassium hydroxide",
    "smiles": "[OH-].[K+]",
    "molecular_weight": 56.11,
    "log_p": -3.17,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "potassium iodide": {
    "name": "Potassium Iodide",
    "smiles": "[K+].[I-]",
    "molecular_weight": 166.0,
    "log_p": -5.99,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "potassium lactate": {
    "name": "Potassium lactate",
    "smiles": "[K+].CC(O)C([O-])=O",
    "molecular_weight": 128.17,
    "log_p": -4.88,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "potassium nitrate": {
    "name": "Potassium nitrate",
    "smiles": "[K+].[O-][N+]([O-])=O",
    "molecular_weight": 101.1,
    "log_p": -3.24,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "potassium perchlorate": {
    "name": "Potassium perchlorate",
    "smiles": "[K+].[O-][Cl](=O)(=O)=O",
    "molecular_weight": 138.55,
    "log_p": -7.75,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "potassium sulfate": {
    "name": "Potassium sulfate",
    "smiles": "[K+].[K+].[O-]S([O-])(=O)=O",
    "molecular_weight": 174.26,
    "log_p": -7.33,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "p-phenylenediamine": {
    "name": "p-Phenylenediamine",
    "smiles": "NC1=CC=C(N)C=C1",
    "molecular_weight": 108.14,
    "log_p": 0.85,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "practolol": {
    "name": "Practolol",
    "smiles": "CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1",
    "molecular_weight": 266.34,
    "log_p": 1.38,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "pralatrexate": {
    "name": "Pralatrexate",
    "smiles": "NC1=NC2=NC=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1",
    "molecular_weight": 477.48,
    "log_p": 0.98,
    "hbd": 5,
    "hba": 9,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dihydrofolate reductase inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "peripheral T-cell lymphoma (PTCL)"
  },
  "pralidoxime": {
    "name": "Pralidoxime",
    "smiles": "C[N+]1=C(\\C=N\\O)C=CC=C1",
    "molecular_weight": 137.16,
    "log_p": 0.32,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholinesterase inhibitor",
    "disease_area": "critical care",
    "indication": "organophosphate poisoning"
  },
  "pralsetinib": {
    "name": "Pralsetinib",
    "smiles": "CO[C@@]1(CC[C@@H](CC1)C1=NC(NC2=NNC(C)=C2)=CC(C)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1",
    "molecular_weight": 533.61,
    "log_p": 4.2,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "pramipexole": {
    "name": "Pramipexole",
    "smiles": "CCCN[C@H]1CCC2=C(C1)SC(N)=N2",
    "molecular_weight": 211.33,
    "log_p": 1.58,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "Parkinson's Disease"
  },
  "pramiracetam": {
    "name": "Pramiracetam",
    "smiles": "CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C",
    "molecular_weight": 269.39,
    "log_p": 0.84,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "senile dementia"
  },
  "pramlintide": {
    "name": "Pramlintide",
    "smiles": "[H]N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@]([H])(NC(=O)[C@H](C)NC(=O)[C@@]([H])(NC(=O)[C@H](CC(N)=O)NC1=O)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@]([H])([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(N)=O",
    "molecular_weight": 3949.45,
    "log_p": -23.83,
    "hbd": 56,
    "hba": 59,
    "rotatable_bonds": 109,
    "approved": true,
    "source": "FDA"
  },
  "pramocaine": {
    "name": "Pramocaine",
    "smiles": "CCCCOC1=CC=C(OCCCN2CCOCC2)C=C1",
    "molecular_weight": 293.41,
    "log_p": 2.97,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "prasterone": {
    "name": "Prasterone",
    "smiles": "[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C",
    "molecular_weight": 288.43,
    "log_p": 3.88,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "prasterone enantate": {
    "name": "Prasterone enantate",
    "smiles": "[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OC(=O)CCCCCC",
    "molecular_weight": 400.6,
    "log_p": 6.4,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "prasugrel": {
    "name": "Prasugrel",
    "smiles": "CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1",
    "molecular_weight": 373.45,
    "log_p": 3.89,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "purinergic receptor antagonist",
    "disease_area": "cardiology | cardiology",
    "indication": "acute coronary syndrome (ACS) | myocardial infarction"
  },
  "pravastatin": {
    "name": "Pravastatin",
    "smiles": "[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC",
    "molecular_weight": 424.53,
    "log_p": 2.44,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HMGCR inhibitor",
    "disease_area": "cardiology | endocrinology | endocrinology",
    "indication": "hypercholesterolemia | hyperlipidemia | myocardial infarction"
  },
  "prazepam": {
    "name": "Prazepam",
    "smiles": "ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1",
    "molecular_weight": 324.81,
    "log_p": 3.93,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "praziquantel": {
    "name": "Praziquantel",
    "smiles": "O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1",
    "molecular_weight": 312.41,
    "log_p": 2.53,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "anthelmintic agent",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "cystic hydatid disease | gastrointestinal parasites | schistosomiasis"
  },
  "prazosin": {
    "name": "Prazosin",
    "smiles": "COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1",
    "molecular_weight": 383.41,
    "log_p": 1.78,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "prednicarbate": {
    "name": "Prednicarbate",
    "smiles": "[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 488.58,
    "log_p": 3.7,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist | phospholipase activator",
    "disease_area": "dermatology | Dermatology | neurology/psychiatry | ophthalmology",
    "indication": "contact dermatitis | dermatitis | eczema | itching"
  },
  "prednisolone": {
    "name": "Prednisolone",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 360.45,
    "log_p": 1.56,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "dermatology | infectious disease | ophthalmology | ophthalmology | ophthalmology | ophthalmology",
    "indication": "conjunctivitis | cyclitis | iritis | punctate keratitis | rosacea | shingles"
  },
  "prednisolone acetate": {
    "name": "Prednisolone acetate",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 402.49,
    "log_p": 2.13,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "ophthalmology, dermatology, infectious disease",
    "indication": "conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis"
  },
  "prednisolone phosphate": {
    "name": "Prednisolone phosphate",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 440.43,
    "log_p": 1.67,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "prednisolone tebutate": {
    "name": "Prednisolone tebutate",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 458.6,
    "log_p": 3.54,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "General surgery",
    "indication": "hemorrhoids"
  },
  "prednisone": {
    "name": "Prednisone",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 358.43,
    "log_p": 1.77,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "dermatology | endocrinology | endocrinology | gastroenterology | gastroenterology | hematology | infectious disease | infectious disease | infectious disease | neurology/psychiatry | ophthalmology | rheumatology | rheumatology | rheumatology | rheumatology | rheumatology | rheumatology",
    "indication": "anemia | ankylosing spondylitis | bursitis | congenital adrenal hyperplasia | conjunctivitis | dermatomyositis | enteritis | epicondylitis | hypercalcemia | meningitis | multiple sclerosis | mycosis | osteoarthritis | psoriasis | psoriatic arthritis | rheumatoid arthritis | ulcerative colitis"
  },
  "prednisone acetate": {
    "name": "Prednisone acetate",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 400.47,
    "log_p": 2.34,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "pregabalin": {
    "name": "Pregabalin",
    "smiles": "CC(C)C[C@H](CN)CC(O)=O",
    "molecular_weight": 159.23,
    "log_p": 1.08,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "pregnenolone": {
    "name": "Pregnenolone",
    "smiles": "[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C",
    "molecular_weight": 316.49,
    "log_p": 4.52,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glutamate receptor modulator",
    "disease_area": "rheumatology",
    "indication": "rheumatoid arthritis"
  },
  "prenylamine": {
    "name": "Prenylamine",
    "smiles": "CC(CC1=CC=CC=C1)NCCC(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 329.49,
    "log_p": 5.43,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "calcium channel blocker",
    "disease_area": "",
    "indication": ""
  },
  "pretomanid": {
    "name": "Pretomanid",
    "smiles": "[O-][N+](=O)C1=CN2C[C@@H](COC2=N1)OCC1=CC=C(OC(F)(F)F)C=C1",
    "molecular_weight": 359.26,
    "log_p": 2.67,
    "hbd": 0,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "nitric oxide donor",
    "disease_area": "",
    "indication": ""
  },
  "prilocaine": {
    "name": "Prilocaine",
    "smiles": "CCCNC(C)C(=O)NC1=CC=CC=C1C",
    "molecular_weight": 220.32,
    "log_p": 2.32,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "local anesthetic",
    "disease_area": "neurology/psychiatry",
    "indication": "anesthetic"
  },
  "primaquine": {
    "name": "Primaquine",
    "smiles": "COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1",
    "molecular_weight": 259.35,
    "log_p": 2.78,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antimalarial agent | DNA inhibitor",
    "disease_area": "infectious disease",
    "indication": "malaria"
  },
  "primidone": {
    "name": "Primidone",
    "smiles": "CCC1(C(=O)NCNC1=O)C1=CC=CC=C1",
    "molecular_weight": 218.26,
    "log_p": 0.54,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "GABA receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "seizures"
  },
  "probenecid": {
    "name": "Probenecid",
    "smiles": "CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O",
    "molecular_weight": 285.37,
    "log_p": 2.2,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "uricosuric blocker",
    "disease_area": "nephrology | rheumatology",
    "indication": "gout | hyperuricemia"
  },
  "probucol": {
    "name": "Probucol",
    "smiles": "CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C",
    "molecular_weight": 516.86,
    "log_p": 9.91,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "atherogenesis inhibitor",
    "disease_area": "cardiology",
    "indication": "coronary artery disease (CAD)"
  },
  "procainamide": {
    "name": "Procainamide",
    "smiles": "CCN(CC)CCNC(=O)C1=CC=C(N)C=C1",
    "molecular_weight": 235.33,
    "log_p": 1.34,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "cardiology | cardiology",
    "indication": "ventricular arrhythmias | ventricular tachycardia (VT)"
  },
  "procaine": {
    "name": "Procaine",
    "smiles": "CCN(CC)CCOC(=O)C1=CC=C(N)C=C1",
    "molecular_weight": 236.31,
    "log_p": 1.77,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HMGCR inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "anesthetic"
  },
  "procaine benzylpenicillin": {
    "name": "Procaine benzylpenicillin",
    "smiles": "CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O",
    "molecular_weight": 570.71,
    "log_p": 2.63,
    "hbd": 3,
    "hba": 8,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "procaine merethoxylline": {
    "name": "Procaine merethoxylline",
    "smiles": "O.[Hg+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.[CH2]C(CN=C(O)C1=CC=CC=C1OCC([O-])=O)OCCOC",
    "molecular_weight": 764.24,
    "log_p": 0.93,
    "hbd": 2,
    "hba": 10,
    "rotatable_bonds": 16,
    "approved": true,
    "source": "FDA"
  },
  "procarbazine": {
    "name": "Procarbazine",
    "smiles": "CNNCC1=CC=C(C=C1)C(=O)NC(C)C",
    "molecular_weight": 221.3,
    "log_p": 1.05,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "monoamine oxidase inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "Hodgkin's lymphoma"
  },
  "procaterol": {
    "name": "Procaterol",
    "smiles": "CC[C@@H](NC(C)C)[C@@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2",
    "molecular_weight": 290.36,
    "log_p": 2.04,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "pulmonary",
    "indication": "asthma"
  },
  "prochlorperazine": {
    "name": "Prochlorperazine",
    "smiles": "CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1",
    "molecular_weight": 373.95,
    "log_p": 4.58,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "gastroenterology | gastroenterology",
    "indication": "nausea | vomiting"
  },
  "procyclidine": {
    "name": "Procyclidine",
    "smiles": "OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1",
    "molecular_weight": 287.45,
    "log_p": 3.94,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "acetylcholine receptor antagonist | antispasmodic",
    "disease_area": "neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry",
    "indication": "akathisia | dystonia | parkinsonism | Parkinson's Disease"
  },
  "profenamine": {
    "name": "Profenamine",
    "smiles": "CCN(CC)C(C)CN1C2=CC=CC=C2SC2=CC=CC=C12",
    "molecular_weight": 312.48,
    "log_p": 5.02,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "butyrylcholinesterase inhibitor | cholinergic receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "Parkinson's Disease"
  },
  "proflavine": {
    "name": "Proflavine",
    "smiles": "NC1=CC2=NC3=C(C=CC(N)=C3)C=C2C=C1",
    "molecular_weight": 209.25,
    "log_p": 2.55,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "progesterone": {
    "name": "Progesterone",
    "smiles": "[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 314.47,
    "log_p": 4.72,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "progesterone receptor agonist",
    "disease_area": "endocrinology | obstetrics/gynecology",
    "indication": "amenorrhea | infertility"
  },
  "proguanil": {
    "name": "Proguanil",
    "smiles": "CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1",
    "molecular_weight": 253.74,
    "log_p": 2.21,
    "hbd": 5,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dihydrofolate reductase inhibitor",
    "disease_area": "infectious disease",
    "indication": "malaria"
  },
  "promazine": {
    "name": "Promazine",
    "smiles": "CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12",
    "molecular_weight": 284.43,
    "log_p": 4.24,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "schizophrenia"
  },
  "promethazine": {
    "name": "Promethazine",
    "smiles": "CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C",
    "molecular_weight": 284.43,
    "log_p": 4.24,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy | neurology/psychiatry",
    "indication": "allergic rhinitis | sedative"
  },
  "propafenone": {
    "name": "Propafenone",
    "smiles": "CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1",
    "molecular_weight": 341.45,
    "log_p": 3.24,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antiarrhythmic",
    "disease_area": "cardiology | cardiology | cardiology",
    "indication": "atrial fibrillation (AF) | ventricular arrhythmias | ventricular tachycardia (VT)"
  },
  "propanoic acid": {
    "name": "Propanoic acid",
    "smiles": "CCC(O)=O",
    "molecular_weight": 74.08,
    "log_p": 0.48,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "propantheline": {
    "name": "Propantheline",
    "smiles": "CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12)C(C)C",
    "molecular_weight": 368.5,
    "log_p": 4.73,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "gastroenterology",
    "indication": "peptic ulcer disease (PUD)"
  },
  "proparacaine": {
    "name": "Proparacaine",
    "smiles": "CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC",
    "molecular_weight": 294.4,
    "log_p": 2.56,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "propiolactone": {
    "name": "Propiolactone",
    "smiles": "O=C1CCO1",
    "molecular_weight": 72.06,
    "log_p": -0.07,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "infectious disease",
    "indication": "antiseptic"
  },
  "propiomazine": {
    "name": "Propiomazine",
    "smiles": "CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1",
    "molecular_weight": 340.49,
    "log_p": 4.83,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "propiverine": {
    "name": "Propiverine",
    "smiles": "CCCOC(C(=O)OC1CCN(C)CC1)(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 367.49,
    "log_p": 3.99,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "urology",
    "indication": "urinary incontinence"
  },
  "propofol": {
    "name": "Propofol",
    "smiles": "CC(C)C1=CC=CC(C(C)C)=C1O",
    "molecular_weight": 178.27,
    "log_p": 3.64,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "benzodiazepine receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "anesthetic"
  },
  "propoxycaine": {
    "name": "Propoxycaine",
    "smiles": "CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC",
    "molecular_weight": 294.4,
    "log_p": 2.56,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "local anesthetic",
    "disease_area": "neurology/psychiatry",
    "indication": "anesthetic"
  },
  "propranolol": {
    "name": "Propranolol",
    "smiles": "CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2",
    "molecular_weight": 259.35,
    "log_p": 2.58,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology | cardiology | neurology/psychiatry",
    "indication": "angina pectoris | hypertension | migraine headache"
  },
  "propyl alcohol": {
    "name": "Propyl alcohol",
    "smiles": "CCCO",
    "molecular_weight": 60.1,
    "log_p": 0.39,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "propylene glycol": {
    "name": "Propylene glycol",
    "smiles": "CC(O)CO",
    "molecular_weight": 76.09,
    "log_p": -0.64,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "propylhexedrine": {
    "name": "Propylhexedrine",
    "smiles": "CNC(C)CC1CCCCC1",
    "molecular_weight": 155.28,
    "log_p": 2.56,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "allergy | endocrinology | otolaryngology",
    "indication": "allergic rhinitis | fever | nasal congestion"
  },
  "propyliodone": {
    "name": "Propyliodone",
    "smiles": "CCCOC(=O)CN1C=C(I)C(=O)C(I)=C1",
    "molecular_weight": 447.01,
    "log_p": 2.01,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "propylparaben": {
    "name": "Propylparaben",
    "smiles": "CCCOC(=O)C1=CC=C(O)C=C1",
    "molecular_weight": 180.2,
    "log_p": 1.96,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "propylthiouracil": {
    "name": "Propylthiouracil",
    "smiles": "CCCC1=CC(=O)NC(=S)N1",
    "molecular_weight": 170.24,
    "log_p": 1.38,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "thyroid peroxidase inhibitor",
    "disease_area": "endocrinology | endocrinology | endocrinology",
    "indication": "goiter | Grave's disease | hyperthyroidism"
  },
  "protionamide": {
    "name": "Protionamide",
    "smiles": "CCCC1=CC(=CC=N1)C(N)=S",
    "molecular_weight": 180.28,
    "log_p": 1.67,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "infectious disease",
    "indication": "tuberculosis"
  },
  "protirelin": {
    "name": "Protirelin",
    "smiles": "[H][C@@](CC1=CN=CN1)(NC(=O)[C@]1([H])CCC(=O)N1)C(=O)N1CCC[C@@]1([H])C(N)=O",
    "molecular_weight": 362.39,
    "log_p": -1.81,
    "hbd": 4,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "thyrotropin releasing hormone receptor agonist",
    "disease_area": "radiology",
    "indication": "thyroid function diagnostic"
  },
  "protokylol": {
    "name": "Protokylol",
    "smiles": "CC(CC1=CC=C2OCOC2=C1)NCC(O)C1=CC=C(O)C(O)=C1",
    "molecular_weight": 331.37,
    "log_p": 2.08,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "adrenergic receptor agonist",
    "disease_area": "infectious disease",
    "indication": "respiratory tract infections"
  },
  "protriptyline": {
    "name": "Protriptyline",
    "smiles": "CNCCCC1C2=CC=CC=C2C=CC2=CC=CC=C12",
    "molecular_weight": 263.38,
    "log_p": 4.3,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "tricyclic antidepressant",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "proxibarbal": {
    "name": "Proxibarbal",
    "smiles": "CC(O)CC1(CC=C)C(=O)NC(=O)NC1=O",
    "molecular_weight": 226.23,
    "log_p": -0.31,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "prucalopride": {
    "name": "Prucalopride",
    "smiles": "COCCCN1CCC(CC1)NC(=O)C1=C2OCCC2=C(N)C(Cl)=C1",
    "molecular_weight": 367.88,
    "log_p": 2.09,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor agonist",
    "disease_area": "gastroenterology",
    "indication": "constipation"
  },
  "prussian blue": {
    "name": "Prussian blue",
    "smiles": "[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#C[Fe-4](C#N)(C#N)(C#N)(C#N)C#N.N#C[Fe-4](C#N)(C#N)(C#N)(C#N)C#N.N#C[Fe-4](C#N)(C#N)(C#N)(C#N)C#N",
    "molecular_weight": 859.24,
    "log_p": 0.28,
    "hbd": 0,
    "hba": 18,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "pseudoephedrine": {
    "name": "Pseudoephedrine",
    "smiles": "CN[C@@H](C)[C@@H](O)C1=CC=CC=C1",
    "molecular_weight": 165.24,
    "log_p": 1.33,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "pyrantel": {
    "name": "Pyrantel",
    "smiles": "[H]\\C(=C(\\[H])C1=NCCCN1C)C1=CC=CS1",
    "molecular_weight": 206.31,
    "log_p": 2.5,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor agonist | nicotinic receptor agonist",
    "disease_area": "infectious disease",
    "indication": "gastrointestinal roundworms"
  },
  "pyrazinamide": {
    "name": "Pyrazinamide",
    "smiles": "NC(=O)C1=NC=CN=C1",
    "molecular_weight": 123.11,
    "log_p": -0.42,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "fatty acid synthase inhibitor",
    "disease_area": "infectious disease",
    "indication": "tuberculosis"
  },
  "pyridostigmine": {
    "name": "Pyridostigmine",
    "smiles": "CN(C)C(=O)OC1=C[N+](C)=CC=C1",
    "molecular_weight": 181.22,
    "log_p": 0.57,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "pyridoxal phosphate": {
    "name": "Pyridoxal phosphate",
    "smiles": "CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O",
    "molecular_weight": 247.14,
    "log_p": 0.52,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "pyridoxine": {
    "name": "Pyridoxine",
    "smiles": "CC1=C(O)C(CO)=C(CO)C=N1",
    "molecular_weight": 169.18,
    "log_p": 0.08,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin B",
    "disease_area": "metabolism",
    "indication": "vitamin B6 deficiency"
  },
  "pyrimethamine": {
    "name": "Pyrimethamine",
    "smiles": "CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1",
    "molecular_weight": 248.72,
    "log_p": 2.52,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dihydrofolate reductase inhibitor",
    "disease_area": "infectious disease",
    "indication": "malaria"
  },
  "pyrithione": {
    "name": "Pyrithione",
    "smiles": "[O-][N+]1=C(S)C=CC=C1",
    "molecular_weight": 127.17,
    "log_p": 0.61,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "pyrophosphoric acid": {
    "name": "Pyrophosphoric acid",
    "smiles": "OP(O)(=O)OP(O)(O)=O",
    "molecular_weight": 177.97,
    "log_p": -0.81,
    "hbd": 4,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "pyruvic acid": {
    "name": "Pyruvic acid",
    "smiles": "CC(=O)C(O)=O",
    "molecular_weight": 88.06,
    "log_p": -0.34,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "pyrvinium": {
    "name": "Pyrvinium",
    "smiles": "CN(C)C1=CC2=C(C=C1)[N+](C)=C(\\C=C\\C1=C(C)N(C(C)=C1)C1=CC=CC=C1)C=C2",
    "molecular_weight": 382.53,
    "log_p": 5.31,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "quaternium-15": {
    "name": "Quaternium-15",
    "smiles": "[Cl-].[H]C(Cl)=C([H])C[N+]12CN3CN(CN(C3)C1)C2",
    "molecular_weight": 251.16,
    "log_p": -2.75,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "quazepam": {
    "name": "Quazepam",
    "smiles": "FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2",
    "molecular_weight": 386.8,
    "log_p": 5.03,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "quetiapine": {
    "name": "Quetiapine",
    "smiles": "OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12",
    "molecular_weight": 383.52,
    "log_p": 2.86,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist | serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "bipolar disorder | schizophrenia"
  },
  "quinagolide": {
    "name": "Quinagolide",
    "smiles": "[H][C@]12C[C@@H](CN(CCC)[C@]1([H])CC1=CC=CC(O)=C1C2)NS(=O)(=O)N(CC)CC",
    "molecular_weight": 395.57,
    "log_p": 2.14,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor agonist",
    "disease_area": "endocrinology",
    "indication": "hyperprolactinemia"
  },
  "quinapril": {
    "name": "Quinapril",
    "smiles": "CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O",
    "molecular_weight": 438.52,
    "log_p": 2.57,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin converting enzyme inhibitor",
    "disease_area": "cardiology | cardiology | cardiology",
    "indication": "angioedema | congestive heart failure | hypertension"
  },
  "quinestrol": {
    "name": "Quinestrol",
    "smiles": "[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC1CCCC1)C=C3",
    "molecular_weight": 364.53,
    "log_p": 5.23,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "estrogen receptor agonist",
    "disease_area": "endocrinology",
    "indication": "menopause"
  },
  "quinethazone": {
    "name": "Quinethazone",
    "smiles": "CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O",
    "molecular_weight": 289.74,
    "log_p": 0.88,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "thiazide diuretic",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "quinidine": {
    "name": "Quinidine",
    "smiles": "[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1",
    "molecular_weight": 324.42,
    "log_p": 3.17,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "cardiology | cardiology | infectious disease",
    "indication": "atrial fibrillation (AF) | malaria | ventricular arrhythmias"
  },
  "quinidine barbiturate": {
    "name": "Quinidine barbiturate",
    "smiles": "CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C",
    "molecular_weight": 556.66,
    "log_p": 3.87,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "quinine": {
    "name": "Quinine",
    "smiles": "[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12",
    "molecular_weight": 324.42,
    "log_p": 3.17,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "hemozoin biocrystallization inhibitor",
    "disease_area": "infectious disease",
    "indication": "malaria"
  },
  "quinupramine": {
    "name": "Quinupramine",
    "smiles": "C1CN2CCC1C(C2)N1C2=CC=CC=C2CCC2=CC=CC=C12",
    "molecular_weight": 304.44,
    "log_p": 4.02,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "quinupristin": {
    "name": "Quinupristin",
    "smiles": "[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1",
    "molecular_weight": 1022.24,
    "log_p": 2.32,
    "hbd": 4,
    "hba": 14,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 50s ribosomal subunit inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-negative bacterial infections"
  },
  "rabeprazole": {
    "name": "Rabeprazole",
    "smiles": "COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1",
    "molecular_weight": 359.45,
    "log_p": 2.99,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATPase inhibitor | gastrin inhibitor",
    "disease_area": "gastroenterology | gastroenterology | gastroenterology",
    "indication": "duodenal ulcer disease | gastroesophageal reflux disease (GERD) | Zollinger-Ellison syndrome"
  },
  "racemethionine": {
    "name": "Racemethionine",
    "smiles": "CSCCC(N)C(O)=O",
    "molecular_weight": 149.22,
    "log_p": 0.15,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "racephedrine": {
    "name": "Racephedrine",
    "smiles": "CN[C@H](C)[C@@H](O)C1=CC=CC=C1",
    "molecular_weight": 165.24,
    "log_p": 1.33,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "radium ra 223 dichloride": {
    "name": "Radium Ra 223 dichloride",
    "smiles": "[Cl-].[Cl-].[223Ra++]",
    "molecular_weight": 293.92,
    "log_p": -5.99,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "raloxifene": {
    "name": "Raloxifene",
    "smiles": "OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2",
    "molecular_weight": 473.59,
    "log_p": 6.08,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "estrogen receptor antagonist | selective estrogen receptor modulator (SERM)",
    "disease_area": "oncology | orthopedics",
    "indication": "breast cancer | osteoporosis"
  },
  "raltegravir": {
    "name": "Raltegravir",
    "smiles": "CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1",
    "molecular_weight": 444.42,
    "log_p": 0.91,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HIV integrase inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "raltitrexed": {
    "name": "Raltitrexed",
    "smiles": "CN(CC1=CC2=C(NC(C)=NC2=O)C=C1)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O",
    "molecular_weight": 458.5,
    "log_p": 1.98,
    "hbd": 4,
    "hba": 7,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "thymidylate synthase inhibitor",
    "disease_area": "oncology",
    "indication": "mesothelioma"
  },
  "ramelteon": {
    "name": "Ramelteon",
    "smiles": "CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2",
    "molecular_weight": 259.35,
    "log_p": 2.57,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "melatonin receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "insomnia"
  },
  "ramipril": {
    "name": "Ramipril",
    "smiles": "[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC",
    "molecular_weight": 416.52,
    "log_p": 2.38,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin converting enzyme inhibitor",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "ranitidine": {
    "name": "Ranitidine",
    "smiles": "CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O",
    "molecular_weight": 314.41,
    "log_p": 1.46,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "gastroenterology",
    "indication": "heartburn"
  },
  "ranolazine": {
    "name": "Ranolazine",
    "smiles": "COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1",
    "molecular_weight": 427.55,
    "log_p": 2.31,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "cardiology",
    "indication": "chronic stable angina"
  },
  "rapacuronium": {
    "name": "Rapacuronium",
    "smiles": "[H][C@@]12C[C@@H]([C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(CC=C)CCCCC1",
    "molecular_weight": 597.91,
    "log_p": 6.91,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "rasagiline": {
    "name": "Rasagiline",
    "smiles": "C#CCN[C@@H]1CCC2=CC=CC=C12",
    "molecular_weight": 171.24,
    "log_p": 1.9,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "monoamine oxidase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "Parkinson's Disease"
  },
  "rebamipide": {
    "name": "Rebamipide",
    "smiles": "OC(=O)C(CC1=CC(=O)NC2=C1C=CC=C2)NC(=O)C1=CC=C(Cl)C=C1",
    "molecular_weight": 370.79,
    "log_p": 2.61,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "free radical scavenger",
    "disease_area": "gastroenterology | gastroenterology",
    "indication": "gastritis | peptic ulcer disease (PUD)"
  },
  "reboxetine": {
    "name": "Reboxetine",
    "smiles": "[H][C@@]1(CNCCO1)[C@H](OC1=CC=CC=C1OCC)C1=CC=CC=C1",
    "molecular_weight": 313.4,
    "log_p": 3.19,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "regadenoson": {
    "name": "Regadenoson",
    "smiles": "CNC(=O)C1=CN(N=C1)C1=NC2=C(N=CN2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C(N)=N1",
    "molecular_weight": 390.36,
    "log_p": -2.43,
    "hbd": 5,
    "hba": 12,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adenosine receptor agonist",
    "disease_area": "radiology",
    "indication": "myocardial perfusion imaging (MPI)"
  },
  "regorafenib": {
    "name": "Regorafenib",
    "smiles": "CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1",
    "molecular_weight": 482.82,
    "log_p": 5.69,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "FGFR inhibitor | KIT inhibitor | PDGFR tyrosine kinase receptor inhibitor | RAF inhibitor | RET tyrosine kinase inhibitor | VEGFR inhibitor",
    "disease_area": "oncology | oncology",
    "indication": "colorectal cancer | gastrointestinal stromal tumors (GIST)"
  },
  "relebactam": {
    "name": "Relebactam",
    "smiles": "OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NC2CCNCC2)C1=O",
    "molecular_weight": 348.38,
    "log_p": -1.14,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "beta lactamase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "relugolix": {
    "name": "Relugolix",
    "smiles": "CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1",
    "molecular_weight": 623.64,
    "log_p": 3.75,
    "hbd": 2,
    "hba": 11,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "gonadotropin releasing factor hormone receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "remdesivir": {
    "name": "Remdesivir",
    "smiles": "CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1",
    "molecular_weight": 602.59,
    "log_p": 2.31,
    "hbd": 4,
    "hba": 13,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "rna polymerase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "remifentanil": {
    "name": "Remifentanil",
    "smiles": "CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC(=O)OC)CC1)C(=O)OC",
    "molecular_weight": 376.45,
    "log_p": 2.0,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "remimazolam": {
    "name": "Remimazolam",
    "smiles": "COC(=O)CC[C@@H]1N=C(C2=CC=CC=N2)C2=CC(Br)=CC=C2N2C(C)=CN=C12",
    "molecular_weight": 439.31,
    "log_p": 4.18,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "benzodiazepine receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "remoxipride": {
    "name": "Remoxipride",
    "smiles": "CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC",
    "molecular_weight": 371.28,
    "log_p": 2.68,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "dopamine receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "repaglinide": {
    "name": "Repaglinide",
    "smiles": "CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O",
    "molecular_weight": 452.6,
    "log_p": 5.22,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "insulin secretagogue",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "rescinnamine": {
    "name": "Rescinnamine",
    "smiles": "[H][C@]12C[C@@H](OC(=O)C=CC3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2",
    "molecular_weight": 634.73,
    "log_p": 4.57,
    "hbd": 1,
    "hba": 10,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "reserpine": {
    "name": "Reserpine",
    "smiles": "[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2",
    "molecular_weight": 608.69,
    "log_p": 4.17,
    "hbd": 1,
    "hba": 10,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vesicular monoamine transporter inhibitor",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "resorcinol": {
    "name": "Resorcinol",
    "smiles": "OC1=CC(O)=CC=C1",
    "molecular_weight": 110.11,
    "log_p": 1.1,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "dermatology | dermatology | dermatology | dermatology",
    "indication": "acne vulgaris (AV) | eczema | psoriasis | seborrheic dermatitis"
  },
  "resorcinol monoacetate": {
    "name": "Resorcinol monoacetate",
    "smiles": "CC(=O)OC1=CC(O)=CC=C1",
    "molecular_weight": 152.15,
    "log_p": 1.32,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "retapamulin": {
    "name": "Retapamulin",
    "smiles": "[H][C@@]12C(=O)CC[C@]11CC[C@@H](C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C",
    "molecular_weight": 517.78,
    "log_p": 5.25,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "protein synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "impetigo"
  },
  "revefenacin": {
    "name": "Revefenacin",
    "smiles": "CN(CCN1CCC(CC1)OC(=O)NC1=CC=CC=C1C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1",
    "molecular_weight": 597.76,
    "log_p": 4.84,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cholinergic receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "ribavirin": {
    "name": "Ribavirin",
    "smiles": "NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",
    "molecular_weight": 244.21,
    "log_p": -3.01,
    "hbd": 4,
    "hba": 8,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antiviral",
    "disease_area": "infectious disease",
    "indication": "hepatitis C"
  },
  "ribociclib": {
    "name": "Ribociclib",
    "smiles": "CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(C=N3)N3CCNCC3)N=C2N1C1CCCC1",
    "molecular_weight": 434.55,
    "log_p": 2.8,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "CDK inhibitor",
    "disease_area": "oncology",
    "indication": "breast cancer"
  },
  "riboflavin": {
    "name": "Riboflavin",
    "smiles": "CC1=C(C)C=C2N(C[C@H](O)[C@H](O)[C@H](O)CO)C3=NC(=O)NC(=O)C3=NC2=C1",
    "molecular_weight": 376.37,
    "log_p": -1.72,
    "hbd": 5,
    "hba": 9,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin B",
    "disease_area": "gastroenterology",
    "indication": "jaundice"
  },
  "ribostamycin": {
    "name": "Ribostamycin",
    "smiles": "[H][C@@]1(O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2N)O[C@H](CO)[C@@H](O)[C@H]1O",
    "molecular_weight": 454.48,
    "log_p": -6.65,
    "hbd": 10,
    "hba": 14,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "rifabutin": {
    "name": "Rifabutin",
    "smiles": "CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21",
    "molecular_weight": 847.02,
    "log_p": 4.62,
    "hbd": 5,
    "hba": 14,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "protein synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "rifampicin": {
    "name": "Rifampicin",
    "smiles": "CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\\C=N\\N4CCN(C)CC4)=C(NC(=O)\\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C",
    "molecular_weight": 822.95,
    "log_p": 4.34,
    "hbd": 6,
    "hba": 15,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "rifamycin": {
    "name": "Rifamycin",
    "smiles": "CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C(O)C4=C3C2=O",
    "molecular_weight": 697.78,
    "log_p": 4.75,
    "hbd": 6,
    "hba": 12,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA directed RNA polymerase inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "leprosy | tuberculosis"
  },
  "rifapentine": {
    "name": "Rifapentine",
    "smiles": "CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\\C=N\\N1CCN(CC1)C1CCCC1)=C2O",
    "molecular_weight": 877.04,
    "log_p": 5.65,
    "hbd": 6,
    "hba": 15,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "RNA polymerase inhibitor",
    "disease_area": "infectious disease",
    "indication": "tuberculosis"
  },
  "rifaximin": {
    "name": "Rifaximin",
    "smiles": "CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C(N=C5C=C(C)C=CN15)C4=C3C2=O",
    "molecular_weight": 785.89,
    "log_p": 6.16,
    "hbd": 5,
    "hba": 13,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "RNA synthesis inhibitor",
    "disease_area": "gastroenterology | gastroenterology | gastroenterology | gastroenterology",
    "indication": "diarrhea | diarrhea, irritable bowel syndrome, hepatic encephalopathy (he) | hepatic encephalopathy (HE) | irritable bowel syndrome"
  },
  "rilmenidine": {
    "name": "Rilmenidine",
    "smiles": "C1CC1C(NC1=NCCO1)C1CC1",
    "molecular_weight": 180.25,
    "log_p": 1.15,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist | imidazoline receptor agonist",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "rilpivirine": {
    "name": "Rilpivirine",
    "smiles": "CC1=CC(\\C=C\\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1",
    "molecular_weight": 366.43,
    "log_p": 4.99,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "non-nucleoside reverse transcriptase inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "riluzole": {
    "name": "Riluzole",
    "smiles": "NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2",
    "molecular_weight": 234.2,
    "log_p": 2.78,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glutamate inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "amyotrophic lateral sclerosis (ALS)"
  },
  "rimantadine": {
    "name": "Rimantadine",
    "smiles": "CC(N)C12CC3CC(CC(C3)C1)C2",
    "molecular_weight": 179.31,
    "log_p": 2.55,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antiviral | RNA synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "influenza A virus infection"
  },
  "rimegepant": {
    "name": "Rimegepant",
    "smiles": "N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)N2C(=O)NC3=NC=CC=C23)C2=C1C=CC=N2)C1=C(F)C(F)=CC=C1",
    "molecular_weight": 534.57,
    "log_p": 4.49,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcitonin antagonist",
    "disease_area": "",
    "indication": ""
  },
  "rimexolone": {
    "name": "Rimexolone",
    "smiles": "[H][C@@]12C[C@@H](C)[C@](C)(C(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 370.53,
    "log_p": 4.5,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "ophthalmology",
    "indication": "anterior uveitis"
  },
  "rimonabant": {
    "name": "Rimonabant",
    "smiles": "CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(Cl)C=C1",
    "molecular_weight": 463.8,
    "log_p": 5.94,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "cannabinoid receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "riociguat": {
    "name": "Riociguat",
    "smiles": "COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=C1C=CC=N2",
    "molecular_weight": 422.42,
    "log_p": 2.44,
    "hbd": 2,
    "hba": 9,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "guanylate cyclase stimulant",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "ripretinib": {
    "name": "Ripretinib",
    "smiles": "CCN1C(=O)C(=CC2=C1C=C(NC)N=C2)C1=C(Br)C=C(F)C(NC(=O)NC2=CC=CC=C2)=C1",
    "molecular_weight": 510.37,
    "log_p": 5.67,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "receptor tyrosine protein kinase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "risdiplam": {
    "name": "Risdiplam",
    "smiles": "CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CCNC2(CC2)C1",
    "molecular_weight": 401.47,
    "log_p": 1.96,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 2/Phase 3",
    "moa": "RNA splicing inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "risedronic acid": {
    "name": "Risedronic acid",
    "smiles": "OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O",
    "molecular_weight": 283.11,
    "log_p": -0.37,
    "hbd": 5,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "risperidone": {
    "name": "Risperidone",
    "smiles": "CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1",
    "molecular_weight": 410.49,
    "log_p": 3.59,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist | serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry | neurology/psychiatry",
    "indication": "bipolar disorder | irritability | schizophrenia"
  },
  "ritiometan": {
    "name": "Ritiometan",
    "smiles": "OC(=O)CSC(SCC(O)=O)SCC(O)=O",
    "molecular_weight": 286.35,
    "log_p": 0.72,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "ritodrine": {
    "name": "Ritodrine",
    "smiles": "C[C@@H](NCCC1=CC=C(O)C=C1)[C@@H](O)C1=CC=C(O)C=C1",
    "molecular_weight": 287.36,
    "log_p": 2.35,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "adrenergic receptor agonist",
    "disease_area": "obstetrics/gynecology",
    "indication": "premature labor"
  },
  "ritonavir": {
    "name": "Ritonavir",
    "smiles": "CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1",
    "molecular_weight": 720.96,
    "log_p": 5.91,
    "hbd": 4,
    "hba": 9,
    "rotatable_bonds": 17,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HIV protease inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "rivaroxaban": {
    "name": "Rivaroxaban",
    "smiles": "ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O",
    "molecular_weight": 435.89,
    "log_p": 2.52,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "coagulation factor inhibitor",
    "disease_area": "cardiology | hematology | hematology | hematology | neurology/psychiatry",
    "indication": "atrial fibrillation (AF) | deep vein thrombosis (DVT) | pulmonary embolism (PE) | stroke | systemic embolism"
  },
  "rivastigmine": {
    "name": "Rivastigmine",
    "smiles": "CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C",
    "molecular_weight": 250.34,
    "log_p": 2.76,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholinesterase inhibitor",
    "disease_area": "neurology/psychiatry | neurology/psychiatry | neurology/psychiatry",
    "indication": "Alzheimer's disease | Parkinson's Disease | senile dementia"
  },
  "rizatriptan": {
    "name": "Rizatriptan",
    "smiles": "CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2",
    "molecular_weight": 269.35,
    "log_p": 1.91,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "migraine headache"
  },
  "rocuronium": {
    "name": "Rocuronium",
    "smiles": "[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1",
    "molecular_weight": 529.79,
    "log_p": 4.41,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "anesthetic"
  },
  "rofecoxib": {
    "name": "Rofecoxib",
    "smiles": "CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1",
    "molecular_weight": 314.36,
    "log_p": 2.56,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "roflumilast": {
    "name": "Roflumilast",
    "smiles": "FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl",
    "molecular_weight": 403.21,
    "log_p": 5.03,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "pulmonary | pulmonary",
    "indication": "bronchitis | chronic obstructive pulmonary disease (COPD)"
  },
  "rolapitant": {
    "name": "Rolapitant",
    "smiles": "C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F",
    "molecular_weight": 500.48,
    "log_p": 5.73,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "neurokinin receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "rolitetracycline": {
    "name": "Rolitetracycline",
    "smiles": "[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCN1CCCC1)=C(O)[C@H]2N(C)C",
    "molecular_weight": 527.57,
    "log_p": 0.47,
    "hbd": 6,
    "hba": 10,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "gram-negative bacterial infections | gram-positive bacterial infections"
  },
  "romidepsin": {
    "name": "Romidepsin",
    "smiles": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C",
    "molecular_weight": 540.71,
    "log_p": 1.43,
    "hbd": 4,
    "hba": 8,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HDAC inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "cutaneous T-cell lymphoma (CTCL)"
  },
  "ropinirole": {
    "name": "Ropinirole",
    "smiles": "CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1",
    "molecular_weight": 260.38,
    "log_p": 2.85,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor agonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "Parkinson's Disease | restless leg syndrome"
  },
  "ropivacaine": {
    "name": "Ropivacaine",
    "smiles": "CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C",
    "molecular_weight": 274.41,
    "log_p": 3.51,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "neurology/psychiatry",
    "indication": "anesthetic"
  },
  "rose bengal": {
    "name": "Rose bengal",
    "smiles": "OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C(O)=C(I)C=C12",
    "molecular_weight": 973.68,
    "log_p": 9.0,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "rose bengal i-131": {
    "name": "Rose bengal I-131",
    "smiles": "OC(=O)C1=C(C(Cl)=C(Cl)C(Cl)=C1Cl)C1=C2C=C([131I])C(=O)C([131I])=C2OC2=C([131I])C(O)=C([131I])C=C12",
    "molecular_weight": 989.68,
    "log_p": 9.0,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "rosiglitazone": {
    "name": "Rosiglitazone",
    "smiles": "CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1",
    "molecular_weight": 357.44,
    "log_p": 2.49,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "insulin sensitizer | insulin sensitizer, ppar receptor agonist | PPAR receptor agonist",
    "disease_area": "Insulin sensitizer",
    "indication": "diabetes mellitus"
  },
  "rosoxacin": {
    "name": "Rosoxacin",
    "smiles": "CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1",
    "molecular_weight": 294.31,
    "log_p": 2.78,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "topoisomerase inhibitor",
    "disease_area": "infectious disease",
    "indication": "urinary tract infections"
  },
  "rosuvastatin": {
    "name": "Rosuvastatin",
    "smiles": "CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\\C=C\\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O",
    "molecular_weight": 481.55,
    "log_p": 2.4,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HMGCR inhibitor",
    "disease_area": "cardiology | cardiology | endocrinology | endocrinology | endocrinology",
    "indication": "atherosclerosis | dyslipidemia | hypercholesterolemia | hyperlipidemia | hypertriglyceridemia"
  },
  "rotigotine": {
    "name": "Rotigotine",
    "smiles": "CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1",
    "molecular_weight": 315.48,
    "log_p": 4.27,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor agonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "Parkinson's Disease | restless leg syndrome"
  },
  "roxadustat": {
    "name": "Roxadustat",
    "smiles": "CC1=NC(C(=O)NCC(O)=O)=C(O)C2=C1C=C(OC1=CC=CC=C1)C=C2",
    "molecular_weight": 352.35,
    "log_p": 2.86,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "roxithromycin": {
    "name": "Roxithromycin",
    "smiles": "CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O",
    "molecular_weight": 837.06,
    "log_p": 2.21,
    "hbd": 5,
    "hba": 17,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 50S ribosomal subunit inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "respiratory tract infections | skin infections | urinary tract infections"
  },
  "rubidium": {
    "name": "Rubidium",
    "smiles": "[Rb]",
    "molecular_weight": 85.47,
    "log_p": -0.38,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "rubidium rb-82": {
    "name": "Rubidium Rb-82",
    "smiles": "[82Rb+]",
    "molecular_weight": 81.92,
    "log_p": -3.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "rucaparib": {
    "name": "Rucaparib",
    "smiles": "CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=C2C(N1)=CC(F)=C3",
    "molecular_weight": 323.37,
    "log_p": 2.98,
    "hbd": 3,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "PARP inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "rufinamide": {
    "name": "Rufinamide",
    "smiles": "NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1",
    "molecular_weight": 238.2,
    "log_p": 0.7,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "voltage-gated sodium channel blocker",
    "disease_area": "neurology/psychiatry",
    "indication": "seizures"
  },
  "rupatadine": {
    "name": "Rupatadine",
    "smiles": "CC1=CC(CN2CCC(CC2)=C2C3=CC=C(Cl)C=C3CCC3=C2N=CC=C3)=CN=C1",
    "molecular_weight": 415.97,
    "log_p": 5.63,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist | platelet activating factor receptor antagonist",
    "disease_area": "allergy | allergy",
    "indication": "allergic rhinitis | urticaria"
  },
  "rutin": {
    "name": "Rutin",
    "smiles": "C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O",
    "molecular_weight": 610.52,
    "log_p": -1.69,
    "hbd": 10,
    "hba": 16,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antioxidant | capillary stabilizing agent | nitric oxide scavenger",
    "disease_area": "allergy | gastroenterology | neurology/psychiatry | otolaryngology | rheumatology",
    "indication": "allergic rhinitis | constipation | irritability | joint pain | nasal congestion"
  },
  "ruxolitinib": {
    "name": "Ruxolitinib",
    "smiles": "N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1",
    "molecular_weight": 306.37,
    "log_p": 3.47,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "JAK inhibitor",
    "disease_area": "hematologic malignancy | hematology",
    "indication": "myelofibrosis | polycythemia vera"
  },
  "sacubitril": {
    "name": "Sacubitril",
    "smiles": "CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C1=CC=CC=C1)NC(=O)CCC(O)=O",
    "molecular_weight": 411.5,
    "log_p": 3.84,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "neprilysin inhibitor",
    "disease_area": "cardiology",
    "indication": "congestive heart failure"
  },
  "safinamide": {
    "name": "Safinamide",
    "smiles": "C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O",
    "molecular_weight": 302.35,
    "log_p": 2.37,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine reuptake inhibitor | glutamate inhibitor | monoamine oxidase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "Parkinson's Disease"
  },
  "salbutamol": {
    "name": "Salbutamol",
    "smiles": "CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1",
    "molecular_weight": 239.31,
    "log_p": 1.31,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "salicylamide": {
    "name": "Salicylamide",
    "smiles": "NC(=O)C1=CC=CC=C1O",
    "molecular_weight": 137.14,
    "log_p": 0.49,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "analgesic agent",
    "disease_area": "endocrinology | neurology/psychiatry",
    "indication": "fever | pain relief"
  },
  "salicylic acid": {
    "name": "Salicylic acid",
    "smiles": "OC(=O)C1=CC=CC=C1O",
    "molecular_weight": 138.12,
    "log_p": 1.09,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "salmeterol": {
    "name": "Salmeterol",
    "smiles": "OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1",
    "molecular_weight": 415.57,
    "log_p": 4.11,
    "hbd": 4,
    "hba": 5,
    "rotatable_bonds": 16,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "pulmonary | pulmonary | pulmonary",
    "indication": "asthma | bronchospasm | chronic obstructive pulmonary disease (COPD)"
  },
  "salsalate": {
    "name": "Salsalate",
    "smiles": "OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O",
    "molecular_weight": 258.23,
    "log_p": 2.31,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "samarium (153sm) lexidronam": {
    "name": "Samarium (153Sm) lexidronam",
    "smiles": "[153Sm+3].OP(O)(=O)CN(CCN(CP(O)([O-])=O)CP(O)([O-])=O)CP(O)([O-])=O",
    "molecular_weight": 586.02,
    "log_p": -3.76,
    "hbd": 5,
    "hba": 9,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA"
  },
  "samidorphan": {
    "name": "Samidorphan",
    "smiles": "NC(=O)C1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]4(CC(=O)CC[C@@]34O)C2=C1O",
    "molecular_weight": 370.45,
    "log_p": 1.25,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "sapropterin": {
    "name": "Sapropterin",
    "smiles": "[H][C@@]1(CNC2=C(N1)C(=O)NC(N)=N2)[C@@H](O)[C@H](C)O",
    "molecular_weight": 241.25,
    "log_p": -1.7,
    "hbd": 6,
    "hba": 7,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phenylalanine 4-hydroxylase stimulant",
    "disease_area": "metabolism",
    "indication": "hyperphenylalaninemia (HPA)"
  },
  "saquinavir": {
    "name": "Saquinavir",
    "smiles": "[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C",
    "molecular_weight": 670.86,
    "log_p": 3.09,
    "hbd": 5,
    "hba": 7,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HIV protease inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "sarecycline": {
    "name": "Sarecycline",
    "smiles": "[H][C@@]12CC3=C(CN(C)OC)C=CC(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2",
    "molecular_weight": 487.51,
    "log_p": 0.11,
    "hbd": 5,
    "hba": 10,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 50s ribosomal subunit inhibitor",
    "disease_area": "dermatology",
    "indication": "acne vulgaris (av)"
  },
  "saxagliptin": {
    "name": "Saxagliptin",
    "smiles": "[H][C@@]12C[C@]1([H])N([C@@H](C2)C#N)C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2",
    "molecular_weight": 315.42,
    "log_p": 1.16,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dipeptidyl peptidase inhibitor",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "scopolamine": {
    "name": "Scopolamine",
    "smiles": "CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1",
    "molecular_weight": 303.36,
    "log_p": 0.92,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "gastroenterology | gastroenterology | neurology/psychiatry",
    "indication": "motion sickness | nausea | vomiting"
  },
  "secnidazole": {
    "name": "Secnidazole",
    "smiles": "CC(O)CN1C(C)=NC=C1N(=O)=O",
    "molecular_weight": 185.18,
    "log_p": 0.48,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholinesterase inhibitor | microtubule inhibitor",
    "disease_area": "infectious disease",
    "indication": "protozoan infection"
  },
  "secobarbital": {
    "name": "Secobarbital",
    "smiles": "CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O",
    "molecular_weight": 238.29,
    "log_p": 1.35,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "segesterone acetate": {
    "name": "Segesterone acetate",
    "smiles": "[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]",
    "molecular_weight": 370.49,
    "log_p": 4.19,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "selegiline": {
    "name": "Selegiline",
    "smiles": "C[C@H](CC1=CC=CC=C1)N(C)CC#C",
    "molecular_weight": 187.29,
    "log_p": 2.18,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "monoamine oxidase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "Parkinson's Disease"
  },
  "selenic acid": {
    "name": "Selenic acid",
    "smiles": "O[Se](O)(=O)=O",
    "molecular_weight": 144.97,
    "log_p": -1.73,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "selenious acid": {
    "name": "Selenious acid",
    "smiles": "O[Se](O)=O",
    "molecular_weight": 128.97,
    "log_p": -1.61,
    "hbd": 2,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "selenium": {
    "name": "Selenium",
    "smiles": "[Se]",
    "molecular_weight": 78.96,
    "log_p": -0.38,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "selenium sulfide": {
    "name": "Selenium Sulfide",
    "smiles": "S=[Se]=S",
    "molecular_weight": 143.09,
    "log_p": 0.92,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "selenomethionine": {
    "name": "Selenomethionine",
    "smiles": "C[Se]CC[C@H](N)C(O)=O",
    "molecular_weight": 196.11,
    "log_p": -0.04,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "selenomethionine se-75": {
    "name": "Selenomethionine Se-75",
    "smiles": "C[75Se]CC[C@H](N)C(O)=O",
    "molecular_weight": 192.07,
    "log_p": -0.04,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "selexipag": {
    "name": "Selexipag",
    "smiles": "CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1",
    "molecular_weight": 496.63,
    "log_p": 3.9,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "IP1 prostacyclin receptor agonist | platelet aggregation inhibitor",
    "disease_area": "pulmonary",
    "indication": "pulmonary arterial hypertension (PAH)"
  },
  "selinexor": {
    "name": "Selinexor",
    "smiles": "FC(F)(F)C1=CC(=CC(=C1)C1=NN(\\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F",
    "molecular_weight": 443.31,
    "log_p": 3.39,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "exportin antagonist",
    "disease_area": "hematologic malignancy",
    "indication": "multiple myeloma"
  },
  "selpercatinib": {
    "name": "Selpercatinib",
    "smiles": "COC1=NC=C(CN2C3CC2CN(C3)C2=CC=C(C=N2)C2=CC(OCC(C)(C)O)=CN3N=CC(C#N)=C23)C=C1",
    "molecular_weight": 525.61,
    "log_p": 3.28,
    "hbd": 1,
    "hba": 10,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ret tyrosine kinase inhibitor",
    "disease_area": "oncology",
    "indication": "medullary thyroid cancer (mtc)"
  },
  "selumetinib": {
    "name": "Selumetinib",
    "smiles": "CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO",
    "molecular_weight": 457.69,
    "log_p": 3.53,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "MEK inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "semaglutide": {
    "name": "Semaglutide",
    "smiles": "CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CN=CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O",
    "molecular_weight": 4113.64,
    "log_p": -11.63,
    "hbd": 57,
    "hba": 56,
    "rotatable_bonds": 149,
    "approved": true,
    "source": "FDA"
  },
  "serdexmethylphenidate": {
    "name": "Serdexmethylphenidate",
    "smiles": "[H][C@@]1(CCCCN1C(=O)OC[N+]1=CC=CC(=C1)C(=O)N[C@@H](CO)C([O-])=O)[C@H](C(=O)OC)C1=CC=CC=C1",
    "molecular_weight": 499.52,
    "log_p": -0.28,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "sertaconazole": {
    "name": "Sertaconazole",
    "smiles": "ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC1=CSC2=C1C=CC=C2Cl",
    "molecular_weight": 437.78,
    "log_p": 7.02,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sterol demethylase inhibitor",
    "disease_area": "infectious disease",
    "indication": "tinea pedis"
  },
  "sertindole": {
    "name": "Sertindole",
    "smiles": "FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2",
    "molecular_weight": 440.95,
    "log_p": 4.63,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "dopamine receptor antagonist | serotonin receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "sertraline": {
    "name": "Sertraline",
    "smiles": "CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12",
    "molecular_weight": 306.24,
    "log_p": 5.18,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "selective serotonin reuptake inhibitor (SSRI)",
    "disease_area": "neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | obstetrics/gynecology",
    "indication": "depression | obsessive compulsive disorder (OCD) | panic disorders | posttraumatic stress disorder | premenstrual syndrome | social anxiety disorder"
  },
  "setmelanotide": {
    "name": "Setmelanotide",
    "smiles": "[H]N([H])C(=O)[C@@H]1CSSC[C@H](N([H])C(=O)[C@H](CCCN=C(N([H])[H])N([H])[H])N([H])C(C)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC2=CN=CN2[H])C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CN([H])C3=CC=CC=C23)C(=O)N1",
    "molecular_weight": 1117.33,
    "log_p": -3.18,
    "hbd": 15,
    "hba": 14,
    "rotatable_bonds": 18,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "melanocortin receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "sevelamer": {
    "name": "Sevelamer",
    "smiles": "NCC=C.ClCC1CO1",
    "molecular_weight": 149.62,
    "log_p": 0.76,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "sevoflurane": {
    "name": "Sevoflurane",
    "smiles": "FCOC(C(F)(F)F)C(F)(F)F",
    "molecular_weight": 200.05,
    "log_p": 2.42,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "membrane integrity inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "anesthetic"
  },
  "sibutramine": {
    "name": "Sibutramine",
    "smiles": "CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1",
    "molecular_weight": 279.85,
    "log_p": 4.74,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "silanol": {
    "name": "Silanol",
    "smiles": "O[SiH3]",
    "molecular_weight": 48.12,
    "log_p": -1.74,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sildenafil": {
    "name": "Sildenafil",
    "smiles": "CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1",
    "molecular_weight": 474.59,
    "log_p": 1.61,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "urology",
    "indication": "erectile dysfunction"
  },
  "silicon": {
    "name": "Silicon",
    "smiles": "[Si]",
    "molecular_weight": 28.09,
    "log_p": -0.38,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "silicon dioxide": {
    "name": "Silicon dioxide",
    "smiles": "O=[Si]=O",
    "molecular_weight": 60.08,
    "log_p": -0.62,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "silodosin": {
    "name": "Silodosin",
    "smiles": "C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F",
    "molecular_weight": 495.54,
    "log_p": 3.07,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "urology",
    "indication": "benign prostatic hyperplasia (BPH)"
  },
  "silodrate": {
    "name": "Silodrate",
    "smiles": "O.[O--].[O--].[Mg++].[Mg++].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O",
    "molecular_weight": 380.84,
    "log_p": -11.22,
    "hbd": 0,
    "hba": 9,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "silver": {
    "name": "Silver",
    "smiles": "[Ag]",
    "molecular_weight": 107.87,
    "log_p": -0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "silver nitrate": {
    "name": "Silver nitrate",
    "smiles": "[Ag+].[O-]N(=O)=O",
    "molecular_weight": 169.87,
    "log_p": -0.24,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "silver sulfadiazine": {
    "name": "Silver sulfadiazine",
    "smiles": "[Ag+].NC1=CC=C(C=C1)S(=O)(=O)[N-]C1=NC=CC=N1",
    "molecular_weight": 357.14,
    "log_p": 1.45,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "simeprevir": {
    "name": "Simeprevir",
    "smiles": "[H][C@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](C[C@@]1([H])C(=O)N(C)CCCC\\C=C/2)OC1=CC(=NC2=C1C=CC(OC)=C2C)C1=NC(=CS1)C(C)C)C(=O)NS(=O)(=O)C1CC1",
    "molecular_weight": 749.96,
    "log_p": 5.25,
    "hbd": 2,
    "hba": 10,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HCV inhibitor",
    "disease_area": "infectious disease",
    "indication": "hepatitis C"
  },
  "simethicone": {
    "name": "Simethicone",
    "smiles": "O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C",
    "molecular_weight": 238.46,
    "log_p": 1.57,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "simvastatin": {
    "name": "Simvastatin",
    "smiles": "[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC",
    "molecular_weight": 418.57,
    "log_p": 4.59,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HMGCR inhibitor",
    "disease_area": "cardiology | cardiology | endocrinology | endocrinology | neurology/psychiatry",
    "indication": "coronary heart disease | hypercholesterolemia | hyperlipidemia | myocardial infarction | stroke"
  },
  "sinapultide": {
    "name": "Sinapultide",
    "smiles": "CC(C)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O",
    "molecular_weight": 2469.45,
    "log_p": 6.48,
    "hbd": 27,
    "hba": 27,
    "rotatable_bonds": 93,
    "approved": true,
    "source": "FDA"
  },
  "sincalide": {
    "name": "Sincalide",
    "smiles": "CSCC[C@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O",
    "molecular_weight": 1143.29,
    "log_p": -1.33,
    "hbd": 13,
    "hba": 16,
    "rotatable_bonds": 33,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Preclinical",
    "moa": "cholecystokinin agonist",
    "disease_area": "",
    "indication": ""
  },
  "siponimod": {
    "name": "Siponimod",
    "smiles": "CCC1=CC(=CC=C1CN1CC(C1)C(O)=O)C(\\C)=N\\OCC1=CC=C(C2CCCCC2)C(=C1)C(F)(F)F",
    "molecular_weight": 516.6,
    "log_p": 6.77,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sphingosine 1-phosphate receptor modulator",
    "disease_area": "neurology/psychiatry",
    "indication": "multiple sclerosis"
  },
  "sirolimus": {
    "name": "Sirolimus",
    "smiles": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC",
    "molecular_weight": 914.19,
    "log_p": 6.18,
    "hbd": 3,
    "hba": 13,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "mTOR inhibitor",
    "disease_area": "pulmonary | transplant | transplant, pulmonary",
    "indication": "lymphangioleiomyomatosis | organ rejection | organ rejection, lymphangioleiomyomatosis"
  },
  "sitagliptin": {
    "name": "Sitagliptin",
    "smiles": "N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F",
    "molecular_weight": 407.32,
    "log_p": 2.02,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dipeptidyl peptidase inhibitor",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "sitaxentan": {
    "name": "Sitaxentan",
    "smiles": "CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl",
    "molecular_weight": 454.91,
    "log_p": 3.96,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "endothelin receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "sodium 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol)": {
    "name": "Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol)",
    "smiles": "[Na+].[H][C@@](COC(=O)CCCCCCCCCCCCCCC)(COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC",
    "molecular_weight": 744.96,
    "log_p": 6.26,
    "hbd": 2,
    "hba": 10,
    "rotatable_bonds": 38,
    "approved": true,
    "source": "FDA"
  },
  "sodium acetate": {
    "name": "Sodium acetate",
    "smiles": "[Na+].CC([O-])=O",
    "molecular_weight": 82.03,
    "log_p": -4.24,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium ascorbate": {
    "name": "Sodium ascorbate",
    "smiles": "[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO",
    "molecular_weight": 198.11,
    "log_p": -5.6,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "sodium aurothiomalate": {
    "name": "Sodium aurothiomalate",
    "smiles": "[Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O",
    "molecular_weight": 390.08,
    "log_p": -8.55,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "sodium aurotiosulfate": {
    "name": "Sodium aurotiosulfate",
    "smiles": "O.O.[Na+].[Na+].[Na+].[Au+].[O-]S([S-])(=O)=O.[O-]S([S-])(=O)=O",
    "molecular_weight": 526.23,
    "log_p": -12.65,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium bicarbonate": {
    "name": "Sodium bicarbonate",
    "smiles": "[Na+].OC([O-])=O",
    "molecular_weight": 84.01,
    "log_p": -4.11,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium bisulfite": {
    "name": "Sodium bisulfite",
    "smiles": "[Na+].OS([O-])=O",
    "molecular_weight": 104.06,
    "log_p": -3.66,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium borate": {
    "name": "Sodium borate",
    "smiles": "[Na+].[Na+].[O-]B1OB2OB([O-])OB(O1)O2",
    "molecular_weight": 201.22,
    "log_p": -10.24,
    "hbd": 0,
    "hba": 7,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium camphorsulfonate": {
    "name": "Sodium camphorsulfonate",
    "smiles": "[Na+].[H][C@]12CC[C@@](CS([O-])(=O)=O)(C(=O)C1)C2(C)C",
    "molecular_weight": 254.28,
    "log_p": -2.07,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "sodium carbonate": {
    "name": "Sodium carbonate",
    "smiles": "[Na+].[Na+].[O-]C([O-])=O",
    "molecular_weight": 105.99,
    "log_p": -8.44,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium chloride": {
    "name": "Sodium chloride",
    "smiles": "[Na+].[Cl-]",
    "molecular_weight": 58.44,
    "log_p": -5.99,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium chromate cr-51": {
    "name": "Sodium chromate Cr-51",
    "smiles": "[Na+].[Na+].[O-][51Cr]([O-])(=O)=O",
    "molecular_weight": 160.92,
    "log_p": -8.61,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium citrate": {
    "name": "Sodium citrate",
    "smiles": "[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O",
    "molecular_weight": 258.07,
    "log_p": -14.24,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "sodium feredetate": {
    "name": "Sodium feredetate",
    "smiles": "[Na+].[O-]C(=O)C[N+]12CC[N+]34CC(=O)O[Fe--]13(OC(=O)C2)OC(=O)C4",
    "molecular_weight": 367.05,
    "log_p": -6.68,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "sodium ferric gluconate complex": {
    "name": "Sodium ferric gluconate complex",
    "smiles": "[O--].[O--].[O--].[Na+].[Fe+3].[Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O",
    "molecular_weight": 2089.31,
    "log_p": -35.16,
    "hbd": 45,
    "hba": 62,
    "rotatable_bonds": 30,
    "approved": true,
    "source": "FDA"
  },
  "sodium fluoride": {
    "name": "Sodium fluoride",
    "smiles": "[F-].[Na+]",
    "molecular_weight": 41.99,
    "log_p": -5.99,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium fluorophosphate": {
    "name": "Sodium fluorophosphate",
    "smiles": "[Na+].[Na+].[O-]P([O-])(F)=O",
    "molecular_weight": 143.95,
    "log_p": -7.21,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium glycerophosphate": {
    "name": "Sodium glycerophosphate",
    "smiles": "[Na+].[Na+].OCC(O)COP([O-])([O-])=O",
    "molecular_weight": 216.04,
    "log_p": -8.81,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "sodium hydroxide": {
    "name": "Sodium hydroxide",
    "smiles": "[OH-].[Na+]",
    "molecular_weight": 40.0,
    "log_p": -3.17,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium iodide": {
    "name": "Sodium iodide",
    "smiles": "[Na+].[I-]",
    "molecular_weight": 149.89,
    "log_p": -5.99,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium lauryl sulfoacetate": {
    "name": "Sodium lauryl sulfoacetate",
    "smiles": "[Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O",
    "molecular_weight": 330.42,
    "log_p": -0.0,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA"
  },
  "sodium metavanadate": {
    "name": "Sodium metavanadate",
    "smiles": "[Na+].[O-][V](=O)=O",
    "molecular_weight": 121.93,
    "log_p": -4.43,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium molybdate": {
    "name": "Sodium molybdate",
    "smiles": "[Na+].[Na+].[O-][Mo]([O-])(=O)=O",
    "molecular_weight": 205.92,
    "log_p": -8.61,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium oxybate": {
    "name": "Sodium oxybate",
    "smiles": "[Na+].OCCCC([O-])=O",
    "molecular_weight": 126.09,
    "log_p": -4.49,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "sodium phosphate p 32": {
    "name": "Sodium phosphate P 32",
    "smiles": "[Na+].[Na+].O[32P]([O-])([O-])=O",
    "molecular_weight": 142.96,
    "log_p": -8.18,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium phosphate, dibasic": {
    "name": "Sodium phosphate, dibasic",
    "smiles": "[Na+].[Na+].OP([O-])([O-])=O",
    "molecular_weight": 141.96,
    "log_p": -8.18,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium phosphate, monobasic": {
    "name": "Sodium phosphate, monobasic",
    "smiles": "[Na+].OP(O)([O-])=O",
    "molecular_weight": 119.98,
    "log_p": -4.56,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium stibogluconate": {
    "name": "Sodium stibogluconate",
    "smiles": "O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[H][C@@]1(O[Sb]2(O)(O[Sb]34([O-])O[C@@H](C([O-])=O)[C@@]([H])(O3)[C@]([H])(O4)[C@H](O)CO)O[C@@H](C([O-])=O)[C@@]1([H])O2)[C@H](O)CO",
    "molecular_weight": 907.88,
    "log_p": -25.71,
    "hbd": 5,
    "hba": 17,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "tyrosine phosphatase inhibitor",
    "disease_area": "infectious disease",
    "indication": "leishmaniasis"
  },
  "sodium sulfate": {
    "name": "Sodium sulfate",
    "smiles": "[Na+].[Na+].[O-]S([O-])(=O)=O",
    "molecular_weight": 142.04,
    "log_p": -7.33,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium sulfide": {
    "name": "Sodium sulfide",
    "smiles": "[Na+].[Na+].[S--]",
    "molecular_weight": 78.05,
    "log_p": -5.99,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sodium tartrate": {
    "name": "Sodium tartrate",
    "smiles": "[Na+].[Na+].O[C@H]([C@@H](O)C([O-])=O)C([O-])=O",
    "molecular_weight": 194.05,
    "log_p": -10.78,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "sodium tetradecyl sulfate": {
    "name": "Sodium tetradecyl sulfate",
    "smiles": "[Na+].CCCCC(CC)CCC(CC(C)C)OS([O-])(=O)=O",
    "molecular_weight": 316.44,
    "log_p": 0.88,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA"
  },
  "sodium zirconium cyclosilicate": {
    "name": "Sodium zirconium cyclosilicate",
    "smiles": "[Na+].[Na+].[Zr].[O-][Si]1([O-])O[Si]([O-])([O-])O[Si]([O-])([O-])O1",
    "molecular_weight": 365.45,
    "log_p": -14.48,
    "hbd": 0,
    "hba": 9,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sofosbuvir": {
    "name": "Sofosbuvir",
    "smiles": "CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1",
    "molecular_weight": 529.46,
    "log_p": 1.66,
    "hbd": 3,
    "hba": 10,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HCV inhibitor",
    "disease_area": "infectious disease",
    "indication": "hepatitis C"
  },
  "solifenacin": {
    "name": "Solifenacin",
    "smiles": "O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1",
    "molecular_weight": 362.47,
    "log_p": 3.86,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "solriamfetol": {
    "name": "Solriamfetol",
    "smiles": "N[C@@H](COC(N)=O)CC1=CC=CC=C1",
    "molecular_weight": 194.23,
    "log_p": 0.65,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine reuptake inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "narcolepsy"
  },
  "somatostatin": {
    "name": "Somatostatin",
    "smiles": "C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O",
    "molecular_weight": 1637.91,
    "log_p": -4.91,
    "hbd": 22,
    "hba": 23,
    "rotatable_bonds": 26,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "somatostatin receptor agonist",
    "disease_area": "hematology",
    "indication": "hemorrhage"
  },
  "sonidegib": {
    "name": "Sonidegib",
    "smiles": "[H][C@]1(C)CN(C[C@@]([H])(C)O1)C1=CC=C(NC(=O)C2=CC=CC(=C2C)C2=CC=C(OC(F)(F)F)C=C2)C=N1",
    "molecular_weight": 485.51,
    "log_p": 5.82,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "smoothened receptor antagonist",
    "disease_area": "oncology",
    "indication": "basal cell carcinoma (BCC)"
  },
  "sorafenib": {
    "name": "Sorafenib",
    "smiles": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1",
    "molecular_weight": 464.83,
    "log_p": 5.55,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "FLT3 inhibitor | KIT inhibitor | PDGFR tyrosine kinase receptor inhibitor | RAF inhibitor | RET tyrosine kinase inhibitor | VEGFR inhibitor",
    "disease_area": "oncology | oncology | oncology",
    "indication": "hepatocellular carcinoma (HCC) | renal cell carcinoma (RCC) | thyroid cancer"
  },
  "sorbitol": {
    "name": "Sorbitol",
    "smiles": "OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO",
    "molecular_weight": 182.17,
    "log_p": -3.59,
    "hbd": 6,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "mucolytic agent",
    "disease_area": "gastroenterology",
    "indication": "constipation"
  },
  "sotagliflozin": {
    "name": "Sotagliflozin",
    "smiles": "CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1",
    "molecular_weight": 424.95,
    "log_p": 3.17,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "sodium/glucose cotransporter inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "sotalol": {
    "name": "Sotalol",
    "smiles": "CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1",
    "molecular_weight": 272.37,
    "log_p": 1.09,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology | cardiology | Cardiology",
    "indication": "angina pectoris | atrial fibrillation (AF) | ventricular arrhythmias"
  },
  "sotorasib": {
    "name": "Sotorasib",
    "smiles": "CC(C)C1=NC=CC(C)=C1N1C(=O)N=C(N2CCN(C[C@@H]2C)C(=O)C=C)C2=CC(F)=C(N=C12)C1=C(O)C=CC=C1F",
    "molecular_weight": 560.61,
    "log_p": 4.48,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ras gtpase inhibitor",
    "disease_area": "oncology",
    "indication": "non-small cell lung cancer (nsclc)"
  },
  "sparfloxacin": {
    "name": "Sparfloxacin",
    "smiles": "C[C@H]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O",
    "molecular_weight": 392.41,
    "log_p": 2.08,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "bacterial DNA gyrase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "spectinomycin": {
    "name": "Spectinomycin",
    "smiles": "[H][C@@]12O[C@H](C)CC(=O)[C@]1(O)O[C@]1([H])[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@@]1([H])O2",
    "molecular_weight": 332.35,
    "log_p": -2.93,
    "hbd": 5,
    "hba": 9,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor",
    "disease_area": "pulmonary | pulmonary",
    "indication": "airsacculitis | chronic respiratory disease"
  },
  "spinosad": {
    "name": "Spinosad",
    "smiles": "[H][C@]1(C[C@@]2([H])C=C[C@@]3([H])[C@]4([H])CC(=O)O[C@@]([H])(CC)CCC[C@]([H])(O[C@@]5([H])CC[C@]([H])(N(C)C)[C@@]([H])(C)O5)[C@@]([H])(C)C(=O)C4=C[C@@]3([H])[C@]2([H])C1)O[C@]1([H])O[C@@]([H])(C)[C@]([H])(OC)[C@@]([H])(OC)[C@@]1([H])OC.[H][C@]1(C[C@@]2([H])C(C)=C[C@@]3([H])[C@]4([H])CC(=O)O[C@@]([H])(CC)CCC[C@]([H])(O[C@@]5([H])CC[C@]([H])(N(C)C)[C@@]([H])(C)O5)[C@@]([H])(C)C(=O)C4=C[C@@]3([H])[C@]2([H])C1)O[C@]1([H])O[C@@]([H])(C)[C@]([H])(OC)[C@@]([H])(OC)[C@@]1([H])OC",
    "molecular_weight": 1477.96,
    "log_p": 11.36,
    "hbd": 0,
    "hba": 22,
    "rotatable_bonds": 18,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor agonist",
    "disease_area": "infectious disease",
    "indication": "lice"
  },
  "spiramycin": {
    "name": "Spiramycin",
    "smiles": "[H][C@@]1(CC[C@@H]([C@@H](C)O1)N(C)C)O[C@H]1\\C=C\\C=C\\C[C@@H](C)OC(=O)C[C@@H](O)[C@H](OC)[C@@H](O[C@]2([H])O[C@H](C)[C@@H](O[C@@]3([H])C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@H]1C",
    "molecular_weight": 843.07,
    "log_p": 2.33,
    "hbd": 4,
    "hba": 16,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 50S ribosomal subunit inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "soft tissue infection | toxoplasmosis | toxoplasmosis, soft tissue infection"
  },
  "spirapril": {
    "name": "Spirapril",
    "smiles": "CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(O)=O)SCCS2",
    "molecular_weight": 466.63,
    "log_p": 2.39,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "angiotensin converting enzyme inhibitor",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "spironolactone": {
    "name": "Spironolactone",
    "smiles": "[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O",
    "molecular_weight": 416.58,
    "log_p": 4.85,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "mineralocorticoid receptor antagonist",
    "disease_area": "cardiology | cardiology | endocrinology | endocrinology | gastroenterology | rheumatology",
    "indication": "congestive heart failure | hepatic cirrhosis | hyperaldosteronism | hypertension | hypokalemia | nephrotic syndrome"
  },
  "squalene": {
    "name": "Squalene",
    "smiles": "CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CC\\C=C(/C)CC\\C=C(/C)CCC=C(C)C",
    "molecular_weight": 410.73,
    "log_p": 10.6,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA"
  },
  "stannous chloride": {
    "name": "Stannous chloride",
    "smiles": "[Cl-].[Cl-].[Sn++]",
    "molecular_weight": 189.62,
    "log_p": -6.37,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "stannous fluoride": {
    "name": "Stannous fluoride",
    "smiles": "F[Sn]F",
    "molecular_weight": 156.71,
    "log_p": 0.46,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "stanozolol": {
    "name": "Stanozolol",
    "smiles": "[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=NNC=C3C[C@]12C",
    "molecular_weight": 328.5,
    "log_p": 4.12,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "androgen receptor agonist",
    "disease_area": "Oncology",
    "indication": "breast cancer"
  },
  "stavudine": {
    "name": "Stavudine",
    "smiles": "CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O",
    "molecular_weight": 224.22,
    "log_p": -0.71,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA directed DNA polymerase inhibitor | nucleoside reverse transcriptase inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "stearic acid": {
    "name": "Stearic acid",
    "smiles": "CCCCCCCCCCCCCCCCCC(O)=O",
    "molecular_weight": 284.48,
    "log_p": 6.33,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 16,
    "approved": true,
    "source": "FDA"
  },
  "steviolbioside": {
    "name": "Steviolbioside",
    "smiles": "C[C@@]12CCC[C@](C)([C@H]1CC[C@@]13CC(=C)[C@@](C1)(CC[C@@H]23)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(O)=O",
    "molecular_weight": 642.74,
    "log_p": -0.2,
    "hbd": 8,
    "hba": 12,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "stiripentol": {
    "name": "Stiripentol",
    "smiles": "CC(C)(C)C(O)\\C=C\\C1=CC2=C(OCO2)C=C1",
    "molecular_weight": 234.29,
    "log_p": 2.84,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "GABA uptake inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "epilepsy"
  },
  "streptomycin": {
    "name": "Streptomycin",
    "smiles": "CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O",
    "molecular_weight": 581.58,
    "log_p": -7.74,
    "hbd": 14,
    "hba": 15,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor",
    "disease_area": "infectious disease",
    "indication": "tuberculosis"
  },
  "streptozocin": {
    "name": "Streptozocin",
    "smiles": "CN(N=O)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O",
    "molecular_weight": 265.22,
    "log_p": -2.89,
    "hbd": 5,
    "hba": 8,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "",
    "moa": "dna alkylating drug",
    "disease_area": "Oncology",
    "indication": "pancreatic cancer"
  },
  "strontium chloride": {
    "name": "Strontium chloride",
    "smiles": "[Cl-].[Cl-].[Sr++]",
    "molecular_weight": 158.53,
    "log_p": -6.37,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "strontium chloride sr-89": {
    "name": "Strontium chloride Sr-89",
    "smiles": "[Cl-].[Cl-].[89Sr++]",
    "molecular_weight": 159.81,
    "log_p": -6.37,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "strontium ranelate": {
    "name": "Strontium ranelate",
    "smiles": "[Sr++].[Sr++].[O-]C(=O)CN(CC([O-])=O)C1=C(C#N)C(CC([O-])=O)=C(S1)C([O-])=O",
    "molecular_weight": 513.49,
    "log_p": -6.18,
    "hbd": 0,
    "hba": 11,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "succimer": {
    "name": "Succimer",
    "smiles": "OC(=O)[C@@H](S)[C@@H](S)C(O)=O",
    "molecular_weight": 182.22,
    "log_p": -0.25,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "succinic acid": {
    "name": "Succinic acid",
    "smiles": "OC(=O)CCC(O)=O",
    "molecular_weight": 118.09,
    "log_p": -0.06,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "succinylcholine": {
    "name": "Succinylcholine",
    "smiles": "C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C",
    "molecular_weight": 290.4,
    "log_p": 0.27,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "sucralfate": {
    "name": "Sucralfate",
    "smiles": "O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O",
    "molecular_weight": 1558.73,
    "log_p": -22.23,
    "hbd": 19,
    "hba": 54,
    "rotatable_bonds": 37,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antacid",
    "disease_area": "gastroenterology",
    "indication": "duodenal ulcer disease"
  },
  "sucrose": {
    "name": "Sucrose",
    "smiles": "OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O",
    "molecular_weight": 342.3,
    "log_p": -5.4,
    "hbd": 8,
    "hba": 11,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "sufentanil": {
    "name": "Sufentanil",
    "smiles": "CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1",
    "molecular_weight": 386.56,
    "log_p": 4.21,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "sugammadex": {
    "name": "Sugammadex",
    "smiles": "O[C@@H]1[C@@H](O)[C@@H]2O[C@H]3O[C@H](CSCCC(O)=O)[C@@H](O[C@H]4O[C@H](CSCCC(O)=O)[C@@H](O[C@H]5O[C@H](CSCCC(O)=O)[C@@H](O[C@H]6O[C@H](CSCCC(O)=O)[C@@H](O[C@H]7O[C@H](CSCCC(O)=O)[C@@H](O[C@H]8O[C@H](CSCCC(O)=O)[C@@H](O[C@H]9O[C@H](CSCCC(O)=O)[C@@H](O[C@H]1O[C@@H]2CSCCC(O)=O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O",
    "molecular_weight": 2002.18,
    "log_p": -7.68,
    "hbd": 24,
    "hba": 48,
    "rotatable_bonds": 40,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "neuromuscular blockade reversal agent",
    "disease_area": "",
    "indication": ""
  },
  "sulbactam": {
    "name": "Sulbactam",
    "smiles": "[H][C@@]12CC(=O)N1[C@@]([H])(C(O)=O)C(C)(C)S2(=O)=O",
    "molecular_weight": 233.24,
    "log_p": -0.79,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "beta lactamase inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "gynecologic infections | intra-abdominal infections | skin infections | skin infections, intra-abdominal infections, gynecologic infections"
  },
  "sulconazole": {
    "name": "Sulconazole",
    "smiles": "ClC1=CC=C(CSC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1",
    "molecular_weight": 397.76,
    "log_p": 6.52,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sterol demethylase inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "tinea corporis | tinea cruris | tinea pedis"
  },
  "sulfabenzamide": {
    "name": "Sulfabenzamide",
    "smiles": "NC1=CC=C(C=C1)S(=O)(=O)NC(=O)C1=CC=CC=C1",
    "molecular_weight": 276.32,
    "log_p": 1.39,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial antifolate",
    "disease_area": "infectious disease | infectious disease",
    "indication": "gram-negative bacterial infections | gram-positive bacterial infections"
  },
  "sulfacetamide": {
    "name": "Sulfacetamide",
    "smiles": "CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1",
    "molecular_weight": 214.25,
    "log_p": 0.09,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PABA antagonist",
    "disease_area": "ophthalmology",
    "indication": "conjunctivitis"
  },
  "sulfacytine": {
    "name": "Sulfacytine",
    "smiles": "CCN1C=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC1=O",
    "molecular_weight": 294.34,
    "log_p": 0.65,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "sulfadiazine": {
    "name": "Sulfadiazine",
    "smiles": "NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1",
    "molecular_weight": 250.28,
    "log_p": 0.86,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial antifolate",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | ophthalmology",
    "indication": "chancroid | conjunctivitis | malaria | meningitis | trachoma | urinary tract infections"
  },
  "sulfadimethoxine": {
    "name": "Sulfadimethoxine",
    "smiles": "COC1=NC(OC)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1",
    "molecular_weight": 310.34,
    "log_p": 0.88,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "sulfadoxine": {
    "name": "Sulfadoxine",
    "smiles": "COC1=NC=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1OC",
    "molecular_weight": 310.34,
    "log_p": 0.88,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dihydropteroate synthase inhibitor",
    "disease_area": "infectious disease",
    "indication": "malaria"
  },
  "sulfamerazine": {
    "name": "Sulfamerazine",
    "smiles": "CC1=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC=C1",
    "molecular_weight": 264.31,
    "log_p": 1.17,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial antifolate",
    "disease_area": "infectious disease | infectious disease",
    "indication": "cholera | coccidiosis"
  },
  "sulfameter": {
    "name": "Sulfameter",
    "smiles": "COC1=CN=C(NS(=O)(=O)C2=CC=C(N)C=C2)N=C1",
    "molecular_weight": 280.31,
    "log_p": 0.87,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dihydrofolate reductase inhibitor",
    "disease_area": "infectious disease",
    "indication": "urinary tract infections"
  },
  "sulfamethazine": {
    "name": "Sulfamethazine",
    "smiles": "CC1=CC(C)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=N1",
    "molecular_weight": 278.34,
    "log_p": 1.48,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PABA antagonist",
    "disease_area": "gastroenterology",
    "indication": "enteritis"
  },
  "sulfamethizole": {
    "name": "Sulfamethizole",
    "smiles": "CC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1",
    "molecular_weight": 270.34,
    "log_p": 1.23,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial antifolate",
    "disease_area": "infectious disease",
    "indication": "urinary tract infections"
  },
  "sulfamethoxazole": {
    "name": "Sulfamethoxazole",
    "smiles": "CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1",
    "molecular_weight": 253.28,
    "log_p": 1.37,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PABA antagonist",
    "disease_area": "gastroenterology | infectious disease | infectious disease",
    "indication": "enteritis | pneumonia | urinary tract infections"
  },
  "sulfametopyrazine": {
    "name": "Sulfametopyrazine",
    "smiles": "COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1",
    "molecular_weight": 280.31,
    "log_p": 0.87,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PABA antagonist",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "malaria | respiratory tract infections | urinary tract infections"
  },
  "sulfanilamide": {
    "name": "Sulfanilamide",
    "smiles": "NC1=CC=C(C=C1)S(N)(=O)=O",
    "molecular_weight": 172.21,
    "log_p": -0.08,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "carbonic anhydrase inhibitor",
    "disease_area": "infectious disease",
    "indication": "vulvovaginal candidiasis"
  },
  "sulfaphenazole": {
    "name": "Sulfaphenazole",
    "smiles": "NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1",
    "molecular_weight": 314.37,
    "log_p": 2.26,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dihydropteroate synthetase inhibitor",
    "disease_area": "infectious disease",
    "indication": "urinary tract infections"
  },
  "sulfapyridine": {
    "name": "Sulfapyridine",
    "smiles": "NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1",
    "molecular_weight": 249.3,
    "log_p": 1.46,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PABA antagonist",
    "disease_area": "infectious disease | infectious disease",
    "indication": "gram-negative bacterial infections | gram-positive bacterial infections"
  },
  "sulfasalazine": {
    "name": "Sulfasalazine",
    "smiles": "OC(=O)C1=CC(=CC=C1O)\\N=N\\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1",
    "molecular_weight": 398.4,
    "log_p": 3.7,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "gastroenterology",
    "indication": "ulcerative colitis"
  },
  "sulfathiazole": {
    "name": "Sulfathiazole",
    "smiles": "NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1",
    "molecular_weight": 255.32,
    "log_p": 1.53,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dihydropteroate synthase inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "gram-negative bacterial infections | gram-positive bacterial infections"
  },
  "sulfinpyrazone": {
    "name": "Sulfinpyrazone",
    "smiles": "O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 404.49,
    "log_p": 3.8,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "uricosuric blocker",
    "disease_area": "rheumatology",
    "indication": "gout"
  },
  "sulfisoxazole": {
    "name": "Sulfisoxazole",
    "smiles": "CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C",
    "molecular_weight": 267.31,
    "log_p": 1.67,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "sulfoxone": {
    "name": "Sulfoxone",
    "smiles": "OS(=O)CNC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(NCS(O)=O)C=C1",
    "molecular_weight": 404.49,
    "log_p": 1.7,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "sulfur hexafluoride": {
    "name": "Sulfur hexafluoride",
    "smiles": "FS(F)(F)(F)(F)F",
    "molecular_weight": 146.06,
    "log_p": 3.17,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "sulindac": {
    "name": "Sulindac",
    "smiles": "CC1=C(CC(O)=O)C2=CC(F)=CC=C2\\C1=C/C1=CC=C(C=C1)S(C)=O",
    "molecular_weight": 356.42,
    "log_p": 4.37,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "rheumatology | rheumatology | rheumatology",
    "indication": "ankylosing spondylitis | osteoarthritis | rheumatoid arthritis"
  },
  "sulpiride": {
    "name": "Sulpiride",
    "smiles": "CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O",
    "molecular_weight": 341.43,
    "log_p": 0.56,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "schizophrenia"
  },
  "sultamicillin": {
    "name": "Sultamicillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(=O)OCOC(=O)[C@@H]1N2C(=O)C[C@@]2([H])S(=O)(=O)C1(C)C",
    "molecular_weight": 594.67,
    "log_p": -0.59,
    "hbd": 2,
    "hba": 11,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antibacterial",
    "disease_area": "infectious disease | infectious disease",
    "indication": "gram-negative bacterial infections | gram-positive bacterial infections"
  },
  "sulthiame": {
    "name": "Sulthiame",
    "smiles": "NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O",
    "molecular_weight": 290.37,
    "log_p": 0.26,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "sultopride": {
    "name": "Sultopride",
    "smiles": "CCN1CCCC1CNC(=O)C1=CC(=CC=C1OC)S(=O)(=O)CC",
    "molecular_weight": 354.47,
    "log_p": 1.7,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Preclinical",
    "moa": "dopamine receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "sumatriptan": {
    "name": "Sumatriptan",
    "smiles": "CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1",
    "molecular_weight": 295.41,
    "log_p": 1.32,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "migraine headache"
  },
  "sunitinib": {
    "name": "Sunitinib",
    "smiles": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C",
    "molecular_weight": 398.48,
    "log_p": 3.33,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "FLT3 inhibitor | KIT inhibitor | PDGFR tyrosine kinase receptor inhibitor | RET tyrosine kinase inhibitor | VEGFR inhibitor",
    "disease_area": "oncology | oncology | oncology",
    "indication": "gastrointestinal stromal tumors (GIST) | neuroendocrine tumors of pancreatic origin (PNET) | renal cell carcinoma (RCC)"
  },
  "suprofen": {
    "name": "Suprofen",
    "smiles": "CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1",
    "molecular_weight": 260.31,
    "log_p": 3.17,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "suvorexant": {
    "name": "Suvorexant",
    "smiles": "[H][C@@]1(C)CCN(CCN1C(=O)C1=C(C=CC(C)=C1)N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2",
    "molecular_weight": 450.93,
    "log_p": 4.11,
    "hbd": 0,
    "hba": 7,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "synthetic camphor": {
    "name": "Synthetic camphor",
    "smiles": "CC1(C)C2CCC1(C)C(=O)C2",
    "molecular_weight": 152.24,
    "log_p": 2.4,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "tacrine": {
    "name": "Tacrine",
    "smiles": "NC1=C2CCCCC2=NC2=CC=CC=C12",
    "molecular_weight": 198.27,
    "log_p": 2.7,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholinesterase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "Alzheimer's disease"
  },
  "tacrolimus": {
    "name": "Tacrolimus",
    "smiles": "CO[C@@H]1C[C@@H](CC[C@H]1O)\\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\\C(C)=C\\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC",
    "molecular_weight": 804.03,
    "log_p": 4.64,
    "hbd": 3,
    "hba": 12,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcineurin inhibitor",
    "disease_area": "transplant",
    "indication": "organ rejection"
  },
  "tadalafil": {
    "name": "Tadalafil",
    "smiles": "[H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1",
    "molecular_weight": 389.41,
    "log_p": 2.21,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "urology",
    "indication": "erectile dysfunction"
  },
  "tafamidis": {
    "name": "Tafamidis",
    "smiles": "OC(=O)C1=CC=C2N=C(OC2=C1)C1=CC(Cl)=CC(Cl)=C1",
    "molecular_weight": 308.12,
    "log_p": 4.5,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "tafenoquine": {
    "name": "Tafenoquine",
    "smiles": "COC1=CC(C)=C2C(OC3=CC=CC(=C3)C(F)(F)F)=C(OC)C=C(NC(C)CCCN)C2=N1",
    "molecular_weight": 463.5,
    "log_p": 5.91,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antimalarial agent",
    "disease_area": "infectious disease",
    "indication": "malaria"
  },
  "tafluprost": {
    "name": "Tafluprost",
    "smiles": "CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\C(F)(F)COC1=CC=CC=C1",
    "molecular_weight": 452.54,
    "log_p": 4.68,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "prostaglandin inhibitor",
    "disease_area": "ophthalmology | ophthalmology",
    "indication": "glaucoma | ocular hypertension"
  },
  "talazoparib": {
    "name": "Talazoparib",
    "smiles": "CN1N=CN=C1[C@@H]1[C@H](NC2=C3C1=NNC(=O)C3=CC(F)=C2)C1=CC=C(F)C=C1",
    "molecular_weight": 380.36,
    "log_p": 2.63,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "PARP inhibitor",
    "disease_area": "oncology",
    "indication": "breast cancer"
  },
  "talbutal": {
    "name": "Talbutal",
    "smiles": "CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O",
    "molecular_weight": 224.26,
    "log_p": 0.96,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "talc": {
    "name": "Talc",
    "smiles": "[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mg++].[Mg++].[Mg++].[Si+4].[Si+4].[Si+4].[Si+4].[O-][H].[O-][H]",
    "molecular_weight": 379.26,
    "log_p": -4.21,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "tamoxifen": {
    "name": "Tamoxifen",
    "smiles": "CC\\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1",
    "molecular_weight": 371.52,
    "log_p": 6.0,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "estrogen receptor antagonist | selective estrogen receptor modulator (SERM)",
    "disease_area": "oncology",
    "indication": "breast cancer"
  },
  "tamsulosin": {
    "name": "Tamsulosin",
    "smiles": "CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O",
    "molecular_weight": 408.52,
    "log_p": 2.34,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "urology",
    "indication": "benign prostatic hyperplasia (BPH)"
  },
  "tannic acid": {
    "name": "Tannic acid",
    "smiles": "OC1=CC(=CC(O)=C1O)C(=O)OC1=C(O)C(O)=CC(=C1)C(=O)OC[C@H]1OC(OC(=O)C2=CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)=C(O)C(O)=C2)[C@H](OC(=O)C2=CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)=C(O)C(O)=C2)[C@@H](OC(=O)C2=CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)=C(O)C(O)=C2)[C@@H]1OC(=O)C1=CC(OC(=O)C2=CC(O)=C(O)C(O)=C2)=C(O)C(O)=C1",
    "molecular_weight": 1701.21,
    "log_p": 4.84,
    "hbd": 25,
    "hba": 46,
    "rotatable_bonds": 21,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "parg inhibitor",
    "disease_area": "gastroenterology",
    "indication": "constipation"
  },
  "tapentadol": {
    "name": "Tapentadol",
    "smiles": "CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1",
    "molecular_weight": 221.34,
    "log_p": 3.08,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "tapinarof": {
    "name": "Tapinarof",
    "smiles": "CC(C)C1=C(O)C=C(\\C=C\\C2=CC=CC=C2)C=C1O",
    "molecular_weight": 254.33,
    "log_p": 4.39,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "aryl hydrocarbon receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "tasimelteon": {
    "name": "Tasimelteon",
    "smiles": "CCC(=O)NC[C@@H]1C[C@H]1C1=CC=CC2=C1CCO2",
    "molecular_weight": 245.32,
    "log_p": 2.25,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "melatonin receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "Non-24-Hour Sleep-Wake Disorder"
  },
  "taurine": {
    "name": "Taurine",
    "smiles": "NCCS(O)(=O)=O",
    "molecular_weight": 125.15,
    "log_p": -1.17,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antioxidant",
    "disease_area": "neurology/psychiatry | neurology/psychiatry | neurology/psychiatry",
    "indication": "anxiety | irritability | sleeplessness"
  },
  "taurocholic acid": {
    "name": "Taurocholic acid",
    "smiles": "[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCCS(O)(=O)=O",
    "molecular_weight": 515.71,
    "log_p": 2.37,
    "hbd": 5,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "taurolidine": {
    "name": "Taurolidine",
    "smiles": "O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1",
    "molecular_weight": 284.36,
    "log_p": -2.67,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "apoptosis stimulant",
    "disease_area": "infectious disease",
    "indication": "catheter-related bloodstream infection"
  },
  "tauroursodeoxycholic acid": {
    "name": "Tauroursodeoxycholic acid",
    "smiles": "[H][C@@]12CC[C@H]([C@H](C)CCC(=O)NCCS(O)(=O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](O)C[C@]2([H])C[C@H](O)CC[C@]12C",
    "molecular_weight": 499.71,
    "log_p": 3.4,
    "hbd": 4,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "tavaborole": {
    "name": "Tavaborole",
    "smiles": "OB1OCC2=CC(F)=CC=C12",
    "molecular_weight": 151.93,
    "log_p": 0.04,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "leucyl-tRNA synthetase inhibitor",
    "disease_area": "infectious disease",
    "indication": "onychomycosis"
  },
  "tazarotene": {
    "name": "Tazarotene",
    "smiles": "CCOC(=O)C1=CN=C(C=C1)C#CC1=CC2=C(SCCC2(C)C)C=C1",
    "molecular_weight": 351.47,
    "log_p": 4.43,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "retinoid receptor agonist",
    "disease_area": "dermatology | dermatology",
    "indication": "cosmetic | sunscreen lotion"
  },
  "tazemetostat": {
    "name": "Tazemetostat",
    "smiles": "CCN(C1CCOCC1)C1=C(C)C(=CC(=C1)C1=CC=C(CN2CCOCC2)C=C1)C(=O)NCC1=C(C)C=C(C)NC1=O",
    "molecular_weight": 572.75,
    "log_p": 4.73,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histone lysine methyltransferase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "tazobactam": {
    "name": "Tazobactam",
    "smiles": "[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(CN1C=CN=N1)S2(=O)=O",
    "molecular_weight": 300.3,
    "log_p": -1.52,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "beta lactamase inhibitor",
    "disease_area": "infectious disease",
    "indication": "pneumonia"
  },
  "technetium tc-99m disofenin": {
    "name": "Technetium Tc-99m disofenin",
    "smiles": "[99Tc].CC(C)C1=CC=CC(C(C)C)=C1NC(=O)CN(CC(O)=O)CC(O)=O",
    "molecular_weight": 449.32,
    "log_p": 2.34,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "technetium tc-99m etidronate": {
    "name": "Technetium Tc-99m etidronate",
    "smiles": "[99Tc].CC(O)(P(O)(O)=O)P(O)(O)=O",
    "molecular_weight": 304.93,
    "log_p": -0.99,
    "hbd": 5,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "technetium tc-99m mebrofenin": {
    "name": "Technetium Tc-99m mebrofenin",
    "smiles": "[Tc].CC1=CC(C)=C(Br)C(C)=C1NC(=O)CN(CC(O)=O)CC(O)=O",
    "molecular_weight": 485.23,
    "log_p": 1.78,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "technetium tc-99m medronate": {
    "name": "Technetium Tc-99m medronate",
    "smiles": "O.O.[98Tc+4].[O-]P([O-])(=O)CP([O-])([O-])=O",
    "molecular_weight": 305.91,
    "log_p": -4.88,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "technetium tc-99m oxidronate": {
    "name": "Technetium Tc-99m oxidronate",
    "smiles": "[99Tc].OC(P(O)(O)=O)P(O)(O)=O",
    "molecular_weight": 290.91,
    "log_p": -1.38,
    "hbd": 5,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "technetium tc-99m pertechnetate": {
    "name": "Technetium Tc-99m pertechnetate",
    "smiles": "O.O.O.O.[98Tc-]",
    "molecular_weight": 169.97,
    "log_p": -3.3,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "technetium tc-99m pyrophosphate": {
    "name": "Technetium Tc-99m pyrophosphate",
    "smiles": "[99Tc+4].[O-]P([O-])(=O)OP([O-])([O-])=O",
    "molecular_weight": 272.85,
    "log_p": -3.34,
    "hbd": 0,
    "hba": 7,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "technetium tc-99m sestamibi": {
    "name": "Technetium Tc-99m sestamibi",
    "smiles": "[Tc+].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-]",
    "molecular_weight": 776.96,
    "log_p": 7.98,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "technetium tc-99m succimer": {
    "name": "Technetium Tc-99m succimer",
    "smiles": "[99Tc].OC(=O)[C@@H](S)[C@@H](S)C(O)=O",
    "molecular_weight": 281.13,
    "log_p": -0.25,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "technetium tc-99m sulfur colloid": {
    "name": "Technetium Tc-99m sulfur colloid",
    "smiles": "[99Tc].S1SSSSSSS1",
    "molecular_weight": 355.44,
    "log_p": 5.18,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "technetium tc-99m tetrofosmin": {
    "name": "Technetium Tc-99m tetrofosmin",
    "smiles": "O.O.[98Tc].CCOCCP(CCOCC)CCP(CCOCC)CCOCC.CCOCCP(CCOCC)CCP(CCOCC)CCOCC",
    "molecular_weight": 898.86,
    "log_p": 6.54,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 38,
    "approved": true,
    "source": "FDA"
  },
  "tecovirimat": {
    "name": "Tecovirimat",
    "smiles": "FC(F)(F)C1=CC=C(C=C1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O",
    "molecular_weight": 376.33,
    "log_p": 2.4,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "orthopoxvirus egress inhibitor",
    "disease_area": "infectious disease",
    "indication": "smallpox"
  },
  "tedizolid": {
    "name": "Tedizolid",
    "smiles": "CN1N=NC(=N1)C1=NC=C(C=C1)C1=C(F)C=C(C=C1)N1C[C@H](CO)OC1=O",
    "molecular_weight": 370.34,
    "log_p": 1.4,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 50S ribosomal subunit inhibitor",
    "disease_area": "infectious disease",
    "indication": "skin infections"
  },
  "tedizolid phosphate": {
    "name": "Tedizolid phosphate",
    "smiles": "CN1N=NC(=N1)C1=CC=C(C=N1)C1=CC=C(C=C1F)N1C[C@H](COP(O)(O)=O)OC1=O",
    "molecular_weight": 450.32,
    "log_p": 1.51,
    "hbd": 2,
    "hba": 9,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "tegafur": {
    "name": "Tegafur",
    "smiles": "FC1=CN(C2CCCO2)C(=O)NC1=O",
    "molecular_weight": 200.17,
    "log_p": -0.02,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "tegafur-uracil": {
    "name": "Tegafur-uracil",
    "smiles": "O=C1NC=CC(=O)N1.FC1=CN(C2CCCO2)C(=O)NC1=O",
    "molecular_weight": 312.26,
    "log_p": -0.95,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "tegaserod": {
    "name": "Tegaserod",
    "smiles": "CCCCCNC(=N)N\\N=C\\C1=CNC2=C1C=C(OC)C=C2",
    "molecular_weight": 301.39,
    "log_p": 2.81,
    "hbd": 4,
    "hba": 3,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "serotonin receptor partial agonist",
    "disease_area": "",
    "indication": ""
  },
  "teicoplanin": {
    "name": "Teicoplanin",
    "smiles": "CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2OC3=C(Cl)C=C(C=C3)[C@@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3NC(C)=O)[C@@H]3NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]5NC(=O)[C@@H](CC6=CC=C(OC1=CC4=C2)C(Cl)=C6)NC(=O)[C@H](N)C1=CC=C(O)C(OC2=CC(O)=CC5=C2)=C1)C1=CC=C(O)C(=C1)C1=C(C=C(O)C=C1OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)[C@H](NC3=O)C(O)=O",
    "molecular_weight": 1879.68,
    "log_p": 1.16,
    "hbd": 24,
    "hba": 33,
    "rotatable_bonds": 20,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-positive bacterial infections"
  },
  "telaprevir": {
    "name": "Telaprevir",
    "smiles": "[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1",
    "molecular_weight": 679.86,
    "log_p": 2.45,
    "hbd": 4,
    "hba": 8,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HCV inhibitor",
    "disease_area": "infectious disease",
    "indication": "hepatitis C"
  },
  "telavancin": {
    "name": "Telavancin",
    "smiles": "CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2OC2=C3OC4=CC=C(C=C4Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]4C(C=C2OC2=C(Cl)C=C(C=C2)[C@@H](O)[C@@H]2NC(=O)[C@H](NC4=O)C4=CC(=C(O)C=C4)C4=C(O)C(CNCP(O)(O)=O)=C(O)C=C4[C@H](NC2=O)C(O)=O)=C3)O[C@@H](C)[C@H]1O",
    "molecular_weight": 1755.66,
    "log_p": 2.69,
    "hbd": 23,
    "hba": 28,
    "rotatable_bonds": 30,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-positive bacterial infections"
  },
  "telbivudine": {
    "name": "Telbivudine",
    "smiles": "CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O",
    "molecular_weight": 242.23,
    "log_p": -1.51,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA polymerase inhibitor",
    "disease_area": "infectious disease",
    "indication": "hepatitis B"
  },
  "telithromycin": {
    "name": "Telithromycin",
    "smiles": "[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1",
    "molecular_weight": 812.02,
    "log_p": 4.93,
    "hbd": 1,
    "hba": 14,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor | bacterial 30s ribosomal subunit inhibitor, bacterial 50s ribosomal subunit inhibitor | bacterial 50S ribosomal subunit inhibitor",
    "disease_area": "infectious disease",
    "indication": "pneumonia"
  },
  "telmisartan": {
    "name": "Telmisartan",
    "smiles": "CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O",
    "molecular_weight": 514.63,
    "log_p": 7.26,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin receptor antagonist",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "telotristat ethyl": {
    "name": "Telotristat ethyl",
    "smiles": "CCOC(=O)[C@@H](N)CC1=CC=C(C=C1)C1=NC(N)=NC(O[C@H](C2=CC=C(Cl)C=C2N2C=CC(C)=N2)C(F)(F)F)=C1",
    "molecular_weight": 574.99,
    "log_p": 4.99,
    "hbd": 2,
    "hba": 9,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "temazepam": {
    "name": "Temazepam",
    "smiles": "CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1",
    "molecular_weight": 300.75,
    "log_p": 2.47,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "temocillin": {
    "name": "Temocillin",
    "smiles": "CO[C@]1(NC(=O)C(C(O)=O)C2=CSC=C2)[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O",
    "molecular_weight": 414.46,
    "log_p": 0.52,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "temozolomide": {
    "name": "Temozolomide",
    "smiles": "CN1N=NC2=C(N=CN2C1=O)C(N)=O",
    "molecular_weight": 194.15,
    "log_p": -2.08,
    "hbd": 1,
    "hba": 7,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA alkylating agent",
    "disease_area": "oncology | oncology",
    "indication": "astrocytoma | glioblastoma"
  },
  "temsirolimus": {
    "name": "Temsirolimus",
    "smiles": "OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC",
    "molecular_weight": 1030.3,
    "log_p": 5.72,
    "hbd": 4,
    "hba": 16,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "mTOR inhibitor",
    "disease_area": "oncology",
    "indication": "renal cell carcinoma (RCC)"
  },
  "tenapanor": {
    "name": "Tenapanor",
    "smiles": "CN1C[C@@H](C2=CC(=CC=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC(=CC=C2)[C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)C2=C(C1)C(Cl)=CC(Cl)=C2",
    "molecular_weight": 1145.07,
    "log_p": 6.16,
    "hbd": 6,
    "hba": 12,
    "rotatable_bonds": 29,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium/hydrogen exchanger inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "teniposide": {
    "name": "Teniposide",
    "smiles": "[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=C(C=C3OCOC3=C1)[C@H]2O[C@]1([H])O[C@]2([H])CO[C@H](O[C@@]2([H])[C@H](O)[C@H]1O)C1=CC=CS1",
    "molecular_weight": 656.66,
    "log_p": 2.75,
    "hbd": 3,
    "hba": 14,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "topoisomerase inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "acute lymphoblastic leukemia (ALL)"
  },
  "tenofovir alafenamide": {
    "name": "Tenofovir alafenamide",
    "smiles": "CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1",
    "molecular_weight": 476.47,
    "log_p": 2.97,
    "hbd": 2,
    "hba": 10,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "hiv gag inhibitor",
    "disease_area": "Infectious disease",
    "indication": "human immunodeficiency virus (hiv-1)"
  },
  "tenofovir disoproxil": {
    "name": "Tenofovir disoproxil",
    "smiles": "[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C",
    "molecular_weight": 519.45,
    "log_p": 3.04,
    "hbd": 1,
    "hba": 15,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA"
  },
  "tenoxicam": {
    "name": "Tenoxicam",
    "smiles": "CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O",
    "molecular_weight": 337.38,
    "log_p": 1.64,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "orthopedics | rheumatology | rheumatology | rheumatology | rheumatology | rheumatology",
    "indication": "ankylosing spondylitis | bursitis | osteoarthritis | periarthritis | rheumatoid arthritis | tendinitis"
  },
  "tepotinib": {
    "name": "Tepotinib",
    "smiles": "CN1CCC(COC2=CN=C(N=C2)C2=CC(CN3N=C(C=CC3=O)C3=CC(=CC=C3)C#N)=CC=C2)CC1",
    "molecular_weight": 492.58,
    "log_p": 4.01,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "terazosin": {
    "name": "Terazosin",
    "smiles": "COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1",
    "molecular_weight": 387.44,
    "log_p": 1.06,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology | urology",
    "indication": "benign prostatic hyperplasia (BPH) | hypertension"
  },
  "terbinafine": {
    "name": "Terbinafine",
    "smiles": "CN(C\\C=C\\C#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12",
    "molecular_weight": 291.44,
    "log_p": 4.88,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "fungal squalene epoxidase inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "tinea corporis | tinea cruris | tinea pedis"
  },
  "terbutaline": {
    "name": "Terbutaline",
    "smiles": "CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1",
    "molecular_weight": 225.29,
    "log_p": 1.52,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "pulmonary | pulmonary | pulmonary",
    "indication": "bronchitis | bronchospasm | emphysema"
  },
  "terconazole": {
    "name": "Terconazole",
    "smiles": "CC(C)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1",
    "molecular_weight": 532.47,
    "log_p": 4.46,
    "hbd": 0,
    "hba": 8,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sterol demethylase inhibitor",
    "disease_area": "infectious disease",
    "indication": "vulvovaginal candidiasis"
  },
  "terfenadine": {
    "name": "Terfenadine",
    "smiles": "CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 471.69,
    "log_p": 6.45,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "histamine receptor antagonist",
    "disease_area": "",
    "indication": ""
  },
  "teriflunomide": {
    "name": "Teriflunomide",
    "smiles": "C\\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F",
    "molecular_weight": 270.21,
    "log_p": 3.0,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dihydroorotate dehydrogenase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "multiple sclerosis"
  },
  "terizidone": {
    "name": "Terizidone",
    "smiles": "O=C1NOCC1\\N=C\\C1=CC=C(\\C=N\\C2CONC2=O)C=C1",
    "molecular_weight": 302.29,
    "log_p": -0.62,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "terpin hydrate": {
    "name": "Terpin hydrate",
    "smiles": "O.CC(C)(O)[C@H]1CC[C@@](C)(O)CC1",
    "molecular_weight": 190.28,
    "log_p": 0.87,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "testolactone": {
    "name": "Testolactone",
    "smiles": "[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]1(C)OC(=O)CC[C@@]21[H]",
    "molecular_weight": 300.4,
    "log_p": 3.59,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "testosterone": {
    "name": "Testosterone",
    "smiles": "[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 288.43,
    "log_p": 3.88,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "testosterone cypionate": {
    "name": "Testosterone cypionate",
    "smiles": "[H][C@@]12CC[C@H](OC(=O)CCC3CCCC3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 412.61,
    "log_p": 6.4,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "testosterone enantate benzilic acid hydrazone": {
    "name": "Testosterone enantate benzilic acid hydrazone",
    "smiles": "[H]N(N=C1CC[C@@]2(C)C(CC[C@@]3([H])[C@]4([H])CC[C@H](OC(=O)CCCCCC)[C@@]4(C)CC[C@]23[H])=C1)C(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1",
    "molecular_weight": 624.87,
    "log_p": 8.24,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "testosterone enanthate": {
    "name": "Testosterone enanthate",
    "smiles": "[H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 400.6,
    "log_p": 6.4,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "testosterone propionate": {
    "name": "Testosterone propionate",
    "smiles": "[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 344.5,
    "log_p": 4.84,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "testosterone undecanoate": {
    "name": "Testosterone undecanoate",
    "smiles": "CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C",
    "molecular_weight": 456.71,
    "log_p": 7.96,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "tetrabenazine": {
    "name": "Tetrabenazine",
    "smiles": "COC1=C(OC)C=C2C3CC(=O)C(CC(C)C)CN3CCC2=C1",
    "molecular_weight": 317.43,
    "log_p": 3.24,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vesicular monoamine transporter inhibitor",
    "disease_area": "infectious disease | neurology/psychiatry",
    "indication": "cholera | Huntington's disease"
  },
  "tetracaine": {
    "name": "Tetracaine",
    "smiles": "CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C",
    "molecular_weight": 264.37,
    "log_p": 2.62,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "membrane integrity inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "anesthetic"
  },
  "tetrachlorodecaoxide": {
    "name": "Tetrachlorodecaoxide",
    "smiles": "O.O=O.[O-][Cl]=O.[O-][Cl]=O.[O-][Cl]=O.[O-][Cl]=O",
    "molecular_weight": 319.82,
    "log_p": -10.27,
    "hbd": 0,
    "hba": 10,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "tetracosactide": {
    "name": "Tetracosactide",
    "smiles": "CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(O)=O",
    "molecular_weight": 2933.49,
    "log_p": -7.96,
    "hbd": 42,
    "hba": 39,
    "rotatable_bonds": 93,
    "approved": true,
    "source": "FDA"
  },
  "tetracycline": {
    "name": "Tetracycline",
    "smiles": "[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O",
    "molecular_weight": 444.44,
    "log_p": -0.21,
    "hbd": 6,
    "hba": 9,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor",
    "disease_area": "dermatology | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "acne vulgaris (AV) | plague | pneumonia | psittacosis | respiratory tract infections | skin infections | urinary tract infections"
  },
  "tetracycline phosphate complex": {
    "name": "Tetracycline phosphate complex",
    "smiles": "[Na+].OP(=O)=O.OP(=O)=O.OP(=O)=O.OP(=O)=O.OP(=O)=O.[O-]P(=O)=O.[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O.[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O.[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O.[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O.[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O",
    "molecular_weight": 2724.06,
    "log_p": -4.3,
    "hbd": 35,
    "hba": 58,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "tetradecyl hydrogen sulfate (ester)": {
    "name": "Tetradecyl hydrogen sulfate (ester)",
    "smiles": "CCCCC(CC)CCC(CC(C)C)OS(O)(=O)=O",
    "molecular_weight": 294.46,
    "log_p": 4.22,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA"
  },
  "tetraferric tricitrate decahydrate": {
    "name": "Tetraferric tricitrate decahydrate",
    "smiles": "O.O.O.O.O.O.O.O.O.O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O",
    "molecular_weight": 967.8,
    "log_p": -25.91,
    "hbd": 0,
    "hba": 21,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA"
  },
  "tetrakis(2-methoxyisobutylisocyanide)copper(i) tetrafluoroborate": {
    "name": "Tetrakis(2-methoxyisobutylisocyanide)copper(I) tetrafluoroborate",
    "smiles": "[Cu+].F[B-](F)(F)F.COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-]",
    "molecular_weight": 602.99,
    "log_p": 6.62,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "tetramethylthiuram monosulfide": {
    "name": "Tetramethylthiuram monosulfide",
    "smiles": "CN(C)C(=S)SC(=S)N(C)C",
    "molecular_weight": 208.38,
    "log_p": 1.41,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "tetrofosmin": {
    "name": "Tetrofosmin",
    "smiles": "CCOCCP(CCOCC)CCP(CCOCC)CCOCC",
    "molecular_weight": 382.46,
    "log_p": 4.1,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 19,
    "approved": true,
    "source": "FDA"
  },
  "tetryzoline": {
    "name": "Tetryzoline",
    "smiles": "C1CN=C(N1)C1CCCC2=CC=CC=C12",
    "molecular_weight": 200.28,
    "log_p": 2.11,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "tezacaftor": {
    "name": "Tezacaftor",
    "smiles": "CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C(F)C=C2N1C[C@@H](O)CO",
    "molecular_weight": 520.5,
    "log_p": 3.4,
    "hbd": 4,
    "hba": 7,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "CFTR channel agonist",
    "disease_area": "pulmonary",
    "indication": "cystic fibrosis"
  },
  "thalidomide": {
    "name": "Thalidomide",
    "smiles": "O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12",
    "molecular_weight": 258.23,
    "log_p": 0.09,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "tumor necrosis factor production inhibitor",
    "disease_area": "oncology",
    "indication": "myeloma"
  },
  "thallous chloride": {
    "name": "Thallous chloride",
    "smiles": "[Cl-].[Tl+]",
    "molecular_weight": 239.84,
    "log_p": -3.38,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "thallous chloride tl-201": {
    "name": "Thallous chloride Tl-201",
    "smiles": "Cl[201Tl]",
    "molecular_weight": 236.42,
    "log_p": 0.31,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "thenalidine": {
    "name": "Thenalidine",
    "smiles": "CN1CCC(CC1)N(CC1=CC=CS1)C1=CC=CC=C1",
    "molecular_weight": 286.44,
    "log_p": 3.85,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "thenyldiamine": {
    "name": "Thenyldiamine",
    "smiles": "CN(C)CCN(CC1=CSC=C1)C1=CC=CC=N1",
    "molecular_weight": 261.39,
    "log_p": 2.71,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "theophylline": {
    "name": "Theophylline",
    "smiles": "CN1C2=C(NC=N2)C(=O)N(C)C1=O",
    "molecular_weight": 180.17,
    "log_p": -1.04,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "thiabendazole": {
    "name": "Thiabendazole",
    "smiles": "N1C2=CC=CC=C2N=C1C1=CSC=N1",
    "molecular_weight": 201.25,
    "log_p": 2.69,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "thiamine": {
    "name": "Thiamine",
    "smiles": "CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N",
    "molecular_weight": 265.36,
    "log_p": 0.61,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin B",
    "disease_area": "metabolism",
    "indication": "thiamine deficiency"
  },
  "thiamylal": {
    "name": "Thiamylal",
    "smiles": "CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O",
    "molecular_weight": 254.36,
    "log_p": 1.52,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glutamate receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "sedative"
  },
  "thiethylperazine": {
    "name": "Thiethylperazine",
    "smiles": "CCSC1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1",
    "molecular_weight": 399.63,
    "log_p": 5.04,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "gastroenterology",
    "indication": "nausea"
  },
  "thimerosal": {
    "name": "Thimerosal",
    "smiles": "[Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O",
    "molecular_weight": 404.82,
    "log_p": -1.42,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "thiohexam": {
    "name": "Thiohexam",
    "smiles": "C1CCC(CC1)NSC1=NC2=CC=CC=C2S1",
    "molecular_weight": 264.42,
    "log_p": 4.23,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "thiopental": {
    "name": "Thiopental",
    "smiles": "CCCC(C)C1(CC)C(=O)NC(=S)NC1=O",
    "molecular_weight": 242.34,
    "log_p": 1.35,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "GABA receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "anesthetic"
  },
  "thioridazine": {
    "name": "Thioridazine",
    "smiles": "CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1",
    "molecular_weight": 370.59,
    "log_p": 5.89,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "Neurology",
    "indication": "psychosis"
  },
  "thiosulfuric acid": {
    "name": "Thiosulfuric acid",
    "smiles": "OS(O)(=O)=S",
    "molecular_weight": 114.15,
    "log_p": -0.32,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "thiotepa": {
    "name": "Thiotepa",
    "smiles": "S=P(N1CC1)(N1CC1)N1CC1",
    "molecular_weight": 189.22,
    "log_p": 0.16,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cytochrome P450 inhibitor",
    "disease_area": "oncology | oncology | oncology",
    "indication": "bladder cancer | breast cancer | ovarian cancer"
  },
  "thiothixene": {
    "name": "Thiothixene",
    "smiles": "CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\\C2=C\\CCN2CCN(C)CC2)C=C1",
    "molecular_weight": 443.64,
    "log_p": 3.47,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "schizophrenia"
  },
  "thiram": {
    "name": "Thiram",
    "smiles": "CN(C)C(=S)SSC(=S)N(C)C",
    "molecular_weight": 240.44,
    "log_p": 2.06,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "ophthalmology",
    "indication": "contact dermatitis"
  },
  "thonzonium": {
    "name": "Thonzonium",
    "smiles": "CCCCCCCCCCCCCCCC[N+](C)(C)CCN(CC1=CC=C(OC)C=C1)C1=NC=CC=N1",
    "molecular_weight": 511.82,
    "log_p": 8.05,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 22,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATPase inhibitor",
    "disease_area": "infectious disease",
    "indication": "ear infections"
  },
  "thonzylamine": {
    "name": "Thonzylamine",
    "smiles": "COC1=CC=C(CN(CCN(C)C)C2=NC=CC=N2)C=C1",
    "molecular_weight": 286.38,
    "log_p": 2.05,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antihistamine",
    "disease_area": "neurology/psychiatry",
    "indication": "itching"
  },
  "threonine": {
    "name": "Threonine",
    "smiles": "C[C@@H](O)[C@H](N)C(O)=O",
    "molecular_weight": 119.12,
    "log_p": -1.22,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "thymol": {
    "name": "Thymol",
    "smiles": "CC(C)C1=CC=C(C)C=C1O",
    "molecular_weight": 150.22,
    "log_p": 2.82,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "GABA receptor positive allosteric modulator",
    "disease_area": "infectious disease | infectious disease",
    "indication": "antiseptic | ringworm"
  },
  "tiagabine": {
    "name": "Tiagabine",
    "smiles": "CC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1",
    "molecular_weight": 375.56,
    "log_p": 5.04,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "GABA uptake inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "seizures"
  },
  "tiaprofenic acid": {
    "name": "Tiaprofenic acid",
    "smiles": "CC(C(O)=O)C1=CC=C(S1)C(=O)C1=CC=CC=C1",
    "molecular_weight": 260.31,
    "log_p": 3.17,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "tibolone": {
    "name": "Tibolone",
    "smiles": "[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC(=O)CC3)C[C@@]([H])(C)[C@@]21[H]",
    "molecular_weight": 312.45,
    "log_p": 3.88,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "androgen receptor agonist | estrogen receptor agonist | progesterone receptor agonist",
    "disease_area": "obstetrics/gynecology | Oncology",
    "indication": "breast cancer | endometriosis"
  },
  "ticagrelor": {
    "name": "Ticagrelor",
    "smiles": "CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1",
    "molecular_weight": 522.58,
    "log_p": 2.01,
    "hbd": 4,
    "hba": 11,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "purinergic receptor antagonist",
    "disease_area": "cardiology | cardiology | cardiology",
    "indication": "acute coronary syndrome (ACS) | acute coronary syndrome (acs), myocardial infarction | myocardial infarction"
  },
  "ticarcillin": {
    "name": "Ticarcillin",
    "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](C(O)=O)C1=CSC=C1)C(O)=O",
    "molecular_weight": 384.44,
    "log_p": 0.55,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "lactamase inhibitor",
    "disease_area": "infectious disease",
    "indication": "gram-negative bacterial infections"
  },
  "ticlopidine": {
    "name": "Ticlopidine",
    "smiles": "ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2",
    "molecular_weight": 263.79,
    "log_p": 3.96,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "purinergic receptor antagonist",
    "disease_area": "hematology | neurology/psychiatry",
    "indication": "stroke | thrombosis"
  },
  "tigecycline": {
    "name": "Tigecycline",
    "smiles": "[H][C@@]12CC3=C(C(O)=C(NC(=O)CNC(C)(C)C)C=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2",
    "molecular_weight": 585.66,
    "log_p": 0.51,
    "hbd": 7,
    "hba": 11,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor | bacterial 30s ribosomal subunit inhibitor, bacterial dna inhibitor | bacterial dna inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | Infectious disease | infectious disease, Infectious disease",
    "indication": "gram-negative bacterial infections | intra-abdominal infections | pneumonia | skin infections | skin infections, pneumonia, intra-abdominal infections, gram-negative bacterial infections"
  },
  "tilarginine": {
    "name": "Tilarginine",
    "smiles": "CNC(=N)NCCC[C@H](N)C(O)=O",
    "molecular_weight": 188.23,
    "log_p": -1.08,
    "hbd": 5,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "tilbroquinol": {
    "name": "Tilbroquinol",
    "smiles": "CC1=C2C=CC=NC2=C(O)C(Br)=C1",
    "molecular_weight": 238.08,
    "log_p": 3.01,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "tiludronic acid": {
    "name": "Tiludronic acid",
    "smiles": "OP(O)(=O)C(SC1=CC=C(Cl)C=C1)P(O)(O)=O",
    "molecular_weight": 318.61,
    "log_p": 2.07,
    "hbd": 4,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "timolol": {
    "name": "Timolol",
    "smiles": "[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1",
    "molecular_weight": 316.43,
    "log_p": 0.5,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "ophthalmology | ophthalmology",
    "indication": "glaucoma | ocular hypertension"
  },
  "tinidazole": {
    "name": "Tinidazole",
    "smiles": "CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O",
    "molecular_weight": 247.28,
    "log_p": 0.53,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antiprotozoal agent",
    "disease_area": "infectious disease | infectious disease | infectious disease | obstetrics/gynecology",
    "indication": "amebiasis | bacterial vaginosis | giardiasis | trichomoniasis"
  },
  "tioconazole": {
    "name": "Tioconazole",
    "smiles": "ClC1=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=CS1",
    "molecular_weight": 387.72,
    "log_p": 5.86,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sterol demethylase inhibitor",
    "disease_area": "infectious disease",
    "indication": "yeast infection"
  },
  "tioguanine": {
    "name": "Tioguanine",
    "smiles": "NC1=NC(=S)C2=C(N1)N=CN2",
    "molecular_weight": 167.2,
    "log_p": 0.6,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "purine antagonist",
    "disease_area": "hematologic malignancy | hematologic malignancy | hematologic malignancy",
    "indication": "acute lymphoblastic leukemia (ALL) | acute myeloid leukemia (AML) | chronic myeloid leukemia (CML)"
  },
  "tiopronin": {
    "name": "Tiopronin",
    "smiles": "CC(S)C(=O)NCC(O)=O",
    "molecular_weight": 163.2,
    "log_p": -0.49,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "chelating agent | reducing agent",
    "disease_area": "urology",
    "indication": "kidney stones"
  },
  "tiotropium": {
    "name": "Tiotropium",
    "smiles": "[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1",
    "molecular_weight": 392.52,
    "log_p": 2.35,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "pulmonary | pulmonary | pulmonary",
    "indication": "bronchitis | chronic obstructive pulmonary disease (COPD) | emphysema"
  },
  "tipiracil": {
    "name": "Tipiracil",
    "smiles": "ClC1=C(CN2CCCC2=N)NC(=O)NC1=O",
    "molecular_weight": 242.67,
    "log_p": 0.29,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "thymidine phosphorylase inhibitor",
    "disease_area": "oncology",
    "indication": "colorectal cancer"
  },
  "tipranavir": {
    "name": "Tipranavir",
    "smiles": "[H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O",
    "molecular_weight": 602.68,
    "log_p": 7.33,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HIV protease inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "tirbanibulin": {
    "name": "Tirbanibulin",
    "smiles": "O=C(CC1=CC=C(C=N1)C1=CC=C(OCCN2CCOCC2)C=C1)NCC1=CC=CC=C1",
    "molecular_weight": 431.54,
    "log_p": 3.32,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "protein tyrosine kinase inhibitor",
    "disease_area": "dermatology",
    "indication": "actinic keratosis (ak)"
  },
  "tirofiban": {
    "name": "Tirofiban",
    "smiles": "CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O",
    "molecular_weight": 440.61,
    "log_p": 2.95,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 14,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "platelet aggregation inhibitor | structural glycoprotein antagonist",
    "disease_area": "cardiology | cardiology",
    "indication": "myocardial infarction | refactory angina"
  },
  "titanium dioxide": {
    "name": "Titanium dioxide",
    "smiles": "O=[Ti]=O",
    "molecular_weight": 79.86,
    "log_p": -0.24,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "tivozanib": {
    "name": "Tivozanib",
    "smiles": "COC1=C(OC)C=C2C(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=CC=NC2=C1",
    "molecular_weight": 454.87,
    "log_p": 5.64,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "VEGFR inhibitor",
    "disease_area": "oncology",
    "indication": "renal cell carcinoma (RCC)"
  },
  "tixocortol": {
    "name": "Tixocortol",
    "smiles": "[H][C@@]12CC[C@](O)(C(=O)CS)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "molecular_weight": 378.53,
    "log_p": 2.72,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "tizanidine": {
    "name": "Tizanidine",
    "smiles": "ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1",
    "molecular_weight": 253.72,
    "log_p": 1.72,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "spasms"
  },
  "tobramycin": {
    "name": "Tobramycin",
    "smiles": "NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O",
    "molecular_weight": 467.52,
    "log_p": -6.3,
    "hbd": 10,
    "hba": 14,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial 30S ribosomal subunit inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease | infectious disease | infectious disease",
    "indication": "bacterial septicemia | meningitis | respiratory tract infections | skin infections | urinary tract infections"
  },
  "tocainide": {
    "name": "Tocainide",
    "smiles": "CC(N)C(=O)NC1=C(C)C=CC=C1C",
    "molecular_weight": 192.26,
    "log_p": 1.59,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "cardiology",
    "indication": "cardiac arrythmia"
  },
  "tofacitinib": {
    "name": "Tofacitinib",
    "smiles": "C[C@@H]1CCN(C[C@@H]1N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N",
    "molecular_weight": 312.38,
    "log_p": 1.54,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "JAK inhibitor",
    "disease_area": "rheumatology",
    "indication": "rheumatoid arthritis"
  },
  "tolazamide": {
    "name": "Tolazamide",
    "smiles": "CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1",
    "molecular_weight": 311.41,
    "log_p": 1.77,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATP channel blocker",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "tolazoline": {
    "name": "Tolazoline",
    "smiles": "C(C1=NCCN1)C1=CC=CC=C1",
    "molecular_weight": 160.22,
    "log_p": 1.23,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "reverse sedative"
  },
  "tolbutamide": {
    "name": "Tolbutamide",
    "smiles": "CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1",
    "molecular_weight": 270.35,
    "log_p": 1.78,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "ATP channel blocker",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "tolcapone": {
    "name": "Tolcapone",
    "smiles": "CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O",
    "molecular_weight": 273.24,
    "log_p": 2.55,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "catechol O methyltransferase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "tolfenamic acid": {
    "name": "Tolfenamic acid",
    "smiles": "CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O",
    "molecular_weight": 261.71,
    "log_p": 4.09,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "tolmetin": {
    "name": "Tolmetin",
    "smiles": "CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1",
    "molecular_weight": 257.29,
    "log_p": 2.19,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "rheumatology | rheumatology",
    "indication": "osteoarthritis | rheumatoid arthritis"
  },
  "tolnaftate": {
    "name": "Tolnaftate",
    "smiles": "CN(C(=S)OC1=CC2=CC=CC=C2C=C1)C1=CC=CC(C)=C1",
    "molecular_weight": 307.42,
    "log_p": 4.95,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "fungal squalene epoxidase inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "tinea corporis | tinea pedis"
  },
  "tolterodine": {
    "name": "Tolterodine",
    "smiles": "CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C",
    "molecular_weight": 325.5,
    "log_p": 5.34,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "urology | urology",
    "indication": "urinary frequency | urinary incontinence"
  },
  "tolvaptan": {
    "name": "Tolvaptan",
    "smiles": "CC1=CC=CC=C1C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCC[C@@H](O)C2=C1C=CC(Cl)=C2",
    "molecular_weight": 448.95,
    "log_p": 5.68,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vasopressin receptor antagonist",
    "disease_area": "cardiology | endocrinology | gastroenterology",
    "indication": "congestive heart failure | hepatic cirrhosis | hyponatremia"
  },
  "topiramate": {
    "name": "Topiramate",
    "smiles": "[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2",
    "molecular_weight": 339.37,
    "log_p": -0.4,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "carbonic anhydrase inhibitor | glutamate receptor antagonist | kainate receptor antagonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "epilepsy | migraine headache"
  },
  "topotecan": {
    "name": "Topotecan",
    "smiles": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O",
    "molecular_weight": 421.45,
    "log_p": 1.85,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "topoisomerase inhibitor",
    "disease_area": "oncology | oncology",
    "indication": "cervical cancer | small cell lung cancer"
  },
  "torasemide": {
    "name": "Torasemide",
    "smiles": "CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1",
    "molecular_weight": 348.43,
    "log_p": 2.53,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "electrolyte reabsorption inhibitor | thromboxane receptor antagonist",
    "disease_area": "cardiology | cardiology | cardiology",
    "indication": "congestive heart failure | edema | hypertension"
  },
  "toremifene": {
    "name": "Toremifene",
    "smiles": "CN(C)CCOC1=CC=C(C=C1)C(=C(\\CCCl)C1=CC=CC=C1)\\C1=CC=CC=C1",
    "molecular_weight": 405.97,
    "log_p": 6.22,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "estrogen receptor antagonist | selective estrogen receptor modulator (SERM)",
    "disease_area": "oncology",
    "indication": "breast cancer"
  },
  "trabectedin": {
    "name": "Trabectedin",
    "smiles": "[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31",
    "molecular_weight": 761.85,
    "log_p": 3.41,
    "hbd": 4,
    "hba": 15,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "antitumor agent",
    "disease_area": "",
    "indication": ""
  },
  "tramadol": {
    "name": "Tramadol",
    "smiles": "COC1=CC=CC(=C1)C1(O)CCCCC1CN(C)C",
    "molecular_weight": 263.38,
    "log_p": 2.63,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "trametinib": {
    "name": "Trametinib",
    "smiles": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1",
    "molecular_weight": 615.4,
    "log_p": 3.94,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "MEK inhibitor",
    "disease_area": "oncology",
    "indication": "melanoma"
  },
  "trandolapril": {
    "name": "Trandolapril",
    "smiles": "[H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O",
    "molecular_weight": 430.55,
    "log_p": 2.77,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin converting enzyme inhibitor",
    "disease_area": "cardiology | cardiology | cardiology",
    "indication": "hypertension | hypertension, myocardial infarction | myocardial infarction"
  },
  "tranexamic acid": {
    "name": "Tranexamic acid",
    "smiles": "NC[C@H]1CC[C@@H](CC1)C(O)=O",
    "molecular_weight": 157.21,
    "log_p": 0.84,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "tranylcypromine": {
    "name": "Tranylcypromine",
    "smiles": "NC1CC1C1=CC=CC=C1",
    "molecular_weight": 133.19,
    "log_p": 1.5,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "monoamine oxidase inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "travoprost": {
    "name": "Travoprost",
    "smiles": "CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F",
    "molecular_weight": 500.55,
    "log_p": 4.43,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "prostanoid receptor agonist",
    "disease_area": "ophthalmology | ophthalmology",
    "indication": "glaucoma | ocular hypertension"
  },
  "trazodone": {
    "name": "Trazodone",
    "smiles": "ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1",
    "molecular_weight": 371.87,
    "log_p": 2.36,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist | serotonin receptor antagonist | serotonin reuptake inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "treosulfan": {
    "name": "Treosulfan",
    "smiles": "CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O",
    "molecular_weight": 278.3,
    "log_p": -2.34,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA synthesis inhibitor",
    "disease_area": "oncology",
    "indication": "ovarian cancer"
  },
  "treprostinil": {
    "name": "Treprostinil",
    "smiles": "[H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1",
    "molecular_weight": 390.52,
    "log_p": 3.58,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "prostanoid receptor agonist",
    "disease_area": "pulmonary",
    "indication": "pulmonary arterial hypertension (PAH)"
  },
  "tretinoin": {
    "name": "Tretinoin",
    "smiles": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O",
    "molecular_weight": 300.44,
    "log_p": 5.6,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "retinoid receptor agonist | retinoid receptor ligand",
    "disease_area": "hematologic malignancy",
    "indication": "acute promyelocytic leukemia (APL)"
  },
  "triamcinolone": {
    "name": "Triamcinolone",
    "smiles": "[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "molecular_weight": 394.44,
    "log_p": 0.62,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "glucocorticoid receptor agonist",
    "disease_area": "dermatology",
    "indication": "corticosteroid-responsive dermatoses"
  },
  "triamterene": {
    "name": "Triamterene",
    "smiles": "NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1",
    "molecular_weight": 253.27,
    "log_p": 0.83,
    "hbd": 3,
    "hba": 7,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker",
    "disease_area": "cardiology | cardiology | endocrinology",
    "indication": "edema | hypertension | hypokalemia"
  },
  "triazolam": {
    "name": "Triazolam",
    "smiles": "CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12",
    "molecular_weight": 343.22,
    "log_p": 4.23,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA"
  },
  "trichlormethiazide": {
    "name": "Trichlormethiazide",
    "smiles": "NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl",
    "molecular_weight": 380.66,
    "log_p": 0.82,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "chloride channel blocker",
    "disease_area": "cardiology | cardiology",
    "indication": "edema | hypertension"
  },
  "trichloroethylene": {
    "name": "Trichloroethylene",
    "smiles": "ClC=C(Cl)Cl",
    "molecular_weight": 131.39,
    "log_p": 2.5,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Preclinical",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "triclabendazole": {
    "name": "Triclabendazole",
    "smiles": "CSC1=NC2=C(N1)C=C(Cl)C(OC1=CC=CC(Cl)=C1Cl)=C2",
    "molecular_weight": 359.67,
    "log_p": 6.04,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "microtubule inhibitor",
    "disease_area": "infectious disease",
    "indication": "tapeworm"
  },
  "triclocarban": {
    "name": "Triclocarban",
    "smiles": "ClC1=CC=C(NC(=O)NC2=CC(Cl)=C(Cl)C=C2)C=C1",
    "molecular_weight": 315.59,
    "log_p": 5.29,
    "hbd": 2,
    "hba": 1,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "other antibiotic",
    "disease_area": "infectious disease",
    "indication": "first-aid antiseptic"
  },
  "triclofos": {
    "name": "Triclofos",
    "smiles": "OP(O)(=O)OCC(Cl)(Cl)Cl",
    "molecular_weight": 229.38,
    "log_p": 1.47,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "triclosan": {
    "name": "Triclosan",
    "smiles": "OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1",
    "molecular_weight": 289.54,
    "log_p": 5.14,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antibacterial agent",
    "disease_area": "infectious disease",
    "indication": "first-aid antiseptic"
  },
  "triethylenetetramine": {
    "name": "Triethylenetetramine",
    "smiles": "NCCNCCNCCN",
    "molecular_weight": 146.24,
    "log_p": -1.92,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "trifarotene": {
    "name": "Trifarotene",
    "smiles": "CC(C)(C)C1=CC(=CC=C1N1CCCC1)C1=CC(=CC=C1OCCO)C1=CC=C(C=C1)C(O)=O",
    "molecular_weight": 459.59,
    "log_p": 5.99,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "retinoid receptor agonist",
    "disease_area": "dermatology",
    "indication": "acne vulgaris (av)"
  },
  "trifluoperazine": {
    "name": "Trifluoperazine",
    "smiles": "CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1",
    "molecular_weight": 407.51,
    "log_p": 4.95,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "schizophrenia"
  },
  "triflupromazine": {
    "name": "Triflupromazine",
    "smiles": "CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F",
    "molecular_weight": 352.43,
    "log_p": 5.26,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "gastroenterology | gastroenterology | neurology/psychiatry",
    "indication": "nausea | psychosis | vomiting"
  },
  "trifluridine": {
    "name": "Trifluridine",
    "smiles": "OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(C(=O)NC1=O)C(F)(F)F",
    "molecular_weight": 296.2,
    "log_p": -0.8,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA directed DNA polymerase inhibitor | thymidylate synthase inhibitor",
    "disease_area": "infectious disease",
    "indication": "virus herpes simplex (HSV)"
  },
  "triflusal": {
    "name": "Triflusal",
    "smiles": "CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(O)=O",
    "molecular_weight": 248.16,
    "log_p": 2.33,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cyclooxygenase inhibitor | platelet aggregation inhibitor | thromboxane synthase inhibitor",
    "disease_area": "cardiology | cardiology | neurology/psychiatry",
    "indication": "atrial fibrillation (AF) | myocardial infarction | stroke"
  },
  "triheptanoin": {
    "name": "Triheptanoin",
    "smiles": "CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC",
    "molecular_weight": 428.61,
    "log_p": 5.9,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 20,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "anticonvulsant",
    "disease_area": "cardiology",
    "indication": "cardiomyopathy"
  },
  "trihexyphenidyl": {
    "name": "Trihexyphenidyl",
    "smiles": "OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1",
    "molecular_weight": 301.47,
    "log_p": 4.33,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "parkinsonism"
  },
  "trilaciclib": {
    "name": "Trilaciclib",
    "smiles": "CN1CCN(CC1)C1=CN=C(NC2=NC3=C(C=C4N3C3(CCCCC3)CNC4=O)C=N2)C=C1",
    "molecular_weight": 446.56,
    "log_p": 2.72,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 2",
    "moa": "CDK inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "trilostane": {
    "name": "Trilostane",
    "smiles": "[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N",
    "molecular_weight": 329.44,
    "log_p": 3.47,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "3beta-hydroxy-delta5-steroid dehydrogenase inhibitor",
    "disease_area": "endocrinology",
    "indication": "Cushing's syndrome"
  },
  "trimebutine": {
    "name": "Trimebutine",
    "smiles": "CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1",
    "molecular_weight": 387.48,
    "log_p": 3.74,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "opioid receptor agonist",
    "disease_area": "gastroenterology",
    "indication": "irritable bowel syndrome"
  },
  "trimetazidine": {
    "name": "Trimetazidine",
    "smiles": "COC1=C(OC)C(OC)=C(CN2CCNCC2)C=C1",
    "molecular_weight": 266.34,
    "log_p": 1.12,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "3-ketoacyl CoA thiolase inhibitor",
    "disease_area": "cardiology",
    "indication": "angina pectoris"
  },
  "trimethadione": {
    "name": "Trimethadione",
    "smiles": "CN1C(=O)OC(C)(C)C1=O",
    "molecular_weight": 143.14,
    "log_p": 0.37,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "oxazolidine antiepileptic",
    "disease_area": "neurology/psychiatry",
    "indication": "seizures"
  },
  "trimethaphan": {
    "name": "Trimethaphan",
    "smiles": "O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1",
    "molecular_weight": 365.52,
    "log_p": 3.66,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "trimethobenzamide": {
    "name": "Trimethobenzamide",
    "smiles": "COC1=CC(=CC(OC)=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1",
    "molecular_weight": 388.46,
    "log_p": 2.58,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "gastroenterology | gastroenterology | gastroenterology",
    "indication": "gastroenteritis | nausea | vomiting"
  },
  "trimethoprim": {
    "name": "Trimethoprim",
    "smiles": "COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC",
    "molecular_weight": 290.32,
    "log_p": 1.26,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dihydrofolate reductase inhibitor",
    "disease_area": "gastroenterology | infectious disease | infectious disease",
    "indication": "diarrhea | ear infections | urinary tract infections"
  },
  "trimetrexate": {
    "name": "Trimetrexate",
    "smiles": "COC1=CC(NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)=CC(OC)=C1OC",
    "molecular_weight": 369.43,
    "log_p": 2.74,
    "hbd": 3,
    "hba": 8,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "dihydrofolate reductase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "trimipramine": {
    "name": "Trimipramine",
    "smiles": "CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12",
    "molecular_weight": 294.44,
    "log_p": 4.12,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "norepinephrine reputake inhibitor | tricyclic antidepressant",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "trioxsalen": {
    "name": "Trioxsalen",
    "smiles": "CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1",
    "molecular_weight": 228.25,
    "log_p": 3.46,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA synthesis inhibitor",
    "disease_area": "dermatology | dermatology",
    "indication": "eczema | vitiligo"
  },
  "tripelennamine": {
    "name": "Tripelennamine",
    "smiles": "CN(C)CCN(CC1=CC=CC=C1)C1=CC=CC=N1",
    "molecular_weight": 255.37,
    "log_p": 2.65,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy | allergy | pulmonary",
    "indication": "allergic rhinitis | asthma | urticaria"
  },
  "triprolidine": {
    "name": "Triprolidine",
    "smiles": "CC1=CC=C(C=C1)C(=C/CN1CCCC1)\\C1=CC=CC=N1",
    "molecular_weight": 278.4,
    "log_p": 3.92,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "histamine receptor antagonist",
    "disease_area": "allergy",
    "indication": "allergic rhinitis"
  },
  "triptorelin": {
    "name": "Triptorelin",
    "smiles": "CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O",
    "molecular_weight": 1311.47,
    "log_p": -2.09,
    "hbd": 18,
    "hba": 15,
    "rotatable_bonds": 33,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "gonadotropin releasing factor hormone receptor agonist",
    "disease_area": "endocrinology | endocrinology | obstetrics/gynecology | obstetrics/gynecology | oncology | oncology",
    "indication": "breast cancer | endometriosis | gender dysphoria | myoma | precocious puberty | prostate cancer"
  },
  "tritoqualine": {
    "name": "Tritoqualine",
    "smiles": "CCOC1=C(OCC)C(OCC)=C(N)C2=C1C(OC2=O)C1N(C)CCC2=CC3=C(OCO3)C(OC)=C12",
    "molecular_weight": 500.55,
    "log_p": 3.64,
    "hbd": 1,
    "hba": 10,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "troglitazone": {
    "name": "Troglitazone",
    "smiles": "CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O",
    "molecular_weight": 441.55,
    "log_p": 4.37,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "insulin sensitizer | PPAR receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "trolamine": {
    "name": "Trolamine",
    "smiles": "OCCN(CCO)CCO",
    "molecular_weight": 149.19,
    "log_p": -1.73,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "trolamine salicylate": {
    "name": "Trolamine salicylate",
    "smiles": "OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O",
    "molecular_weight": 287.31,
    "log_p": -0.64,
    "hbd": 5,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "troleandomycin": {
    "name": "Troleandomycin",
    "smiles": "CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O",
    "molecular_weight": 813.98,
    "log_p": 3.62,
    "hbd": 0,
    "hba": 16,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "protein synthesis inhibitor | ribosomal protein inhibitor",
    "disease_area": "infectious disease | infectious disease, pulmonary, otolaryngology | otolaryngology | otolaryngology | pulmonary",
    "indication": "bronchitis | pneumonia | pneumonia, bronchitis, tonsillitis, sinusitis | sinusitis | tonsillitis"
  },
  "tromantadine": {
    "name": "Tromantadine",
    "smiles": "CN(C)CCOCC(=O)NC12CC3CC(CC(C3)C1)C2",
    "molecular_weight": 280.41,
    "log_p": 1.65,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "tromethamine": {
    "name": "Tromethamine",
    "smiles": "NC(CO)(CO)CO",
    "molecular_weight": 121.14,
    "log_p": -2.34,
    "hbd": 4,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "tropicamide": {
    "name": "Tropicamide",
    "smiles": "CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1",
    "molecular_weight": 284.36,
    "log_p": 2.21,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "ophthalmology | ophthalmology",
    "indication": "cycloplegia diagnostic | mydriasis diagnostic"
  },
  "tropisetron": {
    "name": "Tropisetron",
    "smiles": "[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(=O)C1=CNC3=CC=CC=C13)N2C",
    "molecular_weight": 284.36,
    "log_p": 2.95,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor antagonist",
    "disease_area": "gastroenterology | gastroenterology",
    "indication": "nausea | vomiting"
  },
  "trospium": {
    "name": "Trospium",
    "smiles": "[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1)[N+]21CCCC1",
    "molecular_weight": 392.52,
    "log_p": 3.77,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "urology | urology",
    "indication": "urinary frequency | urinary incontinence"
  },
  "trovafloxacin": {
    "name": "Trovafloxacin",
    "smiles": "[H][C@@]12CN(C[C@]1([H])[C@H]2N)C1=NC2=C(C=C1F)C(=O)C(=CN2C1=C(F)C=C(F)C=C1)C(O)=O",
    "molecular_weight": 416.36,
    "log_p": 1.89,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "bacterial DNA gyrase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "trypan blue free acid": {
    "name": "Trypan blue free acid",
    "smiles": "CC1=CC(=CC=C1\\N=N\\C1=C(C=C2C=C(C=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O)C1=CC(C)=C(C=C1)\\N=N\\C1=C(O)C2=C(N)C=C(C=C2C=C1S(O)(=O)=O)S(O)(=O)=O",
    "molecular_weight": 872.89,
    "log_p": 6.67,
    "hbd": 8,
    "hba": 16,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "tryptophan": {
    "name": "Tryptophan",
    "smiles": "N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O",
    "molecular_weight": 204.23,
    "log_p": 1.12,
    "hbd": 3,
    "hba": 2,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor partial agonist",
    "disease_area": "gastroenterology | gastroenterology | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry",
    "indication": "anxiety | bloating | constipation | fatigue | sleeplessness"
  },
  "tubocurarine": {
    "name": "Tubocurarine",
    "smiles": "[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CCN1C)C2=C6)=C(O)C=C5)=CC(OC)=C4O)C=C3",
    "molecular_weight": 609.74,
    "log_p": 6.7,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "anesthetic"
  },
  "tucatinib": {
    "name": "Tucatinib",
    "smiles": "CC1=CC(NC2=NC=NC3=CC=C(NC4=NC(C)(C)CO4)C=C23)=CC=C1OC1=CC2=NC=NN2C=C1",
    "molecular_weight": 480.53,
    "log_p": 5.09,
    "hbd": 2,
    "hba": 10,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "EGFR inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "tyropanoic acid": {
    "name": "Tyropanoic acid",
    "smiles": "CCCC(=O)NC1=C(I)C=C(I)C(CC(CC)C(O)=O)=C1I",
    "molecular_weight": 641.03,
    "log_p": 4.89,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "tyrosine": {
    "name": "Tyrosine",
    "smiles": "N[C@@H](CC1=CC=C(O)C=C1)C(O)=O",
    "molecular_weight": 181.19,
    "log_p": 0.35,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "ubidecarenone": {
    "name": "Ubidecarenone",
    "smiles": "COC1=C(OC)C(=O)C(C\\C=C(/C)CC\\C=C(/C)CC\\C=C(/C)CC\\C=C(/C)CC\\C=C(/C)CC\\C=C(/C)CC\\C=C(/C)CC\\C=C(/C)CC\\C=C(/C)CCC=C(C)C)=C(C)C1=O",
    "molecular_weight": 863.36,
    "log_p": 17.85,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 31,
    "approved": true,
    "source": "FDA"
  },
  "ubiquinol": {
    "name": "Ubiquinol",
    "smiles": "COC1=C(OC)C(O)=C(C\\C=C(/C)CC\\C=C(/C)CC\\C=C(/C)CC\\C=C(/C)CC\\C=C(/C)CC\\C=C(/C)CC\\C=C(/C)CC\\C=C(/C)CC\\C=C(/C)CCC=C(C)C)C(C)=C1O",
    "molecular_weight": 865.38,
    "log_p": 18.47,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 31,
    "approved": true,
    "source": "FDA"
  },
  "ubrogepant": {
    "name": "Ubrogepant",
    "smiles": "C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CN=C3C[C@]4(CC3=C2)C(=O)NC2=NC=CC=C42)C(=O)N1CC(F)(F)F)C1=CC=CC=C1",
    "molecular_weight": 549.55,
    "log_p": 3.53,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcitonin antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "migraine headache"
  },
  "udenafil": {
    "name": "Udenafil",
    "smiles": "CCCOC1=C(C=C(C=C1)S(=O)(=O)NCCC1CCCN1C)C1=NC(=O)C2=C(N1)C(CCC)=NN2C",
    "molecular_weight": 516.67,
    "log_p": 2.83,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "urology",
    "indication": "erectile dysfunction"
  },
  "ulipristal": {
    "name": "Ulipristal",
    "smiles": "CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12",
    "molecular_weight": 433.59,
    "log_p": 4.97,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "progesterone receptor antagonist",
    "disease_area": "endocrinology",
    "indication": "contraceptive"
  },
  "ulobetasol": {
    "name": "Ulobetasol",
    "smiles": "[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C",
    "molecular_weight": 428.9,
    "log_p": 3.09,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "umbralisib": {
    "name": "Umbralisib",
    "smiles": "CC(C)OC1=C(F)C=C(C=C1)C1=NN([C@@H](C)C2=C(C3=CC=CC(F)=C3)C(=O)C3=CC(F)=CC=C3O2)C2=C1C(N)=NC=N2",
    "molecular_weight": 571.56,
    "log_p": 6.66,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "casein kinase inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "non-hodgkin lymphoma (nhl)"
  },
  "umeclidinium": {
    "name": "Umeclidinium",
    "smiles": "OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2",
    "molecular_weight": 428.6,
    "log_p": 5.14,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "pulmonary | pulmonary | pulmonary",
    "indication": "bronchitis | chronic obstructive pulmonary disease (COPD) | emphysema"
  },
  "undecoylium chloride iodine complex": {
    "name": "Undecoylium chloride iodine complex",
    "smiles": "[Cl-].CCC(=O)OCCNC(=O)C[N+]1=CC=CC=C1",
    "molecular_weight": 272.73,
    "log_p": -2.95,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "undecylenic acid": {
    "name": "Undecylenic acid",
    "smiles": "OC(=O)CCCCCCCCC=C",
    "molecular_weight": 184.28,
    "log_p": 3.38,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "unoprostone": {
    "name": "Unoprostone",
    "smiles": "CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(O)=O",
    "molecular_weight": 382.54,
    "log_p": 4.26,
    "hbd": 3,
    "hba": 4,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA"
  },
  "upadacitinib": {
    "name": "Upadacitinib",
    "smiles": "CC[C@@H]1CN(C[C@@H]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F",
    "molecular_weight": 380.37,
    "log_p": 2.91,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "JAK inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "uracil mustard": {
    "name": "Uracil mustard",
    "smiles": "ClCCN(CCCl)C1=CNC(=O)NC1=O",
    "molecular_weight": 252.1,
    "log_p": 0.35,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "urea": {
    "name": "Urea",
    "smiles": "NC(N)=O",
    "molecular_weight": 60.06,
    "log_p": -0.98,
    "hbd": 2,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "hydroxy radical formation stimulant",
    "disease_area": "dermatology | dermatology | dermatology | dermatology | dermatology | dermatology",
    "indication": "dermatitis | eczema | ichthyosis vulgaris | keratosis | psoriasis | xerosis cutis"
  },
  "urea c-13": {
    "name": "Urea C-13",
    "smiles": "N[13C](N)=O",
    "molecular_weight": 61.05,
    "log_p": -0.98,
    "hbd": 2,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "urea c-14": {
    "name": "Urea C-14",
    "smiles": "N[14C](N)=O",
    "molecular_weight": 62.05,
    "log_p": -0.98,
    "hbd": 2,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "urethane": {
    "name": "Urethane",
    "smiles": "CCOC(N)=O",
    "molecular_weight": 89.09,
    "log_p": 0.1,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Preclinical",
    "moa": "local anesthetic",
    "disease_area": "",
    "indication": ""
  },
  "uridine triacetate": {
    "name": "Uridine triacetate",
    "smiles": "CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)N1C=CC(=O)NC1=O",
    "molecular_weight": 370.31,
    "log_p": -1.14,
    "hbd": 1,
    "hba": 10,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "ursodeoxycholic acid": {
    "name": "Ursodeoxycholic acid",
    "smiles": "[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O",
    "molecular_weight": 392.58,
    "log_p": 4.48,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "vaborbactam": {
    "name": "Vaborbactam",
    "smiles": "OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC1=CC=CS1",
    "molecular_weight": 297.14,
    "log_p": 0.45,
    "hbd": 3,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "beta lactamase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "valaciclovir": {
    "name": "Valaciclovir",
    "smiles": "CC(C)[C@H](N)C(=O)OCCOCN1C=NC2=C1NC(N)=NC2=O",
    "molecular_weight": 324.34,
    "log_p": -0.8,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA polymerase inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "shingles | virus herpes simplex (HSV)"
  },
  "valbenazine": {
    "name": "Valbenazine",
    "smiles": "COC1=C(OC)C=C2[C@H]3C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN3CCC2=C1",
    "molecular_weight": 418.58,
    "log_p": 3.56,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vesicular monoamine transporter inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "dyskinesia"
  },
  "valdecoxib": {
    "name": "Valdecoxib",
    "smiles": "CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O",
    "molecular_weight": 314.37,
    "log_p": 2.96,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "cyclooxygenase inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "valganciclovir": {
    "name": "Valganciclovir",
    "smiles": "CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1NC(N)=NC2=O",
    "molecular_weight": 354.37,
    "log_p": -1.44,
    "hbd": 4,
    "hba": 10,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "cytomegalovirus (CMV)"
  },
  "valine": {
    "name": "Valine",
    "smiles": "CC(C)[C@H](N)C(O)=O",
    "molecular_weight": 117.15,
    "log_p": 0.05,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "valproate bismuth": {
    "name": "Valproate bismuth",
    "smiles": "[Bi+3].CCCC(CCC)C([O-])=O.CCCC(CCC)C([O-])=O.CCCC(CCC)C([O-])=O",
    "molecular_weight": 638.6,
    "log_p": 2.48,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 15,
    "approved": true,
    "source": "FDA"
  },
  "valproic acid": {
    "name": "Valproic acid",
    "smiles": "CCCC(CCC)C(O)=O",
    "molecular_weight": 144.21,
    "log_p": 2.29,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "valrubicin": {
    "name": "Valrubicin",
    "smiles": "[H][C@@]1(C[C@@](O)(CC2=C(O)C3=C(C(O)=C12)C(=O)C1=C(OC)C=CC=C1C3=O)C(=O)COC(=O)CCCC)O[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1",
    "molecular_weight": 723.65,
    "log_p": 2.46,
    "hbd": 5,
    "hba": 13,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "DNA inhibitor | topoisomerase inhibitor",
    "disease_area": "oncology",
    "indication": "bladder cancer"
  },
  "valsartan": {
    "name": "Valsartan",
    "smiles": "CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O",
    "molecular_weight": 435.53,
    "log_p": 4.16,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "angiotensin receptor antagonist",
    "disease_area": "cardiology | cardiology",
    "indication": "congestive heart failure | hypertension"
  },
  "vanadium": {
    "name": "Vanadium",
    "smiles": "[V]",
    "molecular_weight": 50.94,
    "log_p": -0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "vancomycin": {
    "name": "Vancomycin",
    "smiles": "CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2",
    "molecular_weight": 1449.27,
    "log_p": 0.11,
    "hbd": 19,
    "hba": 25,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "bacterial cell wall synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "endocarditis"
  },
  "vandetanib": {
    "name": "Vandetanib",
    "smiles": "COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1",
    "molecular_weight": 475.36,
    "log_p": 5.0,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "EGFR inhibitor | RET tyrosine kinase inhibitor | VEGFR inhibitor",
    "disease_area": "oncology",
    "indication": "medullary thyroid cancer (MTC)"
  },
  "vanillyl butyl ether": {
    "name": "Vanillyl butyl ether",
    "smiles": "CCCCOCC1=CC(OC)=C(O)C=C1",
    "molecular_weight": 210.27,
    "log_p": 2.72,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "vardenafil": {
    "name": "Vardenafil",
    "smiles": "CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1",
    "molecular_weight": 488.61,
    "log_p": 2.07,
    "hbd": 1,
    "hba": 8,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "phosphodiesterase inhibitor",
    "disease_area": "urology",
    "indication": "erectile dysfunction"
  },
  "varenicline": {
    "name": "Varenicline",
    "smiles": "C1C2CNCC1C1=C2C=C2N=CC=NC2=C1",
    "molecular_weight": 211.27,
    "log_p": 1.8,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "smoking cessation"
  },
  "vasopressin": {
    "name": "Vasopressin",
    "smiles": "NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(CC2=CC=C(O)C=C2)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O.NC1CSSCC(NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O",
    "molecular_weight": 2140.49,
    "log_p": -9.73,
    "hbd": 27,
    "hba": 32,
    "rotatable_bonds": 38,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vasopressin receptor agonist",
    "disease_area": "gastroenterology",
    "indication": "abdominal distension"
  },
  "vecuronium": {
    "name": "Vecuronium",
    "smiles": "[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1",
    "molecular_weight": 557.84,
    "log_p": 5.97,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "acetylcholine receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "muscle relaxant"
  },
  "velpatasvir": {
    "name": "Velpatasvir",
    "smiles": "COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C1=CC=CC=C1)C1=NC=C(N1)C1=CC=C2C(COC3=CC4=C(C=CC5=C4NC(=N5)[C@@H]4CC[C@H](C)N4C(=O)[C@@H](NC(=O)OC)C(C)C)C=C23)=C1",
    "molecular_weight": 883.02,
    "log_p": 7.73,
    "hbd": 4,
    "hba": 10,
    "rotatable_bonds": 11,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antiviral",
    "disease_area": "infectious disease",
    "indication": "hepatitis C"
  },
  "vemurafenib": {
    "name": "Vemurafenib",
    "smiles": "CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1",
    "molecular_weight": 489.93,
    "log_p": 5.54,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "RAF inhibitor",
    "disease_area": "oncology",
    "indication": "melanoma"
  },
  "venetoclax": {
    "name": "Venetoclax",
    "smiles": "CC1(C)CCC(CN2CCN(CC2)C2=CC=C(C(=O)NS(=O)(=O)C3=CC=C(NCC4CCOCC4)C(=C3)[N+]([O-])=O)C(OC3=CN=C4NC=CC4=C3)=C2)=C(C1)C1=CC=C(Cl)C=C1",
    "molecular_weight": 868.46,
    "log_p": 8.66,
    "hbd": 3,
    "hba": 11,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "BCL inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "chronic lymphocytic leukemia (CLL)"
  },
  "venlafaxine": {
    "name": "Venlafaxine",
    "smiles": "COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1",
    "molecular_weight": 277.41,
    "log_p": 3.04,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic inhibitor | norepinephrine reuptake inhibitor | serotonin\u2013norepinephrine reuptake inhibitor (SNRI)",
    "disease_area": "neurology/psychiatry | neurology/psychiatry | neurology/psychiatry | neurology/psychiatry",
    "indication": "depression | generalized anxiety disorder (GAD) | panic disorders | social anxiety disorder"
  },
  "verapamil": {
    "name": "Verapamil",
    "smiles": "COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1",
    "molecular_weight": 454.61,
    "log_p": 5.09,
    "hbd": 0,
    "hba": 6,
    "rotatable_bonds": 13,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "calcium channel blocker",
    "disease_area": "cardiology",
    "indication": "hypertension"
  },
  "vericiguat": {
    "name": "Vericiguat",
    "smiles": "COC(=O)NC1=C(N)N=C(N=C1N)C1=NN(CC2=CC=CC=C2F)C2=C1C=C(F)C=N2",
    "molecular_weight": 426.39,
    "log_p": 2.56,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "guanylate cyclase stimulant",
    "disease_area": "",
    "indication": ""
  },
  "vernakalant": {
    "name": "Vernakalant",
    "smiles": "COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1",
    "molecular_weight": 349.47,
    "log_p": 2.64,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "potassium channel blocker",
    "disease_area": "cardiology",
    "indication": "atrial fibrillation (AF)"
  },
  "verteporfin": {
    "name": "Verteporfin",
    "smiles": "COC(=O)CCC1=C2NC(\\C=C3/N=C(/C=C4\\N\\C(=C/C5=N/C(=C\\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C",
    "molecular_weight": 718.81,
    "log_p": 6.72,
    "hbd": 3,
    "hba": 9,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "photosensitizing agent",
    "disease_area": "ophthalmology",
    "indication": "macular degeneration"
  },
  "vibegron": {
    "name": "Vibegron",
    "smiles": "[H][C@@]1(CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)[C@H](O)C1=CC=CC=C1",
    "molecular_weight": 444.54,
    "log_p": 2.77,
    "hbd": 3,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "vidarabine": {
    "name": "Vidarabine",
    "smiles": "NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",
    "molecular_weight": 267.25,
    "log_p": -1.98,
    "hbd": 4,
    "hba": 9,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "antiviral",
    "disease_area": "infectious disease | infectious disease",
    "indication": "varicella-zoster virus (VZV) | virus herpes simplex (HSV)"
  },
  "vigabatrin": {
    "name": "Vigabatrin",
    "smiles": "NC(CCC(O)=O)C=C",
    "molecular_weight": 129.16,
    "log_p": 0.36,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "GABA aminotransferase inhibitor",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "seizures | spasms"
  },
  "vilanterol": {
    "name": "Vilanterol",
    "smiles": "OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl",
    "molecular_weight": 486.44,
    "log_p": 4.61,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 16,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "pulmonary",
    "indication": "chronic obstructive pulmonary disease (COPD)"
  },
  "vilazodone": {
    "name": "Vilazodone",
    "smiles": "NC(=O)C1=CC2=CC(=CC=C2O1)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1",
    "molecular_weight": 441.54,
    "log_p": 4.03,
    "hbd": 2,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin reuptake inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "vildagliptin": {
    "name": "Vildagliptin",
    "smiles": "OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N",
    "molecular_weight": 303.41,
    "log_p": 1.17,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dipeptidyl peptidase inhibitor",
    "disease_area": "endocrinology",
    "indication": "diabetes mellitus"
  },
  "viloxazine": {
    "name": "Viloxazine",
    "smiles": "CCOC1=CC=CC=C1OCC1CNCCO1",
    "molecular_weight": 237.3,
    "log_p": 1.45,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "norepinephrine reuptake inhibitor",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "vinblastine": {
    "name": "Vinblastine",
    "smiles": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=C2C=CC=C1)C(=O)OC",
    "molecular_weight": 810.99,
    "log_p": 3.99,
    "hbd": 3,
    "hba": 12,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "microtubule inhibitor | tubulin polymerization inhibitor",
    "disease_area": "hematologic malignancy | hematologic malignancy | hematologic malignancy | infectious disease | oncology | oncology",
    "indication": "Hodgkin's lymphoma | Kaposi sarcoma | mycosis | small lymphocytic lymphoma (SLL) | testicular carcinoma | true histiocytic lymphoma (THL)"
  },
  "vincristine": {
    "name": "Vincristine",
    "smiles": "[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@H]5C[N@](C[C@](O)(CC)C5)CCC5=C4NC4=CC=CC=C54)C(=O)OC)N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC",
    "molecular_weight": 824.97,
    "log_p": 3.52,
    "hbd": 3,
    "hba": 12,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "tubulin polymerization inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "acute lymphoblastic leukemia (ALL)"
  },
  "vindesine": {
    "name": "Vindesine",
    "smiles": "[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(N)=O)[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=C2C=CC=C1)C(=O)OC",
    "molecular_weight": 753.94,
    "log_p": 2.73,
    "hbd": 5,
    "hba": 10,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "tubulin polymerization inhibitor",
    "disease_area": "oncology | oncology | oncology",
    "indication": "breast cancer | melanoma | non-small cell lung cancer (NSCLC)"
  },
  "vinflunine": {
    "name": "Vinflunine",
    "smiles": "CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)C1=CC(OC)=C(C=C41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CC3=C1NC1=CC=CC=C31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC",
    "molecular_weight": 816.94,
    "log_p": 5.08,
    "hbd": 2,
    "hba": 11,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "microtubule inhibitor",
    "disease_area": "oncology",
    "indication": "bladder cancer"
  },
  "vinorelbine": {
    "name": "Vinorelbine",
    "smiles": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC",
    "molecular_weight": 778.95,
    "log_p": 4.75,
    "hbd": 2,
    "hba": 11,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "tubulin polymerization inhibitor",
    "disease_area": "oncology",
    "indication": "non-small cell lung cancer (NSCLC)"
  },
  "viomycin": {
    "name": "Viomycin",
    "smiles": "[H][C@@]1(C[C@H](O)NC(=N)N1)[C@]1([H])NC(=O)\\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CNC1=O)NC(=O)C[C@@H](N)CCCN)=C\\NC(N)=O",
    "molecular_weight": 685.7,
    "log_p": -8.67,
    "hbd": 16,
    "hba": 13,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "protein synthesis inhibitor",
    "disease_area": "infectious disease",
    "indication": "tuberculosis"
  },
  "vismodegib": {
    "name": "Vismodegib",
    "smiles": "CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1",
    "molecular_weight": 421.31,
    "log_p": 4.71,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "hedgehog pathway inhibitor | smoothened receptor antagonist",
    "disease_area": "oncology",
    "indication": "basal cell carcinoma (BCC)"
  },
  "vitamin a": {
    "name": "Vitamin A",
    "smiles": "C\\C(=C/CO)\\C=C\\C=C(/C)\\C=C\\C1=C(C)CCCC1(C)C",
    "molecular_weight": 286.46,
    "log_p": 5.51,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  },
  "vitamin e": {
    "name": "Vitamin E",
    "smiles": "CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C",
    "molecular_weight": 430.72,
    "log_p": 8.84,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "voclosporin": {
    "name": "Voclosporin",
    "smiles": "[H][C@@]1([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC1=O)C(C)C",
    "molecular_weight": 1214.65,
    "log_p": 3.44,
    "hbd": 5,
    "hba": 12,
    "rotatable_bonds": 16,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "calcineurin inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "vonoprazan": {
    "name": "Vonoprazan",
    "smiles": "CNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1",
    "molecular_weight": 345.4,
    "log_p": 2.65,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "potassium-competitive acid antagonist",
    "disease_area": "gastroenterology",
    "indication": "peptic ulcer disease (PUD)"
  },
  "vorapaxar": {
    "name": "Vorapaxar",
    "smiles": "[H][C@@]12C[C@]3([H])C[C@@H](CC[C@@]3([H])[C@H](\\C=C\\C3=CC=C(C=N3)C3=CC(F)=CC=C3)[C@]1([H])[C@@H](C)OC2=O)NC(=O)OCC",
    "molecular_weight": 492.59,
    "log_p": 5.63,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "thrombin inhibitor",
    "disease_area": "cardiology | cardiology",
    "indication": "myocardial infarction | peripheral artery disease (PAD)"
  },
  "voriconazole": {
    "name": "Voriconazole",
    "smiles": "C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1",
    "molecular_weight": 349.32,
    "log_p": 2.18,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "cytochrome P450 inhibitor",
    "disease_area": "infectious disease | infectious disease | infectious disease",
    "indication": "aspergillosis | esophageal candidiasis | skin infections"
  },
  "vorinostat": {
    "name": "Vorinostat",
    "smiles": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1",
    "molecular_weight": 264.32,
    "log_p": 2.47,
    "hbd": 3,
    "hba": 3,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "HDAC inhibitor",
    "disease_area": "hematologic malignancy",
    "indication": "cutaneous T-cell lymphoma (CTCL)"
  },
  "vortioxetine": {
    "name": "Vortioxetine",
    "smiles": "CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1",
    "molecular_weight": 298.46,
    "log_p": 3.86,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor agonist | serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "depression"
  },
  "voxelotor": {
    "name": "Voxelotor",
    "smiles": "CC(C)N1N=CC=C1C1=C(COC2=CC=CC(O)=C2C=O)C=CC=N1",
    "molecular_weight": 337.38,
    "log_p": 3.62,
    "hbd": 1,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "hemoglobin modulator",
    "disease_area": "",
    "indication": ""
  },
  "voxilaprevir": {
    "name": "Voxilaprevir",
    "smiles": "CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1)C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCC(F)(F)C1=C(O2)N=C2C=C(OC)C=CC2=N1)C(C)(C)C",
    "molecular_weight": 868.95,
    "log_p": 4.96,
    "hbd": 3,
    "hba": 11,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA"
  },
  "warfarin": {
    "name": "Warfarin",
    "smiles": "CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2",
    "molecular_weight": 308.33,
    "log_p": 3.61,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "vitamin K antagonist",
    "disease_area": "cardiology | cardiology | hematology | hematology | hematology, cardiology",
    "indication": "atrial fibrillation (AF) | deep vein thrombosis (DVT) | deep vein thrombosis (dvt), pulmonary embolism (pe), atrial fibrillation (af), myocardial infarction | myocardial infarction | pulmonary embolism (PE)"
  },
  "xamoterol": {
    "name": "Xamoterol",
    "smiles": "OC(CNCCNC(=O)N1CCOCC1)COC1=CC=C(O)C=C1",
    "molecular_weight": 339.39,
    "log_p": -0.24,
    "hbd": 4,
    "hba": 6,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Phase 3",
    "moa": "adrenergic receptor agonist",
    "disease_area": "",
    "indication": ""
  },
  "xanthinol": {
    "name": "Xanthinol",
    "smiles": "CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C",
    "molecular_weight": 311.34,
    "log_p": -2.28,
    "hbd": 2,
    "hba": 9,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA"
  },
  "xenon xe-127": {
    "name": "Xenon Xe-127",
    "smiles": "[127Xe]",
    "molecular_weight": 126.91,
    "log_p": 0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "xenon xe-129": {
    "name": "Xenon Xe-129",
    "smiles": "[129Xe]",
    "molecular_weight": 128.9,
    "log_p": 0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "xenon-133": {
    "name": "Xenon-133",
    "smiles": "[133Xe]",
    "molecular_weight": 132.91,
    "log_p": 0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "ximelagatran": {
    "name": "Ximelagatran",
    "smiles": "CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(\\N)=N\\O)C1CCCCC1",
    "molecular_weight": 473.57,
    "log_p": 1.1,
    "hbd": 4,
    "hba": 7,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "xylometazoline": {
    "name": "Xylometazoline",
    "smiles": "CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C",
    "molecular_weight": 244.38,
    "log_p": 3.15,
    "hbd": 1,
    "hba": 2,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor agonist",
    "disease_area": "allergy | otolaryngology",
    "indication": "allergic rhinitis | nasal congestion"
  },
  "xylose": {
    "name": "Xylose",
    "smiles": "OC[C@@H](O)[C@H](O)[C@@H](O)C=O",
    "molecular_weight": 150.13,
    "log_p": -2.74,
    "hbd": 4,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "",
    "disease_area": "",
    "indication": ""
  },
  "yohimbine": {
    "name": "Yohimbine",
    "smiles": "[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2",
    "molecular_weight": 354.45,
    "log_p": 2.65,
    "hbd": 2,
    "hba": 4,
    "rotatable_bonds": 1,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "adrenergic receptor antagonist",
    "disease_area": "cardiology | cardiology",
    "indication": "bradycardia | cardiac arrythmia"
  },
  "yttrium y-90": {
    "name": "Yttrium Y-90",
    "smiles": "[90Y]",
    "molecular_weight": 89.91,
    "log_p": -0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "zafirlukast": {
    "name": "Zafirlukast",
    "smiles": "COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C",
    "molecular_weight": 575.69,
    "log_p": 5.7,
    "hbd": 2,
    "hba": 7,
    "rotatable_bonds": 8,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "leukotriene receptor antagonist",
    "disease_area": "pulmonary",
    "indication": "asthma"
  },
  "zalcitabine": {
    "name": "Zalcitabine",
    "smiles": "NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1",
    "molecular_weight": 211.22,
    "log_p": -0.5,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "nucleoside reverse transcriptase inhibitor",
    "disease_area": "infectious disease",
    "indication": "human immunodeficiency virus (HIV-1)"
  },
  "zaleplon": {
    "name": "Zaleplon",
    "smiles": "CCN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C#N",
    "molecular_weight": 305.34,
    "log_p": 2.64,
    "hbd": 0,
    "hba": 5,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "zanamivir": {
    "name": "Zanamivir",
    "smiles": "[H][C@]1(OC(=C[C@H](N=C(N)N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO",
    "molecular_weight": 332.31,
    "log_p": -3.79,
    "hbd": 7,
    "hba": 7,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "neuraminidase inhibitor",
    "disease_area": "infectious disease",
    "indication": "influenza A virus infection"
  },
  "zanubrutinib": {
    "name": "Zanubrutinib",
    "smiles": "NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C1=CC=C(OC2=CC=CC=C2)C=C1",
    "molecular_weight": 471.56,
    "log_p": 4.22,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 6,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "Bruton's tyrosine kinase (BTK) inhibitor",
    "disease_area": "",
    "indication": ""
  },
  "zeaxanthin": {
    "name": "Zeaxanthin",
    "smiles": "C\\C(\\C=C\\C=C(/C)\\C=C\\C1=C(C)C[C@@H](O)CC1(C)C)=C/C=C/C=C(\\C)/C=C/C=C(\\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C",
    "molecular_weight": 568.89,
    "log_p": 10.55,
    "hbd": 2,
    "hba": 2,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "ziconotide": {
    "name": "Ziconotide",
    "smiles": "[H][C@]12CSSC[C@]3([H])NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC[C@]([H])(NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC1=O)C(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC3=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N2",
    "molecular_weight": 2639.19,
    "log_p": -16.21,
    "hbd": 42,
    "hba": 45,
    "rotatable_bonds": 38,
    "approved": true,
    "source": "FDA"
  },
  "zidovudine": {
    "name": "Zidovudine",
    "smiles": "CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O",
    "molecular_weight": 267.25,
    "log_p": -0.2,
    "hbd": 2,
    "hba": 6,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "nucleoside reverse transcriptase inhibitor",
    "disease_area": "infectious disease | infectious disease",
    "indication": "acquired immunodeficiency syndrome (AIDS) | human immunodeficiency virus (HIV-1)"
  },
  "zileuton": {
    "name": "Zileuton",
    "smiles": "CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1",
    "molecular_weight": 236.3,
    "log_p": 2.73,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "leukotriene synthesis inhibitor | lipoxygenase inhibitor",
    "disease_area": "pulmonary",
    "indication": "asthma"
  },
  "zimelidine": {
    "name": "Zimelidine",
    "smiles": "CN(C)C\\C=C(\\C1=CC=C(Br)C=C1)C1=CC=CN=C1",
    "molecular_weight": 317.23,
    "log_p": 3.84,
    "hbd": 0,
    "hba": 2,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Withdrawn",
    "moa": "selective serotonin reuptake inhibitor (SSRI)",
    "disease_area": "",
    "indication": ""
  },
  "zinc": {
    "name": "Zinc",
    "smiles": "[Zn]",
    "molecular_weight": 65.39,
    "log_p": -0.0,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "zinc acetate": {
    "name": "Zinc acetate",
    "smiles": "[Zn++].CC([O-])=O.CC([O-])=O",
    "molecular_weight": 183.48,
    "log_p": -2.49,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "zinc ascorbate": {
    "name": "Zinc ascorbate",
    "smiles": "[Zn++].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO.[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO",
    "molecular_weight": 415.62,
    "log_p": -5.21,
    "hbd": 6,
    "hba": 12,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "zinc chloride": {
    "name": "Zinc chloride",
    "smiles": "[Cl-].[Cl-].[Zn++]",
    "molecular_weight": 136.3,
    "log_p": -5.99,
    "hbd": 0,
    "hba": 0,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "zinc dibutyldithiocarbamate": {
    "name": "Zinc dibutyldithiocarbamate",
    "smiles": "[Zn++].CCCCN(CCCC)C([S-])=S.CCCCN(CCCC)C([S-])=S",
    "molecular_weight": 474.16,
    "log_p": 5.44,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 12,
    "approved": true,
    "source": "FDA"
  },
  "zinc gluconate": {
    "name": "Zinc gluconate",
    "smiles": "[Zn++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O",
    "molecular_weight": 455.68,
    "log_p": -9.66,
    "hbd": 10,
    "hba": 14,
    "rotatable_bonds": 10,
    "approved": true,
    "source": "FDA"
  },
  "zinc oxide": {
    "name": "Zinc oxide",
    "smiles": "O=[Zn]",
    "molecular_weight": 81.39,
    "log_p": -0.12,
    "hbd": 0,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "zinc phenolsulfonate": {
    "name": "Zinc phenolsulfonate",
    "smiles": "[Zn++].OC1=CC=C(C=C1)S([O-])(=O)=O.OC1=CC=C(C=C1)S([O-])(=O)=O",
    "molecular_weight": 411.73,
    "log_p": 0.59,
    "hbd": 2,
    "hba": 8,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "zinc sulfate": {
    "name": "Zinc sulfate",
    "smiles": "[Zn++].[O-]S([O-])(=O)=O",
    "molecular_weight": 161.45,
    "log_p": -1.34,
    "hbd": 0,
    "hba": 4,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "ziprasidone": {
    "name": "Ziprasidone",
    "smiles": "ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1",
    "molecular_weight": 412.95,
    "log_p": 3.81,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist | serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "bipolar disorder | schizophrenia"
  },
  "zirconium chloride hydroxide": {
    "name": "Zirconium chloride hydroxide",
    "smiles": "O[Zr]Cl",
    "molecular_weight": 143.68,
    "log_p": 0.13,
    "hbd": 1,
    "hba": 1,
    "rotatable_bonds": 0,
    "approved": true,
    "source": "FDA"
  },
  "zofenopril": {
    "name": "Zofenopril",
    "smiles": "C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC1=CC=CC=C1",
    "molecular_weight": 429.56,
    "log_p": 4.04,
    "hbd": 1,
    "hba": 5,
    "rotatable_bonds": 7,
    "approved": true,
    "source": "FDA"
  },
  "zoledronate d,l-lysine monohydrate": {
    "name": "Zoledronate D,L-Lysine Monohydrate",
    "smiles": "O.NCCCCC(N)C(O)=O.OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O",
    "molecular_weight": 436.3,
    "log_p": -2.41,
    "hbd": 8,
    "hba": 8,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "zoledronic acid": {
    "name": "Zoledronic acid",
    "smiles": "OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O",
    "molecular_weight": 272.09,
    "log_p": -1.12,
    "hbd": 5,
    "hba": 5,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA"
  },
  "zolmitriptan": {
    "name": "Zolmitriptan",
    "smiles": "CN(C)CCC1=CNC2=CC=C(C[C@H]3COC(=O)N3)C=C12",
    "molecular_weight": 287.36,
    "log_p": 1.92,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "serotonin receptor agonist",
    "disease_area": "neurology/psychiatry",
    "indication": "migraine headache"
  },
  "zolpidem": {
    "name": "Zolpidem",
    "smiles": "CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1",
    "molecular_weight": 307.4,
    "log_p": 3.25,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 3,
    "approved": true,
    "source": "FDA"
  },
  "zonisamide": {
    "name": "Zonisamide",
    "smiles": "NS(=O)(=O)CC1=NOC2=CC=CC=C12",
    "molecular_weight": 212.23,
    "log_p": 0.62,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "sodium channel blocker | T-type calcium channel blocker",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "epilepsy | seizures"
  },
  "zopiclone": {
    "name": "Zopiclone",
    "smiles": "CN1CCN(CC1)C(=O)OC1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1",
    "molecular_weight": 388.82,
    "log_p": 1.57,
    "hbd": 0,
    "hba": 7,
    "rotatable_bonds": 2,
    "approved": true,
    "source": "FDA"
  },
  "zotepine": {
    "name": "Zotepine",
    "smiles": "CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12",
    "molecular_weight": 331.87,
    "log_p": 4.88,
    "hbd": 0,
    "hba": 3,
    "rotatable_bonds": 4,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist | serotonin receptor antagonist",
    "disease_area": "neurology/psychiatry",
    "indication": "schizophrenia"
  },
  "zucapsaicin": {
    "name": "Zucapsaicin",
    "smiles": "COC1=C(O)C=CC(CNC(=O)CCCC\\C=C/C(C)C)=C1",
    "molecular_weight": 305.42,
    "log_p": 3.79,
    "hbd": 2,
    "hba": 3,
    "rotatable_bonds": 9,
    "approved": true,
    "source": "FDA"
  },
  "zuclopenthixol": {
    "name": "Zuclopenthixol",
    "smiles": "OCCN1CCN(CC\\C=C2\\C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1",
    "molecular_weight": 400.98,
    "log_p": 4.24,
    "hbd": 1,
    "hba": 4,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA",
    "clinical_phase": "Launched",
    "moa": "dopamine receptor antagonist",
    "disease_area": "neurology/psychiatry | neurology/psychiatry",
    "indication": "bipolar disorder | schizophrenia"
  },
  "zytron": {
    "name": "Zytron",
    "smiles": "COP(=S)(NC(C)C)OC1=CC=C(Cl)C=C1Cl",
    "molecular_weight": 314.17,
    "log_p": 4.24,
    "hbd": 1,
    "hba": 3,
    "rotatable_bonds": 5,
    "approved": true,
    "source": "FDA"
  }
}